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Abstract 
This thesis presents the findings from a detailed study of possible barriers to adoption of Point-
of-Care Testing (POCT) within hospital-based healthcare.  The issues concerned have been 
identified and categorised from a systematic review of the published literature over the period 
2000-2016.  The opinions of clinicians working in the UK have been obtained via face-to-face 
interviews and an online survey tool using semi-quantitative techniques by way of subsequent 
analysis.  These data have then been compared with the outcomes from interviews with those 
employed in the US healthcare system.  Based on these findings, a more targeted appraisal of 
the opinions of international Clinical Bioscientists was then undertaken.  Overall, the central aim 
of the work was to categorise and better understand the core issues that have been identified 
as impeding the clinical uptake of POCT in both the UK and internationally.  Importantly, the 
focus of the work was on how the most significant barriers can be overcome based on this new 
understanding of the circumstances. 
There is a clear disconnect between the opinions of those responsible for operating POCT and 
those responsible for test data quality assurance, i.e. the Clinical Bioscientists, regardless of 
location.  In particular, it was found that this relates mostly to specific quality-related issues, 
including the complexity of regulatory requirements and control of diagnostic testing.  While 
economic issues were generally found to impact most significantly upon POCT adoption, it is 
indicated that the role of the medical insurer within the US healthcare system acts as an 
additional hurdle as compared to the situation in the UK (NHS).  
Based on the research findings described herein a number of recommendations are made for 
overcoming the various barriers to POCT adoption in hospital-based healthcare, including; 
development of a sufficient evidence base for the clinical/economic benefits; development of 
regional procurement strategies; improved connectivity to the patient record systems; 
improved training processes; increased central laboratory service support, and; improved 
quality assurance processes. 
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Chapter 1 
Introduction to the Research 
1.1 History of Modern Diagnostic Testing 
The examination and analysis of a range of bodily fluids has long been recognised as being a 
critical step in the successful diagnosis and management of various medical conditions.  Over 
the last century, the focus and approach to diagnostic testing has shifted dramatically with 
respect to benefits that have been gained from a range of fundamental scientific and 
technological developments, moving it from a basic physical assessment of bodily fluids towards 
a more detailed evaluation of their biochemical composition and the quantification of specific 
biomarkers related to pathology.   
In historical terms, urine has been used for analytical purposes in the diagnosis of certain 
medical conditions due to its ease of acquisition, ready availability and relative abundance 
(Bolodeoku, Olukoga et al. 1998).  The practice of visually examining a patient's urine for blood 
or other symptoms of disease is referred to as uroscopy and was considered routine practice as 
long ago as the late medieval period.  It was then scientific breakthroughs such as the 
development of the microscope and the discovery of the complex constituents of blood laid the 
foundations for modern diagnostic tools and tests. 
During the 18th century, medicine advanced significantly with the creation of textbooks 
categorising many new forms of disease and the introduction of drugs such as digitalis and 
opium.  Furthermore, it was during this period that fundamental developments were 
established with regard to how examination of body temperature, pulse rate and blood pressure 
could be used for the deduction of a successful diagnosis.  More sophisticated diagnostic 
techniques came to the fore in the 19th century, coinciding with the political, industrial and 
philosophical revolutions that were occurring on a global scale at that time (Berger 1999a).  
Medical practice developed at a rapid rate during the 1800’s and so the provision of clinical 
diagnosis and disease management shifted from a primarily home bedside-based activity to that 
of hospital-based care where the more novel technologies and innovative techniques were 
accessible to a wider range of the population. 
The development and progressive introduction of further laboratory tests to diagnose an 
increasing catalogue of diseases meant that dedicated clinical laboratories began to emerge as 
permanent fixtures of hospitals and other related healthcare facilities by the beginning of the 
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20th century.  Interest in the detailed chemical evaluation of blood during this period can be 
correlated with the introduction of the hypodermic needle into widespread clinical practice 
(Bolodeoku, Olukoga et al. 1998).  Likewise, microbiology and clinical chemistry developed into 
commonly recognised areas of medical specialist activity.  Furthermore, blood banking for 
transfusions that were necessary during complex surgical procedures was introduced in the 
early part of the 20th century and this in turn necessitated blood grouping and basic functional 
testing (Berger 1999b).  The introduction of clinical biochemistry as a specialism into the hospital 
laboratory setting, rather than relying solely on general physicians to undertake increasingly 
complicated testing, was recognition of both the success of the laboratory service and the need 
to ensure appropriate levels of quality assurance in the undertaking of such tests via provision 
of the requisite skills and dedicated expertise.  This subsequently led to a career path for the 
training and certification of dedicated laboratory technicians, biomedical scientists and related 
specialisms. 
1.2 Adoption of Centralised Analytical Testing 
The mid-20th century onwards saw diagnostic testing of blood samples begin to be utilised on a 
much larger scale globally.  Blood remains the most investigated bodily fluid in terms of 
biochemical and other forms of assessment.  As the use of such tests increased, dedicated rooms 
(i.e. laboratories) became commonplace within hospitals equipped with the resources necessary 
for methods required to carry out the tests.  This was a reflection of the fact that chemicals 
(quite often too hazardous for general purpose use) and particular (dedicated) pieces of 
equipment were now essential to deliver the required analytical service (Huckle 2008). 
As the demonstrably positive effects of accurate laboratory based diagnostic testing were 
established clinically, this then led to an increasing volume of test requests being made by 
physicians within hospitals and other healthcare settings.  This resulted in a number of 
laboratory tests and procedures (e.g. blood picture tests) emerging as routine components in 
the assessment of a patient’s condition (Kotlarz 1998).  As the underpinning technology 
continued to develop the associated analysis became increasingly more sophisticated and the 
value of precision in the diagnostic process began to be recognised as being of the upmost 
importance. 
It has been suggested that 3 fundamental factors contributed to this adoption of centralised 
testing within hospitals and the development of the clinical laboratory service (Moore 2005).  
Firstly, the emergence of technology that allowed for more sophisticated analysis of specimens 
was an obvious driving force, particularly with regard to the benefits for more effective 
management of patients with less common medical conditions and diseases.  Secondly, an 
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increasing requirement for appropriate logistics to co-ordinate testing led to the further 
embedding of an adequately resourced central laboratory service within hospitals that could 
meet the needs of both the patient and physician in terms of speed of access and convenience.  
This requirement incorporated efficiencies in the collection and preservation of samples, testing 
of specimens and the reporting of test results in a structured and organised manner.  The notion 
of a centralised diagnostic testing service within a dedicated laboratory was deemed to be the 
most effective way to meet these requirements effectively.  Thirdly, the economics of funding 
the costs of this increased testing followed on subsequently from the other logistical 
considerations with an increasing need for a laboratory-based testing service capable of 
delivering diagnostic tests at higher volume in an economically-viable and sustainable way.  Only 
by concentration of test volumes within a dedicated laboratory service would it be possible to 
provide the economy of scale required to achieve this latter requirement. 
The introduction of quality assurance schemes was a natural extension of the growth in 
diagnostic testing during the 20th century and directly aided the elimination of both variable and 
non-variable factors that had hitherto affected the value of the data provided by such tests 
(Bolodeoku, Olukoga et al. 1998).  This significantly enhanced the quality of the data provided 
by the central laboratory service and added real clinical value in a way that was recognised as 
being of high importance.  The tightly controlled confines of a dedicated laboratory and the 
provision of centralised quality assured testing systems and methods were seen as being highly 
favourable in terms of achieving consistent levels of reproducibility and repeatability in test 
outcomes and thereby increased their uptake significantly. 
1.3 The Need for Faster Results: Turnaround Time (TAT) 
The ever-increasing volume of diagnostic tests undertaken within hospitals has meant that the 
clinical laboratory service has continuously been required to adopt advances in technology in 
order to maintain service levels.  Such adoption issues include the use of modern equipment, 
automated specimen processing, computerised reporting of results and more efficient specimen 
transportation systems (Steindel, Howanitz 2001).  Despite this requirement, research has 
indicated that, in recent decades, laboratories have often found it difficult to meet the internally 
set goals for test turnaround time (TAT) (Hilborne, Oye et al. 1989, Steindel, Howanitz 1997). 
In terms of satisfaction levels for the provision of laboratory services, TAT is quite often the 
primary measure of performance utilised.  The obvious benefits of a faster TAT include more 
efficient patient management and quicker clinical intervention, which for many time-critical 
conditions are a major factor in the level of quality of care provided and the subsequent quality 
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of life of the patient post-treatment.  Clearly, the reduced levels of morbidity and mortality that 
result from faster test result TAT are a major aspect in this respect. 
The definition of a specific TAT value has 3 components; pre-analytic, i.e. collection of the 
sample and its transport to the laboratory; analytic, and; post-analytic, i.e. the communication 
of the test results to the ward or individual clinician.  There have been some successful solutions 
with regard to improving the TAT values within the central laboratory service within hospitals 
and clinical centres, including; pneumatic tubing systems; decentralised testing such as satellite 
laboratories and Point-of-Care Testing (POCT), and improved information technology (IT) 
(Manor 1999). 
Pneumatic tubing systems are interconnecting arrangements of tubes joining the various clinical 
areas of a hospital building to the centralised analysis laboratory facility that have been proven 
to be successful in reducing the pre-analytical phase of TAT (Fleisher, Schwartz 1995, McQueen 
1993, Green 1995).  Not only can this method potentially save time in the transport of samples 
to the laboratory, it can also relieve the requirement for personnel to carry-out this role in 
person.  The benefits in terms of efficiency of this diagnostic system TAT process are therefore 
obvious, albeit that they are somewhat limited in terms of overall additional value achieved in 
terms of the accuracy of the test itself.   
By comparison, decentralised testing is based on a twofold ideology vis-à-vis; firstly, through the 
use of satellite laboratories distributed throughout the hospital or clinical institution and, 
secondly; via the use of POCT technologies that directly undertake the diagnostic testing of 
specimens in a 1-step process close to the patient.  Hence, decentralised testing seeks to move 
testing (back) to the site of patient care, which raises obvious issues in that it is very much 
against the trend of centralisation that evolved throughout the majority of the 20th century.  
Setting up such satellite laboratories in areas where rapid patient care is essential, i.e. in the 
Emergency Department/Room (ED/R) can help reduce the pre-analytical phase of TAT.  
However, it is recognised that post-analytical issues may still persist.  Furthermore, satellite 
laboratories have been found to often duplicate services that are already provided by the central 
laboratory service (Manor 1999) which can therefore result in obvious economic inefficiencies.   
Improved IT serves primarily to address the post-analytical phase of TAT with respect to the 
effective and timely communication and review of diagnostic test results.  Computerisation of 
information systems reduces the risk of human error in the delivery of test results.  Furthermore, 
the instantaneous nature of computer-based reporting has been found to significantly decrease 
the time with respect to the reviewing of results (Bluth, Lambert et al. 1992). 
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1.4 Development of POCT 
Historically, the availability of key technologies has been the main factor in determining where 
and how diagnostic testing would be performed.  For example, large and complex biochemical 
analysers are most efficiently utilised in a centralised environment.  In this regard, batched 
testing allows for an economy of scale to be achieved and quality control systems to be 
developed and implemented successfully (Kost, Ehrmeyer et al. 1999).  Technological 
advancements that occurred in the late 20th century in areas such as microfluidics, biosensors 
and biomarker development have allowed for the development of a range of so-called Point-of-
Care Testing (POCT) devices, which have permitted the relocation of diagnostic testing back to 
the site of patient care.  POCT was developed with the aim of reducing test TAT via providing for 
the collection, analysis and review of results within minutes (Manor 1999).  In this regard, it 
seeks to accomplish more effective patient management leading to increased quality of care 
while attaining economic savings through the reduced length of stay for patients in hospitals 
(McDonald, Smith 1995). 
At the outset of the implementation of POCT, simple chemical test methods were used in a strip-
based format by clinicians and nurses, with such non-invasive procedure requiring little, if any, 
expertise.  With the ongoing development of more sophisticated technologies that now 
underpin the new generation of POCT devices, issues have emerged with respect to clinically 
acceptable accuracy levels in terms of test sensitivity when compared to the technologies 
utilised within a central laboratory service (Huckle 2008).   
Early POCT devices were not without their flaws, design issues made it difficult for device 
operators to utilise the devices in a reliable manner in order to produce results of adequate 
quality (Lewandrowski, Gregory et al. 2011).  The issues surrounding both the number and 
complexity of the steps required to be performed by the POCT operator resulted in the 
opportunity for a high number of user errors that can directly affect the quality of test data 
produced.  Furthermore, issues involving the lack of an electronic data management system and 
the absence of safeguarding mechanisms to control who operates the devices, including issues 
such as the use of inappropriate test strips, have traditionally been problematical 
(Lewandrowski, Gregory et al. 2011). 
Due to the initial issues that limited the functionality of POCT devices and the quality of the 
associated data, the growth of the sector was somewhat modest at first.  However, with 
advances in both the technology and the way by which it is provided, the prevalence of POCT 
has increased significantly over the last decade.  Growth rates in uptake are increasing steadily 
in terms of use, particularly within the United States (Larsson, Greig-Pylypczuk et al. 2015).  In 
terms of a global perspective, it is estimated that the worldwide market for POCT was almost 
 6 
$15.1 billion in 2012 and is predicated to reach $19.3 billion by 2018 (Point of Care Diagnostics, 
BCC Research, 2014).  It is, however, important to recognise that POCT exists as 2 different 
market sectors, namely the “professional market” (incorporating testing within clinical settings 
in areas such as critical care, infectious disease, cardiac markers, diabetes, lipids, coagulation 
and haematology) and the “non-professional market” (incorporating “over-the-counter” POCT 
including home glucose monitoring and pregnancy tests).  The “professional market” was 
estimated to be worth $5.66 billion in 2011 and was projected to grow to $6.76 billion by 2016 
(St John, Price 2014).  The POCT market therefore can be seen to be currently dominated by 
“over-the counter” and home-use products which can be utilised with minimal need for 
regulation. 
1.5 Technologies Underpinning the Implementation of POCT 
To understand the fundamental technologies that underpin POCT, it is firstly necessary to 
determine its different configurations.  In this respect, the concept of its utility can occur in 2 
differing forms; vis-à-vis a handheld format (i.e. bedside device) or a desktop analyser format 
(i.e. near-bedside device).  It should be noted that the desktop configuration of POCT analysers 
remains significantly smaller in size compared to that of a typical analyser found in the central 
laboratory.  The technology utilised to develop POCT has been further influenced by several key 
operational requirements, namely; the devices should be simple to use; reagents and 
consumables should be easily stored with relatively long shelf life; results should be comparable 
with those from an established central laboratory service method and, finally; all components 
of the device and the test method itself should be safe to use (Price, St John et al. 2010).  A 
general realisation is that the handheld format of POCT primarily incorporates the use of 
(bio)chemically-responsive strips (both quantitative and qualitative) while the desktop-format 
will tend to utilise more complex built-in microfluidics, not dissimilar to those present in the 
corresponding central laboratory apparatus.   
Bedside POCT devices are generally handheld systems that range from small dipsticks, of the 
type used for basic urinalysis, to dedicated test cartridge-based devices, such as those used for 
blood gas analysis.  Handheld devices often entirely negate the need for specific sampling, 
labelling or transport of specimens by utilising direct interventions such as “finger-stick” 
capillary sampling techniques for blood analysis (St John, Price 2014).  Dipstick devices are the 
most basic form of POCT that can incorporate a reagent that responds directly to a targeted 
analyte.  Whereas, they can simply involve a visual colour change, they more commonly involve 
the use of reflectance technology or fluorescence spectrophotometry (in the case of 
immunosensors) to provide an estimate of the amount (concentration) of the analyte that is 
present in the sample.  The most popular form of a device that incorporates a test strip is that 
 7 
used with a glucose meter, which dominates the testing area with respect to the management 
of insulin dependent diabetes.  These particular meters commonly use photometric or 
electrochemical detection systems in order to provide a measurement of blood sugar level to 
the device operator (patient).  International normalised ratio (INR) measurement in the 
management of patients on warfarin (anticoagulation) therapy is a further area associated with 
the intensive use of handheld test-strip based POCT technology, which again incorporates the 
use of optical and electrochemical detection (St John, Price 2014).  With respect to the category 
of devices with dedicated test cartridges, these tend to utilise some sort of sensor substrate and 
microfluidic technology.  The benefit of a cartridge/reader device is that an extensive testing 
menu can be made available through the use of a single device capable of operating with a 
number of different cartridge-based tests. 
Near-bedside devices are commonly desktop POCT devices which share common operating 
principles with a number of central laboratory test devices.  In essence their purpose is to 
migrate the laboratory service to areas of clinical need, where space tends to be at a premium 
and operators will normally be non-specialists.  Therefore, desktop POCT devices have followed 
a general trend of miniaturisation and increasing computer processing power in order to meet 
the diagnostic requirements (St John, Price 2014).  The continued technological development of 
microfluidics has therefore been key in this respect.  Microfluidic devices have several innate 
advantages in their use, the most notable of which are a low sample and reagent volume, high 
capability of integration and small feature sizes (Jung, Han et al. 2015).  The most prominent 
desktop POCT device are those for the analysis of blood gas composition and associated 
concentration parameters.  These devices also tend to utilise test cartridge technology, and so 
are different to the handheld devices in that the sensors here are designed to be re-usable in 
this configuration (St John, Price 2014).  Again, this has the benefit of allowing for a single device 
to provide an extensive testing menu to the area of critical care in which it is located.  
1.6 Benefits Potentially Available through POCT 
The potential clinical benefits that are available through the use of POCT depend upon the 
setting in which they are employed, i.e. use for self-testing in primary care or as a directed 
diagnosis routine in secondary care.  In a wider sense, POCT represents an advancement in 
healthcare provision and hence contributes to the realisation of health service reform targets 
within the processes being undertaken by governments globally.  All of these stakeholders share 
a number of many common ambitions, including; improving access, increasing quality of care to 
all sectors of society, reducing costs and becoming more patient-centred (Price, St John 2012). 
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With regard to self-testing, POCT can bring the obvious benefit of self-management of a 
condition by the patient themselves, reducing the requirement for regular visits to a general 
practitioner, saving time and increasing convenience for both the patient and clinician.  
Furthermore, increased education and awareness of a condition can subsequently increase 
adherence to a treatment regime and therefore lead to more effective control of disease or 
condition (Price 2001). 
Much of the established research on the use of POCT in primary care has indicated that it is of 
limited value in terms of improving clinical outcome (Price 2001, Grodzinsky, Wirehn et al. 2004).  
Notwithstanding these limitations, POCT use in primary care has the potential to provide 
benefits in terms of patient satisfaction and organisational efficiencies.  However, the clinical 
outcome benefits of POCT, often arising from an earlier intervention in a time-critical situation, 
are difficult to obtain as these occurrences are much less common in primary care settings 
(Junker, Schlebusch et al. 2010).  As such, it is proposed that quite radical system-level changes 
would be required in order to allow primary care clinicians to take full advantage of the benefits 
that are potentially available through the use of POCT. Many of the issues that need to be 
considered to create this environment relate to workload, reimbursement and clinical 
governance, all of which are more difficult to attain control of in primary care (Turner, Van den 
Bruel et al. 2016).  The rapid TAT associated with POCT can make it an effective and quick rule-
out method for certain conditions thereby negating the need for further tests and shortening 
the length of time to a successful diagnosis.  Overall, it is difficult to gauge whether or not POCT 
can provide a cost-effective solution within primary care, as its success or otherwise is heavily 
influenced by both the health system environment and the particular type of test in question 
(Laurence, Moss et al. 2010). 
In the secondary care setting the intrinsic nature of POCT serves to improve TAT values through 
the reduction of a number of pre- and post-analytical steps such as sample transport, sample 
preparation, data entry and the forwarding of test reports to clinical specialists.  In a hospital 
setting, the use of POCT has therefore a number of consequences, including; quicker clinical 
intervention, improved patient management, reduced hospital length of stay, reduced 
opportunity for pre/post analytical errors and a less invasive test method. 
In the case of a critically ill patient, faster clinical intervention via the improvement in the TAT 
offered by POCT can have a significant impact on the achievement of a successful clinical 
outcome.  This is particularly in the case for a time-critical condition such as acute coronary 
syndrome (ACS) where more rapid intervention can have a major effect on improving morbidity 
and mortality rates.  With traditional testing that utilises the central laboratory service, such a 
patient’s condition, as indicated by analysis of their blood, urine, etc., may have already changed 
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significantly by the time a test result is received, resulting in a possibility of a critical clinical 
decision being made with out-of-date information and hence increasing the risk to the health of 
the patient.  Therefore, the provision of real-time data through the use of POCT is seen as being 
more beneficial clinically despite any potential minor reduction in the analytical capabilities that 
such devices may have in comparison to those utilised in the central laboratory (Harvey 1999).  
Furthermore, the use of POCT during surgery can reduce theatre time and patient blood loss 
through improved test TATs, which then has a subsequent positive effect by way of reduced 
post-operative recovery for the patient (Price 2001).  As a specific example, cardiopulmonary 
bypass patients are at increased risk to excessive perioperative blood loss and subsequently 
there is a possible requirement for blood transfusion.  Blood component administration (i.e. 
heparin anticoagulation) can be used to reduce blood loss and hence minimises the requirement 
for transfusion, however, dosage control of this therapeutic method is an empiric technique 
related to the TAT of laboratory tests.  Rapid POCT devices can be used in this regard to provide 
more targeted and precise administration, hence minimising the potential for blood loss and the 
associated need for transfusion (Despotis, Joist et al. 1997). 
This form of timelier clinical intervention also leads to the subsequent benefit of improved 
patient management, in that it allows for transfer of the patient through the clinical pathway in 
a more efficient manner, hence allowing the clinical institution to be more effective in the 
utilisation of its resources.  POCT has the potential to reduce both the number and complexity 
of the diagnostic tests carried out which can result in a reduction in the requirement for other 
forms of laboratory evaluation.  This can then provide for a more effective use of resources i.e. 
personnel, equipment, clinical space etc. (St-Louis 2000).  Incorporation of POCT into existing 
clinical pathways allows for the rapid progression of the patient when test results lie within an 
expected range.  Also, in the case of an unexpected result, intervention can occur at the earliest 
opportunity (Harvey 1999).  Overcrowding (especially in the ED/R) and prolonged waiting times 
within hospitals have been linked to adverse clinical outcomes in addition to decreased patient 
satisfaction.  Improved patient management through the use of POCT has an obvious role to 
play in addressing such issues (Larsson, Greig-Pylypczuk et al. 2015). 
More effective patient management often results in a reduction in the length of stay in hospital 
for patients.  This is seen as one of the primary advantages of POCT use, particularly in the 
context of the immediate and direct benefits of early intervention (Price 2001).  The benefits of 
a reduction in the length of stay in hospital are twofold, firstly; the levels of patient satisfaction 
will be improved with the more effective management of the clinical episode and, secondly; 
there will be a more effective use of the limited resources available which can result in an 
economic benefit for the clinical institution. 
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Improvement of test TAT values via the reduction in number of steps associated with analytical 
testing can clearly result in a reduced risk of operator error in both the pre- and post-analytical 
phases.  For example, the use of POCT can reduce the risk of placing a specimen within the wrong 
sample tube and/or incorrectly transcribed results (Harvey 1999).  Furthermore, the use of POCT 
negates the requirement for sample transport which, for example in the case of blood gas 
testing, overcomes issues regarding the possibility of induced sample instability that may occur 
during the journey to the central laboratory. 
POCT can often provide diagnostic results using only microlitre volumes of blood, i.e. just a few 
drops, hence making it less invasive.  This carries the obvious benefits to both the patient and 
device operator of convenience and satisfaction.  Furthermore, due to the significant reduction 
in sample volumes required in comparison to Central Laboratory Testing (CLT) methods, the use 
of POCT can reduce the risk of iatrogenic blood loss and associated anaemia, while also 
conserving blood products that potentially would be required for transfusion purposes (St-Louis 
2000).  The use of microlitre sampling volumes has also been shown to both significantly reduce 
the amount of blood lost by a patient thereby removing the requirement for a blood transfusion 
to be administered (Tinmouth, McIntyre et al. 2008).  In terms of safety, POCT methods can also 
reduce the risks involved in contact of patient blood with the device operator (Harvey 1999). 
1.7 Recognised Failings of POCT in Secondary Care 
Despite the benefits and potential for improved clinical outcomes offered by the use of POCT 
devices in secondary (hospital) based healthcare their uptake and use within has not been 
without issue.  First generation POCT devices suffered from a number of problems related to an 
inconsistency in device performance and hence problems in attaining reliable results.  The 
operation of such devices required a relatively large number of steps to be performed and hence 
this introduced the opportunity for user error (Lewandrowski, Gregory et al. 2011).  Clearly, any 
actions that might be taken by a clinician based on an erroneous test result can have severe 
implications, particularly within the secondary critical care setting.  Therefore, these issues had 
a significant impact upon trust and confidence with the use of early POCT devices used for 
diagnostic testing.  The lack of an electronic reporting system and the absence of safeguarding 
controls to ensure operator competency also contributed to the conditions necessary for a 
quality of result to be produced.  One particular concern in this regard was the possibility of 
inappropriate use of the test strip/reagent (Lewandrowski, Gregory et al. 2011). 
The more recent generation of improved POCT devices and their associated diagnostic protocols 
have sought to overcome these issues and hence uptake of these systems has increased.  
However current research indicates that manufacturer expectations for their continued uptake 
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are not being met in a significant proportion of major hospitals in the United States (Loten, Attia 
et al. 2010).  To date, studies have not been able to ascertain the reasons for this less than 
expected growth in the utilisation of POCT devices.  It is possible that the negative clinician 
perceptions of and a lack of confidence in these technologies is still a major underlying factor 
that limits the uptake of POCT.  It is suggested that concerns over the accuracy of the resulting 
data attained in a non-emergency situation have also acted to slow the adoption of POCT 
(Larsson, Greig-Pylypczuk et al. 2015).  While some evidence is provided with respect to 
manufacturer’s expectations, the notion that the uptake of POCT in secondary care is less than 
what was expected moving into the 21st century, as far as clinicians are concerned, is intrinsically 
difficult to provide an evidence base for as no such base of data exists.  
A significant challenge that continues to face the application of POCT in the secondary care 
setting is the provision of a very reliable and accurate diagnostic testing system by way of the 
existing central laboratory service.  Despite the fact that the central laboratory in many ways 
exceeds the actual clinical need, the expectation remains that POCT will replicate this 
performance with a significantly reduced TAT value.  Substantial research has been carried out 
comparing the analytical performance of POCT with that of the equivalent CLT provision and has 
highlighted a variable and/or reduced performance of POCT (Hjortshøj, Venge et al. 2011, Khan, 
Vasquez et al. 2006, Shephard, Whiting 2006, Dommelen, Tiel et al. 2010, Lenters-Westra, 
Slingerland 2009).  It is noted that such variance or reduction in performance has a number of 
possible causes including the use of whole blood as the test sample (rather than determination 
made from serum or plasma) and the use of novel sensing technologies such as electrical 
conductivity as a measurement parameter (St-Louis 2000). 
Whereas, initially it was the technological aspects of POCT that have tended to attract attention, 
currently the emphasis has shifted to how and where it should be applied in order to best attain 
the recognised benefits that it presents.  Therefore, it is being increasingly accepted that 
technological factors alone are no longer the primary underpinning issue with regard to 
explaining the limitations of POCT device uptake within the hospital-based healthcare 
environment.  There have been indications that despite the use of POCT to reduce TAT values 
within secondary care, this hasn’t translated into a positive impact on clinical outcome.  
Research has also found that, within the ED/R environment, the quicker availability of test 
results from POCT has not led to a reduction in admissions or associated length of stay for 
patients.  This therefore suggests that the availability of test results from POCT devices are not 
the principal factor that is restricting the progression of a patient through the care pathway 
(Kendall, Reeves et al. 1998).  Hence, in reality the indication is that the potential benefits 
available through the utilisation of POCT are negated somewhat due to the limited effect of 
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improved TAT values on the overall clinical outcome.  In a broader sense, it is therefore the 
ability of the clinical pathways to take advantage of the improved TAT values that will ultimately 
determine the effectiveness of POCT in practice with respect to workflow and patient care.  
Benefits such as reduced admission and/or length of stay in hospital and the improved clinical 
outcomes are seen as being highly dependent on several factors which vary across healthcare 
settings.  As such, the real-world implementation of POCT is a much more complex process than 
it might at first seem (Larsson, Greig-Pylypczuk et al. 2015).  For example, delays in radiology 
testing have been shown to extend the total length of stay within critical care areas such as the 
ED/R (Miele, Andreoli et al. 2006).  Thus, in these circumstances any improvement in the test 
TAT is negated entirely. 
In this respect, there is an ongoing debate as to the true value of POCT within the secondary 
healthcare system.  In particular, this relates to how it should be integrated within the clinical 
care pathways.  This is in a stark contrast to the broad acceptance of POCT that is apparent in 
the self-testing (primary care or home-based) environment, specifically with regard to blood 
glucose testing for diabetics, INR monitoring for patients receiving anticoagulation therapy, and 
pregnancy/fertility tests.  The successful utilisation of POCT within this sector clearly verifies the 
benefits that this particular type of patient-centric testing can bring with respect to the 
miniaturisation of analytical instrumentation in order to manage a chronic medical condition or 
disease in a more effective manner.  It is therefore apparent that the various factors restricting 
the more widespread adoption of POCT within the clinical environment are not really well 
understood.  Hence, the work reported in this thesis therefore seeks to address the nature and 
scale of the issues that affect POCT uptake and usage in secondary care.  For the purposes of the 
study, such factors are suggested as being barriers to the more widespread uptake of these 
devices.  It is therefore proposed that a better understanding of their origin and source will lead 
to solutions that enable the more effective utilisation of POCT in hospital-based care for the 
direct benefit of patients. 
1.8 Development of the Research Aims & Objectives 
It is widely recognised that the uptake of POCT and, importantly its utilisation within the clinical 
environment, is lower than might be expected.  The nature and relative importance of the issues 
(real or perceived) that have been identified as being possible impediments to the more 
widespread adoption of POCT are not fully understood.  Indeed, much of the information that 
purports to describe the inadequacies of POCT devices would seem to be anecdotal in nature 
with most lacking any form of primary data to back up these claims.  Hence, it is important to 
understand the precise origins of such impediments to POCT uptake in order to enable an 
appropriate assessment of their utility to be undertaken.   
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Thus, the central aim of this research is to better understand and categorise the core issues that 
have been identified as impeding the clinical uptake of POCT in a hospital-based environment, 
i.e. the barriers to adoption.  Furthermore, this research aims to assess these identified 
impediments from a global perspective by considering any role that the nature of the funding of 
the healthcare process (i.e. free at the point of delivery versus insurance based) has on the 
findings.  In doing so, key objectives of the research are: 
• To determine from a systematic review of the academic literature the actual issues that 
affect the adoption of POCT devices within the hospital-based clinical environment; 
• To categorise the issues identified from the literature as a means of understanding in 
detail their relative contribution to adoption of POCT devices in the hospital 
environment;  
• To determine, in order of priority, which issues are currently impacting the adoption of 
POCT devices within the clinical environment; 
• To determine the relationship between those issues identified from a consideration of 
the academic literature and the opinions of clinicians within the UK healthcare 
environment on the same issues; 
• To compare and contrast clinical perspectives (opinions) on those issues that are seen 
as impediments to the uptake of POCT from clinicians working in the UK healthcare 
system, i.e. that is free at the point of delivery, with those in the US system where the 
cost of healthcare provision is insurance-based; 
• To assess how the perception of issues effecting the uptake of POCT, including their 
impact and relevance, varies with respect to the specific clinical role; 
• To determine the global experiences of clinical bioscientists, as the professional group 
most closely aligned to hospital based diagnostic testing, in relation to the identified 
barriers to adoption of POCT; 
• To identify the key advantages and potential benefits of POCT use within secondary 
healthcare; 
• To identify the major disadvantages deemed to result from the use of POCT; 
• To determine the clinical areas/situations in which POCT can provide the most benefit 
in secondary care; 
• To suggest how the most significant barriers to adoption of POCT in the relevant 
secondary healthcare systems can be overcome based on the findings of the studies 
undertaken, i.e. what are the possible solutions that may encourage more effective 
adoption? 
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1.9 Layout of the Thesis 
The research outcomes of this thesis are presented in a total of 8 chapters, including this 
introduction to the work.  Given the nature of the project objectives, Chapter 2 presents the 
Methodology and Chapter 3 the Literature Review.  The decision for this order is based on 2 
important considerations; firstly, primary data on the barriers to adoption of POCT within 
secondary (hospital) care is particularly scarce and so a method to appraise and categorise the 
key areas for consideration from published sources is required prior to undertaking the 
literature review itself and, secondly, since assessment of the available literature will form the 
foundation of the research on clinical opinion of POCT uptake this should be carried out in a 
systematic way and so the findings from the literature review that are presented in Chapter 3, 
are essentially the first of the results chapters.  With this in mind, the overall layout is as follows: 
• Chapter 1 – Introduction to the Research 
• Chapter 2 – Research Methodology 
• Chapter 3 – Systematic Narrative Review of the Published Literature on Barriers to the 
Clinical Adoption of POCT within the Hospital-Based Environment 
• Chapter 4 – Clinical Perspectives on Barriers to Adoption of POCT from within the UK 
National Health Service (NHS)  
• Chapter 5 – Clinical Perspectives on Barriers to Adoption of POCT from within the US 
Health System 
• Chapter 6 – Perspectives on Barriers to Adoption of POCT from within the Global Clinical 
Biosciences Cohort 
• Chapter 7 – Statistical Analysis 
• Chapter 8 – Conclusions and Recommendations for Future Work 
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Chapter 2 
Research Methodology 
2.1 Research Design 
In order to achieve the key objectives of this research, as set out in Chapter 1, a research 
methodology has been adopted that provides for the identification of, and the collection of 
clinical opinion on, barriers to adoption of point-of-care testing (POCT).  The systematic nature 
of the research design is adapted from the model proposed by Saunders, Lewis and Thornhill as 
a means of guiding business research (Saunders, Lewis et al. 2015).  This method is known as 
“the research onion” and represents a means of describing the different layers of a research 
process, as illustrated in Figure 2.1.  Due to its systematic nature, it has a high level of 
adaptability and can be used in a variety of contexts (Bryman 2015).  Working from the outside 
inwards, the model follows a progression by which the research methodology can be designed, 
with each layer representing a more detailed stage of the research process. 
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Strategy 
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Time 
Horizon 
Techniques & 
Procedures 
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Multi Method 
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Research 
Action 
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Case Study 
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Sectional 
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& Data Analysis 
Figure 2.1 – Schematic representation of the Research Onion Model (Saunders, Lewis et al. 
2015). 
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2.2 Research Philosophy 
The research philosophy adopted influences the assumptions that can be made and how data is 
both collected and analysed.  There are various philosophies that may be applied with respect 
to attaining the objectives of a project and hence that which is employed will influence how the 
research will be conducted (Goddard, Melville 2004).  It is therefore important to be aware of 
the philosophy that is being applied and to ensure that it relates directly to the intended aim of 
the research.  A series of 4 core philosophies were considered for the research to be undertaken 
here and the merits of each appraised in the context of how well it can provide for the required 
outcomes to be achieved.   
Positivism uses the natural sciences as a fundamental focus to explain how and why things 
happen through measurement, statistical logic and verification.  It lends itself very much to 
quantifiable observations.  Therefore, a positivist approach will generally involve the collection 
of large data sets that will lead to easily-comparable information.  The key advantage of 
positivism is that there is a clear theoretical focus to the research and this allows for a high 
degree of control of the process.  However, this philosophy can also have significant limitations 
when an understanding of social processes is required and how these can be perceived, 
including the subsequent variation across individuals and associated relationships.  Therefore, 
the positivist philosophy is essentially focused on facts (Wilson 2014).   
The philosophy of interpretivism is focused on understanding using the qualitative tools of the 
social sciences.  As such, it relies on the interaction between a trained researcher and a subject 
as a means of measuring some phenomena, and so typically involves the use of both observation 
and interviews.  Sample numbers tend to be smaller than in a positivist philosophy with 
emphasis more on elucidating a meaning and understanding from the data.  The interpretivist 
philosophy is much more adaptive to change than positivism and allows for circumstances that 
are more complicated and contextual.  However, data collection can be complex and time-
consuming, and there is uncertainty with regard to the findings that may or may not appear as 
a result.  Nevertheless, in the right circumstances it allows for the consideration of how 
individual people differ and hence goes beyond the simple reporting of observable objects 
(Saunders, Lewis et al. 2015).   
In addition to positivism and interpretivism there is also realism and pragmatism.  Realism is 
another scientific philosophy and so can overlap with positivism somewhat.  It is again based on 
data collection and tends to use high sample numbers with the collection process usually highly 
structured.  Realism (specifically critical realism) accepts that deceptions exist and that factors 
may occur between the researcher and subject based on their individual reality.  This approach 
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can influence the relationships between individuals and the wider groups to which they belong, 
thereby providing a way to engage in multi-level research (Novikov, Novikov 2013).   
By comparison, the pragmatic research philosophy is one that overlaps aspects of both 
positivism and interpretivism, with the research question then being central to the design of the 
research tools employed.  Pragmatism recognises that there are many different ways of 
interpreting research findings, that no single point of view can ever give the entire picture and 
that there may be multiple realities that need to be considered (Saunders, Lewis et al. 2015). 
The interface between the natural and social sciences is becoming increasingly blurred within 
healthcare research.  There is now an understanding that user/patient perspectives must be 
considered appropriately when assessing health services and the utilisation of technology within 
such.  For example, it is now recognised that the use of quantitative methods alone, such as 
basic questionnaires, fail to allow for an appropriate qualitative analysis and may miss rich 
insight on participant experience (Kuljis, Money et al. 2016).  Although much of the work to be 
carried out in this research is to be interpretive in nature, a number of the methods employed 
need to be more quantitative in order to progress the research effectively.  Therefore, although 
small sample numbers and qualitative studies may be appropriate in parts of the overall work 
programme, larger numbers and a more quantitative approach are needed to deliver an 
understanding at a more specific level.  Hence, based on these considerations, a pragmatic 
philosophy has been adopted here.   
2.3 Research Approach 
There are 3 main research approaches that can be used to further the objectives of this work; 
deductive, inductive and abductive.  A consideration of the fit of each process to effectively 
deliver the research outcomes of interest here was undertaken.  Deductive research concerns 
creating a hypothesis that is based on a pre-existing theory and subsequently designing research 
to test it (Silverman 2005).  The deductive approach is often employed with a positivist 
philosophy that uses statistical analysis to test the hypotheses by determining if results lie within 
the expected boundaries.   
While the deductive approach is seen as being top-down, the inductive approach works in the 
opposite direction.  This approach utilises observations rather than theory as its starting point, 
wherein data are used to search for patterns and connections.  As a result, there is often no 
framework that defines how data are to be collected, but rather the focus of the research is to 
acquire data that might then subsequently be connected via some theoretical basis (Flick 2011). 
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By comparison, an abductive approach utilises the most likely reasoning that can lead to a 
rational solution (Bryman, Bell 2015).  Hence, the abductive research approach uses 
observations to give the best prediction of a solution to a problem.  
Based on a consideration of these various attributes, the research to be undertaken here will 
utilise an inductive approach in that it uses observations associated with the barriers to adoption 
of hospital-based POCT to determine their relative validity across clinical sectors.  In doing so, 
the primary data obtained will be used to better understand and categorise the various 
contributory issues that have been identified as being impediments to the clinical uptake of 
POCT.  In this way, the research objectives as set out in Chapter 1 will be achieved.  The 
advantage of applying an inductive approach here is that it allows for conclusions to be drawn 
from sometimes incomplete observations. 
2.4 Methodological Choice 
After deciding on the research approach, the next layer of the “research onion” involves the 
determination of the actual types of research methods to be used in order to conduct the 
investigation.  Essentially, this process of research design considers whether qualitative or 
quantitative methods will be used, or if a mixture of both is required.  In this regard, a “mono” 
study will only use the one type of data collection technique, be it quantitative or qualitative 
while a “multi” study uses more than one quantitative or else more than one qualitative 
technique.  A “mixed methods” approach uses both qualitative and quantitative techniques to 
analyse the research data. 
As indicated earlier, quantitative research techniques better lend themselves to studies that 
generate large amounts of data, so that statistical methods of analysis can be used effectively 
(May, 2011).  Qualitative research presents the challenge of the data being defined by the 
number and type of respondents or objects being studied.  A means to control widespread 
variation in the responses received is to use scripted interviews or text questions.  This, coupled 
with targeted open-ended questions that allow the respondent to expand further on the more 
specific information sought, can enhance the scope of the process substantially.  Qualitative 
techniques are often used to study social phenomena (Feilzer 2010) but can also be adapted to 
attain and interpret more specific responses such as clinical opinion. 
Based on these considerations, mixed methods are to be used in this research.  This approach 
provides a number of advantages, in that it fits well with the pragmatic philosophy of this 
research, i.e. allowing the research question to frame how the methodology will develop.  
Secondly, this is a flexible approach that can be applied to a range of stages of a complex 
investigation.  Furthermore, this approach will allow for the comparison to be made of results 
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obtained from studies employing both large and small sample sets.  A mixed methods approach 
has been utilised in healthcare research before, specifically with regards to understanding 
barriers to organisational adoption of technology within the medical sector (Paré, Raymond et 
al. 2014), and hence this choice of method is validated somewhat.  To this end, the mixed 
methods research can be conducted in both a simple or complex manner.  A simple mixed 
methods design involves the use of one type of research technique followed by the other, for 
example an observation study (qualitative) followed by a survey study (quantitative).  As a 
development of this approach, a complex mixed methods design involves using quantitative 
techniques to analyse qualitative data.  For example, quantifying the number of responses in a 
series of interviews that fall within a particular category of answer.  As such, it is this complex 
mixed methods design that will be used in this research.  The advantage of this approach is that 
quantitative data that reflects the point-of-view of participants can be presented in a clear and 
concise manner. 
2.5 Research Strategy 
If required, study design can avail of multiple strategies in order to address the research 
question and so the research should not be limited as such (Saunders, Lewis et al. 2015).  In the 
“research onion” model there are 8 strategies including:  A survey strategy, where structured 
studies can be used to collect large amounts of data from participants, who are often sizeable 
in number. An experimental strategy, to compare results with expected outcomes in cases 
where these are known.  An action strategy, that aims to bring about change using the results 
and findings from the research carried out and that analyses current practices to determine if 
they exist as the most ideal approach.  A case study strategy which, as the name suggests, 
focuses on a particular scenario to draw conclusions, for example to draw generalisations or 
perhaps to determine differences between specific conditions (Bryman 2015, Silverman 2005).  
Grounded theory utilises qualitative data and is frequently used in the field of social sciences 
research (Bryman 2015).  This strategy does not use preconceived theories to determine the 
research but instead uses the research question to define the methodology (and so is often used 
within the pragmatic philosophy).  As such, grounded theory investigates actualities in the real 
world and analyses these without any preconceptions.  This is often achieved through the use 
of interview survey studies (Allan 2003).  Ethnography focuses on the study of people or 
cultures, where the researcher takes the point of view of the subject that they are studying.  A 
close observation of individuals or societies can aid understanding of cultural relations and 
perspectives (Bryman 2015).  An archival research strategy involves the use of existing materials 
to conduct research and form conclusions (Flick 2011).  For example, this may be through the 
application of a systematic literature review, i.e. using previous bodies of information to collate 
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data and analyse it appropriately.  The final research strategy here is the narrative inquiry 
strategy which utilises qualitative information such as letters, autobiographies, conversations, 
interviews, etc. to understand how individuals can create meaning and understanding through 
previous narratives (Clandinin, Connelly 1999). 
Based on these considerations, multiple strategies will be implemented in this research in order 
to meet the objectives as defined in Chapter 1.  An archival research strategy will be employed 
in order to fully understand and categorise the indicated barriers to adoption of POCT within 
the relevant knowledge base.  Both survey and grounded theory strategies will be used to collect 
data from clinical professionals participating in the study, which aligns well with the pragmatic 
philosophy employed.  These strategies will be used to attain the opinion of the clinicians with 
respect to adoption and utilisation of POCT.  Furthermore, since a solutions-based approach is 
underlying this research it is therefore hoped that findings can be used to stimulate action within 
the relevant healthcare bodies and device industry in regard to how POCT is employed, and 
hence an action research strategy is also required here.   
2.6 Time Horizon 
The time horizon for the research simply refers to the period over which the research is 
concerned.  A cross-sectional perspective provides a snapshot of a situation at a given time.  
Hence, it will report in the context of how phenomena exist at a certain point of time or over a 
specified period.  For example, a longitudinal time horizon involves data being collected over a 
significant time frame and can hence be used to assess changes over this period (Goddard, 
Melville 2004).  Although this research will involve archival research over an extended period of 
time through the application of a systematic literature review, the primary survey-based 
research to be carried out will be cross-sectional in nature.  This approach will allow for the 
primary research findings to be compared to those issues deemed to be impeding the 
implementation of POCT within hospitals as determined from consideration of the published 
literature over an extended period. Hence, solutions to overcoming these barriers can be 
developed in terms of the experience of those who use them directly. 
2.7 Techniques & Procedures 
The core of the research onion model considers the techniques and procedures to be used to 
collect the data required to conduct the research investigation.  In the context of this work, the 
initial step in devising solutions to overcoming the barriers to adoption of POCT is to firstly fully 
understand the barriers that have been identified by experts in the field.  Therefore, a systematic 
literature review will be carried out in order to frame and collate the types of barrier concerned.  
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This information will be used to develop the survey tools needed to attain the data for analysis 
that form the foundations of the research process. 
The primary data needed to obtain a cross-sectional snapshot of the current situation regarding 
the uptake of POCT will be facilitated by a set of well-defined survey tools.  These will be used 
to acquire primary data from healthcare clinicians through both face-to-face interviews and on-
line questionnaires.  By way of following the pragmatic philosophy of this research, the 
secondary data gathered by the systematic literature review will be used to frame the on-line 
survey and interview studies so that they can directly attain the key primary data needed.  The 
complex mixed methods approach leads to the choice of both survey and interview studies.  
While the survey studies will be used to increase participation and hence achieve the required 
sample numbers, the interview studies will be used to accumulate vital qualitative information 
in order to add value to the quantitative data collected through the surveys. 
It is recognised that employing 2 methods of data collection gives rise to the potential that each 
method could influence participant response to the survey.  A main advantage of online survey 
tools is that interviewer effects are avoided (Duffy, Smith et al. 2005) and hence there can be 
no interviewer influence and/or bias affecting participant response.  However, a serious issue 
with online survey studies is the methodical difficulties in determining population and random 
samples (Dillman, Bowker 1999).  For the purpose of this piece of research, both streams of data 
are to be analysed as being the same, with neither stream being afforded a stronger weighting 
of value over the other in terms of the responses given.  However, the face-to-face aspect will 
allow for more detailed explanation of certain responses, in which some specific pieces of 
information of high value can be collected.  In order to ensure the 2 streams of data can be 
considered as a uniform data set an appropriately managed assessment of the survey responses 
collected by the study through both channels is to be undertaken.  This process of analysis is 
required in order to determine if these data can be amalgamated with sufficient integrity, with 
the distribution of scaled responses to be analysed and compared appropriately.  
Quantitative methods will be used to analyse the qualitative data in order to identify key trends 
in the data.  These techniques are expected to accommodate the solutions-based ideology of 
this research and allow for conclusions to be derived that will enhance POCT utility in hospital-
based healthcare.  This reflects the inductive approach of the research with the observations 
made forming the foundation for key patterns/connections to be identified accordingly. 
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2.8 Realisation of Research Objectives 
The methods employed by this research must directly act to achieve the research objectives as 
described in Chapter 1.  A brief summary of how the methodology developed will attain such 
targets is described here: 
• To determine from a systematic review of the academic literature the actual issues that 
affect the adoption of POCT devices within the hospital-based clinical environment; 
• To categorise the issues identified from the literature as a means of understanding in 
detail their relative contribution to adoption of POCT devices in the hospital 
environment;  
• To determine, in order of priority, which issues are currently impacting the adoption of 
POCT devices within the clinical environment; 
The first 3 research objectives are serviced by a longitudinal time horizon as a means of 
identifying and understanding the barriers to adoption of POCT that have been raised by experts 
in the sector throughout this century.  A systematic review of the relevant academic literature 
is to be implemented to identify and subsequently categorise such issues.  An assessment of 
frequency, in terms of citation within the relevant knowledge base evaluated, will be used to 
attain a measure of priority (in terms of current impact upon adoption) that issues hold. 
• To determine the relationship between those issues identified from a consideration of 
the academic literature and the opinions of clinicians within the UK healthcare 
environment on the same issues; 
Primary data will be attained through the use of survey studies based upon the findings and 
assessment of the systematic literature review.  The first of which, executed with a sample of 
UK clinicians, will be used to validate findings and add a cross-sectional dimension to the time 
horizon of the research, providing insight into the current situation with respect to clinical 
opinion on barriers to uptake.  The purpose of this study is to determine which barriers identified 
within the literature exist in reality (at least within the UK NHS) and which are perhaps historical 
barriers that have been fully or partly resolved.  Furthermore, the primary data will be used to 
validate and help determine the order of priority in terms of current impact upon POCT 
adoption, as addressed by the third research objective above.  Mixed methods are to be 
exploited through the primary data collection of the research, using both face-to-face interviews 
and an online survey tool to both attain detailed narrative on responses whilst maintaining a 
maximum level of clinical participation. 
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• To compare and contrast clinical perspectives (opinions) on those issues that are seen 
as impediments to the uptake of POCT from clinicians working in the UK healthcare 
system, i.e. that is free at the point of delivery, with those in the US system where the 
cost of healthcare provision is insurance-based; 
The UK study will be replicated almost identically within a sample of the US health system as a 
means of achieving this research objective.  Again, this will be a cross-sectional study.  The face-
to-face aspect of the study design is to be maintained in order to preserve the rich information 
available through this method of execution.  Findings of this study will be subsequently mapped 
onto the findings of the previous clinical study as a means of identifying similarities and any 
discrepancies between the primary data sets gathered. 
• To assess how the perception of issues effecting the uptake of POCT, including their 
impact and relevance, varies with respect to the specific clinical role; 
• To determine the global experiences of clinical bioscientists, as the professional group 
most closely aligned to hospital based diagnostic testing, in relation to the identified 
barriers to adoption of POCT; 
As with the previous 2 primary studies, a third (almost identical) study, again based principally 
upon the findings of the systematic literature review study, is to be executed with the aim of 
satisfying these 2 objectives of the research.  As the previous study investigates the influence of 
underlying healthcare model it is important that this 3rd study will negate such influences (if 
indeed, they do exist).  As a result, this study is to be executed internationally by means of an 
electronic survey tool.  This also carries the benefit of allowing maximum participation. 
• To identify the key advantages and potential benefits of POCT use within secondary 
healthcare; 
• To identify the major disadvantages deemed to result from the use of POCT; 
• To determine the clinical areas/situations in which POCT can provide the most benefit 
in secondary care; 
• To suggest how the most significant barriers to adoption of POCT in the relevant 
secondary healthcare systems can be overcome based on the findings of the studies 
undertaken, i.e. what are the possible solutions that may encourage more effective 
adoption? 
While the 3 primary studies will be implemented to meet the research objectives as described 
above, all 3 will be designed in such a way that the findings of each can be amalgamated and 
assessed as a mean of achieving the final 4 objectives, as noted here.  Primary data will be 
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collected in order to make an assessment on the key advantages/benefits and disadvantages of 
POCT, along with the clinical areas in which most benefit can be realised.  Finally, the primary 
data will be used to make recommendations as to how the most significant barriers to hospital-
based uptake of POCT can be potentially overcome. 
In order to clarify findings somewhat, inferential statistics will be applied, where relevant, to the 
study responses.  The association of categorical variables and the comparison of opinions 
between response groups will be statistically analysed using the Chi-square test and the 
calculation of odds ratios with 95% confidence intervals.  Calculation of p-values using the Chi-
square test will allow for the testing of a specific null hypothesis; a significant p-value (i.e. < 0.05) 
rejects the null hypothesis and, in doing so, answers 2 questions; what do the response results 
tell me about the population? And, what are the strength of such results?  An odds ratio can be 
used to compare the responses of various groups, by dividing the odds of an event happening 
in one group by the odds of an event happening in the other.  If there is no difference in odds, 
then of course the odds ratio would be 1.  95% confidence intervals can be applied to provide a 
guidance on the true odds ratio; that the figure would lie within this interval 95% of the time.  
Inferential statistics will be applied to clarify differences in responses, if any, potentially 
influenced by specific clinical role by analysing the responses from the different clinical groups 
within the primary studies.  Furthermore, such methods will be applied, where appropriate, in 
a comparison of response profiles of the investigated study groups, i.e. UK vs US clinicians and 
Clinicians vs Clinical Bioscientists. 
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Chapter 3 
Systematic Narrative Review of the Published Literature on 
Barriers to the Clinical Adoption of POCT within the Hospital-
Based Environment 
3.1 Study Objective 
Advances in science and technology continue to play an integral role in the provision of effective 
healthcare.  A detailed understanding of the pathologies and/or genetic disorders that give rise 
to various medical conditions is critical for the provision of appropriate and timely treatment.  
The benefits offered by new (and improved) diagnostic technologies for the management of 
diseases and attendant medical conditions are well established (Murray 1996, Fitzsimons, Sun 
et al. 2007, Rosenson 2010, Khan, Aurigemma 2012).  However, it can be argued that the 
expense associated with their introduction is a significant factor in the continuing year-on-year 
increases in the cost of healthcare (Herndon, Hwang et al. 2007, Goyen, Debatin 2009, St John, 
Price 2013).  Hence, it is clear that an assessment of the true utility of diagnostic testing 
platforms needs to be fully considered in an effective cost-benefit context.  This is particularly 
the case for emerging technologies such as Point-of-Care Testing (POCT). 
A major consideration for the realisation of global health reform targets is the timely delivery of 
advances in research, i.e. early adoption.  A number of factors have been demonstrated to cause 
significant variation in the speed of adoption of innovative healthcare processes and associated 
improved patient outcomes.  Such challenges are pertinent to even the most technologically 
advanced countries (Chassin, Galvin 1998, Schuster, McGlynn et al. 1998, Kohn 2000, Ferlie, 
Shortell 2001).  Recent advances in sensor technologies and biomarker development have 
allowed clinical diagnostic testing to be moved closer to the patient and to be used outside of 
the traditional central laboratory setting, leading to the development of a real need for POCT.  
The use of POCT is attractive because, theoretically, it permits immediate access to test results 
for the effective management of patients.  It also purports to reduce the Turn Around Time (TAT) 
for laboratory analysis data to reach the clinician by eliminating some of the pre-analytical 
requirements, e.g. sample transport, sample preparation (centrifugation, separation, etc.) and 
post-analytical steps, e.g. data entry and forwarding of the test reports.  The need to reduce the 
TAT of laboratory tests is not new and has been addressed (at least in part) over a number of 
years by the use of augmentations to central laboratory test regimes such as dedicated 
pneumatic sampling systems, on-site phlebotomists, satellite laboratories, robotic transport 
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mechanisms, automated laboratory equipment and computerised information retrieval and 
reporting systems.  Notwithstanding these significant advances, the need for rapid whole-blood 
and/or urine testing that is close to the patient site is still very real.  The development of more 
sophisticated POCT devices for measuring an increasing range of analytes and the associated 
enhancement in their sensitivity and selectivity has added additional pressures to have the latest 
diagnostic systems as widely available as possible, especially outside of major trauma centres 
(St-Louis 2000, Altieri, Camarca 2001, Yager, Domingo et al. 2008, Willmott, Arrowsmith 2010, 
Price, St John et al. 2010, St John 2010).  In this respect, there is significant debate amongst 
stakeholders within the healthcare sector with regard to the real value of POCT.  Specifically, 
even though there have been major advances in the diagnostic technologies that underpin POCT 
device utility, this has not lead to their uptake within the hospital sector at the levels that might 
have been expected (Loten, Attia et al. 2010). 
The nature and relative importance of the various barriers (real and/or perceived) that have 
been identified as impeding the more widespread adoption of POCT in the clinical environment 
are not well understood.  Current areas of controversy seem to stem from contrasting opinions 
regarding the clinical value of the data derived from POCT devices and how it is recorded and 
integrated within the care pathway.  At one end of the scale, engineering and related 
improvements have led to claims that the devices are “fool-proof”, i.e. they can be used without 
the need for device specific quality measures or structured training.  At the other end, there is 
a strongly held belief that the quality control requirements for data emanating from POCT 
devices should be exactly the same as that required for central laboratory equipment (Tirimacco, 
Tate et al. 2010).  This range of opinion is not limited to the quality control in POCT but rather 
covers all areas where a direct comparison can be made between POCT and Central Laboratory 
Testing (CLT) services that have become synonymous with barriers to adoption of POCT. 
As might be expected, the prevalence of published works that use the term “point-of-care 
testing” as a key search term is high, e.g. the Medline bibliographic database returned 1816 
results.  Interestingly, 1688 of these 1816 records (93%) were published from 2000 until 2015, 
with the remainder published between 1991 and 1999.  Hence, increased research has been 
undertaken within the subject area in recent years as health services globally have placed an 
increasing focus on improving the quality of patient care.  In this respect, many articles that 
focus on POCT speak of the advantages which are possible to achieve with these near patient 
technologies and the great potential of such systems to enhance healthcare.  Whereas a 
significant number of the published works consider the barriers to the implementation of POCT, 
few provide suggestions as to how these can be overcome (or indeed avoided).  Clearly, to 
provide solutions to enable the effective clinical implementation of POCT, it is necessary to first 
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fully understand the nature of the barriers concerned.  A key task in this regard is the collation 
of specific concerns raised by experts in the field.  It is therefore the objective of this study to 
identify, categorise and critically evaluate the known barriers to clinical implementation of POCT 
through a detailed assessment of relevant literature on the topic in the period 2000 to 2015.  It 
is noted that in a review such as this, contrasting opinions may be found especially between 
clinicians who practice within different healthcare systems (e.g. those that operate in the UK, 
USA and Europe).  This is important due to the differences in the healthcare systems and 
associated variances in regulatory structures as well as the prevailing financial models for 
reimbursement.  Therefore, this literature review provides an overview of the various barriers 
to adoption of POCT within the hospital-based clinical environment, without focusing on any 
specific healthcare system in particular. 
3.2 Study Development & Design 
An expansion in the volume and types of information that have been published on POCT in 
recent years, together with the increasing complexity of interrelated branches of the associated 
knowledge base, spanning biomarkers and microfluidics to health economics and social science, 
dictates the need for a systematic search approach and a structured appraisal of previously 
published research (Taylor 2003).  Hence, the methodology employed here has been adapted 
from that used for systematic review of healthcare interventions (Higgins, Green 2011) as 
follows: 
• Definition of the search question(s). 
• Construction of the search formula. 
• Specification of inclusion/exclusion criteria. 
• Identification of relevant bibliographic databases and associated search engines. 
• Operation of search formula on selected databases and search engines and the 
application of the inclusion/exclusion criteria to filter results. 
• Supplementary searches undertaken based on reference lists from all of the literature 
obtained. 
Hence, barriers to the adoption of POCT in clinical practice form the basis of the central search 
question.  Identification and categorisation of these issues is then the first step in the process of 
understanding their origin (real or perceived).  Whereas search terms should be focused in order 
to identify specific barriers and avoid the capture of superfluous information, they should still 
be broad enough in scope to attain all of the relevant published data.  To this end, the search 
process employed here was based on that suggested by Taylor (Taylor 2003) and incorporates 
standard Boolean algebra to convert the search question into targeted concept groups.  The 
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number of terms contained within the concept groups was “fine-tuned” by performing trial 
searches on some relevant bibliographic databases in order to gauge the levels of relevant 
literature items being returned from the search process.  The concept groups devised in this way 
generated the following core search formula: 
(barrier OR obstacle OR impediment OR disadvantage OR prevention OR problem OR 
issue) 
AND 
(adoption OR uptake OR acceptance OR usage OR approval OR utilisation OR utilization 
OR success) 
AND 
("point of care" OR poct OR "near patient" OR npt) 
AND 
(technology OR device OR machine OR instrument OR apparatus) 
Importantly, this formula was utilised to search the entire text of the published papers within 
the selected databases. 
For the purposes of this study, POCT refers to any assay or diagnostic test performed outside 
the central laboratory in a hospital (excluding radiology).  Inclusion/exclusion criteria were used 
to identify relevant literature sources and to qualify the associated information within the 
search results returned.  To be included in the study, papers had to focus on diagnostic POCT 
used within the clinical environment and so any articles focusing specifically on home use and/or 
self-testing have been omitted, along with any literature with a specific emphasis on such testing 
performed within the remit of primary care.  Papers reporting the use of non-diagnostic POCT 
devices, e.g. Personal Digital Assistants (PDAs) or other phone or tablet-based decision support 
systems providing a link to clinical knowledge bases were also omitted.  All of the papers 
selected were limited to those published in the English language.  Furthermore, to be included 
papers must have been published in the period January 2000 to December 2015 which reflects 
the period when there was a significant expansion in the published literature produced within 
the subject area. 
This search protocol was then applied to a set of 6 electronic databases, namely; Medline, 
Compendex, Inspec, Web of Science, Technology Research Database and PubMed.  In order to 
evaluate the usefulness of each database, the sensitivity and precision of the searches were 
calculated.  The sensitivity of a particular database search to returning relevant information was 
calculated by taking the number of relevant articles by an individual database and dividing it by 
the total number of relevant articles obtained from all 6 database searches (after removal of 
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duplicates).  The higher the sensitivity of a database search, the larger the quantity of relevant 
literature returned.  Likewise, the precision of each database was determined as a measure of 
relevant articles returned divided by the total number of hits obtained from that particular 
database search.  As such, this represents an evaluation of the ability of a database to avoid 
returning irrelevant items and is essentially a measure of the predictive value of a particular 
database search.  Although a higher sensitivity is more beneficial, ideally a balance between 
sensitivity and precision is required in order to return a more manageable set of search results 
for assessment. 
The searches of the main databases were supplemented using the “Google Scholar” web-based 
search engine.  Due to the more simplistic nature of this web interface (and its associated 
limitations) the search formula was modified such that only the first concept group was used to 
access papers, as follows: 
(barrier OR obstacle OR impediment OR disadvantage OR prevention OR problem OR 
issue) 
AND 
“point of care” 
*Note:  This formula was applied to search only the titles of articles. 
Once the searches of 6 electronic databases was carried out and relevant papers identified, full 
text copies of each were obtained for systematic review within the study.  In order to 
supplement the review further, the reference lists provided within each of the articles was 
reviewed in full to identify other valuable papers within the field that may have been missed by 
the search process.  The references cited within the latter group of publications were also 
searched as a final phase of the search process. 
3.3 Study Results  
Outputs from the structured searches carried out on each of the 6 electronic bibliographic 
databases and the Google Scholar web search engine are shown in Table 3.1 in respect of 
number of hits, relevance of hits, sensitivity and precision.  Overall, the total number of relevant 
hits returned from the combined searches was 31 after the removal of duplicates.  
In addition, 24 papers of significant value were identified from the reference lists of the 31 
papers returned from the database searches that met the inclusion criteria obtainable.  A further 
10 publications were found in the reference lists of this additional set of papers, giving a final 
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total of 65 papers meeting the inclusion criteria.  After removal of 2 papers for which a full text 
copy could not be sourced, 63 key articles were subsequently assessed in detail. 
As indicated in Table 3.1, in terms of sensitivity and precision, 3 of the databases searched 
performed well in the study, while the other 3 performed quite poorly.  Medline demonstrated 
the highest level of sensitivity, returning 17 of the 31 (55%) relevant hits from the initial search, 
which translated into a precision of 8%.  Web of Science also provided a precision of 8%, 
however, it had a lower sensitivity of 35% by comparison.  PubMed was next best in terms of 
sensitivity, providing a value of 23% and a precision of 7%.  The inclusion of Medline, Web of 
Science and PubMed in the top 3 is perhaps unsurprising given their respective focus on 
medicine and life sciences as opposed to the emphasis on engineering, science and technology 
in the other 3 databases; Compendex, Inspec and the Technology Research Database.  It should 
also be noted there was a significant degree of overlap between the higher performing 
databases. 
Table 3.1 – Literature review search sensitivity and precision results by database. 
Database Total Hits Relevant Hits Sensitivity Precision 
Medline 218 18 55% 8% 
Compendex 209 2 6% 1% 
Inspec 83 4 13% 5% 
Web of Science 136 11 35% 8% 
Technology Research Database 83 1 3% 1% 
PubMed 99 7 23% 7% 
Google Scholar 53 7 23% 13% 
Based on a detailed assessment of the topics reported in each the 63 articles utilised in the 
study, 4 distinct categories of barrier to clinical adoption of POCT devices were identified, as 
follows: 
• Economic issues. 
• Quality assurance & regulatory issues. 
• Device performance & data management issues. 
• Staff & operational issues. 
The allocation of each of the articles to these categories is provided in Table 3.2. 
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Table 3.2 – Categorisation of articles assessed within the literature review process by barrier to 
POCT adoption. 
Barrier Category References Total % of 
Assessed 
Articles 
Economic issues. (Zydron, Woodworth et al. 2011, St-
Louis 2000, Vashist, Luppa et al. 
2015, Pearson 2006, Nichols 2003, 
Nichols 2005, Rajendran, Rayman 
2014, Migliore, Ratti et al. 2009, 
Price 2001, Huckle 2006, Melo, 
Clark et al. 2011, Price 2002, Huckle 
2008, Foster, Despotis et al. 2001, 
Huckle 2010, McNerney, Daley 
2011, Hortin 2005, Crook 2000, 
Creed 2001, FitzGibbon, Huckle et 
al. 2010b, Louie, Tang et al. 2000, 
FitzGibbon, Huckle et al. 2010a, 
FitzGibbon, Brown et al. 2007, 
Halpern 2000, Linder 2007, 
Boonlert, Lolekha et al. 2003, 
FitzGibbon, Huckle et al. 2011, 
Fermann, Suyama 2002, 
Lewandrowski, Flood et al. 2008, 
Gregory, Lewandrowski 2009, Blick 
2001, Lee-Lewandrowski, 
Lewandrowski 2009, Lee-
Lewandrowski, Corboy et al. 2003, 
Goodwin 2008, Lee-Lewandrowski, 
Lewandrowski 2001, Dhawan, 
Heetderks et al. 2015, Giuliano, 
Grant 2002, Freedman 2002, 
Cvitkovic 2011, Lee, Shin et al. 
2011) 
40 63% 
Quality assurance & regulatory 
issues. 
(St-Louis 2000, Vashist, Luppa et al. 
2015, Tantra, van Heeren 2013, 
Plerhoples, Zwemer et al. 2004, 
Pearson 2006, O'Kane, McManus et 
al. 2011, Nichols 2003, Nichols 
2005, Rajendran, Rayman 2014, 
Kiechle, Main 2000, Murray, 
Fitzmaurice et al. 2004, Price, Kricka 
2007, Huckle 2006, Melo, Clark et 
al. 2011, Meier, Jones 2005, Huckle 
2008, Huckle 2010, McNerney, 
41 65% 
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Daley 2011, Crook 2000, Creed 
2001, FitzGibbon, Huckle et al. 
2010b, Luppa, Müller et al. 2011, 
Louie, Tang et al. 2000, FitzGibbon, 
Huckle et al. 2010a, Briggs, Kimber 
et al. 2012, FitzGibbon, Brown et al. 
2007, Halpern 2000, FitzGibbon, 
Meenan et al. 2007, Linder 2007, 
Boonlert, Lolekha et al. 2003, 
Groves 2005, FitzGibbon, Huckle et 
al. 2011, Fermann, Suyama 2002, 
Lewandrowski, Flood et al. 2008, 
Gregory, Lewandrowski 2009, Lee-
Lewandrowski, Lewandrowski 2009, 
Lee-Lewandrowski, Corboy et al. 
2003, Lee-Lewandrowski, 
Lewandrowski 2001, Giuliano, 
Grant 2002, Cvitkovic 2011, Lee, 
Shin et al. 2011) 
Device performance & data 
management issues. 
(Zydron, Woodworth et al. 2011, 
You, Chung et al. 2013, Swayze, 
Rich 2012, St-Louis 2000, Vashist, 
Luppa et al. 2015, Shephard 2011, 
Sheikholeslam, Pritzker et al. 2011, 
Perry, Fitzmaurice et al. 2010, 
Nichols 2003, Knaebel, Irvin et al. 
2013, Nichols 2005, Rebel, Rice et 
al. 2012, Rajendran, Rayman 2014, 
Kiechle, Main 2000, Murray, 
Fitzmaurice et al. 2004, Melo, Clark 
et al. 2011, Meier, Jones 2005, 
Huckle 2008, Huckle 2010, Crook 
2000, Carraro, Plebani 2009, Louie, 
Tang et al. 2000, FitzGibbon, Huckle 
et al. 2010, FitzGibbon, Brown et al. 
2007, Halpern 2000, Linder 2007, 
Groves 2005, Fermann, Suyama 
2002, Gregory, Lewandrowski 2009, 
Blick 2001, Goodwin 2008, Lee-
Lewandrowski, Lewandrowski 2001, 
Dewsnap, Mcowan 2006, Cvitkovic 
2011) 
34 54% 
Staff & operational issues. (Zydron, Woodworth et al. 2011, 
Pearson 2006, Price, Kricka 2007, 
Price 2001, Price 2002, Huckle 
2008, Foster, Despotis et al. 2001, 
18 29% 
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Huckle 2010, Crook 2000, 
FitzGibbon, Brown et al. 2007, 
Halpern 2000, FitzGibbon, Meenan 
et al. 2007, FitzGibbon, Huckle et al. 
2011, Fermann, Suyama 2002, Blick 
2001, Lee-Lewandrowski, 
Lewandrowski 2001, Giuliano, 
Grant 2002, Freedman 2002) 
No specific barriers identified. (Kodogiannis 2013, Kitchen, Kitchen 
et al. 2012, Myers, Browne 2007) 
3 5% 
It should be noted that 3 of the 63 papers assessed were categorised as having been identified 
against no specific barriers to POCT adoption. Despite meeting all the set criteria, these articles 
tended to focus on the positive impact which the implementation of POCT can bring, rather than 
on any particular impediments to their adoption within the clinical environment. 
Of the 63 articles reviewed, 15 (24%) were produced as an output from original research that 
provides results from a survey or a clinical study while the remaining 48 (76%) were either expert 
opinion-based papers or review articles.  Overall 59 (94%) of the sources were journal articles, 
4 of which were published in online only journals and, in total, 58 were published in peer 
reviewed journals.  Of the remainder, 2 were book chapters and 2 were sourced from published 
conference proceedings.  For the purposes of this investigation the original research, expert 
opinion pieces and review articles have all been taken as being of equal importance without any 
application of a “hierarchy of evidence”.  While the value of more rigorous research 
methodologies and/or structures is recognised here, the rationale for this was to take all 
available evidence and systematically assess the entire body of work available in order to 
develop a pool of information upon which to base a primary study to validate such.  A lack of 
primary research investigating the barriers to adoption of POCT exists, which is a driving factor 
in the development of this research, hence making it difficult to differentiate existing work based 
on a hierarchical level of importance. However, for completeness, a brief discussion of the 
findings of the original research subset has been included. 
3.4 Discussion 
Each of the categories of barrier to adoption of POCT defined herein was assessed with regard 
to the key issues considered within the relevant published works as outlined below.   
3.4.1 Economic Issues 
The set of 40 articles reviewed in respect to economic issues indicated that, at varying levels, 
circumstances of this nature were directly impacting on the adoption of POCT in an adverse 
manner within the clinical environment.  Whereas 8 of these works alluded to economic 
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impediments in a non-specific sense, the remaining articles were found to focus on 5 specific 
issues: 
1. The cost per test of POCT is higher than that of traditional CLT. 
When considered on a simple test-by-test basis, traditional batch testing methods offered by 
central laboratory facilities are generally found to be less expensive than POCT (St-Louis 2000, 
Vashist, Luppa et al. 2015, Price 2001, Huckle 2006, Price 2002, Huckle 2008, Crook 2000, Creed 
2001, FitzGibbon, Huckle et al. 2010, Lewandrowski, Flood et al. 2008, Lee-Lewandrowski, 
Lewandrowski 2009, Lee-Lewandrowski, Corboy et al. 2003, Goodwin 2008, Cvitkovic 2011, Lee, 
Shin et al. 2011).  In large measure this is deemed to be due to the disposable nature of POCT 
technologies and how this affects consumable costs.  For example, St-Louis (St-Louis 2000) 
reports evidence that POCT costs for glucose and for blood gas/electrolyte testing have been 
calculated to be 1.1 to 4.6 times that of the equivalent CLT.  15 of the 63 assessed articles (24%) 
made reference to this particular issue which indicates its level of significance.  Hence, for many 
stakeholders within the healthcare sector, a simple head-to-head cost analysis indicates a higher 
per test cost of POCT and is therefore seen as a major issue in the justification of their adoption.  
A previous survey of clinicians and nurses found that 80% of respondents either “strongly 
agreed” or “agreed” that the cost per test of point-of-care devices acted as a barrier to the 
adoption of such devices for cardiac marker measurement (FitzGibbon, Huckle et al. 2010).  In 
the same investigation, a survey of laboratory scientists found that 65% of respondents either 
“strongly agreed” or “agreed” with the same statement.  Conversely, 7 of the assessed articles 
(St-Louis 2000, Creed 2001, Goodwin 2008, Huckle 2008, Lewandrowski, Flood et al. 2008, Lee-
Lewandrowski, Lewandrowski 2009, Lee-Lewandrowski, Corboy et al. 2003) allude to the fact 
that this type of simple financial analysis is not a sufficient means for assessment of the true 
value of a POCT system.  It is argued that apparent gains, such as improved quality of care for 
patients, reduced length-of-stay in hospitals, improved test TATs, etc. are not adequately 
represented in such an approach.   
2. The cost-effectiveness of a POCT system is difficult to gauge and cost comparison 
studies against traditional CLT methods are complex. 
When considering the potential gains that are obtainable through the use of POCT technologies, 
a significant difficulty lies in placing a specific financial value on the benefits which may be 
realised over a longer time scale (Fermann, Suyama 2002, Goodwin 2008, Lewandrowski, Flood 
et al. 2008, Lee-Lewandrowski, Lewandrowski 2009, Lee-Lewandrowski, Corboy et al. 2003, Lee-
Lewandrowski, Lewandrowski 2001).  In particular, overall economic savings from POCT are not 
as immediately apparent as those of laboratory-based batch testing and therefore performing 
cost comparisons can be challenging.  Furthermore, Hortin (Hortin 2005) indicates that 
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perspective plays a major role in determining the cost-effectiveness of POCT and is specifically 
dependant on the opinion of the representation of labour costs and the allocation of personnel 
time as a result of the use of POCT.  Conducting an adequate cost-effectiveness study on a POCT 
system is complex (Zydron, Woodworth et al. 2011, St-Louis 2000, Rajendran, Rayman 2014, 
Foster, Despotis et al. 2001) and historically a wide range of evaluation methods have been used 
in an attempt to accomplish this which has made any direct comparison of results difficult 
(Giuliano, Grant 2002).  It is also stated that, in most instances, the primary cost justification for 
POCT is based on the assumption that “time is money” which makes the application of precise 
cost-effectiveness studies difficult (Foster, Despotis et al. 2001).  Debate is growing with respect 
to the cost-effectiveness of POCT and arguments exist on either side with some being of the 
opinion that it is more expensive than CLT, while others are of the belief that it is cheaper than 
CLT.  Some of the latter opinion suggests that it is more expensive but brings other benefits such 
as reduced patient length of stay (Louie, Tang et al. 2000). 
Of the articles assessed, 6 also indicate that outcome measures and the costs of POCT are often 
location-specific which adds to the difficulties in making comparisons across multiple sites 
(Zydron, Woodworth et al. 2011, St-Louis 2000, Foster, Despotis et al. 2001, Crook 2000, Lee-
Lewandrowski, Lewandrowski 2001, Nichols 2005).  Therefore, it is difficult for an organisation 
to follow any sort of standardised approach in justifying a POCT system, as due to a lack of 
reliable outcome data, no such robust approach to their assessment exists. 
3. The initial costs of implementing a POCT system can be high. 
There are considerable direct and indirect costs associated with implementing any new system 
within a clinical environment, and in this respect a POCT system is no different (Lee-
Lewandrowski, Lewandrowski 2009, Zydron, Woodworth et al. 2011).  In times of reduced 
budgets across the healthcare sector, the difficulties in justifying such a system become even 
greater.  It has been stated in the relevant literature that if the central laboratory is unable to 
carry out tests away from their normal environment, then the implementation of a POCT system 
almost certainly will be more expensive than the cost of performing more tests in a central 
facility (Foster, Despotis et al. 2001).  Even if certain tests currently offered by central services 
were to be removed there would still need to be a period of overlap when both standard CLT 
and POCT are being carried out which will then incur increased costs, at least on a temporary 
basis. 
In the case of POCT, direct costs include the purchase or lease of new instruments along with 
consumables such as the disposable test substrates and reagents, etc., while indirect costs relate 
to training of staff, quality assurance, etc.  The increased complexity of devices and their 
multiplex operations can lead to extensive (and expensive) indirect costs such as training and 
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competency assessment (Vashist, Luppa et al. 2015).  However, other operational aspects, such 
as information technology (IT) connectivity, also need to be taken into consideration when 
calculating the true cost of implementation (Nichols 2003, Boonlert, Lolekha et al. 2003, Blick 
2001).  For example, it is estimated that the IT connectivity costs for cardiac marker POCT 
devices could be as high as £20,000 per centre (FitzGibbon, Huckle et al. 2010).   
A further issue resulting from POCT implementation is that of increased testing, i.e. their 
availability may lead to a rise in the number of tests undertaken due to the technology being 
more accessible.  Clearly, implementing a new diagnostic regime without overwhelming 
evidence as to the benefits to be realised makes it difficult to convince stakeholders that such a 
system will eventually deliver a more cost-effective provision, especially if their introduction will 
increase the amount of diagnostic testing taking place. 
4. The allocation of budgets for POCT is not appropriate. 
There are indications within the articles assessed here that, in general, POCT does not attract 
specific budget allocations and it is therefore suggested that spend profiles within the relevant 
healthcare budgets need to be adapted in order to take this into account (Huckle 2006, Huckle 
2008, Creed 2001, FitzGibbon, Huckle et al. 2011).  This problem is most prevalent in areas of 
so-called traditional “silo budgeting” where separate departments receive separate budgets.  In 
many of the NHS trusts within the UK, the clinical pathology is still centrally funded and receives 
the same remittance, irrespective of workload (Creed 2001).  This in effect means that a clinical 
specialty which takes on responsibility for aspects of its own pathology workload by adopting 
POCT receives no central funding but has to bear the cost pressures from existing departmental 
budget allocations.  If the use of POCT by one department deducts from the budget of another, 
this could lead to an efficient use of available resources and services.  It is therefore suggested 
that a payment model based on the patient care pathway might be a way to maximise the 
benefits of timely and accurate diagnosis. 
5. Reimbursement is a major hurdle to POCT implementation. 
Reimbursement is described in the literature reviewed here as a major barrier to POCT adoption 
(FitzGibbon, Huckle et al. 2011, FitzGibbon, Huckle et al. 2010, Gregory, Lewandrowski 2009, 
Blick 2001, Vashist, Luppa et al. 2015, Huckle 2006, Melo, Clark et al. 2011, Huckle 2010).  
Essentially the problem lies with determining who pays for the test to be carried out and this 
varies from country to country.  It would seem that political control of reimbursement has 
prevented significant growth in the adoption of POCT, especially within the European healthcare 
structures (Huckle 2006).  In some European countries, such as France and Spain, limitations 
prevent doctors from performing any form of diagnostic tests which adds a further dimension 
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to an already complex problem.  There are a limited number of products that can be reimbursed, 
but these vary widely between the USA and Europe and even more so within the individual 
European countries.  Political structures have been under pressure to reduce healthcare 
spending due to the global economic crisis and so the reimbursement of POCT products, that 
may appear to be more expensive than CLT, is difficult to attain.  There has been a reduction in 
growth of POCT uptake even in the leading markets such as Germany and the USA.   
Depending on the reimbursement structure in operation, POCT may significantly affect the 
revenue generated by clinician consultation fees.  For example, in some European countries a 
clinician will have an initial consultation with a patient after which they will send off the sample 
for laboratory analysis with the results then presented at a subsequent consultation. This 
scenario commonly results in the payment of 2 fees as well as the cost of the test(s) to the 
clinician (Huckle 2010).  In theory, the implementation of POCT can result in the loss of the 
second consultation fee which is obviously a major issue with regard to the expected payment 
structure.  With regard to the associated payment for POCT testing, it is suggested how the use 
of diagnostic related groups (DRGs) could control the utilisation of POCT and avoid unnecessary 
testing, by inclusion of the cost of testing within a flat rate for the entire episode of care 
regardless of how many tests are performed (Gregory, Lewandrowski 2009). 
Although not categorised within the 5 areas of primary focus for economic considerations as 
outlined above, McNerney and Daley make an interesting point that is worth highlighting.  They 
suggest that there has been a lack of investment in diagnostic tests, including POCT, due to the 
fact that developing new drugs can yield a much more attractive commercial economic return.  
As a consequence of this lack of investment, problems identified in the past as being addressable 
via POCT are not being overcome and may still persist in current devices thereby limiting their 
utility and adoption (McNerney, Daley 2011). 
Clearly, impediments of an economic nature have been recognised as being highly relevant 
within this systematic literature review.  Specifically, the higher cost per test of POCT and the 
difficulties in performing adequate cost-benefit and/or cost-effectiveness studies on their utility 
have been found to be of upmost significance.  Clearly, these 2 issues are interlinked.  A 
successful solution to determining the value of the benefits obtainable through the use of POCT, 
i.e. improved quality of care, quicker intervention, reduced lengths of hospital stay, fewer 
admissions, etc. would allow an accurate calculation of the real cost-benefit/cost-effectiveness 
of such systems, hence being able to justify any extra expense on a per test basis. 
In terms of publication frequency on economic issues, a slight clustering (15 of 40 articles) was 
identified in the period 2008 to 2011.  It is suggested that this may have been in response to the 
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global economic recession which was causing significant reductions in public sector budgets at 
this time. 
3.4.2 Quality Assurance & Regulatory Issues 
Impediments relating to quality assurance and regulatory requirements were also frequently 
recognised in the literature review study, being highlighted in 41 of the assessed articles.  Of 
these, 11 made reference to quality assurance and regulatory issues as posing a significant 
challenge to POCT adoption in a general manner, with no focus on any particular area.  Within 
the remainder, the following 3 issues were highlighted in a more precise fashion: 
1. Device operation by untrained or non-competent staff. 
The dispersion of POCT devices throughout all areas of a healthcare system gives rise to 
opportunities for untrained or non-competent staff to use the devices.  This can lead to a 
disregard for certain quality assurance steps and procedures, including essential aspects of 
quality control.  The high dependence on operator competency in terms of test quality of POCT 
escalates this issue,  which has been highlighted as a specific area of concern for POCT and is 
therefore seen as a barrier for its effective clinical adoption (Vashist, Luppa et al. 2015, Pearson 
2006, O'Kane, McManus et al. 2011, Nichols 2003, Rajendran, Rayman 2014, Kiechle, Main 2000, 
Meier, Jones 2005, Crook 2000, Creed 2001, Luppa, Müller et al. 2011, Louie, Tang et al. 2000, 
Briggs, Kimber et al. 2012, Halpern 2000, Fermann, Suyama 2002, Lee-Lewandrowski, 
Lewandrowski 2009, Giuliano, Grant 2002, Huckle 2006). 
Quality issues can occur due to user errors such as the inappropriate storage of reagents and 
the incorrect collection of blood specimens (Fermann, Suyama 2002, Nichols 2005).  
Furthermore, devices that have been incorrectly calibrated by non-competent staff have been 
known to affect the results from POCT devices in an adverse manner (Fermann, Suyama 2002, 
FitzGibbon, Meenan et al. 2007).  There are indications that a lack of training, poor 
standardisation in obtaining blood samples and insufficient internal/external quality assessment 
are the main reasons for the underperformance of POCT (Briggs, Kimber et al. 2012).   
It should be noted that POCT devices have been found to be more challenging regarding quality 
control monitoring in comparison to traditional CLT methods.  A survey of clinicians (including 
nurses) and clinical bioscientists has found that the majority of both clinical groups “disagreed” 
or “strongly disagreed” that POCT devices reduced the amount of quality monitoring required 
for cardiac marker measurement (FitzGibbon, Huckle et al. 2010).  This highlights the need for 
appropriate training of POCT operators in order to ensure that adequate quality assurance 
procedures are in place along with tighter control over who can perform POCT and has access 
to such devices. 
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2. Complex regulatory requirements. 
Regulations for accreditation of analytical testing methods are complex with regard to POCT and 
a number of articles have referred to the burden imposed by such requirements, implying that 
they inhibit its implementation within clinical institutions (Cvitkovic 2011, Plerhoples, Zwemer 
et al. 2004, Creed 2001, Linder 2007, Groves 2005, Gregory, Lewandrowski 2009, Lee-
Lewandrowski, Corboy et al. 2003, Lee-Lewandrowski, Lewandrowski 2001).  For example, 
reference is made to the rigorous reporting and documentation requirements that can make 
POCT difficult to maintain in some cases (Plerhoples, Zwemer et al. 2004).  Furthermore, it has 
been found that, at times, regulations written for traditional CLT instrumentation are blindly 
applied to modern POCT devices (Groves 2005).  This is an inappropriate approach which poses 
significant challenges to the non-laboratory operators of the devices.   
Testing and accreditation regulations are intended to ensure certain quality assurance 
procedures are adhered to, however, a notable indication in the relevant literature base states 
that it appears that, in the past, regulations in the UK, whilst managed by Chemical Pathology 
Accreditation (CPA), attempted to stop the trend towards the decentralisation of laboratories 
by restricting the type and size of laboratory that could become accredited (Creed 2001).  
Instead of using accreditation to improve quality, Creed is of the opinion that the regulators 
endeavoured to “move the goalposts” by enforcing overly complex regulations in order to 
safeguard the future of the central laboratory.  However, the CPA is now absorbed and managed 
by the United Kingdom Accreditation Service (UKAS), with laboratories now assessed to ISO 
15189, the recognised international standard for medical laboratories. 
Additionally, there can be further problems with the process by which new requirements are 
established.  For example, changing regulatory requirements is a challenge with regard to 
managing a POCT program (Gregory, Lewandrowski 2009).  Maintaining compliance with an 
evolving set of regulatory requirements can be an even more difficult task.  There have also been 
indications of the challenges in maintaining regulatory compliance for a POCT system 
(Lewandrowski, Flood et al. 2008, Lee-Lewandrowski, Corboy et al. 2003), especially in larger 
institutions.  These issues tend to stem from the dispersed nature of the devices, making them 
more difficult to control and regulate than those in a centralised laboratory system. 
The regulatory control requirements of POCT products and their use will depend on the where 
they are marketed.  In Europe, regulation lies specifically within the Diagnostics Directive (a sub-
section of the Medical Devices Directive), while in the US the product must either meet Food & 
Drug Administration (FDA) approval standards or be compliant with the Clinical Laboratory 
Improvement Act (CLIA) which allows diagnostic products to be used in approved laboratory 
facilities (Huckle 2010).  This approach establishes the suitability of a facility to perform POCT 
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activities and also assesses the suitability of a POCT product for use at such a facility.  Regulations 
imposed by CLIA divide POCT into 2 categories; waived and non-waived tests.  Waived tests are 
defined as tests that use simple but accurate methods with either a small probability of error or 
that pose no significant risk of harm if they are performed incorrectly.  The non-waived category 
of tests includes both moderate and more highly complex sub-types (Lee-Lewandrowski, 
Lewandrowski 2001).  Utilising this regulatory approach can, however, result in further 
complexities.  A POCT analyser may be classed as being waived for testing a certain group of 
analytes and the rapid turnaround of results may increase the desire of clinicians to have 
additional testing available at the patient site.  Moreover, adding a further analyte to the test 
menu for this analyser may promote its use to the non-waived category, which then requires 
more significant personnel qualifications for the user, advanced quality control requirements 
and other function testing (Cvitkovic 2011). 
3. Product qualification. 
There have also been indications that regulations relating to product qualification/approval for 
POCT devices have acted as a barrier to their development and clinical uptake (Tantra, van 
Heeren 2013, Huckle 2008, McNerney, Daley 2011).  Indications suggest that the complexity of 
the registration processes discourages economic investment in the development of POCT 
devices (McNerney, Daley 2011).  Clearly, a lack of investment in the area directly impacts upon 
the potential for the more widespread implementation of POCT. 
Concerns regarding quality assurance and regulatory requirements have been found to be highly 
relevant by this literature review study.  In particular, device operation by untrained/non-
competent staff was found to be significant, with quality assurance/control aspects being 
pertinent in 21 of the 63 assessed articles (33%).  Furthermore, overly complex regulatory 
requirements for the accreditation of POCT have been identified as a significant barrier to their 
more widespread uptake within the clinical environment.  A major difficulty in controlling the 
use of POCT is deemed to be due to the dispersed nature of the devices.  Measures have been 
taken in the past to try and overcome this issue, such as the requirement for authorisation codes 
for use for such devices.  However, this proved to be an inadequate solution in most cases, for 
instance there are notified problems with clinicians forgetting their assigned codes, which 
directly affected intervention times in the care of critically ill patients.  The perceived issue of 
overly complex regulatory issues may well be true for POCT.  Operators who are not from a 
laboratory background may find the regulations more difficult to comply with compared to 
those with more experience in the traditional methods of analytical testing.  Therefore, the 
clinical specialty of the user is an important consideration in this regard. 
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The frequency of publications across the review period that address quality assurance and 
regulatory aspects of POCT remained fairly constant, indicating that all of these issues are of on-
going concern. 
3.4.3 Device Performance & Data Management Issues 
Device performance and data management issues were cited as acting as barriers to the 
adoption of POCT within the clinical environment in 34 of the assessed articles.  There were 3 
main areas of focus within this category: 
1. Reduced analytical performance in comparison to centralised laboratory testing. 
19 articles made reference to poor analytical performance of POCT devices as being a barrier to 
their adoption (Zydron, Woodworth et al. 2011, You, Chung et al. 2013, St-Louis 2000, Vashist, 
Luppa et al. 2015, Shephard 2011, Sheikholeslam, Pritzker et al. 2011, Perry, Fitzmaurice et al. 
2010, Knaebel, Irvin et al. 2013, Nichols 2005, Rebel, Rice et al. 2012, Rajendran, Rayman 2014, 
Murray, Fitzmaurice et al. 2004, Melo, Clark et al. 2011, Huckle 2008, Huckle 2010, Carraro, 
Plebani 2009, Louie, Tang et al. 2000, FitzGibbon, Brown et al. 2007, Goodwin 2008), including 
issues with their specificity, sensitivity and precision.  The technological performance of POCT 
devices is a topic of much ongoing debate.  This lack of performance, whether real or perceived, 
has been cited in 30% of the assessed articles within this review and so must be considered as a 
significant barrier to POCT adoption.  As an example, there are indications within the literature 
reviewed here alluding to the poor correlation between POCT and CLT results for International 
Normalised Ratio (INR) testing (a measurement of blood coagulation in the circulatory system 
often associated with monitoring the effectiveness of anticoagulation therapy) (Murray, 
Fitzmaurice et al. 2004, Perry, Fitzmaurice et al. 2010).  Furthermore, there are references to 
the variable performance and low reproducibility of POCT devices, including evidence from a 
study of 8 POCT instruments (7 of which were National Glycohemoglobin Standardisation 
Program (NGSP) certified), 6 of which were found to have produced clinically unacceptable 
reproducibility (St-Louis 2000, Melo, Clark et al. 2011).   
Poor analytical performance can lead to serious problems with “false negatives” (and “false 
positives”) within test results.  A survey of clinical bioscientists, clinicians and nursing staff found 
this to be a major concern (FitzGibbon, Brown et al. 2007).  In particular, “false negatives” can 
result in a lack of timely medical intervention which can have disastrous consequences for some 
patients. 
2. Connectivity and data management problems. 
Data management issues often stem from a lack of adequate connectivity capabilities.  15 
articles assessed in this review have highlighted the generally poor connectivity of POCT devices 
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(Swayze, Rich 2012, St-Louis 2000, Vashist, Luppa et al. 2015, Rajendran, Rayman 2014, Kiechle, 
Main 2000, Meier, Jones 2005, Huckle 2010, Carraro, Plebani 2009, FitzGibbon, Huckle et al. 
2010, Halpern 2000, Gregory, Lewandrowski 2009, Blick 2001, Goodwin 2008, Lee-
Lewandrowski, Lewandrowski 2001, Cvitkovic 2011).  It is accepted that this issue is not specific 
to POCT devices and may apply to any dispersed system within the healthcare sector where IT 
connectivity is crucial.  However, this implication has been widely recognised by champions of 
POCT in healthcare.  For example, the work of the Connective Industry Consortium (CIC), first 
convened in 1999, was highlighted in the reviewed literature with respect to creating 
connectivity standards for POCT devices (Cvitkovic 2011).  However, some 18 years later, POCT 
devices are often found not to be compliant with these standards, either due to a lack of 
updating original submissions or the manufacturer’s unwillingness to embrace the fundamental 
requirements of the CIC standards.  Connectivity has been said to be at the core of POCT 
“growing pains” (St-Louis 2000).  The effects of a lack of adequate connectivity are most readily 
seen in large institutions or within multi-site systems where a dispersed set of devices can create 
a number of data management issues (Nichols 2003, Crook 2000, Halpern 2000, Groves 2005, 
Fermann, Suyama 2002).   
Poor connectivity of POCT devices may lead to a number of subsequent problems.  For example, 
a lack of a direct link between POCT results and the patient record system can result in the 
duplication of tests due to clinicians being unable to access the most up-to-date data sets (Crook 
2000, Groves 2005).  This has the associated effect of increasing the overall cost of a diagnostic 
testing system which is already under scrutiny with regard to the additional expenditure which 
it may incur.  Moreover, POCT results are normally presented in a simplistic manner, which often 
must be manually recorded by the operator due to the lack of adequate connectivity.  Issues can 
then occur with the transposition of the values attained from POCT test results due to the limited 
amount of data that can be stored on them (Nichols 2005).  A POCT system, due to its 
decentralised nature, relies on having adequate IT connectivity in order to perform effectively.  
The problems identified here indicate the significance of this issue in terms of impeding the 
utilisation of POCT to its full potential.  
3. Poor usability of devices. 
This review has uncovered a number of usability issues associated with POCT devices.  Firstly, a 
lack of standardisation can cause confusion for operators.  It is stated that devices that are 
similar in design may operate differently or have different features.  Since clinical staff 
commonly rotate between various sites, this issue can become a significant problem for those 
who are required to operate a “similar” device in different environments (Swayze, Rich 2012).  
Calibration and reference sources for POCT devices have also been indicated as issues (Crook 
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2000, Goodwin 2008).  Clearly, a comparison of results from different devices on the same site 
will be difficult if they have been calibrated with different reference solutions.   
Furthermore, inadequate clarity of the output of POCT results and poor user instructions have 
also been cited as factors that contribute to adverse events.  It has been found that ease-of-use 
is an issue that still needs to be addressed with regard to POCT implementation (Linder 2007).  
This particular aspect is seen as a significant impediment to the adoption of such devices as their 
performance is much more dependent on the operator compared to that of traditional CLT 
(Nichols 2005).   
Adverse incidents caused by poor build quality of POCT devices and associated test cartridges 
have been reported.  Evidence has been found in the literature reviewed here of a study in which 
there were 4 incidents of the glass capillary tube fracturing in a POCT HIV testing kit (Dewsnap, 
Mcowan 2006).  Although not a frequently occurring problem, it is important to note that 
portable instruments such as POCT devices must be of an adequately robust nature. 
The significance of a real or perceived reduction in analytical performance of POCT in 
comparison to CLT is apparent by its prevalence in the articles assessed in this study, with this 
issue having been cited in 19 of the 63 (30%) reviewed.  Clearly, a clinician will not perform a 
new type of analytical test if they see it as being inferior to an existing method and hence 
evidence of efficacy is essential.  Furthermore, connectivity and data management problems 
have also been identified as being highly significant.  Again, this issue may emanate from the 
dispersed nature of POCT systems and must be managed accordingly to accommodate their 
successful implementation. 
The frequency of publications on device performance and data management related matters 
remained fairly constant across the review period, with the exception of a slight increase in 
2010-2011, 8 of the 34 articles pertaining to this category of barrier were published across these 
2 years.  The majority of these papers indicated some focus on reduced analytical performance, 
suggesting a more intense scrutiny on the performance of POCT devices.  It is noted that, the 
capabilities of the devices in the period question were likely to be superior to earlier generations 
of the same instruments, however, with technological advancements also comes increased user 
expectation. 
3.4.4 Staffing & Operational Issues 
A total of 18 articles indicated that staffing and operational issues have acted as barriers to the 
adoption of POCT within the clinical environment.  The nature of the barriers within this category 
focus on 6 main issues: 
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1. Reduced levels of staff satisfaction and increased friction between staff groups. 
Levels of staff satisfaction can be directly affected by the implementation of a POCT system, 
according to the findings of this review study.  Several papers indicate how users experience an 
increased work-load when operating POCT devices (Zydron, Woodworth et al. 2011, Fermann, 
Suyama 2002, Giuliano, Grant 2002).  Furthermore, it has been suggested that laboratory staff 
may fear a degradation of their role or ultimately loss of employment due to the introduction of 
POCT (Fermann, Suyama 2002).   
A number of the articles assessed also suggest that relations between clinicians and laboratory 
staff can be affected due to the implementation of a POCT system (Fermann, Suyama 2002, 
FitzGibbon, Brown et al. 2007, Halpern 2000, FitzGibbon, Meenan et al. 2007, Blick 2001).  There 
are suggestions that these concerns mostly emanate from the removal of the vital role of quality 
assurance and test-result verification when not performed in the central laboratory 
environment, rather than issues of ownership per se (FitzGibbon, Meenan et al. 2007).  
However, the implementation of POCT can lead to tension in the hospital environment with 
regard to “turf” battles, political in nature, in which one clinical group sees its dominance and 
expertise being invaded by another group that is performing similar functions with what is 
assumed to be less training and at (supposed) lower cost (Halpern 2000, Blick 2001).  Satisfaction 
levels of users can also be affected by the confidence that they have with the system being used.  
Various measures have been taken in order to allay concerns regarding the technical and 
analytical performance of POCT.  For example, the National Institute of Health (NIH) in the USA 
has funded 4 POCT technology centres and the National Institute of Clinical Excellence (NICE) in 
the UK has set up a diagnostics assessment group (Huckle 2010).  Greater acceptance of POCT 
by central laboratory staff has allowed for their involvement in ensuring the quality assurance 
of instruments and the attendant results.  Hence, progress on addressing this particular barrier 
to hospital-based clinical adoption of POCT has been more positive in recent years. 
2. Resistance of the central laboratory to pass control of testing to others. 
Several articles have cited resistance of the central laboratory staff to release control of testing 
to others as a barrier to the adoption of POCT (Fermann, Suyama 2002, Huckle 2008, Halpern 
2000).  This desire to retain control generally originates from concerns regarding the quality 
assurance of test data, rather than from fears over any loss of job responsibility or professional 
distinction.  There are indications that the central laboratory is not interested in sharing 
administrative or operational control of laboratory testing with a clinician group that is not 
formally trained (Halpern 2000).  Furthermore, it is suggested that there is a reluctance of 
central analytical facilities to accept that sufficient technical and analytical performance can now 
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be achieved using POCT devices (Huckle 2010).  The central laboratory is unlikely to be content 
to release control over testing until they are fully satisfied that this is the case and that suitable 
training regimes are mandatory. 
3. Inappropriate use of POCT. 
This study has also found that inappropriate use of POCT has acted as a barrier to its wider 
implementation.  The availability of tests may cause an increase in inappropriate testing (Crook 
2000).  Using POCT devices simply because they are available and easily accessible (and not 
because they are the most appropriate option) significantly increases testing costs, which may 
cause the POCT system to be economically unviable.  
4. Alterations to clinical care pathways. 
Difficulties surrounding operational changes needed with regard to established clinical care 
pathways and role of the central laboratory in supporting them have been cited as issues in a 
number of the articles assessed in this review study (Zydron, Woodworth et al. 2011, Price, 
Kricka 2007, Huckle 2008, Huckle 2010, FitzGibbon, Huckle et al. 2011, Lee-Lewandrowski, 
Lewandrowski 2001).  It has been stated within the reviewed literature that the need to change 
current practices to realise clinical benefits is one of the 4 main challenges for POCT 
implementation (Price, Kricka 2007).  This proposition is reinforced in 2 related pieces of 
literature by Price (Price 2001, Price 2002) which suggest that POCT will only become widely 
used if the potential savings promised can actually (and demonstrably) be realised.  Moreover, 
these benefits will only be delivered if the advantage of POCT delivery is built into a new clinical 
protocol in which the results are speedily and efficiently acted upon.  Clearly, simply placing 
POCT devices into the current clinical pathways and workflow will not provide an efficient 
solution.  For POCT to deliver both a clinical and economic benefit, the information provided by 
the test must result in either more rapid treatment or discharge, or otherwise lead to a positive 
alteration in the care provided.  This is not always the case, for example in the assessment of 
chest pain using cardiac markers, it has been reported that while rigidly applying a rapid cardiac 
rule out protocol based on POCT data would greatly reduce admissions, in practice clinical 
judgment and other diagnostic information typically take precedent (Boyd, Dixon et al. 2012, 
Dixon, Eatock et al. 2009).  
The literature reviewed describes how technology that causes disruptive complex workflow 
changes creates barriers to its adoption (Zydron, Woodworth et al. 2011).  Such changes are 
required in order to fully realise the benefits of POCT and so any disruption must be managed 
to minimise any resistance to adoption.  Difficulties exist when attempting to implement a POCT 
system in an institution with an existing fully functional central laboratory.  For example, as 
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pneumatic tube systems for sample transport are often already connected to acute care areas, 
then the central laboratory is effectively close in proximity to these areas.  Hence, access to the 
central laboratory resources is often maintained alongside the POCT (and commonly overlap 
with them) thereby nullifying many potential benefits of the new systems (Foster, Despotis et 
al. 2001). 
5. Management structure and clinical governance. 
With regard to the management of POCT, 3 papers refer specifically to the type of structure that 
is required in order for such a system to run efficiently (Zydron, Woodworth et al. 2011, Pearson 
2006, Price, Kricka 2007).  These publications all refer to “silo management” thinking that has 
been prominent within the healthcare services for many years.  It is proposed that a huge 
obstacle to successful implementation of POCT is a lack of a suitable interdepartmental 
management structure.  It is suggested how the “silo” approach places too much emphasis on 
the management of individual departments, rather than giving consideration to the organisation 
as whole in a manner that emphasises the patient journey (Price, Kricka 2007).  However, the 
implementation of a functional interdepartmental management structure is notoriously difficult 
(Zydron, Woodworth et al. 2011).  Furthermore, it has been stated that poor understanding of 
managers, and also many clinicians, with respect to the clinical governance implications of key 
issues such as diagnostic performance, clinical and economic outcomes, organisational impact 
and cost-effectiveness of the patient episode makes it difficult to implement a whole-system 
approach to the implementation of POCT (Pearson 2006). 
6. Reluctance to change health service practice. 
It has been suggested within the literature reviewed that most organisations are subject to a 
“status-quo bias”, which prevents change unless there is overwhelming evidence for significant 
improvements being gained in doing so (Zydron, Woodworth et al. 2011).  In terms of POCT, this 
inherent bias against behavioural change within a healthcare service is seen as one of the largest 
managerial obstacles to its increased implementation.  A number of articles cite a lack of 
evidence (or at least the occurrence of conflicting evidence) for the potential benefits and 
outcomes of implementing a POCT system, as making it hard to justify the necessary changes 
and economic outlay required (Zydron, Woodworth et al. 2011, Giuliano, Grant 2002, Freedman 
2002). 
The 2 most significant barriers in terms of staffing and operational issues are, firstly, reduced 
staff satisfaction levels and friction between clinical groups and, secondly, the effect of 
alternative diagnostic testing such as POCT on the existing clinical care pathways.  It is suggested 
that clinical pathways must be adapted to accommodate the efficient use of POCT or else the 
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potential benefits available will not be obtained.  Furthermore, it may transpire that the adapted 
pathways will somewhat allay concerns regarding increased workloads of front-line clinical staff. 
The highest number of publications relating to management structure and clinical governance 
were found at the beginning of the review period (2000 to 2002), indicating that these issues 
have been of concern from the advent of POCT usage (in this century).  The fact that in 
subsequent years the frequency of such papers tails off may be due to the increased acceptance 
of the central laboratory that acceptable diagnostic testing can now be achieved outside of their 
confines with adequate quality assurance protocols in place, and that furthermore that clinical 
care pathways are continuing to evolve to accommodate the use of safe and effective POCT. 
15 of the 63 assessed articles were deemed as being primary or original research, with the 
remaining 48 being expert opinion or review pieces.  The original pieces of research were 
assessed as a subset of the literature to determine any extra value could be accrued from the 
more robust methodologies applied.  By way of assessment, of the 15 articles; 10 made 
reference to quality assurance & regulatory issues; 6 indicated economic issues; 5 noted device 
performance & data management issues, and; 2 cited staff & operational issues.  An interesting 
finding here was that, of the 3 articles not citing any barriers to adoption, 2 of them were found 
to be original research.  The indication here is that primary research studies, without the 
application of expert clinical opinion, may lack the capability to determine the impediments to 
POCT uptake.  A consideration of the barrier categories themselves can explain the spread of 
citations here.  The most cited category, quality assurance & regulatory issues, is one that can 
be defined through primary studies such as the investigation of testing error rates.  While some 
assessment of economics can be made, such as a simple cost per test analysis, it is difficult to 
assess longer term economic impacts through primary research due to the difficulties in placing 
a financial value on improved quality of life due to the intervention of POCT in comparison to 
CLT.  Likewise, original research studies can be used to assess some device performance, by 
comparing the results of different devices, however longer-term impacts become more difficult 
to gauge.  Staffing & operational issues, cited by just 2 articles here, is very much a subjective 
area based on opinion, including the satisfaction levels of staff.  As a result, it is difficult to use 
primary research to investigate this area.  Less than 24% of the assessed literature here was 
found to be original or primary research, indicating the lack of primary research in the area and 
the difficulties in performing such.  As a result of this, and due to the subjective nature of some 
of the research area, all research articles assessed have been treated as equal without a 
“hierarchy of evidence” applied in this case.  However, the importance of robust and original 
research is recognised and it is the intention of this body of research to produce such. 
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A summary of the various barriers identified in this study, along with the corresponding 
references, is provided in Table 3.3. 
Table 3.3 – Summary of impediments identified. 
Category Specific Impediment References 
Economic issues: 
 
The cost per test of POCT is 
higher than traditional central 
laboratory testing. 
(St-Louis 2000, Vashist, Luppa et 
al. 2015, Price 2001, Huckle 2006, 
Price 2002, Huckle 2008, Crook 
2000, Creed 2001, FitzGibbon, 
Huckle et al. 2010, Lewandrowski, 
Flood et al. 2008, Lee-
Lewandrowski, Lewandrowski 
2009, Lee-Lewandrowski, Corboy 
et al. 2003, Goodwin 2008, 
Cvitkovic 2011, Lee, Shin et al. 
2011) 
The cost-effectiveness of a POCT 
system is difficult to gauge and 
cost comparison studies against 
traditional central laboratory 
testing methods are complex. 
(Fermann, Suyama 2002, Goodwin 
2008, Lewandrowski, Flood et al. 
2008, Lee-Lewandrowski, 
Lewandrowski 2009, Lee-
Lewandrowski, Corboy et al. 2003, 
Lee-Lewandrowski, Lewandrowski 
2001, Hortin 2005, Zydron, 
Woodworth et al. 2011, St-Louis 
2000, Rajendran, Rayman 2014, 
Foster, Despotis et al. 2001, 
Giuliano, Grant 2002, Louie, Tang 
et al. 2000, Crook 2000, Nichols 
2005) 
The initial costs of implementing 
a POCT system can be high. 
(Lee-Lewandrowski, 
Lewandrowski 2009, Zydron, 
Woodworth et al. 2011, Foster, 
Despotis et al. 2001, Vashist, 
Luppa et al. 2015, Nichols 2003, 
Boonlert, Lolekha et al. 2003, Blick 
2001, FitzGibbon, Huckle et al. 
2010) 
The allocation of budgets for 
POCT is not appropriate. 
(Huckle 2006, Huckle 2008, Creed 
2001, FitzGibbon, Huckle et al. 
2011) 
Reimbursement is a major hurdle 
to POCT implementation. 
(FitzGibbon, Huckle et al. 2011, 
FitzGibbon, Huckle et al. 2010, 
Gregory, Lewandrowski 2009, 
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Blick 2001, Vashist, Luppa et al. 
2015, Huckle 2006, Melo, Clark et 
al. 2011, Huckle 2010) 
Reference to economic issues in 
a non-specific manner. 
(Pearson 2006, Migliore, Ratti et 
al. 2009, McNerney, Daley 2011, 
FitzGibbon, Brown et al. 2007, 
Halpern 2000, Linder 2007, 
Dhawan, Heetderks et al. 2015, 
Freedman 2002) 
Quality assurance 
& regulatory 
issues: 
 
Device operation by untrained or 
non-competent staff. 
(Vashist, Luppa et al. 2015, 
Pearson 2006, O'Kane, McManus 
et al. 2011, Nichols 2003, 
Rajendran, Rayman 2014, Kiechle, 
Main 2000, Meier, Jones 2005, 
Crook 2000, Creed 2001, Luppa, 
Müller et al. 2011, Louie, Tang et 
al. 2000, Briggs, Kimber et al. 
2012, Halpern 2000, Fermann, 
Suyama 2002, Lee-Lewandrowski, 
Lewandrowski 2009, Giuliano, 
Grant 2002, Huckle 2006, Nichols 
2005, FitzGibbon, Meenan et al. 
2007, FitzGibbon, Huckle et al. 
2010) 
Complex regulatory 
requirements. 
(Cvitkovic 2011, Plerhoples, 
Zwemer et al. 2004, Creed 2001, 
Linder 2007, Groves 2005, 
Gregory, Lewandrowski 2009, Lee-
Lewandrowski, Corboy et al. 2003, 
Lee-Lewandrowski, Lewandrowski 
2001, Lewandrowski, Flood et al. 
2008) 
Product qualification. (Tantra, van Heeren 2013, Huckle 
2008, McNerney, Daley 2011) 
Reference to quality assurance & 
regulatory issues in a non-
specific manner. 
(St-Louis 2000, Murray, 
Fitzmaurice et al. 2004, Price, 
Kricka 2007, Melo, Clark et al. 
2011, Huckle 2010, FitzGibbon, 
Huckle et al. 2010b, FitzGibbon, 
Huckle et al. 2010a, FitzGibbon, 
Brown et al. 2007, Boonlert, 
Lolekha et al. 2003, FitzGibbon, 
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Huckle et al. 2011, Lee, Shin et al. 
2011) 
Device 
performance & 
data management 
issues: 
 
Reduced analytical performance 
in comparison to centralised 
laboratory testing. 
(Zydron, Woodworth et al. 2011, 
You, Chung et al. 2013, St-Louis 
2000, Vashist, Luppa et al. 2015, 
Shephard 2011, Sheikholeslam, 
Pritzker et al. 2011, Perry, 
Fitzmaurice et al. 2010, Knaebel, 
Irvin et al. 2013, Nichols 2005, 
Rebel, Rice et al. 2012, Rajendran, 
Rayman 2014, Murray, 
Fitzmaurice et al. 2004, Melo, 
Clark et al. 2011, Huckle 2008, 
Huckle 2010, Carraro, Plebani 
2009, Louie, Tang et al. 2000, 
FitzGibbon, Brown et al. 2007, 
Goodwin 2008) 
Connectivity and data 
management problems. 
(Swayze, Rich 2012, St-Louis 2000, 
Vashist, Luppa et al. 2015, 
Rajendran, Rayman 2014, Kiechle, 
Main 2000, Meier, Jones 2005, 
Huckle 2010, Carraro, Plebani 
2009, FitzGibbon, Huckle et al. 
2010, Halpern 2000, Gregory, 
Lewandrowski 2009, Blick 2001, 
Goodwin 2008, Lee-
Lewandrowski, Lewandrowski 
2001, Cvitkovic 2011, Nichols 
2003, Crook 2000, Groves 2005, 
Fermann, Suyama 2002) 
Poor usability of devices. (Swayze, Rich 2012, Crook 2000, 
Goodwin 2008, Linder 2007, 
Nichols 2005, Dewsnap, Mcowan 
2006) 
Staff & 
operational issues: 
 
Reduced levels of staff 
satisfaction and increased 
friction between staff groups. 
(Zydron, Woodworth et al. 2011, 
Fermann, Suyama 2002, Giuliano, 
Grant 2002, FitzGibbon, Brown et 
al. 2007, Halpern 2000, 
FitzGibbon, Meenan et al. 2007, 
Blick 2001, Huckle 2010) 
Resistance of the central 
laboratory to pass control of 
testing to others. 
(Fermann, Suyama 2002, Huckle 
2008, Halpern 2000, Huckle 2010) 
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Inappropriate use of POCT. (Crook 2000) 
Alterations to diagnostic testing 
for clinical care pathways. 
Zydron, Woodworth et al. 2011, 
Price, Kricka 2007, Huckle 2008, 
Huckle 2010, FitzGibbon, Huckle 
et al. 2011, Lee-Lewandrowski, 
Lewandrowski 2001, Price, Kricka 
2007, Price 2001, Price 2002) 
No existing interdepartmental 
management structure with clear 
clinical governance for POCT. 
(Zydron, Woodworth et al. 2011, 
Pearson 2006, Price, Kricka 2007) 
Reluctance to change health 
service practice. 
(Zydron, Woodworth et al. 2011, 
Giuliano, Grant 2002, Freedman 
2002) 
This in-depth systematic literature review has identified a number of impediments to the more 
widespread adoption of POCT within the clinical environment.  The issues concerned have been 
categorised and their significance assessed in terms of the prevalence of each within the set of 
papers identified.  The most significant barriers, real or perceived, can be seen as being 
interlinked in a number of ways.  If the actual cost-effectiveness of a POCT system could be more 
accurately determined, including the inclusion of the longer-term benefits, then the higher cost 
per test of POCT when compared on a like-by-like basis with traditional CLT could be more 
readily justified.  Furthermore, a number of the impediments to adoption of POCT devices 
emanate from their more dispersed nature of in the healthcare setting, including appropriate 
data management and maintaining compliance with regulatory requirements.  It is possible that 
improving the connectivity of such devices with patient record systems could support the 
development of adequate solutions to these and related barriers to adoption.  If clinical 
pathways can be effectively adapted to work with the dispersed nature of POCT systems, then 
more of the potential benefits can be realised without any fear of reducing the quality of the 
analytical information.  In this way, staff satisfaction and confidence in the systems would be 
improved.  Clearly, further work is required to demonstrate the health and economic benefits 
of adopting POCT in specific clinical pathways. 
With respect to satisfying and achieving the objectives of this body of research, the study 
described here has attended to the first 3 objectives as defined in Chapter 1, namely; to 
determine from a systematic review of the academic literature the actual issues that affect the 
adoption of POCT devices within the hospital-based clinical environment; to categorise the 
issues identified from the literature as a means of understanding in detail their relative 
contribution to adoption of POCT devices in the hospital environment, and; to determine, in 
order of priority, which issues are currently impacting the adoption of POCT devices within the 
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clinical environment.  Firstly, the barriers to adoption have been identified from the relevant 
academic literature base.  Secondly, these barriers have been categorised accordingly into the 
4 classifications as has been described in this chapter.  Thirdly, the identified barriers have been 
assessed with respect to their frequency of citation amongst the evaluated literature, with the 
categories defined in an order of priority.  The basis of this order is determined by taking 
frequency of citation within relevant literature as a measure of impact upon POCT uptake 
throughout the assessed time-period.   
The categorisation approach adopted here is seen as a significant step in overcoming the 
identified barriers to adoption and facilitating the more widespread use of POCT devices within 
the clinical environment.  It is recognised that some of the findings from the literature that have 
been assessed in this study are somewhat anecdotal and so direct further primary research of 
clinical opinion has been undertaken to separate real from perceived.  In this way, it is intended 
that the most significant impediments to the adoption of POCT will be identified and solutions 
to overcome them devised as per the overall aims and objectives of this thesis. 
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Chapter 4 
Clinical Perspectives on Barriers to Adoption of POCT from within 
the UK National Health Service (NHS) 
4.1 Study Objective 
The substantial systematic review of published literature reported in Chapter 3 has identified 
and categorised the various issues that are deemed to act as impediments to the more 
widespread uptake of Point-of-Care Testing (POCT) within the clinical environment.  However, 
much of the information presented in these publications has been found to be anecdotal and at 
times the information provided appears to be contradictory.  Hence, the purpose of the study 
reported here is to gain primary data that can be used to verify the key issues that determine at 
first hand clinical perspectives on the utility of POCT within the UK National Health Service (NHS).  
Clearly, attaining direct clinical experience and relevant opinion on the real and/or perceived 
issues affecting POCT uptake is crucial in order to provide solutions that can maximise their 
future function and utility.  The aim of the study is therefore to capture the opinion of clinicians 
in regard to their experience of POCT usage and to collate the various advantages and 
disadvantages that this form of testing offers to medical diagnostics in the hospital healthcare 
sector.  The fundamental considerations are threefold: (1) to assess the significance of the 
categories of barrier to adoption of POCT identified from the systematic review of the published 
literature; (2) to assess the relevance of these considerations within the hospital-based clinical 
environment, and (3) to prioritise each category in terms of its current impact on the 
effectiveness of clinical diagnostics.  Hence the outcomes from this study will be used to 
supplement and augment the information derived from the published works reviewed with 
regard to identifying any further issues that might contribute to the clinical uptake of POCT 
devices.  In this respect, the key research objective addressed here can be stated as determining, 
in order of priority, the issues that are currently impacting the adoption of POCT devices within 
the hospital-based clinical environment. 
As a key theme of this research is to provide a solutions-based approach, the study also aims to 
gain valuable clinical opinion on how to overcome the core issues i.e. what are the most effective 
routes to increased uptake of effective POCT within the clinical environment? 
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4.2 Study Development & Design 
A survey tool was identified as being the most appropriate and effective method to collect the 
required primary source information and subsequently a draft questionnaire was developed, 
with the issues identified from literature at the core of the questions used therein.  Initial 
consultations with senior cardiologists (n=4) provided a means to carry out a pilot study of the 
survey tool.  These initial engagements were carried out in a face-to-face interview format and 
the outcomes indicated that the survey should be amended to include the following features: 
• Tick boxes to allow the more rapid completion of the survey; and  
• A visual scaling system, using a 1 - 10-point scale similar to that already used by senior 
clinicians in the appraisal of junior doctors should be adopted for questions requiring a 
semi-quantitative response. 
The amended study tool underwent a second pilot phase via face-to-face interviews with a 
sample (n=2) of senior hospital based acute care clinicians and based on the additional feedback 
received, some further refinement of the structure and language was undertaken.  The survey 
study questionnaire was then passed through a third and final pilot phase consultation process 
with the assistance of clinical bioscience professionals (n=2).  This third pilot phase was 
conducted via 2 different survey formats; a face-to-face interview and also via an electronic 
submission.  The latter aspect was facilitated to gauge the effectiveness of the remote 
completion of the final form of the survey tool.  Following the various stages of pilot scale clinical 
validation, the survey tool, data acquisition process and analysis methods were critiqued in 
order to ensure that the questionnaire would attain sufficient data to be able to address the key 
research aims of the study.   
The final survey design comprises 26 core questions and focuses on the most prevalent 
impediments to adoption of POCT found within the relevant literature, categorised into 4 key 
areas: (1) economic issues; (2) quality assurance and regulatory issues; (3) device performance 
and data management issues and (4) staff and operational issues.  The operational version of 
the questionnaire utilised in this study can be found in Appendix A. 
The survey study utilised 2 avenues to attain the primary information required to meet the core 
objectives.  Firstly, in-depth face-to-face interviews were carried out to acquire detailed 
opinions on the potential advantages, disadvantages and overall clinical utility of POCT from 
senior (consultant-level) clinicians.  Secondly, an online electronic version of the survey aimed 
at a range of clinician specialisms was used to maximise participation and hence increase the 
overall value of the information collected.  Both configurations of the survey tool included an 
identical question set in order to ensure results would be directly comparable. 
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In terms of study execution, due to the geographical location of the project base, the 5 Health 
& Social Care Trusts in Northern Ireland (HSCNI) were selected as a representative sample of the 
UK NHS.  Subsequently, an adjunct study was carried out at a Healthcare Trust in England 
(Frimley Health Foundation Trust) as a means to verify that the findings from the NI Healthcare 
Trusts were a true representation of the wider UK NHS system. 
The study was peer reviewed and duly authorised by the Faculty of Computing and Engineering 
Ethics Filter Committee, in accordance with Ulster University’s research governance guidelines.  
Subsequently, the study was further assessed via the NI Research & Development Application 
Gateway (http://www.research.hscni.net/ni-rd-application-gateway) in order to attain the 
required research governance approvals from all of the participating Health Trusts.  The HSCNI 
Southern Trust acted as the Lead Trust in terms of the research governance approval process.  
The approval process was then extended to Frimley Health Foundation Trust via the Gateway 
process.  In the latter case, the requirements were slightly different than that for the HSCNI 
system and difficulties were encountered in translating the individual Trust placement 
agreements to the “research passport” system used in the wider NHS system that operates in 
England and Wales.  As a result of this added complexity and the associated time pressures, the 
Frimley aspect of the study was reduced to electronic participation only, which allowed the local 
research & development department at this Trust to process the approval directly through a 
time efficient process. 
The Chair of the POCT Committee in each participating NI Health Trust agreed to act as a local 
collaborator for the study and aided in the identification and recruitment of consultant-level 
clinicians with a knowledge of the clinical utility of POCT to participate in the face-to-face 
interviews.  Furthermore, the local collaborators directly assisted with the distribution of the 
electronic survey amongst appropriate specialist-level colleagues with a knowledge of the 
clinical utility offered by POCT diagnostics. 
4.3 Study Results 
In consideration of the primary study conducted within the 5 NI Health Trusts, 27 face-to-face 
interviews with consultant level clinicians were carried out and a further 21 specialised clinicians 
participated through the electronic form of the study, giving a combined total of 48 responders.   
It was decided that an appropriately managed assessment of the 2 streams of survey responses 
collected by the study, i.e. from the face-to-face and electronic versions was necessary to ensure 
that they could be a considered as a uniform data set and the answers grouped accordingly.  
Hence, a process of analysis was devised in order to determine if these data could be 
amalgamated with sufficient integrity.  The free-response questions included in the question set 
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were not subjected to the grouping test process due to the likelihood of high variability in the 
answers obtained.  Analysis was carried out via a comparison of the response distribution across 
the scaled answers from both streams of the survey data, with all but 2 questions being deemed 
appropriately comparable.  The 2 questions flagged as not being sufficiently comparable in 
terms of response distribution are addressed later. 
Table 4.1 provides a breakdown of study participants in terms of their clinical specialty.  
Emergency medicine clinicians are clearly the most represented within this study, with 15 
participants. 
Table 4.1 - Breakdown of study participants with respect to clinical speciality (n = 48). 
Clinical Specialty Number of Respondents 
Emergency Medicine 15 
Clinical Biosciences 7 
General Medicine 7 
Anaesthetics & Intensive Care 6 
Paediatrics 3 
Obstetrics & Gynaecology 3 
Cardiology 2 
Respiratory 2 
Renal 1 
POCT Experts1 2 
All 48 respondents indicated that POCT devices were used to diagnose patients in their area of 
clinical practice.  Participants were asked to give an estimation of how many tests were 
performed using POCT as a percentage of all diagnostic tests performed in their area of clinical 
practice, with an average figure of 20% returned based on 44 responses (4 participants were 
unable/unwilling to provide a value).   
Figure 4.1 indicates a measure of proficiency and training in the practical use of POCT devices 
declared by respondents.  It should be noted that it was not a necessary requirement for 
participants to have personally used the devices, but rather the focus was more on knowledge 
of the clinical utility that this particular type of diagnostic testing device can offer.  The majority 
of study participants ranked themselves as having a basic level capability (unsupervised use) (21 
                                                           
1 Trust Lead Pharmacist and Anti-Coagulation Specialist Nurse were identified as having expert 
knowledge on the area and were subsequently invited to participate. 
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of 48 respondents), or as being competent (unsupervised use and maintenance of devices) (17 
of the 48 respondents). 
 
Figure 4.1 - Levels of expertise in the personal use of POCT devices of study participants (n=48). 
Figure 4.2 outlines the most common types of point-of-care test used in the respective clinical 
care area of study participants.  Blood gas and blood glucose tests were the most dominant 
being indicated by 85% and 79% of respondents respectively.  This is perhaps unsurprising due 
to their embedded use within healthcare pathways in the UK.  Two other tests specified by over 
half of the clinicians within the study were urine pregnancy tests (54% of respondents) and blood 
lactate tests (52% of respondents).  Although not prevalent amongst the main list of tests 
reported, the following were additionally utilised by a notable portion of respondents, albeit 
with their use being less prevalent; C-reactive protein (CRP), rupture of membranes (ROM), 
bilirubin, neutrophil gelatinase-associated lipocalin (NGAL), faecal occult, foetal scalp pH and 
other blood chemistries including D-dimer and platelet function testing. 
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Question 2 - Participant Expertise in the Practical Use of a 
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Figure 4.2 - Most common POCT devices used in participant's area of clinical practice with respect 
to percentage of respondents (n=48). 
In this primary survey study, the vast majority of respondents (94%) indicated that they had 
never experienced any level of patient mistrust of POCT devices.  Only 3 of the 48 study 
participants claimed to have experience of patients querying the capability of a POCT device, 
with 1 clinician interviewed stating that this was exclusively “on the occasion that POCT blood 
glucose results were not normal and the patient knew that their levels were well controlled”.  
The same clinician was of the opinion that this was in fact not a negative aspect of the process 
of near-patient testing and that such patient queries could be used to re-check devices to ensure 
that they were calibrated correctly and that the result was indeed correct.  Notwithstanding this 
report, none of the participants indicated any experience of patients requesting evidence of the 
capability of a POCT device or refusing to have a test carried out using a POCT device. 
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4.3.1 Economic Issues 
Clinicians were questioned about a number of issues pertaining to economic considerations 
associated with POCT operation that were attained from the systematic review of the published 
literature.  In terms of the actual cost per test of POCT, 36 out of 48 respondents (75%) agreed 
that it was higher than that of a comparable analysis sourced through central laboratory testing 
(CLT), as indicated in Figure 4.3.  In comparison, just 15% of respondents disagreed with this 
statement, while 10% were either not sure or did not provide a response. 
 
Figure 4.3 - Clinician indication of POCT cost per test in comparison to CLT (n=48). 
Notable comments obtained from those in agreement with the higher cost of POCT included: 
• “The dilemma is increased cost versus quicker turnaround times.” 
• “Yes, but this doesn't take into account the cost of staff in the lab.” 
Clinicians were also asked to rate their agreement or otherwise with the statement that POCT 
provides longer term economic benefits, for example reduced hospital stay, reduced outpatient 
appointments, etc.  These responses were given on a 10-point scale, with the distribution of 
opinion outlined in Figure 4.4.  Whilst a significant proportion (38%) of responses were neutral, 
over half of responses (52%) either “agreed” or “strongly agreed” with the question posed here.  
Just 10% of participants “disagreed” or “strongly disagreed” with this statement. 
Yes
75%
No
15%
Not sure / No 
response
10%
Question 7a - Do you agree that the cost per test of POCT 
is higher than CLT?
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Figure 4.4 - Clinician opinion on the longer term economic benefits attainable through the use of 
POCT (n=48). 
One consultant who “agreed” with the statement added that “POCT reduces time spent by 
patients in the Emergency Department (ED).  Audits show that the central laboratory can't meet 
the required one-hour vein-to-brain time as they claim.” 
The 5 respondents whose opinions were within the 1-4 are of the scale were asked why the 
longer term economic benefits theoretically available through the use of POCT were not being 
realised fully within their institution.  Their responses were as follows. 
• “With a good laboratory infrastructure already in place here, POCT merely duplicates an 
existing service.” 
• “It is difficult to quantify and prove these savings down the line, POCT does not radically 
alter patient management or treatment.” 
• “There is not a high enough volume of tests performed using POCT.” 
• “I don’t think there are longer term economic benefits, there are only clinical benefits to 
bedside diagnosis.” 
• “My main experience is prior to admission, I couldn’t say if POCT is being used to expedite 
discharge decisions.” 
Despite the perceived higher cost per test of POCT, as indicated in Question 7a (Fig. 4.3), 
clinicians also tended to be of the opinion that the use of a POCT system is in fact cost-effective, 
with 36 out of the 48 participants (75%) indicating that this was the case, as displayed in Figure 
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4.5.  By comparison, 17% of participants did not believe that the use of such a near patient 
system is cost-effective, with 8% not sure or unable to give a response.  Comments obtained 
from these consultants included the following: 
• “Quick decisions outweigh the extra costs.” 
• “On paper, yes, but you need clear clinical pathways and adherence to these pathways.  
Costs versus quality of care is the dilemma.” 
 
Figure 4.5 - Clinician indication of the cost-effectiveness of a POCT system (n=48). 
Study participants were questioned about procurement, reimbursement and budgeting for 
POCT with respect to the interdepartmental nature of such testing.  Sharing of POCT resources 
between departments was identified in the literature as being problematic in terms of 
determining who actually pays for both the devices and test strips/cartridges.  As shown by 
Figure 4.6, responses on this topic were found to be very varied with the clinical opinion 
obtained showing no particular trend.   
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Figure 4.6 - Clinician opinion on procurement, reimbursement and budgeting for POCT with 
respect to the interdepartmental nature of such devices (n=46). 
One consultant who “agreed” with this statement added that there was no interdepartmental 
sharing of devices in their institution, while another commented that interdepartmental use was 
beginning to be prohibited in order to eliminate risk of cross-infection issues.  Hence, it is 
possible that this type of reduction in sharing of devices between departments within clinical 
institutions may be partly responsible for the varied response to this particular question.  Of the 
19 respondents who “disagreed” or “strongly disagreed” with the statement in this question, 17 
indicated that it did in fact make it difficult to employ the POCT devices effectively.  Some 
comments added by these individuals include: 
• “Our POCT Blood Gas Analyser is abused by the ward regularly, but we also use drugs 
testing from the Emergency Department.” 
• “A lot of people don't understand the benefit of POCT, the ward is picking up the cost for 
using POCT rather than the lab, even though it is taking work off the lab and the ward is 
not being funded for it.” 
• “All the money comes out of one pot.  This would be easier to manage if there was a 
centralised budget for POCT.” 
Study participants were subsequently questioned on the relevance of a range of economic issues 
within their own clinical institutions including; difficulties in justifying the use of POCT due to 
the higher cost per test in comparison to traditional testing methods; difficulties in justifying the 
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implementation of a POCT system due to unclear cost-effectiveness and complexities in making 
accurate comparisons to traditional methods of testing; difficulties in justifying the 
implementation of a POCT system due to high initial outlay costs; issues with regards to budget 
contributions due to the “silo” nature of separate departmental budgeting, and; difficulties in 
obtaining reimbursement for POCT.  The distribution of responses to these questions are 
outlined in Figure 4.7.  For the most part, opinion appears to be significantly varied.  It was 
apparent from respondent comments that much of this variation with regards to the economic 
issues was based on the dilemma of increased costs versus improved quality of care.  Whereas, 
some institutions seemed to act solely on clinical justification, others tended to be of the opinion 
that the benefits of POCT were much exaggerated and that in reality such devices do not provide 
the clinical benefits promised.  In this respect, the increased cost is seen as a very relevant and 
significant impediment to their adoption.  The strongest trend shown here was to indicate that 
any difficulty in obtaining reimbursement for POCT is not a relevant issue within the UK clinical 
institutions, with 20 of 45 respondents (44%) specifying this response.  Comments added by 
consultants who were of this opinion included “reimbursement will come out of the lab budget” 
and “the only problem is getting the upfront money to get the device in the first place”.  It should 
be noted that part (b) of this question was one of the 2 questions that were flagged for having 
a notable amount of variation between responses from the face-to-face and electronic versions 
of the survey tool.  Whereas, the electronic responses had strong variation across all categories, 
the face-to-face participants were quite polarised in their opinion, with 20 of 27 responses being 
in the “not relevant” or “very relevant” categories.  Perhaps, an explanation for this may lie in 
the seniority of respondents.  All face-to-face participants were at consultant level, while 
electronic participants represented a range of specialisms, from trainees upwards.  It is 
therefore possible that a more polarised opinion is found within the face-to-face responses here 
is due to the stronger opinions held by consultant-level clinicians that has been gained through 
a greater wealth of experience of POCT implementation.  By comparison, many of the 
respondents in the electronic survey may not yet have developed a strong opinion one way or 
the other. 
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Figure 4.7 - Clinician opinion on relevance of specific economic issues within their own clinical 
institution (n=48). 
4.3.2 Quality Assurance & Regulatory Issues 
With regards to concerns involving quality assurance and regulatory procedures, clinicians were 
questioned on the most commonly noted of these issues that arose from the systematic review 
of the academic literature.  The initial focus was on how the dispersion of POCT devices across 
the clinical environment contributes to their (potential) use by untrained or non-competent 
staff.  Participant responses to this question are outlined in Figure 4.8.  The most dominant 
response to this particular question were in the “agree” and “strongly agree” categories of the 
10-point scale, with 29% of participants responding in each.  By comparison, the “disagree” and 
“strongly disagree” categories were specified by 15% and 10% of respondents. respectively, 
whilst 17% of clinicians gave a “neutral” response. 
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Figure 4.8 - Clinician opinion on how the dispersed nature of POCT devices leads to use by 
untrained or non-competent staff, resulting in quality assurance issues (n=48). 
Comments by consultants interviewed face-to-face who disagreed or strongly disagreed with 
this statement indicated that the majority were of the opinion that “tight enough” controls were 
in place in order to overcome such a risk.  In particular, the use of operator specific barcodes to 
access the devices and the maintenance of detailed training records, were cited as examples of 
good practice in this regard.  However, overall 28 of the total 48 respondents “agreed” or 
“strongly agreed” that this aspect of POCT practice led to problems in trusting the test data 
generated.  Furthermore, 18 of these 28 particular individuals indicated that these specific issues 
made it more difficult to utilise POCT to attain a timely and reliable diagnosis in comparison to 
that offered by CLT. 
Participants were questioned on the complexity of current regulations for analytical testing 
accreditation for POCT.  It should be noted that from the face-to-face interviews it was apparent 
that a number of clinicians were entirely unaware of the regulatory requirements, resulting in 6 
participants within this cohort choosing not to answer this question due to a lack of knowledge.  
Responses to this question are outlined in Figure 4.9.  The most dominant response here was 
that of a “neutral” standing, with 15 of 42 participants (36%) giving this opinion.  The apparent 
lack of knowledge noted may have contributed to this neutral response.  Response to this 
question was generally varied.  One consultant participating within the face-to-face aspect of 
the study and who was in agreement with this statement added that there was “therefore an 
increased risk of mistakes by operators” due to this complexity.  However, another consultant 
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interviewed who disagreed with this statement commented “they are not overly complex, the 
problem is that regulations aren’t available for all types of POCT device as there is a lack of 
standardisation”.   
 
Figure 4.9 - Clinician opinion on the complexity of regulatory requirements for analytical testing 
accreditation of POCT (n=42). 
Of the 11 respondents who returned in the 7-10 range of the ranking scale for this question, 8 
subsequently believed that this complexity made it more difficult to attain a timely and reliable 
diagnosis in comparison to utilising CLT.  The 3 in disagreement here believed that the over-
complexity of POCT impacted negatively upon quality management, rather than on the day-to-
day usage of such devices. 
In consideration of compliance with regulations that apply to the operation of POCT devices, 
clinicians were asked for their opinions on the level of operator training and support provided 
to them by their central laboratory service.  The results are outlined in Figure 4.10.  Almost half 
of the 48 participants (48%) indicated that the level of training and support provided was either 
“high” or “very high”.  However, it should be noted that a significant number of respondents 
who returned answers in the “neutral”, “low” and “very low” categories indicated that was due 
to the fact that manufacturers provided operator training and support rather than the central 
lab, an arrangement that they indicated that they were happy with.  Of the 12 respondents in 
the “low” category, 9 indicated that this lack of training and support did not make it more 
difficult to attain a timely and reliable diagnosis in comparison to the case when utilising CLT. 
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Figure 4.10 - Clinician opinion on the level of operator training and support on regulatory 
compliance for POCT provided by their central laboratory (n=48). 
With regard to the relevance of quality assurance and regulatory issues within the local clinical 
institutes of study participants, Figure 4.11 outlines respondent opinion on specific issues found 
to be prevalent within the reviewed literature, namely; errors caused by incorrect quality 
assurance procedures; untrained/non-competent staff operating the devices; issues for non-
laboratory operators of devices due to regulations written for traditional laboratory equipment 
being blindly applied to POCT; issues with maintaining regulatory compliance due to a number 
of changes in the regulations; issues with maintaining regulatory compliance due to the 
dispersed nature of POCT, and; a lack of development of POCT devices caused by product 
approval hurdles that discouraging economic investment in their development.  It should be 
noted that a number of face-to-face participants chose not to answer any of the 3 questions 
regarding accreditation regulations (13b, 13c and 13d) due to a lack of knowledge on the area 
(4, 7 and 6 participants, respectively) and that 4 clinicians did not answer the question regarding 
product approval hurdles (13e), again due to a lack of knowledge in the area. 
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Figure 4.11 - Clinician opinion on relevance of specific quality assurance and regulatory issues 
within their own clinical institution (n=48). 
It can be seen in 4 of the 5 areas addressed here, i.e. all but that regarding use of devices by 
untrained or non-competent staff, that the dominant response was that these issues were not 
relevant within participant’s place of work.  Although this may genuinely be the case, it may also 
be worth considering that the apparent lack of knowledge by senior clinicians in these areas 
contributes to their lack of awareness towards any such issues that may actually exist in reality.  
The single issue here that did not receive a dominant “not relevant” response was that regarding 
the use of devices by non-competent or untrained staff and the resulting errors that can result 
from such actions.  From the responses recorded it can be seen that this particular issue is rarely 
relevant within the surveyed hospitals and/or Health Trusts, indicating perhaps that this does 
happen.  However, quality assurance issues with respect to diagnostic tests can have serious 
consequences and even a rare occurrence may have unacceptable consequences in terms of 
patient management and welfare.  One consultant who commented further added “this is 
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infrequent but can be very important, if we have 300 patients a day and one gets a wrong result 
then it could be very serious”. 
4.3.3 Device Performance & Data Management Issues 
Device performance and data management issues formed the third most prevalent category of 
barrier that was highlighted by the systematic literature review study, as reported in Chapter 3.  
Within this category, an issue that was commonly identified in the reviewed literature was that 
of the perceived reduced level of analytical performance that POCT provides in comparison to 
CLT.  Figure 4.12 outlines the clinical opinion obtained from this primary UK clinician survey with 
respect to the level of analytical performance of POCT and shows clearly that there is strong 
agreement between the majority participants that the level of performance is adequate, 
thereby contradicting the indication given by literature.  Indeed, 46% of study participants 
regarded the performance of POCT devices as “high”, while a further 37% rated them as having 
“very high” performance in comparison to CLT instruments.  No clinicians regarded the analytical 
performance of POCT devices as being “very low”, and only one of the 48 gave a “low” response.  
The final 15% of participants gave a response in the “neutral” area of the ranking scale. 
 
Figure 4.12 - Clinician opinion on the level of analytic performance of POCT devices (n=48). 
The general consensus amongst the UK NHS clinical consultants interviewed was that the level 
of performance provided by the CLT service was absolutely the gold standard but that it was 
often significantly above and beyond the actual clinical requirement at the time of the test.  
Therefore, although it is recognised that the core diagnostic power of POCT devices cannot 
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match that of the technology offered by the central laboratory, their level of performance is 
high enough to be clinically acceptable.  The slight variability in opinion of respondents is 
deemed to be due to the fact that the level of analytical performance of POCT devices depends 
heavily on the nature of the test, i.e. whereas the more embedded and clinically accepted POCT 
tests such as blood gas tests offer excellent analytical performance, some other tests such as D-
dimer and troponin can provide either conflicting results or a less sensitive result in comparison 
to the equivalent CLT output and are therefore seen as being clinically inferior.  Other interesting 
comments by interviewees include: 
• “There is some variation between POCT and CLT but this is accepted, POCT has 
limitations which the user must be aware of.  POCT devices are used with very specific 
cut-off values so results can sometimes fall into grey areas.” 
• “A lot of POCT devices measure different parameters to the lab and so they are not 
comparable.  It would be desirable to be able to perform tests using both POCT and CLT 
and combine the results to build a more complete picture.” 
Another perceived concern that was identified from the literature review is the lack of 
connectivity of POCT devices to central healthcare systems and patient records.  Figure 4.13 
outlines that clinical opinion collated from within this study on this issue and indicates that, in 
general, the connectivity and data management capabilities of a POCT system do indeed tend 
to be significantly poorer in comparison to the system utilised by the central laboratory service.  
Some 17 of 48 participants (36%) indicated that connectivity and data management were “very 
poor” while 16 participants (33%) indicated that they were “poor”.  Comparatively, just 8% of 
participants indicated a “neutral” response here and only 6% gave a response indicating that 
connectivity and data management of POCT was “good”.  Although, 17% (8 of 48 clinicians) did 
regard these attributes as being “very good” for POCT, the comments made by participants 
indicated a commonly held opinion that there was often no direct data entry available through 
the use of POCT, and that results therefore had to either be hand-written or printed and 
attached manually to physical patient records.  There are clearly a number of potential problems 
stemming from this finding that are related to the clinical management of patients; for example, 
clinicians may be unable to look up previous test results for comparison, and likewise the results 
of tests carried out in one department may not be visible within another leading to the 
duplication of the tests being carried out.  However, difficulties with connectivity does not 
necessarily mean that solutions are not available and POCT manufacturers will often provide an 
exclusive interface for their range of products.  One consultant interviewed commented 
regarding this aspect thus: “Connectivity is possible but usually there is a big cost.  POCT 
connectivity is very fragmented while central lab instruments all tend to work under one 
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interface.  There is a big need for a single IT system that controls all POCT systems but still 
provides the full functionality of the individual interfaces.” 
 
Figure 4.13 - Clinician opinion on the connectivity and data management capabilities of a POCT 
system (n=48). 
Although, it would appear that POCT connectivity and data management is not at the same level 
as that of the central laboratory provision, this does not translate necessarily into problems with 
everyday usage regarding the deduction of a timely and reliable diagnosis.  Of the 33 
respondents who rated the connectivity and data management as “poor” or “very poor”, 25 
suggested that this does not make it more difficult to make a timely and reliable diagnosis when 
compared to utilising test data from the central laboratory system.  The consensus is that in the 
experience of many users, POCT was employed mainly in time-critical situations in order to make 
a quick clinical decision, where trends are typically not as important and hence there is little 
value in looking back at previous test results.  Therefore, simply from a diagnostic point of view, 
this lack of connectivity and the lack of ability to maintain up-to-date test data within the patient 
records does not affect patient management as much as might have been expected. 
A further impediment identified from the literature was the usability of the devices and 
specifically some inherent difficulties in performing the actual tests within the near-patient 
clinical setting.  However, as outlined in Figure 4.14, participants within this study have indicated 
that the usability of POCT devices is generally straightforward and that no major issues with 
usability exist.  Some 70% of respondents rated the use of POCT devices as being “very easy”, 
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with a further 13% regarding them as “easy” with respect to their answers given on the 10-point 
scale.  No participants in the study deemed the use of POCT devices to be “very difficult”.  Just 
5 of 47 responses (11%) to this question were in the “difficult” segment of the scale, while the 
remaining 6% were given as “neutral” responses. 
 
Figure 4.14 - Clinician opinion on the difficulty of performing tests using POCT devices (n=47). 
One consultant interviewed added that “there may be pitfalls however because the use of the 
devices seems so easy; training is still required”.  Of the 5 respondents who indicated that the 
use of such devices was difficult, 1 suggested that the only way to overcome such difficulty was 
through the placement of dedicated staff in the clinic by the central laboratory service to 
operate the devices throughout the respective Health Trust or hospital. 
With regard to the relevance of specific device performance and data management issues, study 
participants were questioned on a number of aspects with the responses shown in Figure 4.15.  
It can be seen that 2 specific issues are generally seen by clinicians as having “low” relevance 
namely; devices producing a reduced analytical performance in comparison to CLT instruments 
and operators encountering difficulties with use of POCT devices.  Some 71% of respondents 
indicated that a reduced analytical performance was of either “no” or “low” relevance in their 
place of work.  Responses here echoed the earlier sentiment that although POCT was not as 
analytically capable as CLT, it was still clinically acceptable.  Additionally, 61% of respondents 
indicated that device usability problems were also of “no” or “low” relevance in their respective 
hospital or Health Trust.   Moreover, they indicated that in many cases the only difficulties with 
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the use of POCT stemmed from a lack of familiarity with the device or when the operator has 
not used a particular device in a while.  One consultant added here that “overcoming a lack of 
familiarity is down to the quality of both training and SOP (standard operating procedures) in 
place within the institution”.  The most varied response here was with respect to issues caused 
by poor connectivity to central healthcare and patient record systems.  The variation in opinion 
on relevance of data management issues would suggest that although the poor connectivity 
does not affect the ability to reach a diagnosis in the immediate short term (as stated in clinician 
responses to Question 15), some other data management issues are apparent.  Two clinicians 
commented here that archived information and permanent records are important, and hence 
the use of POCT inhibits the ability of the respective Health Trust to maintain patient records 
which may be valuable at a later date with respect to ongoing treatment or reviews. 
 
Figure 4.15 - Clinician opinion on relevance of specific device performance and data management 
issues within their own clinical institution (n=48). 
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4.3.4 Staff & Operational Issues 
The fourth category of impediment to the uptake of POCT highlighted identified within the 
relevant literature is that associated with staff and operational issues.  Participants in the survey 
were asked to give their opinion as to the impact of POCT upon the workload of those operating 
the devices.  As shown in Figure 4.16, 18 of the 48 respondents (38%) “strongly disagreed” with 
the assertion that POCT significantly increased the workload of front line clinical staff, while a 
further 13 respondents (27%) gave an answer indicating “disagreement”.  Another 15% of 
participants gave a “neutral” response while a total of 20% of participants gave an answer in the 
“agree” and “strongly agree” categories combined.  It can therefore be seen that there is 
significant disagreement with the notion of increased workload due to the operation of POCT 
devices.  Justification of this opinion by the clinical knowledge base can be ascertained from the 
comments given by consultants interviewed in person as part of the study: 
• “It’s more time consuming to send a sample to the lab; filling out forms, filling samples, 
chasing results etc.” 
• “POCT actually alleviates workload; there are less forms, less labels and less chasing the 
lab for results.” 
• “POCT reduces workload as you don’t have to chase the lab for results.” 
• “It takes longer for a nurse to take a blood sample and chase the lab for a result.” 
• “Chasing the laboratory for results is more work than using POCT.” 
It should be noted here that there is significant information to indicate that the more immediate 
nature of test results offered by POCT actually alleviates the workload of front line clinical staff 
by eliminating the need to “chase up” results from the central laboratory.  Of the 10 respondents 
who had the opinion that POCT significantly increases the workload of device operators 
(answering in either the “agree” or “strongly agree” areas of the ten-point rating scale), 7 
believed that this did not lead to a reduction of staff satisfaction.  Comments from these 
respondents included “staff satisfaction actually increases due to instant results” and “the 
advantages of using POCT outweigh the extra workload and staff understand this”. 
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Figure 4.16 - Clinician opinion of the impact of POCT upon the workload of device operators 
(n=48). 
A further issue that was identified from the literature study is that of the apparent reluctance of 
the CLT service to release the control of diagnostic testing to other cohorts within the respective 
hospital or Health Trust.  In this respect, clinical opinion was significantly varied with regards to 
how true this particular issue is in reality, as outlined by Figure 4.17.  Opinion on this particular 
issue is divided fairly uniformly across the scale, with 21% of participants “strongly disagreeing”, 
15% “disagreeing”, 19% “agreeing” and 15% “strongly agreeing” with this statement.  The 
highest response area was that of a “neutral” response, provided by 14 of 47 respondents (30%).   
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Figure 4.17 - Clinician opinion of the reluctant of the central laboratory to release the control of 
testing (n=47). 
Comments from those “disagreeing” or “strongly disagreeing” with this statement include: 
• “The laboratory is happy to release control as long as testing is carried out correctly.” 
• “POCT will always be seen as a threat to the laboratory, but laboratory workloads are 
increasing and the movement of POCT out to the wards is cushioning this.” 
• “POCT is actually a burden on the laboratory staff, it would make it a lot easier for the 
lab if control was passed on.” 
• Conversely, those who “agree” or “strongly agree” with the statement commented that: 
• “The lab is paranoid about POCT, there is no trust in the devices.” 
• “The lab is very sceptical about POCT; a lack of governance caused these issues.” 
• “There is a reluctance but this is understandable; that is their governance role.  They are 
understaffed and need dedicated staff to look after POCT, which makes it hard for me to 
get the devices I want.” 
Importantly, of the 16 respondents who indicated there was indeed a reluctance by the central 
laboratory to release the control of diagnostic testing (giving responses to Question 19a in the 
“agree” or “strongly agree” areas of the 10-point scale), 13 believed that this acted as an 
impediment to the more widespread adoption of POCT within the clinical environment.  
Interestingly, 1 consultant interviewed added here that the reluctance was not apparent for all 
types of POCT, and that the central laboratory were happy to release control of testing for blood 
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gases and blood sugars to other areas of the institution simply because of the volume of tests 
required was so high. 
Participants in the study were asked to give their opinion as to how adequately the clinical care 
pathway and role of the central laboratory have been altered to incorporate the use of POCT.  
Responses to this question are outlined in Figure 4.18.  The most frequent response here was in 
the “agree” category, i.e. that the pathways and role of the central lab had indeed been altered 
sufficiently, with 34% of the response given in this area.  A further 21% of participants “strongly 
agreed” with this notion, while 26% gave a “neutral” response.  Notably, the response levels 
were low in “disagree”, just 6 of 47 (13%) respondents indicating that this was the case, while a 
further 3 “strongly disagreed” (6%).  Hence, this particular issue is not seen to be a major 
concern to this clinical group in reality.  However, it should be noted that this was the second 
question that was found as having a disconnect in the response distribution between the 2 
strands of the study (face-to-face and electronic submission) that was used to appropriately 
amalgamate the data.  Whereas the face-to-face responses resulted in 73% of participants being 
in the “agree” or “strongly agree” category for this statement, the online responses were much 
more varied, with 48% of participants indicating a “neutral” opinion on the subject.  It is possible 
that the wording of the question, which included 2 different aspects for consideration, i.e. both 
the clinical care pathway and role of the central laboratory, may have led to the more varied 
opinions offered by the online respondents whilst the face-to-face participants had the 
opportunity to clarify this appropriately.  Hence, in an electronic setting, respondents may have 
been more likely to indicate a neutral opinion. 
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Notwithstanding the possibility for confusion, more than half of the respondents here “agree” 
that the clinical care pathway and role of the central laboratory have been altered sufficiently 
to incorporate the use of POCT.  Some interesting comments from interviewed participants in 
this regard include: 
• “NICE guidelines now include POCT.” 
• “The clinical care pathway is evolving all the time in order to control the introduction of 
POCT”. 
• “Some pathways have been altered sufficiently, however there are still a number that 
throw in the use of POCT with very little thought.” 
It should be noted that of the 9 respondents who indicated that there was poor accommodation 
for POCT within clinical care pathway (by “disagreeing” or “strongly disagreeing” with the 
statement), 6 believed this did not affect the ability to make a timely and reliable diagnosis using 
POCT in comparison to CLT.   
By way of an assessment of the relevance of specific staff and operational issues that were found 
within the academic literature, participants were questioned on 6 key areas, as highlighted in 
Figure 4.19.  These  issues are specifically; reduced staff satisfaction levels and increased friction 
between clinical staff groups due to the use of POCT; impeded uptake of POCT caused by the 
reluctance of the central laboratory service to release the control of diagnostic testing; 
inappropriate use of POCT, including over-use and reliance on test results; benefits of POCT 
being negated due to a requirement for clinical care pathways and role of the central lab to be 
altered sufficiently; POCT system running inefficiently due to the requirement for an 
interdepartmental management structure with clear clinical governance for POCT, and; 
difficulties implementing POCT due to a reluctance to change within healthcare bodies along 
with a lack of evidence justifying POCT.  Four of these 6 issues were seen as having a dominant 
“not relevant” response by participants within this study.  Reduced staff satisfaction and friction 
between staff groups that occur as a result of the utilisation of POCT are not seen as being 
relevant issues within the UK hospitals and Health Trusts included in this research, with 76% of 
respondents indicating these as having “no” or “rare” relevance.  Furthermore, 50% of 
respondents indicated that the resistance of the central laboratory to release control of testing 
was either “not relevant” or “rarely relevant” in terms of impeding the more widespread 
adoption of POCT within their clinical place of work (23% of participants indicated this issue was 
sometimes relevant).   A total of 67% of respondents indicated that alterations to clinical care 
pathways and the role of the central laboratory were either “not relevant” or “rarely relevant”.  
Additionally, 57% of participants believe that there is “no relevance” or “little relevance” with 
regard to the requirement of an interdepartmental management structure with clear clinical 
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governance for POCT, with 1 consultant commenting that testing accreditation for POCT nullifies 
this problem within their Health Trust.   
 
Figure 4.19 - Clinician opinion of relevance of specific staff and operational issues within their own 
clinical institution (n=48). 
The remaining 2 issues displayed much more varied responses and the most frequent response 
to each was in the “sometimes relevant” category, although this would not be considered a 
significant majority in either case (27% of responses for inappropriate use of POCT and 31% of 
responses for reluctance to change and a lack of evidence).  Inappropriate use of POCT saw much 
disagreement, comments from interviewed consultants include the following: 
• “POCT enhances the clinical picture but sometimes tests are carried out and results are 
ignored.” 
• “There is overuse due to the appropriate pathways not being in place.” 
• “POCT is often used simply as a delay tactic to buy more time before a decision is made.” 
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• “Yes, but overuse in terms of results does not affect patient management.” 
• “There is a lack of application of clinical skills, but this can be said for all blood tests, not 
just POCT.” 
Opinion was also very much divided with respect to any difficulties encountered with 
implementing POCT due to general reluctance to change within the health system and a lack of 
evidence justifying the use of POCT.  Some participant comments in the response to this issue 
include: 
• “There is a lot of enthusiasm for POCT and companies are spending a fortune on 
development and the associated evidence of usefulness.” 
• “There is a lot of evidence coming out for POCT, the issue is proving it will be used 
regularly enough to justify it.” 
• “There is lots of evidence now, the issue is funding the service.” 
• “Not so much reluctance but the evidence isn’t great, POCT always lags behind the lab 
in terms of development.” 
• “Not as much reluctance but there is a lack of evidence and understanding of the benefits 
of quicker results.” 
4.3.5 Other General Issues 
In addition to the highly-specified aspects of the survey tool, participants were also questioned 
more generally with respect to their opinion of the real value of POCT.  This final part of the 
study gave an opportunity for free response by the respondents.  Firstly, participants were asked 
to indicate the main advantages that POCT offered in comparison to CLT.  The responses 
provided are summarised in order of frequency as follows: 
• Rapid turnaround time (TAT), resulting in a quicker decision/diagnosis and earlier clinical 
intervention (96% of respondents). 
• More efficient patient management (27% of respondents). 
• Improved patient/operator satisfaction and convenience (27% of respondents). 
• Improved quality of care and better patient outcomes (18% of respondents). 
• Avoids sample transfer where there is no laboratory on site or within close proximity 
(9% of respondents). 
• Ease of use (7% of respondents). 
• Helps meet political targets i.e. TAT targets and patient waiting times (4% of 
respondents). 
• Provides the ability to the clinician to repeat tests (4% of respondents). 
• Less reliance on a chain of services where delays are more likely (4% of respondents). 
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• Cost savings (4% of respondents). 
• Reliability and accuracy (4% of respondents). 
• POCT provides a good backup service when laboratory or sample transport systems are 
down (individual response). 
• Avoids sample stability issues during transport (individual response). 
• Transfers some of the laboratory workload to the wards (individual response). 
• Provides control of when the sample is tested to the clinician and the opportunity to 
perform serial testing (individual response). 
• Overcomes issues with bad access to hospital services (individual response). 
Clearly, the overwhelming response was that of a rapid TAT, resulting in a quicker 
decision/diagnosis and earlier clinical intervention, which was indicated by 96% of participants 
in this study.  Efficiency in patient management and patient/operator satisfaction and 
convenience are also both significant at 27% each. 
Similarly, participants were questioned with regard to the main disadvantages of using POCT in 
comparison to CLT.  The responses are summarised as follows in order of frequency as follows: 
• Increased cost (31% of respondents). 
• Poor quality / inaccuracy of result obtained by untrained or non-competent staff and 
the consequent risk to the safety of the patient (31% of respondents). 
• Lack of connectivity to central healthcare and patient record systems (22% of 
respondents). 
• Quality management requires significant resources and is difficult to control due to 
dispersed nature (20% of respondents). 
• Staff training requires a lot of time (20% of respondents). 
• Reduced accuracy compared to CLT and duplication of tests carried out by the central 
laboratory (18% of respondents). 
• Difficulty in ensuring continued staff competency and unfamiliarity caused by a lack of 
regular use (13% of respondents). 
• Inappropriate use i.e. over-use and reliance on results undermining clinical expertise 
(11% of respondents). 
• Results and subsequent interpretation highly dependent on operator competency (11% 
of respondents). 
• Takes up a lot of staff time (11% of respondents). 
• Auditing and clinical governance is difficult due to fragmentation of the service; lines of 
accountability are very unclear (7% of respondents). 
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• Requires awareness of limitations otherwise use is dangerous (4% of respondents). 
• Little support from senior management for POCT (4% of respondents). 
• Lack of a specific budget for POCT (individual response). 
• Financial benefits are difficult to prove despite an improvement in patient care 
(individual response). 
• Sufficient skills are required to perform POCT and so it may not be a 24-hour service 
(individual response). 
• Added responsibility on another healthcare professional with regards to calibration, 
ordering test strips etc. (individual response). 
• Maintenance of devices is difficult (individual response). 
• Devices are less reliable in terms of breaking down (individual response). 
• Lack of troubleshooting help when devices break down (individual response). 
• POCT not widely available in all institutions (individual response). 
In this case, it is the increased cost of POCT and the poor quality/inaccuracy of the results 
obtained by untrained or non-competent staff (and the consequent risk to the safety of patients) 
that are the 2 disadvantages that appeared as the most common, being indicated by 31% of 
respondents for each. 
With respect to the clinical value of POCT, participants in the study were further asked to give 
their opinion on which diseases and/or conditions benefitted most from the use of POCT.  The 
responses from this consideration of clinical opinion are summarised in order of frequency as 
follows: 
• Respiratory conditions i.e. blood gas testing (67% of respondents). 
• Diabetes i.e. blood glucose testing (67% of respondents). 
• Blood coagulation, i.e. International Normalised Ratio (INR) monitoring (42% of 
respondents). 
• Cardiac conditions, i.e. cardiac marker testing (29% of respondents). 
• Sepsis testing (29% of respondents). 
• Urine pregnancy testing, i.e. in ED or surgery (18% of respondents). 
• Other blood tests, i.e. HBA1C, lactate etc. (18% of respondents). 
• Monitoring of foetus condition during pregnancy (16% of respondents). 
• General trauma and internal bleeding, i.e. emergency conditions (13% of respondents). 
• Drug addict patients, (11% of respondents). 
• Brain injury and critical care patients, i.e. ventilated (7% of respondents). 
• Gastroenterology (individual response). 
 83 
• Patients with mental health issues (individual response). 
• General surgery (individual response). 
• Hypotensive patients (individual response). 
• Influenza (individual response). 
• Infectious diseases in developing countries (individual response). 
Respiratory conditions (i.e. blood gases) and diabetes (i.e. blood glucose monitoring) were found 
to be the 2 most prominent diseases served by POCT here, both having been cited in responses 
by 67% of study respondents.   
In order to further satisfy the solutions-based approach undertaken in this research, participants 
were asked to provide suggestions as to how any of the real or perceived barriers to the 
adoption of POCT technologies could be overcome.  The responses obtained according to 
frequency are as follows: 
• Audit the use of POCT to provide evidence of clinical and/or economic benefits to stake 
holders as a way to overcome issues such as mistrust of POCT and a lack of full backing 
for its implementation by the healthcare system (36% of respondents). 
• Better connectivity to central healthcare systems and interfaces (27% of respondents). 
• Improved training processes, including re-training and mandatory centralised training 
(24% of respondents). 
• Reduced costs from manufacturers for both the devices and their implementation via a 
form of a central POCT funding (20% of respondents). 
• Regional consensus/strategy on POCT procurement (18% of respondents). 
• Increased laboratory support for implementation and after-care, i.e. dedicated team to 
look after QA in POCT (18% of respondents). 
• Improved QA processes and auditing processes for POCT to ensure confidence in them 
(13% of respondents). 
• Closer collaboration between the areas involved (11% of respondents). 
• Treat the introduction of POCT tests in the same as that employed for the introduction 
of new drugs, i.e. through a proper change management project (4% of respondents). 
• Increase availability of POCT though the system (4% of respondents). 
• Increase use of POCT in primary care (individual response). 
• Give feedback on POCT performance to stakeholders following implementation 
(individual response). 
• Improve user-friendliness of devices (individual response). 
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• Adopt a more streamlined path from device development to clinical use (individual 
response). 
• Manufacturers encouraged to provide free pilots of POCT systems so that benefits can 
be witnessed first-hand (individual response). 
• Increased transparency of governance arrangements and expectations throughout the 
application process for such devices (individual response). 
• Improvements to the sampling and analytical capabilities of the devices (individual 
response). 
• Restrict the use of POCT to controlled environments, i.e. specialist clinics; based on the 
fact that 24-hour access machines are difficult to regulate and there are issues with 
ensuring the competency of operators (individual response). 
The most common suggestion offered here was to audit the use of POCT in order to provide 
evidence to stakeholders of any clinical and/or economic benefits attainable in order to 
overcome issues such as laboratory mistrust and a lack of full backing by the full health system, 
as indicated by 36% of study respondents.   
Considering the current impact on POCT adoption, the survey participants were asked to rank 
the 4 categories of issue identified from systematic literature review study (economic, quality 
assurance & regulatory, device performance & data management and staff & operational issues) 
on a scale of 1 to 4, with 1 being the most important in regard to POCT uptake and 4 being least.  
These data were managed using a tiered scoring system to accumulate the categories into a final 
ranking order, where a category would receive 4 points for a first-place ranking, 3 for a second-
place ranking, 2 for a third-place ranking and 1 point for a fourth-place ranking.  The scoring 
frequency of the resulting responses are provided in Figure 4.20.  Using this scoring system, 
economic issues along with device performance and data management were both ranked as 
having the most current impact on POCT uptake within UK hospitals and Health Trusts, with a 
score of 123 each.  The third most important category in this regard was found to be device and 
data management issues with a score of 105, with staff and operational issues placed as having 
least current impact on POCT uptake with a score of 99. 
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Figure 4.20 - Clinician opinion on the ranking of relevance of categories of barrier to adoption of 
POCT (n=45). 
4.4 Discussion 
The primary data collected herein is intended to test the validity of the findings from the 
systematic literature review reported in Chapter 3.  The core objective is to determine which 
issues actually exist in reality for the adoption of POCT and what the significance of these are in 
clinical practice.  The study group was chosen as a sample of the UK NHS which has been selected 
as an example of a healthcare system free at the point of delivery. 
Interestingly, the ranking by study participants of the barrier to adoption categories in terms of 
current impact upon POCT uptake (Question 26) mirrors the findings from the systematic 
literature review study, in that economic issues along with quality assurance and regulatory 
issues were found as being the most prevalent categories cited in both the literature and within 
UK hospitals and Health Trusts.  This clearly gives a strong indication of the significance and 
relevance of these categories in regard to improving the uptake of POCT.   
Notwithstanding their obvious significance, it is important to consider these categories in finer 
detail in order to better understand the fundamental underlying issues.  Focusing firstly on the 
economics of POCT, there is clear agreement amongst the majority of clinicians in this study that 
the cost per test is higher than that associated with CLT.  It is also important to note that the 
majority of participants also suggested that the use of a POCT system is cost-effective.  
Therefore, the dilemma here is very much with respect to weighing up the increased costs 
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barrier with respect to current impact on POCT adoption.
 86 
against the benefits to clinical care that POCT can bring, as confirmed by comments made by 
those interviewed in the face-to-face aspect of the study.  If benefits to clinical care are 
apparent, then increased cost cannot be considered a barrier to uptake as improved care should 
always take precedence in a healthcare system free at the point of delivery such as the UK NHS.  
This is because this system must be run in a cost-effective manner.  While reduced costs may 
bear a short-term economic advantage, the overall efficiency of the system will suffer.  It has 
been demonstrated that the improved quality of care in the NHS results in overall cost savings 
through both quality-adjusted life years and reduced patient lengths of stay (Meacock, 
Kristensen et al. 2014).  The issue arises when benefits to the quality of clinical care are not 
obvious and/or are difficult to measure adequately.  There is expert opinion within the academic 
literature suggesting that, while POCT can provide longer term economic benefits (for example 
those attainable through a reduced length of stay for patients in hospital and reduced numbers 
of outpatient appointments), there is difficulty in placing a financial value on such gains attained 
over the longer timescale (St John 2010, Crook 2000).  Accurately evaluating both the clinical 
and long-term economic value attainable through the use of POCT is necessary to overcome 
these particular perceived issues of increased cost.  Attaining cost-effectiveness data was 
indicated to be problematic by a significant proportion of participants due to the apparent lack 
of a defined budget for POCT.  In many cases, the financing of POCT comes out of one overall 
pot (i.e. a yearly budget for a department), making the measurement of their cost-effectiveness 
difficult.  Procurement, reimbursement and budgeting were generally found to be areas of 
significant debate in this study with regard to accommodating the interdepartmental nature of 
POCT deployment.  This variation in opinion is potentially due to the utilisation of POCT devices 
being different across the hospitals and Health Trusts considered as part of the study.  A number 
of clinicians commented that the interdepartmental sharing of POCT devices was due to be 
stopped or had already been prohibited in their workplace due to cross-infection concerns.  
However, other consultants interviewed commented that access to the devices in their 
departments was often abused by other departments without any reimbursement for their use.  
It is therefore difficult to define the extent to which POCT devices are used as interdepartmental 
resources in reality.  The concept of “silo budgeting” (of separate budgets for different 
departments) and current reimbursement methods have already been noted for their 
incompatibility with an interdepartmental technology such as POCT in the literature base 
reviewed in Chapter 3, with reimbursement being labelled “the final barrier to a significant POCT 
market” (Huckle 2006).  
Consideration of specific economic barriers to POCT adoption within the hospitals and Health 
Trusts surveyed indicated that 3 issues were seen by approximately half of the participants as 
being of significant relevance within their place of work.  Firstly, difficulties in justifying the 
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implementation of a POCT system due to the true cost-effectiveness of such a system being 
difficult to gauge and the direct cost comparison studies against traditional CLT methods being 
complex.  Secondly, difficulties due to the relatively high initial implementation costs.  Thirdly, 
difficulties associated with the higher cost per test of POCT in comparison to CLT.  Although this 
evidence may not be enough to suggest that these issues are endemic across all clinical areas in 
the UK NHS, clearly there are certainly pockets within the surveyed Health Trusts where they 
are seen as being highly relevant.  Variation in responses with respect to economic issues does 
not appear to follow any pattern based on clinical specialty and it is likely that these economic 
issues are the product of specific budgeting and procurement implementation within individual 
hospitals and Health Trusts.  When analysing the economic issues, it is clear that there is 
significant debate regarding the true value of POCT with regard to assessing the increased cost 
versus the possible clinical benefits that this type of near patient of testing can bring.  In 
Northern Ireland (as in the rest of the UK) health services are continuing to experience reduced 
funding, therefore the economic impact of all services will always be highly scrutinised.  As such, 
the cost of new technologies is a major consideration in the process of adoption along with the 
complexity and scale of the technology, in addition to aspects such as; trialability; consistency 
with existing values; previous experiences of stakeholders and user needs/requirements 
(Llewellyn, Procter et al. 2014).  However, common themes were relayed by respondents that 
could be used to further understand and overcome the issues surrounding costs and economics.  
Firstly, the requirement for a centralised POCT budget is clear, and would allow greater control 
of POCT spending, leading to increased transparency of the process which would then allow for 
a more accurate understanding of the cost-effectiveness realised through POCT use.  Secondly, 
a significant proportion of respondents have indicated that there needs to be centralised 
procurement and a more clearly defined purchasing strategy for POCT and that this would allow 
for a more efficient use of devices within clinical institutions.  It is apparent that individual 
departments are commonly purchasing their own devices but that these are not used frequently 
enough to justify the costs involved.  A more centralised procurement process would allow 
devices to be purchased and utilised on a joint basis between departments with the attendant 
benefits this brings.  Thirdly, based on this study, it is clear that there is a lack of strong evidence 
on clinical outcome improvements that POCT can provide which are needed to convince 
stakeholders that the benefits from such devices justify the cost of their implementation.  The 
lack of evidence and literature on cost-effectiveness is not limited to POCT alone, yet is a 
characteristic of the diagnostic sector as a whole within healthcare delivery.  This is a 
consequence of the traditional model of reimbursement strategy employed in laboratory 
medicine, based upon the complexity of test as a function of delivery as a cost-per-test service, 
hence discouraging the development of an appropriate evidence base (St John, Price 2013).  In 
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summary, although economic issues impact upon the uptake of POCT, much of this is a reflection 
of the nature of the current financial environment within UK healthcare system, rather than any 
specific characteristics of the POCT devices themselves.  This type of testing, although more 
expensive than CLT, is nonetheless deemed to be cost-effective by healthcare professionals and 
so emphasis should be placed on providing the evidence of the clinical benefits that justify any 
increased costs at the outset.  
Similarly, when considering quality assurance and regulatory issues relating to POCT use, several 
important points are noted.  Firstly, it is apparent from a significant number of responses that 
the decentralised nature of the devices gives rise to increased opportunity for their use by 
untrained or non-competent staff.  Further analysis with respect to the demographics of 
participant responses indicates that those from the clinical biosciences speciality (n=7) gave an 
average response of 9.5 on the 10-point scale used, indicating strong agreement that this was 
the case.  However, by comparison, respondents from general medicine (n=7) averaged a 
response of 3.6 on the same scale, indicating significant disagreement.  Hence, a clear 
disconnect in opinion is recognised between those clinicians who are essentially responsible for 
the quality of testing within their respective hospital or Health Trust, and those who actually 
utilise the POCT devices for patient care.  The perspective of those most associated with the 
central laboratory is perhaps understandable, quality within this area is dependent on a small 
number of highly skilled individuals operating sophisticated instruments who are the direct 
responsibility of the central laboratory service.  Conversely, quality for POCT is dependent on a 
large number of analytically unskilled individuals operating smaller, less sophisticated devices, 
who are not part of the personal management structure of the central laboratory.  Such quality 
issues are not limited to untrained individuals specifically, but rather there are a number of 
concerns by the central laboratory regarding the use of devices by clinical staff, namely; the 
integration of daily quality control procedures into an already hectic role; device maintenance 
and troubleshooting, and; an impact on workflow within the respective clinical unit.  Expert 
opinion has suggested that this can be overcome through the operation of POCT by laboratory 
personnel within the clinical units via the implementation of satellite laboratories (Shaw 2016).  
It has been demonstrated that, despite POCT users undertaking comprehensive training, 
operators were often unwilling or unable to carry out simple tasks with POCT, due to infrequent 
errors in the experience of the user and unfamiliarity with devices (O'Kane, McManus et al. 
2011).  The suggestion provided once more is that the increased support for POCT by staff from 
the central laboratory could be a solution to overcoming these concerns.   
Regulatory requirements, imposed in an attempt to ensure quality, were also raised as an area 
of concern in the literature study.  Specifically, managing a POCT system to maintain such 
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regulatory requirements has been cited as a possible impediment to their wider uptake (Lee-
Lewandrowski, Lewandrowski 2001).  These issues relate to a number of areas including; the 
dispersed nature of the devices making them difficult to ensure compliance, a lack of knowledge 
by clinicians on the exact specifics of the regulatory requirements and the regulatory 
requirements for POCT being overly complex.  It was apparent from responses in this area of the 
study that a lack of knowledge does indeed exist, 6 clinicians did not respond to this particular 
question due to a lack of knowledge and a strong variation in responses overall was noted.  
Increased education on the regulatory requirements must be delivered to clinicians involved 
with POCT, difficulties arise when central laboratory personnel (who have knowledge of the 
regulatory requirements) are expected to ensure compliance for a dispersed system of devices 
that other clinical cohorts utilise on a day-to-day basis.  Furthermore, while the evidence base 
for internal quality control has been increasing with respect to CLT, literature with respect to 
POCT is very limited, leading to wide variation on what is considered to be acceptable quality 
control practice in this regard (Holt, Freedman 2016).  Considering the complexity of 
requirements, participant response indicated that the regulations were complicated, however 
there is also an acceptance of the requirement to ensure quality assurance matches that of the 
central laboratory.  Therefore, this situation is accepted to ensure quality.  For example, if the 
regulations for the laboratory are complex then POCT regulations must match this regardless of 
their uniqueness.  It is clear that in order to ensure compliance with regulations there must be 
a link between those who are responsible for testing quality, i.e. the central laboratory and the 
clinical groups that utilise POCT devices.   
Levels of operator training and general support for POCT by the central laboratory showed no 
strong trend according to results of this study.  A more detailed analysis and consideration of 
comments made by face-to-face responders in this study indicates that poor levels of support 
by the central laboratory are not necessarily considered to be a barrier to the uptake of POCT.  
Of the respondents that stated that the level of support and training that they had received from 
the central laboratory was low, the majority suggested that this was due to the fact that much 
of the training (and support) is actually provided by the device manufacturers themselves.  This 
direct support was overseen by the central laboratory service, an arrangement that the clinicians 
are, in general terms, very satisfied with.   
Consideration of the specific quality-related barriers to POCT adoption within the hospitals and 
Health Trusts surveyed via Question 13 found that the majority of study participants found these 
issues not to be relevant or to be rarely relevant.  The consensus amongst these clinicians was 
that, although potentially errors could happen through the use of POCT, adequate controls were 
in place to prevent them from happening within their areas of practice.  It should be noted that 
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even if errors are very small (in terms of a percentage of the number of tests completed), this 
could still be catastrophic with respect to the provision of patient care and wellbeing.  A 
disconnect has been noted here between the opinions of those clinicians who work in clinical 
biosciences and those in other areas of hospital-based care in that the former are of the opinion 
that quality issues are more of a significant impediment to POCT use than those who actually 
use the tests as a diagnostic tool.   
With respect to overcoming any quality related issues, 2 common themes were apparent.  
Firstly, provision of improved training processes would help to overcome the significant 
impediment associated with devices being operated by untrained or non-competent staff.  Even 
if untrained or non-competent staff do not operate devices in a particular institution, there have 
been suggestions by study participants that the fear of this problem is enough to introduce a 
lack of trust, leading to reluctance from the central laboratory to promote decentralised testing.  
These attributes that healthcare technologies acquire through the course of often contested 
deliberations regarding adoption have been termed “technology identities” and have been 
recognised as being an explanation for non-adoption of POCT (Peirce, Faulkner et al. 2015).  One 
potential way of implementing improved training processes would be to introduce mandatory 
centralised (regional) training for POCT use, much in the same way that training for blood 
transfusions is managed.  The second common solution involves improved quality assurance 
processes and auditing to be carried out with a dedicated team to oversee this.  It is more than 
likely that this team would be provided by the central laboratory service.  In order to ensure that 
the devices remain compliant with regulations it is necessary that there is appropriate 
(increased) aftercare support provided by the central laboratory service. Currently, it seems that 
once implementation and initial training is carried out these support levels can be low in many 
cases.  It is possible that this is a consequence of the design of POCT systems.  Manufacturers of 
such devices have recognised that the main consumers/users of POCT in the future will be health 
professionals from a non-laboratory background and hence made significant effort to 
incorporate adequate internal quality controls within the devices so that the expertise of a 
trained laboratory professional is not required for routine operation and utilisation.  Therefore, 
the newly incorporated internal quality control checks have displaced the requirement for some 
traditional control methods somewhat and in doing so potentially reduced the obligation for 
laboratory intervention (Gill, Shephard 2010). 
The dynamic between those groups, firstly utilising the POCT devices in the clinic and, secondly, 
the central laboratory service that are responsible for test quality, has been found to be a 
fundamental consideration with respect to determining the reality of barriers to uptake of POCT.  
Central to this notion is the perceived reluctance to allow control of diagnostic testing beyond 
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the tight laboratory confines.  Clinical opinion on this controversial area is seen to be significantly 
varied according to the results of this study.  By separating responses into different clinical 
specialties some interesting findings can be appreciated.  On the 10-point scale used (where 10 
is strongly agree), emergency medicine clinicians (n=15) averaged a response of 6.7, 
anaesthetics and intensive care clinicians (n=5) averaged a response of 9.2, while those from 
within the clinical biosciences discipline (n=7) averaged a response of just 4.  Perhaps 
unsurprisingly, those clinicians who are less directly associated with the central laboratory are 
in more agreement with this statement than those with closer associations.   The majority of 
comments from respondents within the clinical biosciences environment were based around an 
opinion that, although the use of POCT displaced tests away from the central laboratory and 
hence reduced workload somewhat, this increased the risk of quality assurance errors being 
made by non-laboratory clinicians who were perceived as not being competent to perform such 
diagnostic tests. Some clinicians working outside of the central laboratory did comment that this 
reluctance to release the control of testing was understandable as diagnostic testing was the 
governance role of the service.  However, a substantial number were in agreement that this 
issue significantly impacts upon the more widespread adoption of POCT within their clinical 
workplace.  Again, it must be considered that improved training processes, along with increased 
aftercare support from the central laboratory, would do much to overcome the notion of 
clinician incompetence held by the clinical biosciences cohort.  There is some recognition of the 
fact that this barrier is actually a necessary one, due to the potential dangers associated with 
quality errors in terms of patient care and wellbeing.  Quality assurance becomes more complex 
as diagnostic testing becomes more decentralised, with a greater number of individuals having 
access to the devices.  Despite controls implemented by manufacturers, POCT instruments are 
still greatly dependent on the expertise of the operator.  As such, institutional principles of a 
quality management system must be rigorously adhered to by the operators of POCT devices, 
all of whom should be trained appropriately before they are permitted to operate the devices 
(Larsson, Greig-Pylypczuk et al. 2015).  Comments made by all of the clinicians surveyed within 
this study indicate that they are unanimously of the opinion that POCT, and any other type of 
clinical technology for that matter, must be implemented and adopted into healthcare 
institutions in a controlled manner.   
There were indications from the literature study that the implementation of POCT significantly 
increases the workload of clinical staff, hence acting as an impediment to its uptake and causing 
levels of dissatisfaction amongst these staff (Zydron, Woodworth et al. 2011, Fermann, Suyama 
2002, Giuliano, Grant 2002).  However, although there were variations in the results, the 
majority of respondents in this study indicated that this was not the case in reality.  In fact, most 
comments made by clinicians specified that performing a test using POCT took either the same 
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or less time than sending a sample to the central laboratory and then “chasing up” the result.  
An analysis of the demographics of responses indicates that the clinical biosciences cohort are 
more of the opinion that POCT increases the workload of front line clinical staff in comparison 
to that of staff of the other disciplines in that, on the 10-point scale used to answer this question 
(where 1 was strongly disagree and 10 was strongly agree), general medicine clinicians (n=7) 
averaged a response of 3.4, while the clinical biosciences participants (n=7) averaged a response 
of 6.9.  Clinicians working less closely with the central laboratory service tended to disagree 
more with the idea that this issue exists due to their belief that using POCT approximately 
equates to or is less than the time required to take a sample, send it to the lab and wait for a 
result.  Conversely, professionals with closer links to the central laboratory argue that POCT 
increases the workload for their staff as in many cases they are responsible for ensuring the 
quality assurance of the devices via appropriate checks (quality control, calibration etc.).  It must 
be considered however that increased workload does not solely encompass the performing of 
tests and QA procedures, but also includes an increased amount of training that operators must 
undergo in order to satisfy regulatory requirements (Rooney, Schilling 2014).  With this in mind, 
it is difficult to argue that POCT does not add a burden of time to an already busy role of the 
typical clinical user.   
The consistent disconnect in opinion between the central laboratory and mainstream clinical 
groups raises questions regarding whether the role of the central laboratory (and also relevant 
clinical care pathways) have adapted sufficiently to incorporate the efficient use of a POCT 
system.  In this regard, the results from this study are inconclusive, in that a significant variation 
in opinion was obtained.  Typically, patient pathways and the role of the central laboratory have 
adapted in areas where POCT has been embedded over a longer period of time, such as in 
diabetes management and warfarin control.  Glucose testing is the largest sector of the 
professional POCT market, i.e. that performed by healthcare professionals and not by patients 
using “over the counter” devices (St John, Price 2014).  The development of patient pathways 
and role of the central laboratory in the area of diabetes management, for example, is due to 
the trust that has built up over time with respect to the quality management of devices and the 
high reliability of results.  Therefore, similar levels of trust are clearly required in other areas to 
allow the health service to adapt fully.  This can be attained through the provision of clear 
evidence of performance and reliability of such tests.  By assessment of the current rates of 
growth within the professional POCT market, infectious diseases is the most rapidly growing 
sector (St John, Price 2014) and as such may become more embedded within delivery of 
secondary healthcare in the near future. 
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The final category of barrier to adoption of POCT that was identified by the literature review 
study focused on device performance and data management.  Interestingly, usability and 
analytical performance of POCT devices were found not to be major issues for the clinicians that 
took part in this primary study.  These particular issues may have been a problem historically, 
but it would seem that with the development of new technologies and evolution of devices this 
is no longer the case.  Developments in both paper-based and “lab on chip”-based microfluidic 
POCT devices have significantly expanded the range and complexity of these types of tests 
available and their associated analytical capabilities.  Key developments in this regard include 
miniaturised, automated technologies and the development of long-term reagent storage 
strategies (Vashist, Luppa et al. 2015). 
Connectivity and data management capabilities of POCT devices, however, were generally rated 
as being “poor” or “very poor” by participants in this study.  Nevertheless, the majority of the 
respondents who indicated this also were of the opinion that the poor connectivity or data 
management did not make it more difficult to attain a timely and reliable diagnosis.  The general 
consensus here was that POCT is used to obtain real time results that aid quick decisions, often 
in situations where access to previously recorded data is not important for direct patient care.  
Therefore, it would seem that, although the connectivity and data management capabilities of 
POCT are poor in comparison to that for CLT instruments, this does not act as an impediment to 
their intended utility overall.  Nonetheless, better connectivity of the results from POCT devices 
to central healthcare systems was a common consideration for clinicians with respect to 
potential solutions to overcoming barriers to their uptake.  It was apparent that the core issue 
here lies with the sheer number of different interfaces with which the different types of POCT 
device needed to be compatible.  Whereas, CLT instrumentation generally all runs under one 
common interface, POCT devices are very fragmented in this respect thereby causing data 
management issues.  The creation of a standardised interface for POCT would be a fairly simple 
and inexpensive solution to overcoming this problem. 
The general utility of POCT was evaluated as part of this study in order attain as complete an 
assessment of the barriers to its adoption as possible.  With respect to the potential benefits, 
the information gathered here categorically indicates that a rapid TAT and hence quicker clinical 
decisions/interventions are the most important advantages that POCT has in comparison to CLT.  
It is not unexpected that those who have used or have knowledge of the utility of POCT in their 
area of clinical specialty, will see this as the most obvious benefit.  Other common advantages 
offered by POCT include increased efficiency with respect to patient management and improved 
satisfaction and convenience for both operator and patient.  Unsurprisingly, the most indicated 
diseases/conditions deemed to benefit most from the use of POCT were the 3 areas where these 
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technologies have become most widely accepted and embedded, specifically blood glucose 
monitoring for diabetic patients, INR monitoring for patients receiving warfarin therapy and 
respiratory conditions.   
By comparison, the 2 most common disadvantages of POCT in comparison to CLT were increased 
cost and quality issues stemming from untrained or non-competent staff using the devices.  The 
reason that there is no definite “stand out” disadvantage indicated here is likely due to the fact 
that issues with POCT are highly dependent on the environment in which they are utilised.  
Whereas, the nature of technology will generally lend itself to improving TAT no matter where 
it is deployed, disadvantages such as quality issues are related to a number of factors such as 
how often the device is used in a certain department, the level of training and re-training that is 
carried out by the clinical institution and the turnover/rotation of staff within a department.  
What we can deduct from variation of response in this study is that opinion on the value of POCT 
is highly dependent on a range of factors including how the devices are utilised within a specific 
clinical environment and the associated support for their role.   
4.5 NHS Validation 
In order to validate the results from the 5 HSCNI Trusts as representing a true reflection of the 
wider UK health system as a whole, the electronic component of the study was hence replicated 
at NHS Frimley Health Foundation Trust.  In total, 7 clinicians from this Trust took part, 5 from 
an emergency medicine background and 2 from a clinical haematology background.  In terms of 
the economic considerations, the results were in line with what was indicated by the main study, 
namely that the majority of clinicians agreed that the cost of POCT was higher than CLT, yet also 
indicated that the use of POCT was cost-effective and that longer-term economic benefits were 
available through its use.  In regard to quality issues, the results also followed trends seen in the 
main NI study, in that opinion was varied and a certain disconnect was identified between those 
utilising POCT and those responsible for POCT.  Polarised opinion between clinical cohorts was 
noted with respect to; quality issues caused by the dispersion of devices leading to use by 
untrained or non-competent staff, over-complexity of analytical testing accreditation 
regulations for POCT and, levels of operator training and support for POCT provided by the 
central laboratory.  One notable difference between this study and the main NI study was 
identified in the category of device performance and data management, specifically the 
connectivity of POCT.  Whereas, those in the 5 NI Trusts generally rated connectivity as being 
poor, in the UK NHS study it was rated as being significantly high.  This suggests that It is perhaps 
worth investigating if the systems and interfaces used in the NHS Trusts in comparison to HSCNI 
Trusts to see if the Northern Ireland system is lagging somewhat in this respect.  However, this 
is beyond the scope of the current study.  Considering the other issues in this category, both 
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analytical performance and usability were comparable in both parts of the study (NI and UK).  
The final category of staff and operational issues, like the main primary study conducted in NI, 
displayed much variation in opinion.  However, it was difficult to identify any disconnect in 
opinion between clinical cohorts.   
The study described here has been executed as a means of achieving the fourth research 
objective as defined in Chapter 1; to determine the relationship between those issues identified 
from a consideration of the academic literature (in Chapter 3) and the opinions of clinicians 
within the UK healthcare environment on the same issues.  The findings of the academic 
literature have been used to frame this study that has successfully attained primary data used 
to determine such a relationship.  Furthermore, the study has been used to help achieve the 
final 4 objectives as defined earlier in Chapter 1, namely; to identify the key advantages and 
potential benefits of POCT use within secondary healthcare; to identify the major disadvantages 
deemed to result from the use of POCT; to determine the clinical areas/situations in which POCT 
can provide the most benefit in secondary care, and; to suggest how the most significant barriers 
to adoption of POCT in the relevant secondary healthcare systems can be overcome based on 
the findings of the studies undertaken, i.e. what are the possible solutions that may encourage 
more effective adoption?  Data on the advantages/benefits, disadvantages, areas of potential 
best practice and recommendations for overcoming barriers has been collated and will be used 
along with such information gathered from the following 2 primary studies in order to fully 
achieve these objectives. 
Notwithstanding the minor variations noted above, it can be deducted that the results of the 
main NI centric study are indeed representative of the wider UK health system as a whole.  
However, it is acknowledged that the UK system is not homogeneous with respect to utility and 
experience of POCT.  Moreover, it does not reflect that of POCT as a global entity.  Hence, it is 
deemed important to gain clinical opinion from within a health system significantly different in 
nature to the UK system of free healthcare provision, where the management of care is 
determined by specified clinical pathways based on resolution of the episode and quality of care, 
rather than on supplementary factors such as the level and substance of an individual’s 
insurance policy, as in the US system of healthcare.  To this end, research was conducted in the 
US healthcare system and the results compared to findings in the UK as outlined in the next 
chapter. 
4.6 Statistical Comment 
In addition to that described here, a statistical analysis has been applied in order to further 
investigate the perceived differences in opinion observed between those responsible for POCT 
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(denoted here as clinical bioscientists) and the clinicians who are responsible for use and 
operation of the devices as diagnostic tools.  Specifically, this study has indicated 3 areas where 
such differences in opinion exist.  Firstly, that the decentralised nature of POCT gives rise to 
opportunities for untrained / non-competent staff to use the devices, hence leading to certain 
quality assurance issues (Q10).  Clinical bioscientists were found to have a very polarised and 
strong opinion that this was the case.  By analysing the data by way of the Chi-square test 
through a comparison of responses by clinical bioscientists versus clinicians, a p-value of 0.011 
was returned.  Being under the threshold value (<0.05) it can hence be deducted that the 
differences of response between these 2 clinical groups are indeed statistically significant and 
are not down to chance.   
The second area where clinical groups appeared to offer differing responses was with respect 
to whether the utilisation of POCT significantly increased the workload of front-line clinical staff, 
where clinical bioscientists were of a stronger opinion that this was the case.  Again, by 
application of the Chi-square test, a p-value of 0.039 was returned.  Once more, this has 
determined this difference in opinion as being statistically significant.   
The third identified area where differences in opinion were observed between the clinical 
groups was with respect to the reluctance to allow the control of diagnostic testing to move 
outside of the confines of the clinical laboratory (Q19).  As was to be expected, clinical 
bioscientists were found to be less in agreement with this statement in comparison to clinicians.  
Following the same process of analysis as before, a p-value of 0.306 was found in this case.  Being 
above the threshold value, this suggests that the difference in opinion found here may be down 
to chance and cannot be deemed as being a statistically significant difference. 
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Chapter 5 
Clinical Perspectives on Barriers to Adoption of POCT from within 
the US Healthcare System 
5.1 Study Objective 
The research described herein follows on logically from the findings of the core study presented 
within Chapter 4, which focused on the barriers (real and/or perceived) to the uptake and 
utilisation of Point-of-Care Testing (POCT) devices within the UK National Health Service (NHS), 
i.e. in circumstances where provision of care that is free of charge at the point of delivery.  In a 
global sense, it is recognised that such UK-centric findings do not truly reflect the healthcare 
sector as a whole and that a comparison with a system that has a more direct charging model is 
warranted.  Accordingly, the research reported here utilises a representative sample of the US 
health system, where economics and levels of the patient’s health insurance play a more 
influential role with respect to the treatment provided for resolution of the medical episode 
(Shi, Singh 2015, Feldstein 2012).  The significance of the role that economic factors can play in 
the adoption of POCT devices is already apparent from research carried out to this point and so 
focusing on a setting where economics plays an enhanced role in service delivery has the 
potential to yield findings of much interest.  As such, the key research objective here is to 
determine if there is a significant difference in the perspectives to POCT uptake between the 2 
healthcare service models and specifically if the underlying economic model of the relevant 
health system has an influence on clinical opinion regarding the usefulness and utilisation of 
POCT devices within the hospital environment. 
5.2 Study Development & Design 
In order to ensure that the comparison provided a fair account of any significant differences 
between UK and US clinical practice, the overall study design for the latter was, as far as possible, 
a duplicate of that employed for the former.  Any differences reflect the need to make some 
appropriate changes to facilitate the intended study group.  Furthermore, emphasis was placed 
upon attaining insight into why there may be differences of opinion based on the model of 
healthcare delivery.  In particular, it was deemed important to implement the face-to-face 
aspect of the study in order to attain detailed opinions on the potential advantages, 
disadvantages and overall clinical utility of POCT from senior consultant-level clinicians and to 
this end field work was undertaken. 
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Utilising existing Ulster University connections, the University of Massachusetts (UMass) was 
selected as the collaborating organisation and suitable clinicians within the UMass Memorial 
Hospital (clinical partner of the UMass Medical School) in Worcester, MA were identified and 
invited to take part in the study through face-to-face interviews to be conducted on site at the 
hospital.  This group of clinicians was therefore selected as a representative sample of the US 
health system for the purposes of the proposed comparison.  With the assistance of a local 
collaborator at UMass Memorial Hospital, it was possible to recruit a sufficient number of 
clinicians to participate in the face-to-face interviews rather than use an on-line version of the 
(slightly modified) questionnaire.  
Careful consideration was given to how to best adapt the study configuration to account for the 
nature of the US healthcare system whilst maintaining an appropriate frame of reference to 
allow comparison of the outcomes with those from the UK study.  In order to achieve this 
important end, it was decided that the questions should be identical to those in the UK study 
with 1 additional question, this being “Are you aware of any differences between the US and UK 
healthcare systems that could affect the uptake of POCT within the clinical environment?”  In 
this way, any fundamental differences in the respective health systems that could influence 
and/or affect uptake and utilisation of POCT devices should be evident. 
Existing research governance and ethical approvals used for the UK study were submitted to the 
relevant office at the UMass Memorial Hospital and approvals granted to enable the interaction 
with clinicians to be undertaken. 
5.3 Study Results 
A total of 21 face-to-face interviews were carried out with senior clinicians on the site of the 
UMass Memorial Hospital, Worcester, MA.  A range of clinical specialties were targeted for these 
interviews in order to provide as diverse a background as possible with respect to the POCT 
experience of the study participants.  Table 5.1 provides a breakdown of respondents in terms 
of their clinical specialty.  The most represented categories were clinical biosciences, general 
medicine and POCT experts with 4 participants each.  The POCT experts, all of whom were 
identified as having substantial knowledge on the area were advanced nurse practitioners in this 
case, who play a significant clinical role within the US healthcare system with respect to the 
utilisation of POCT. 
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Table 5.1 - Breakdown of study participants with respect to clinical speciality (n = 21). 
 
1Four advanced nurse practitioners in emergency medicine, cardiology, immunology and general 
specialisms were identified as having expert knowledge on the area and were subsequently 
invited to participate in the study. 
Of the total (21) participants, 19 indicated that POCT devices were used in their area of clinical 
practice.  The 2 respondents who did not indicate this to be so, were involved in paediatric 
neurology and psychiatry.  However, they did have substantial knowledge on the clinical utility 
of POCT devices and so were deemed to be valuable to the study.  Those respondents that were 
currently utilising POCT in their area of clinical practice were asked to give an estimation of how 
many such tests were performed as a percentage of all of the diagnostic tests performed in their 
respective areas, with the average figure returned being 21%.  This is a very similar result to 
findings of the UK study where the value was 20% (based on 44 responses). 
To further gauge the background and skills of the participant group, clinicians were questioned 
with respect to the nature of their particular expertise in the practical use of POCT devices, with 
the data presented in Figure 5.1.  Proficiency with actual POCT devices was significantly varied 
in this group, with the most popular response being “untrained in the use of POCT devices” (7 
of 21 respondents).  However, 6 of 21 respondents stated that they were “highly proficient” and 
were in fact recognised trainers of the use of POCT, while 5 participants rated themselves as 
having “basic level capability” in the unsupervised use of these devices. 
Clinical Specialty Number of 
Respondents 
Emergency 
Medicine 
1 
Clinical Biosciences 4 
General Medicine 3 
Orthopaedics 2 
Paediatrics 2 
Dermatology 1 
Cardiology 3 
Psychiatry 1 
POCT Experts1 4 
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Figure 5.1 - Areas of clinical expertise as a function of POCT use by study participants (n=21). 
Figure 5.2 outlines the most common types of POCT utilised within the respective clinical care 
area of the respondents.  Various types of blood test available through the use of POCT were of 
most prevalence with blood gas and blood glucose tests along with urinalysis and urine 
pregnancy tests all featuring highly.  Within this study, only blood glucose POCT assays were 
used by over half of respondents (53%).  In comparison, 4 tests were used by over half of 
participants in the UK study (blood gas, blood glucose, urine pregnancy and blood lactate), with 
blood gas and blood glucose being very prevalent, used by 85% and 79% of clinicians 
respectively.  In general, it would seem that the more specialised the clinical background of the 
respondent, the more specific (and specialised) the type of test used.  For example, the 
Dermatology specialist participating in this study indicated that they used POCT for analysis of 
skin samples and it is unlikely that this particular test would be used in any other area of practice 
on a routine basis. 
Not completed 
training.
33%
Use under 
supervision.
0%
Basic level capability 
(unsupervised use).
24%
Competent 
(unsupervised use 
and maintenance).
14%
Highly proficient 
(recognised trainer).
29%
Question 2 - Participant expertise in the practical use of a 
POCT device
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Figure 5.2 - Most common POCT devices used in various areas of clinical practice with respect to 
percentage of respondents for each (n=19). 
5.3.1 Economic Issues 
The US clinical participants were questioned on the issues surrounding the economics of 
diagnostic testing within the hospital environment.  Answers were significantly varied in terms 
of the actual cost per test of POCT in comparison to that undertaken utilising Central Laboratory 
Testing (CLT), as outlined in Figure 5.3.  Just 7 of 21 participants agreed that the cost of POCT 
was higher than CLT (33%), while 9 (43%) thought the opposite.  The remaining 5 participants 
were not sure and opted not to give a response to this question. 
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Figure 5.3 - Clinician indication of POCT cost per test in comparison to that for CLT (n=21). 
Notable comments from those participants who agree that POCT has a higher cost per test than 
CLT include: 
• “Cost borne by the patient is often higher, and cost to the clinic is higher in order to meet 
training and regulatory requirements.” 
• “Universally central laboratory testing is cheaper, however POCT brings in more income 
for the clinic.” 
By contrast, some comments made by respondents who disagreed with this statement include: 
• “The increased efficiency of POCT must be considered.” 
• “Budget reimburses a minimal amount for POCT.” 
• “The hospital has privatised the laboratory off-site”. 
Participants were also asked to give their considered opinion on the statement that POCT 
provides longer term economic benefits, for example reduced hospital stay, reduced outpatient 
appointments etc.  As previously, the responses were given on a 10-point scale with the resulting 
data summarised in Figure 5.4.  Over half of the responses (57%) either “agreed” or “strongly 
agreed” that POCT provided these longer term economic benefits, thereby representing the 
majority of the response group.  However, a significant proportion of respondents remained 
“neutral” (24%) in this respect, while 19% of respondents either “disagreed” or “strongly 
disagreed” with the statement.   
Yes
33%
No
43%
Not sure / No 
response
24%
Question 7a - Do you agree that the cost per test of POCT 
is higher than CLT?
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Figure 5.4 - Clinician opinion on the longer term economic benefits attainable through the use of 
POCT (n=21). 
One comment made here by a participating orthopaedic consultant (who gave a “neutral” 
response) was of particular interest: 
• “This depends entirely on the setting.  For an anaesthetist, yes this would be the case.  
However, in my case I don’t want the result immediately, this would waste time and slow 
things down.  Sending the test to the laboratory and sending the patient home improves 
patient flow.  The patient will usually return in a week’s time for an outpatient 
appointment anyway so we can discuss the result then.  Therefore, POCT in my opinion 
has limited long term benefits and using the central laboratory actually improves patient 
management.” 
Those who “disagreed” or “strongly disagreed” with this statement were questioned further as 
to why they thought that potential economic benefits are not being realised through the use of 
POCT.  Responses were as follows: 
• “Length of stay and further tests are driven by the data, the method of test is not 
significant.” 
• “Benefits are not being realised because there is a poor relationship between the 
hospital and the laboratory.  There are tremendous bureaucratic hurdles.” 
Strongly Disagree 
(Response 1-2)
9%
Disagree (Response 
3-4)
10%
Neutral (Response 5-
6)
24%
Agree (Response 7-8)
38%
Strongly Agree 
(Response 9-10)
19%
Question 7b - On a scale of 1 to 10, to what extent do you 
agree or disagree that, POCT provides longer term 
economic benefits e.g. reduced hospital stay, reduced 
outpatient appointments etc.
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• “I don’t think longer term economic benefits are available through the use of POCT.  It is 
only useful for critically ill patients.  If the test is not required within 5 minutes then the 
sample should be sent to the laboratory.” 
• “POCT is more expensive and provides testing on a reduced number of analytes, I don’t 
believe economic benefits are available.” 
Generally, participant opinion was that the utilisation of a POCT system was cost-effective.  As 
shown in Figure 5.5, 18 of 21 clinicians indicated that this was the case.  Interestingly, no 
respondents indicated that they disagreed with this statement, while 3 were not sure and opted 
not to give a response.  One participant added: 
• “POCT is cost-effective, not cost-saving.  In my opinion it makes good use of the extra 
expense incurred.” 
Comments also were made here with respect to the importance of test accuracy.  Clinicians 
were of the opinion that POCT provides a cost-effective system as long as the accuracy of the 
testing concerned is good enough to enable a clinical judgement to be made and, in particular, 
additional tests are not having to be carried out subsequently by CLT thereby causing duplication 
of tests and associated increase in costs. 
 
Figure 5.5 - Clinician opinion of the cost-effectiveness of a POCT system (n=21). 
Significant variation in the responses made to questions on procurement, reimbursement and 
budgeting with respect to POCT and the intrinsic interdepartmental nature of such were 
Yes
86%
No
0%
Not sure / No 
response
14%
Question 7c - Would you agree that the use of a POCT 
system is cost-effective?
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received, as summarised in Figure 5.6.  Some 33% of respondents either “disagreed” or “strongly 
disagreed” that the interdepartmental nature of POCT was sufficiently accommodated for 
within their area of clinical practice, while 33% of responses were “neutral”, and 34% of 
responses “agreed” or “strongly agreed” that these factors were sufficiently accommodated for 
in their experience.  Although there were some indications in the comments received that the 
significant majority of POCT devices within the US hospital concerned were not utilised on an 
interdepartmental basis (and hence the question was not entirely relevant to their situation), 
there were some other interesting comments with respect to the economic nature of the US 
health system, including: 
• “The hospital wants to make money and the laboratory is more expensive to the patient 
than POCT and so budgeting and reimbursement do not accommodate POCT very well.” 
• “The laboratory has been outsourced to a private company.  The hospital gives a budget 
to the department for diagnostic tests that POCT comes out of.” 
• “The majority of POCT use is in inpatient situations where we are moving towards DRG 
(Diagnostic Related Group) costing where the hospital is paid for the incident rather on 
how many tests are carried out, as was done previously.” 
Figure 5.6 - Clinician opinion on procurement, reimbursement and budgeting for POCT with 
respect to the interdepartmental availability of such devices (n=15). 
Importantly, all of those respondents who “disagreed” or “strongly disagreed” with the premise 
that the interdepartmental nature of POCT was sufficiently accommodated indicated that it was 
difficult to utilise POCT to its full potential as a result. 
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interdepartmental nature of POCT, especially where it is a 
shared resource.
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As was the case for the UK study, the US sector participants were questioned on the relevance 
of certain economic related issues that were identified from the systematic literature review.  
These issues include; difficulties in justifying the use of POCT due to the higher cost per test in 
comparison to traditional testing methods; difficulties in justifying the implementation of a 
POCT system due to unclear cost-effectiveness and complexities in comparing to traditional 
methods of testing; difficulties in justifying the implementation of a POCT system due to high 
initial outlay costs; issues with regards to budget contributions due to the “silo” nature of 
separate departmental budgeting, and; difficulties in obtaining reimbursement for POCT.  The 
responses are summarised in Figure 5.7 and reveal that the dominant response for all 5 issues 
is that of “not relevant”, but that otherwise the level of response varies somewhat across the 
issues.  In terms of the higher cost per test of POCT acting as a barrier to utilisation, clinicians 
generally indicated that clinical gains were most important and that the required immediacy of 
test result took precedence over cost.  As a result, 13 of the 20 responses received here (1 
clinician chose not to give a response here due to lack of knowledge) indicated that this issue 
was either “not relevant” or “rarely relevant” within their area of work.  However, there was 
also an observation made by a participant that if a rapid result was not important then POCT 
should not be used because of the increased cost and also because laboratory tests were trusted 
more by clinicians.  There was much more variation seen with respect to opinion on difficulties 
gauging the true cost-effectiveness and making economic comparisons with traditional 
diagnostic testing methods.  Only 6 of 20 respondents here indicated this was “not a relevant” 
issue to them, while a further 6 respondents indicated that this issue was either “fairly relevant” 
or “very relevant” within their institution.  The strongest trends here were seen with respect to 
budget contributions towards POCT due to “silo budgeting” and difficulties in obtaining 
reimbursement for POCT, wherein 9 and 12 participants, respectively, indicated that these 
issues were “not relevant” to them.  An important consideration with respect to reimbursement 
was raised by comments made by a participant that indicated that reimbursement is not an issue 
as long as you use the particular test/device recommended by the insurer.  In this regard, the 
participant indicated that insurance cover that the patient has determines what brand of test 
can be utilised by the clinician.  This is similar to the situation with insurance cover and drugs, 
where certain tiers of cover may insure for branded drugs, while others will only insure cheaper 
generic alternatives.  If the recommended test is not available and another is used instead, then 
reimbursement may not be made by the insurer.  This is clearly a major difference between the 
US and UK healthcare systems.  When the issue of high initial implementation costs for POCT 
was considered, only 3 responses indicated this issue is “fairly relevant” or “very relevant” 
indicating that this is not a significant issue in terms of impeding the update of POCT uptake in 
the US healthcare system. 
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Figure 5.7 - Clinician opinion on relevance of specific economic issues associated with POCT within 
their areas of clinical practice (n=21). 
5.3.2 Quality Assurance & Regulatory Issues 
Whilst quality assurance issues may be similar across various healthcare systems (both free at 
the point of delivery and insurance based), there is potential for national/regional regulatory 
requirements to have a significant effect upon how POCT may be utilised.  The US clinicians were 
questioned on whether the dispersed nature of POCT devices contributed to their use, or 
potential misuse, by untrained or non-competent users, with the results summarised in Figure 
5.8.  Interestingly, opinion was quite polarised with respect to this perceived barrier to POCT 
adoption, in that while 50% of respondents either “agreed” or “strongly agreed” that this was 
indeed an issue, 45% of participants also either “disagreed” or “strongly disagreed”. 
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Figure 5.8 - Clinician opinion on how the dispersed nature of POCT devices can lead to their use by 
untrained or non-competent staff, resulting in quality assurance issues (n=20). 
Some of the interesting comments from those who were in agreement with the proposition 
include: 
• “Devices are common in outpatient areas and a wide range of staff have access.” 
• “CLIA (Clinical Laboratory Improvement Amendments of 1988) waived tests are a huge 
worry as people don’t need much training to use them.  Just because the tests are easy 
to use does not mean they are not complex in nature.” 
Conversely, comments from those participants who were in disagreement with this being an 
issue include: 
• “It doesn’t matter who uses the device, it’s the info that comes out and the clinical 
judgement made on that.  Anybody can use the device, that is not important.” 
• “The laboratory watch over everything carefully so it is not a problem.” 
• “We have refresher training every 6 months so that staff are always competent.” 
It is interesting to note that of the participants who “agreed” or “strongly agreed” that an issue 
existed with untrained or non-competent staff potentially utilising the POCT devices (50% of 
total response), 3 (15% of total response) indicated that they believed this did not produce a 
difficulty in attaining a timely and reliable diagnosis in comparison to traditional CLT.  The reason 
for this was their belief that POCT devices should be fool-proof with no opportunity for error, 
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and that anything that required complex steps in the operation of such a test should not be 
available as a POCT device. 
When questioned about the complexity of the current accreditation for analytical testing based 
on POCT, a number of participants were unsure of the regulations involved.  As a result, 3 
participants did not give a response to this particular question.  The overall spread of clinical 
opinion obtained here is indicated in Figure 5.9.  Significant variation in response is seen here, 
with those in the “strongly agree” category being of the lowest number (6%).  Opinion was then 
evenly split across the 4 other categories; “agree”, “neutral”, “disagree” and “strongly disagree”.  
Comments from clinicians ranged from belief that there were not enough regulations in place, 
leading to big problems with quality assurance, to tests being promoted from (CLIA) waived to 
non-waived categories on the manufacturer’s recommendation, meaning very few staff have 
the qualifications necessary to perform the test.  An example of this that was cited was that if a 
manufacturer does not recommend its use for critically ill patients, what normally is a waived 
test (and requires basic qualifications to operate) becomes a non-waived test when utilised 
within the ICU (Intensive Care Unit) environment.  Interestingly, 3 of the 5 clinicians who 
responded in the “agree” and “strongly agree” categories were of the belief that “overly 
complex” regulations did not affect the ability to attain a timely and reliable POCT diagnosis in 
comparison to CLT.  Generally, these individuals were of the opinion that regulatory 
requirements were only a barrier to uptake of devices prior to implementation and that once 
the devices were fully deployed this no longer posed a problem to actual device use. 
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Another important consideration with respect to the role of regulatory requirements is the 
appropriate training of staff to comply with such requirements.  Levels of training can of course 
impact directly on the uptake and utilisation of POCT.  In this study, participants were asked 
about the levels of training and support on regulatory compliance that was provided by the 
central laboratory in their place of work with the results shown in Figure 5.10.  The responses 
were again varied with 4 participants not giving a reply to this question, which was again due to 
their lack of knowledge on the regulatory requirements in place.  Some 44% of participants 
responded in the “very low” area of the 10-point scale, with 1 clinician suggesting that the 
reason for the lack of training and support provided was because the laboratory saw POCT as 
direct competition to their services and hence income, and so did not want to support it.  
Another responder indicated that, in general, it was clinical staff who trained other clinical staff 
and that the (central) laboratory did not reach out to help.  However, 31% of participants also 
responded within the “high” category, and a further 19% indicated that a “very high” level of 
training and support was provided by the CLT service.  These latter responders also indicated 
that the on-site laboratory looked after POCT and provided full oversight.  It should again be 
noted that all of participants interviewed in this study were from the same US hospital and so 
this variance in opinion strongly suggests that there is no coherent strategy for POCT use.  
 
Figure 5.10 - Clinician opinion on the on the levels of regulatory compliance and operator training 
and support for POCT provided by their central laboratory service (n=16). 
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Of the 7 respondents who indicated a “very low” level of training and support provided, 5 
believed that this subsequently made it more difficult to attain a timely and reliable diagnosis 
utilising POCT in comparison to CLT.  The 2 participants who didn’t believe this to be the case 
were of the opinion that adequate training and support was attained without the involvement 
of the CLT and so this was therefore not seen as an issue. 
For this category of barrier to adoption of POCT, the issues identified as prevalent within the 
previously reviewed literature were analysed in terms of their relevance to US clinicians and 
their respective clinical specialities with opinion on the relevance of these issues summarised in 
Figure 5.11.  The issues of interest included; errors caused by incorrect quality assurance 
procedures by untrained/non-competent staff operating the POCT devices; issues for non-
laboratory operators of devices due to regulations written for traditional laboratory equipment 
being blindly applied to POCT; issues with maintaining compliance due changes in the 
regulations associated with POCT; issues with maintaining regulatory compliance due to the 
dispersed nature of POCT, and; a lack of development of POCT devices caused by product 
approval hurdles discouraging economic investment in their development.  In this case, 6 
clinicians did not give a response for questions 13b, 13c and 13d due to their lack of knowledge 
on the regulatory requirements for POCT.  Overall, the highest response category was “not 
relevant”, suggesting that these issues are not of high importance within the US clinical 
environment investigated here.  Although over just half of the respondents here were of the 
opinion that quality assurance errors caused by untrained or non-competent staff operating 
devices was not a significant issue within their place of work, there was some uncertainty as to 
whether errors are not being routinely monitored and then only come to light if they are 
reported.  Therefore, there is a distinct possibility that error rates are higher than those reported 
due to untrained or non-competent staff operating devices.  Similarly, whilst 7 of the 14 (actual) 
responders were of the opinion that lack of regulatory compliance caused by the dispersed 
nature of POCT devices was not a relevant issue in their area of work, 1 clinician did specifically 
comment that, in their experience, glucometers were difficult to control in this respect, being 
used in 2 locations by approximately 3000 nursing staff and hence making them notoriously 
difficult to adhere to regulatory compliance.  The strongest opinion offered by the respondents 
here was that 70% of participants indicated that product approval hurdles did not discourage 
economic investment in the development of POCT.  In fact, comments attained here imply that 
in the US there are many drivers for POCT development, including the military, who have been 
a big supporter of POCT since the heightened threat of bioterrorism.  In addition, the FDA (Food 
& Drug Administration) in the US are also very keen to develop new POCT technologies.  The 
clinicians involved in this study were generally of the opinion that issues regarding 
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reimbursement for POCT was the main impediment to new device development and thereby 
the economic investment required. 
 
Figure 5.11 - Clinician opinion on the relevance of specific quality assurance and regulatory issues 
within their clinical institution (hospital) (n=20). 
5.3.3 Device Performance & Data Management Issues 
Device performance and data management issues were also assessed in this study.  The first 
area of investigation focused on the perceived reduction in analytical performance of POCT 
devices in comparison to traditional CLT instruments, and how this can affect their uptake 
and/or utilisation.  As can be seen in Figure 5.12, the US clinicians were generally of the opinion 
that the analytic performance of POCT devices was good, with 58% of responses rating them 
“high” and a further 21% rating them as “very high” (7-8 and 9-10 on the 10-point scale 
respectively).  The remaining 21% of responses were of a “neutral” opinion (5-6 on the 10-point 
scale).  Interestingly, no participants believed that the analytical performance of POCT devices 
was “poor” or “very poor” using this scaled method of response.  The comments made by the 
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clinicians suggested a general thought that POCT devices were there to be used as a screening 
service rather than a fundamental diagnostic testing service, and hence their analytical 
capability was appropriate to perform this function.  Specific comments included: 
• “By nature, POCT is not as accurate as the central laboratory, but POCT is used as a 
screening test and not as a diagnosis, and is fit for this purpose.” 
• “There are inherent limits to a POCT device but these are stated by the device.  This is a 
compromise for the convenience of the test.” 
• “POCT is viewed as a screening exam so is not perfect.” 
• “Blood glucose testing provides a good example of the analytical quality of POCT.  The 
result is clinically acceptable but not up to central laboratory standards.  Problems arise 
when clinical staff are unaware of the limitations in comparison to traditional lab 
testing.” 
 
Figure 5.12 - Clinician opinion on the level of analytic performance offered by POCT devices (n=19). 
As shown in Figure 5.13, when clinicians were asked about the connectivity of POCT devices to 
central healthcare and patient record systems, opinion was significantly varied.  Based on the 
comments made by participants it was apparent that POCT connectivity varied from one 
department to another.  Whereas, in some departments such as Immunology, results were 
simply written into records, in others such as the Emergency Room (Department) results were 
directly linked with electronic record systems.  It would seem that the departments directly 
entering POCT results into record systems were worried that some detail could be missed due 
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to the lack of an automatic process.  Clearly, the substantial variation in levels of data 
connectivity across the hospital led to the variance in opinion on this matter. 
 
Figure 5.13 - Clinician opinion on the connectivity and data management capabilities of a POCT 
system (n=19). 
The 7 respondents who indicated connectivity as being “poor” or “very poor” (using this scaled 
method of response) in comparison to CLT were asked if this poor connectivity made it more 
difficult to attain a timely and reliable diagnosis and all 7 denoted that this indeed was the case.  
In terms of assessing the difficulty of performing tests using POCT, as illustrated in Figure 5.14, 
76% of participants were of the opinion that POCT devices were “very easy” to use when 
compared to traditional instruments.  A further 10% of respondents signified their operation as 
being “easy”, whilst the remaining 14% of study participants gave a “neutral” response.  In this 
case, no respondents were of the opinion that the operation of POCT devices was either 
“difficult” or “very difficult”. 
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Figure 5.14 - Clinician opinion on the degree of difficulty associated with performing tests using 
POCT devices (n=21). 
Opinion on the relevance of specific issues relating to device performance and data 
management that were identified in the relevant literature (Chapter 3) is outlined in Figure 5.15.  
The strongest opinion recorded was that 80% of respondents indicated that operators did not 
encounter significant difficulties with the use of POCT in their place of work.  Furthermore, 40% 
of respondents indicated that a reduced analytical performance from POCT devices was “not 
relevant” to them within their specific workplace, while a further 25% of respondents replied 
that this particular issue was “rarely relevant” to them and 25% more were of the opinion that 
this was “sometimes relevant” to them.  The remaining 2 responders thought that this specific 
issue was “fairly relevant” to them.  Hence, it can be determined from this study that this issue 
is not of significant relevance within the US clinical institution concerned.  The replies to the 
issue of connectivity and subsequent data management that might result from the reduced 
capabilities of POCT showed more variation.  While 40% of respondents again signified a “not 
relevant” response, 35% indicated that this issue was “very relevant” to them, thereby giving a 
substantially polarised opinion.  As noted in the responses to Question 15a, there was significant 
variance in opinion with respect to the connectivity levels of POCT devices in comparison to that 
associated with the more traditional CLT methods.  It was apparent from these responses that 
the levels of connectivity varied greatly from one department and/or clinical area to another. 
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Figure 5.15 - Clinician opinion on the relevance of specific device performance and data 
management issues within their clinical environment (n=20). 
5.3.4 Staff & Operational Issues 
The final category considered within this study was that of staff and operational issues with 
respect to the utilisation of a POCT system.  One of the key issues in this respect was that of the 
workload of front line clinical staff who are the operators of POCT devices in practice, and in 
particular the impact that this has on their effective utilisation.  The pool of opinion here, as 
summarised in Figure 5.16, indicates a modest level of agreement with this proposition, with 5% 
of respondents stating that they “agree” and a further 9% that they “strongly agree” with the 
use of POCT significantly increasing the workload of front line clinical staff.  Conversely, 38% of 
respondents were seen to be “strongly disagreeing” with this statement, while a further 24% 
“disagreed”.  The remaining 24% of participants gave a “neutral” response in this instance.  
Much of the dialogue attained from study participants supported the opinion that POCT did not 
significantly increase the workload of device operators.  Comments in this regard included: 
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• “POCT is not used efficiently here.  If a certain parameter is needed quickly, POCT will be 
used to attain this, but a blood sample is always taken and sent to the laboratory for 
further parameters anyway, even when they are available through the use of the point-
of-care test already carried out.  Therefore, the staff are taking blood as they would be 
doing anyway.” 
• “Staff would be doing the same amount of work anyway by taking blood samples and 
chasing up the laboratory for results.” 
• Sending samples to the laboratory requires time in chasing up the results so there is no 
significant addition with POCT.” 
It should be noted that the small number of participants (n=3) who “agreed” or “strongly 
agreed” that there was a significant increase in workload as a result of the use of POCT all were 
of the opinion that this reduced staff satisfaction levels in comparison to utilising the traditional 
CLT method.  The reasoning behind this was that front line clinical staff wanted to be involved 
directly in patient care and that the operation of POCT was seen as a hindrance and a distraction 
from this ideal. 
 
Figure 5.16 - Clinician opinion of the impact of POCT use on the workload of device operators 
(n=21). 
A significant issue identified from the literature review outlined in Chapter 3 was the perceived 
reluctance of the central laboratory to allow the control of testing to be passed to users.  The 
participant response to this proposition for the US clinician study, as summarised in Figure 5.17, 
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was significantly varied, as it was also found to be the case for the data from the UK study.  A 
substantial proportion of the study group were of the opinion that the central laboratory was 
indeed reluctant to allow the control of testing to be transferred to the clinical environment, 
with 32% of respondents “agreeing” and a further 26% of respondents “strongly agreeing” with 
this statement.  The corresponding “neutral” responses and those in “disagreement” were 
found to be relatively low (11% and 5%, respectively), with 26% of respondents “strongly 
disagreeing” with this statement. 
 
Figure 5.17 - Clinician opinion on the reluctance of the central laboratory to release the control of 
POCT testing to the clinic (n=19). 
Comments made by the US clinicians who were in agreement that this reluctance exists, 
suggested that this was as a result of the CLIA regulations rather than a stance being made by 
those in the central laboratory themselves, and that these regulations have been imposed in 
order to protect the role of the central laboratory as an entity throughout the entire US 
healthcare system.  Interestingly, comments made by participants from the clinical biosciences 
cohort indicated that there was belief that this reluctance was a necessity.  Comments in this 
regard included: 
• “Letting someone else control quality is a risk if they are not trained in laboratory 
methods.  There is evidence that non-laboratory operators are more prone to error.” 
• “Nursing staff don’t understand laboratory tests and if a clinical decision is made on an 
incorrect result then it is considered a lab test that has gone wrong.” 
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Of the 11 responses that fall within the “agree” or “strongly agree” category, 9 were of the 
opinion that this reluctance acts as an impediment to the more widespread adoption of POCT 
within the near patient clinical environment in the US.  One participant noted that this was 
especially true within the outpatient setting. 
As illustrated by Figure 5.18, when clinicians were questioned on the clinical care pathway and 
the role of the central laboratory and the extent that these had been altered in order to 
accommodate POCT, participant response was fairly evenly split across the scale.  The “strongly 
disagree” response represented 20%, with 10% as “disagree”, 20% as a neutral response, 30% 
“agree” and the remaining 20% as “strongly agree”.  Focusing on those who “strongly disagreed” 
that sufficient alteration to the clinical pathway had been made, there would seem to be 2 
interrelated reasons for their responses, based on comments made by clinicians.  Firstly, there 
was an opinion that the current system that involves joint responsibility for quality between the 
laboratory and clinicians does not work as there is no clear line of responsibility.  Secondly, there 
was an opinion that alteration to the clinical pathway was not required as POCT should simply 
be used in time-critical situations where and when it is needed, and not as part of the standard 
clinical pathway in place of the traditional CLT service.  Of the 6 participants who “disagreed” or 
“strongly disagreed” that sufficient accommodation had been made, it is interesting to note that 
2 believed this situation did not affect their ability to attain a timely and reliable diagnosis in 
comparison to utilising CLT. 
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The relevance of other specific issues in this category of possible impediments to the adoption 
of POCT were investigated in terms of how they affected participants in their specific place of 
work.  Specifically, 6 issues were explored and results presented in Figure 5.19.  The dominant 
issues were; reduced staff satisfaction levels and friction between staff groups as a result of 
POCT usage; inappropriate use of POCT including over-use and a reliance on test results 
undermining clinical expertise; a failure to attain potential benefits through POCT use due to 
significant alterations to the clinical care pathway and the role of the central laboratory in this 
regard, and; inefficiencies in the  use of POCT due to the requirement for an interdepartmental 
management structure with clear clinical governance.  Importantly, the most pronounced 
opinion attained through this study alluded to the fact that POCT was actually under-utilised 
rather than over-used.  Comments made by clinicians explained this perspective further and 
included: 
• “We could be doing more POCT but people are risk averse and send samples to the lab 
instead, sometimes even if there is a clear clinical benefit to utilising POCT.” 
• “Over-use is a risk but it is unlikely to happen due to a lack of reimbursement for POCT.” 
• “POCT could help in a lot of situation but a lack of training means some operators don’t 
understand when to utilise it for full benefit.” 
Although the “not relevant” response was the most common with respect to the reluctance of 
the central laboratory to release control affecting the more widespread uptake of POCT (7 
responses), there were also 5 responses that indicated that this was either “fairly relevant” or 
“very relevant”.   
The final issues studied in this category addressed difficulties implementing POCT due to a 
reluctance to change and a lack of evidence justifying the utility of POCT.  Opinion here was 
substantially varied but there was enough data to suggest this is a relevant issue in reality within 
the US healthcare system; 5 responses indicated that this issue was “not relevant”, 6 clinicians 
signified it to be “fairly relevant”, and a further 5 clinicians were of the opinion that this 
particular issue was “very relevant” to them within their area of practice.  Comments made by 
participants that allude to this perceived reluctance to change include: 
• “There is a lot of inertia.  Logistics, workflow, financial and territorial considerations 
always come before actual clinical benefit.” 
• “There is resistance towards moving extra work towards nursing staff.” 
• “Not a lack of evidence but a big resistance to change.” 
• “We had to perform our own side-by-side comparison between POCT and CLT to prove 
the system as there was not enough evidence.” 
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Figure 5.19 - Clinician opinion of specific staff and operational issues within their own clinical 
institution that affect the use of POCT (n=21). 
5.3.5 Other General Issues 
Outside of the main categories of enquiry, participants were questioned from a more general 
perspective with regard to their opinion of the real value of POCT.  In this section, participants 
were afforded the opportunity to answer more freely through text boxes rather than numeric 
scales and tick-boxes.  The focus in the first instance addressed the main advantages offered by 
POCT when compared to CLT usage.  The responses attained are summarised below in order of 
the frequency with which each occurred: 
• Rapid turn-around-time (TAT), resulting in a quicker decision/diagnosis and earlier 
clinical intervention (93% of respondents). 
• Improved patient/operator satisfaction and convenience (37% of respondents). 
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• More efficient patient management (30% of respondents). 
• Improved quality of care and better patient outcomes (19% of respondents). 
• Avoidance of sample transfer where there is no laboratory on site or within close 
proximity (7% of respondents). 
• Help to meet political targets i.e. TAT targets and patient waiting times (7% of 
respondents). 
• Provides the ability to the clinician to repeat tests (7% of respondents). 
• Less reliance on a chain of services where delays are more likely (7% of respondents). 
• Ease of use (7% of respondents). 
• Cost savings (7% of respondents). 
• Improved reliability and accuracy (7% of respondents). 
• POCT provides a good backup service when laboratory or sample transport systems are 
down (individual response). 
• Avoidance of sample stability issues during transport (individual response). 
• Transfer of some of the laboratory workload to the wards (individual response). 
• Provides control of when the sample is tested to the clinician and the opportunity to 
perform serial testing (individual response). 
• Overcomes problems of poor access to hospital/medical care (individual response). 
As was the case for the UK study (Chapter 4), the overwhelming response was that of a rapid 
TAT, resulting in a quicker decision/diagnosis and earlier clinical intervention, as indicated by 
93% of clinicians within the study.  Improved patient/operator satisfaction and convenience 
along with more efficient patient management were both again found to be significant 
advantages, denoted by 37% and 30% of participant response respectively. 
The main disadvantages of POCT usage in comparison to utilising CLT was then considered.  
Participant response in this case is summarised below, again in order of the frequency with 
which each occurred: 
• Poor quality/inaccuracy of results obtained by untrained or non-competent staff and 
the consequent risk to the safety of the patient (30% of respondents). 
• Staff training requires a lot of time (22% of respondents). 
• Increased costs (22% of respondents). 
• Reduced accuracy compared to CLT and duplication of tests carried out by the central 
laboratory (22% of respondents). 
• Quality management requires significant resources and is difficult to control due to 
dispersed nature of the devices (19% of respondents). 
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• Inappropriate use, i.e. over-use and reliance on (POCT) results undermining clinical 
expertise (19% of respondents). 
• Difficulty in ensuring continued staff competency and unfamiliarity caused by a lack of 
regular use (19% of respondents). 
• Lack of connectivity to central healthcare and patient record systems (19% of 
respondents). 
• Takes up a lot of staff time (15% of respondents). 
• Results and subsequent interpretation highly dependent on operator competency (11% 
of respondents). 
• Requires awareness of limitations otherwise their use is dangerous (7% of respondents). 
• Difficult to reach the standard of CLT as it is difficult to control a range of 
staff/departments/management structures in comparison to control within the 
confines of the laboratory (7% of respondents). 
• Auditing and clinical governance is difficult due to fragmentation of the service; lines of 
accountability are very unclear (7% of respondents). 
• Lack of a specific budget for POCT (individual response). 
• Little support from senior management for POCT (individual response). 
• Requires buy-in from other departments which is often hard to attain (individual 
response). 
• Financial benefits are difficult to prove, despite an improvement in patient care 
(individual response). 
• Specific skills are required to perform POCT and so it may not really be a 24-hour service 
(individual response). 
• Added responsibility on another healthcare professional with regard to calibration, 
ordering of test strips, etc. (individual response). 
• Maintenance of devices is difficult (individual response). 
Clearly, the most common response here was that of poor quality/inaccuracy of the POCT results 
that may be obtained by untrained or non-competent staff and the consequent risk to the safety 
of patients that this brings, as indicated by 30% of respondents.  Interestingly, the frequency of 
this response is significantly less than that associated with the main advantage of POCT, i.e. 
improved TAT. 
When asked for their opinion on where POCT can be best utilised within the healthcare system, 
and more specifically which diseases and/or conditions benefited most from its use, the 
frequency of the collated responses was as follows: 
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• Respiratory conditions, i.e. blood gas testing (70% of respondents). 
• Diabetes, i.e. blood glucose testing (70% of respondents). 
• Blood coagulation, i.e. International Normalised Ratio (INR) monitoring (48% of 
respondents). 
• Cardiac conditions, i.e. cardiac marker testing (30% of respondents). 
• Sepsis testing, i.e. blood poisoning or septicaemia (19% of respondents). 
• Urine pregnancy testing, i.e. in ED or surgery (19% of respondents). 
• Other blood tests, i.e. HBA1C, lactate, etc. (19% of respondents). 
• Monitoring of foetus condition during pregnancy (15% of respondents). 
• Drug abuse (15% of respondents). 
• General trauma and internal bleeding, i.e. emergency conditions (11% of respondents). 
• Brain injury and critical care patients, i.e. ventilated (7% of respondents). 
• Gastroenterology (individual response). 
• Patients with mental health issues (individual response). 
• General surgery (individual response). 
• Hypotensive patients (individual response). 
• Influenza (individual response). 
• Infectious diseases in developing countries (individual response). 
As above, the 2 most frequent responses here can be seen to relate to the value of POCT in the 
diagnosis/monitoring of respiratory conditions (i.e. blood gases) and diabetes (i.e. blood glucose 
monitoring), with both having been indicated by 70% of participants. 
The ultimate objective in gaining an understanding the barriers to the adoption of POCT is of 
course to provide a way to overcome them.  Therefore, it was deemed important in this study 
to gain clinicians feedback on how this could be potentially achieved.  Study participants were 
therefore asked directly to suggest possible solutions to overcoming any of the real and/or 
perceived barriers to the adoption of POCT technologies.  The frequency of the responses 
received were as follows: 
• Audit the use of POCT to provide evidence of clinical and/or economic benefits to stake 
holders as a way to overcome issues such as mistrust of POCT and a lack of full backing 
for its implementation by the healthcare system (41% of respondents). 
• Better connectivity to central healthcare systems and interfaces (26% of respondents). 
• Increased laboratory support for implementation and after-care, i.e. a dedicated team 
to look after QA in POCT (26% of respondents). 
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• Improved training processes, including re-training and mandatory centralised training 
(19% of respondents). 
• Reduced costs from manufacturers for both the devices and their implementation via a 
form of a central POCT funding (19% of respondents). 
• Closer collaboration between the clinical and support areas involved (19% of 
respondents). 
• Improved QA processes and auditing processes for POCT to ensure confidence in them 
(19% of respondents). 
• Regional consensus/strategy on POCT procurement (15% of respondents). 
• Treat the introduction of POCT tests in the same way as that employed for the 
introduction of new drugs, i.e. through a proper change management project (7% of 
respondents). 
• Increase availability of POCT though the healthcare system (7% of respondents). 
• Increase use of POCT in primary care (individual response). 
• Give feedback on POCT performance to stakeholders following its implementation 
(individual response). 
• Improve user-friendliness of devices (individual response). 
• Adopt a more streamlined path from device development to clinical use (individual 
response). 
• Manufacturers should be encouraged to provide free pilots of POCT systems so that 
benefits can be witnessed first-hand (individual response). 
• Increased transparency of governance arrangements and expectations throughout the 
application process for the deployment of such devices (individual response). 
• Restrict the use of POCT to controlled environments, i.e. specialist clinics; based on the 
fact that 24-hour access machines are difficult to regulate and there are issues with 
ensuring the competency of operators (individual response). 
As was found to also be evident from an analysis of the response obtained in the UK study, the 
most frequent suggestion made by US clinicians was that overcoming barriers to POCT adoption 
requires evidence of the clinical and/or economic benefits in order to overcome issues such as 
laboratory mistrust and a lack of full backing by the health system, as cited by 41% of 
participants. 
A further area of assessment made relates to the importance of the categories of barrier that 
impact upon POCT uptake in the US healthcare system.  Respondents were asked to rank the 4 
main categories of barrier identified from the systematic literature review study (i.e. economic, 
quality assurance & regulatory, device performance & data management and staff & operational 
 126 
issues), with 1 being most important in regard to POCT uptake and 5 least.  The resulting data 
was managed using a tiered scoring system to attain a final ranking order, where a category 
would receive 4 points for a first-place ranking, 3 for a second-place ranking, 2 for a third-place 
ranking and 1 point for a fourth-place ranking.  The scoring frequencies of the resulting 
responses are provided in Figure 5.20.   
As seen here, economic issues were found to be the category that has the most significant 
impact on POCT uptake, with a score of 65, while the staff & operational issues and quality 
assurance & regulatory issues were ranked closely together with scores of 48 and 46 
respectively.  Device performance & data management issues were found to have least impact 
with a score of 41. 
 
Figure 5.20 - Clinician opinion on the ranking of important of the main four categories of barrier to 
adoption of POCT as identified from the systematic literature review (n=21). 
The final area of evaluation here incorporated the extra question posed to participants in this 
study with respect to the UK study carried out in Chapter 4.  The clinicians taking part in this 
study were asked if they were aware of any differences between the UK and US health systems 
that could affect the uptake of POCT within the clinical environment.  The comments offered by 
clinicians are as follows: 
• “Very wasteful of money in the US.  There is very little regulation on the tests that doctors 
order.  The efficiency of tests is not considered by the health system, only cost.  There is 
better data on efficiency of healthcare decisions in the UK.  In the US, they do not want 
Economic Issues, 65
Quality Assurance & 
Regulatory Issues, 46
Device Performance 
& Data Management 
Issues, 41
Staff & Operational 
Issues, 48
Question 26 - Ranking order of identified categories of 
barrier with respect to current impact on POCT adoption.
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to take on more costs, but nobody is looking at the overall efficiency of the system.  
Insurers look at the increased cost per test of POCT and do not want to pay for it.” 
• “The US system does not have socialised medicine.  Many patients don't have insurance 
or have poor insurance, and so the tests which doctors decide on can come out of the 
patient's pocket.” 
• “The UK has more ability to make centralised systems - electronic record systems are 
nationwide.  In the US, patients are very demanding and essentially, they drive the 
changes that they want.  In the UK, there is better team-based healthcare but in the US 
the MD (medical doctor) does huge majority of work.” 
• “In the UK if it makes clinical sense to do it then you can do it.  In the US, there is the 
additional hurdle of if the insurance covers the test or not.  Using POCT may result in 
hospital not being paid - the central lab is much easier to track and bill.  The UK system 
is more self-regulated, the US is more imposed by insurers and therefore individuals are 
less aware of cost-effectiveness than UK.” 
• “Things which work well in other countries take a long time to get FDA (Food & Drug 
Administration) approvals in the US and so this causes delays in getting new 
technologies to patient care.” 
• “In the US, manufacturers are trying to push tests into practices even though they aren't 
medically the best solution.” 
• “Current healthcare reform (Obama Care) in the US means that any changes must 
conform with this process - POCT can help with the change to reimbursement on 
outcomes rather than the number of tests as physicians will be more interested in quick 
outcomes, however the current changes already in place will make it difficult to 
implement additional changes to bring POCT in further.” 
• “The costs of testing to the patient in the US private system is the main difference that 
can affect the uptake of testing.” 
• “There have been huge changes already in the US with “Obama Care”.  The UK is more 
practical and cost-conscious, there is much less ordering of unnecessary tests and more 
use of clinical judgement.  Fear of litigation in the US discourages POCT use.” 
• “The UK is more cost sensitive.  The US has more variability between hospitals, but trends 
will be same in both; pockets of high adoption in the small areas where POCT is 
necessary.” 
• “The UK is more centralised than the US.  In Europe, it is much easier to get devices 
approved.  Australia is about 10 years ahead of the US in terms of sports medicine 
devices.” 
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• “Cultural differences are important - The US public like pills, India like injections, other 
places like tests.  The NHS is a centralised model, i.e. if the wrong antibiotics are given 
then they are picking up the cost and they are also acting as the insurer.  In a closed loop 
system like this there will be more adoption of anything which will increase the efficiency 
of care.  In the US, increased efficiency does not mean increased income for the hospital.” 
• “In the UK, there are limits i.e. what can be done for a certain patient in a certain age 
group.  US there are no limits to the care that can be given.” 
• “US don't have socialised medicine, it is very much fee for service.  Money prescribes 
what we do here to an extent.  Lawsuits are a worry over here.  In a capitated system 
here, a physician is given a lump e.g. $10,000 to keep a patient healthy for a year, and 
keep the excess so there is a big incentive to keep a patient healthy and reduce hospital 
visits and diagnostic tests.  POCT can help with this.” 
• “Funding in the UK is centralised and so easier to calculate savings and costings.  The US 
is very fragmented and so here it is easier to have winners and losers through the 
system.” 
5.4 Discussion 
The data collected by the completion of this US based clinician study has been used as a 
comparison to that attained from the findings from the UK Healthcare service study presented 
in Chapter 4.  The overall objective here is to determine the effects, if any, that national location 
and/or the underlying healthcare payment model of the relevant health system have on clinical 
opinion of the value and utilisation of POCT devices within the hospital environment. 
An understanding of the wider-ranging issues in terms of healthcare model make-up can be 
attained by analysing comments made by clinicians to the extra question added to this study 
relating to differences between the UK and US health systems that could affect the uptake of 
POCT.  The 2 main areas of focus indicated here by clinicians were that of costs and the 
“centralisation” of healthcare.  It has been found that, in the opinion of participants in this study, 
the UK system of healthcare is much more focused on the efficiency of delivery in comparison 
to the US.  Whereas, the UK system can make decisions based solely on “clinical sense”, the 
insurance model in the US has been described as an “additional hurdle” with respect to delivery 
of care.  The capitalist-driven system of the US means that the delivery of care is directed much 
more by the patient and/or insurer.  As a result, those who can afford medical care are actually 
better off than a UK patient.  However, the UK system provides the same level of care to all, 
without exclusion, meaning all UK patients are better off than an individual in the US who can’t 
afford medical care (Marsden 2006).  It has been indicated by participants in this study that 
many insurers will not want to pay for the increased cost per test of POCT in comparison to CLT 
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within the US health system.  As such, overall efficiencies are often ignored in this respect.  
Furthermore, it has been suggested that patients with poor or no health insurance coverage will 
not want to make use of POCT as the increased cost will be coming out of their own pocket.  
Hence, the UK model, free at the point of delivery, is thought to be much more self-regulated 
than the US, in which, according to the clinicians interviewed, there is very little regulation of 
tests ordered by doctors.  According to the base of opinion gathered by this study, this results 
in individuals within the US health system being much less aware of the cost-effectiveness of 
healthcare provision.  The US has been found to spend the most per capita on healthcare of any 
country in the world and yet has failed to match the advances in population health of other 
wealthy nations (US Burden of Disease Collaborators 2013).  From a top-down perspective, this 
indicates the operation of an inefficient system. 
Clinical opinion here also indicates, perhaps unsurprisingly due to the geographical disparity in 
terms of size, that the UK system is much more “centralised” in comparison to that in the US.  
For example, it was suggested in this study that nationwide patient record systems exist almost 
everywhere in the UK while they are often not available in the US.  In 2012, it was found that 
only 44% of hospitals in the US had implemented what was considered to be at least a “basic 
level” electronic patient health record system (DesRoches, Charles et al. 2013).  Hence, the 
implementation of new technologies on a national scale is more difficult in a substantially more 
fragmented system such as in the US.  It is also thought that the more disjointed nature of the 
US system results in a much slower process in terms of regulatory approval of new technologies, 
with 1 clinician indicating this while adding that “Australia is about 10 years ahead of the US in 
terms of sports medicine devices” for this reason.  While the US system of approval has faced 
criticism, mainly from industry, for being too slow, risk adverse and expensive, the European 
system of approval has also faced criticism, despite being a much faster process.  This has 
centred around the notion that the European regulatory framework of using the Conformité 
Européenne (CE) Marking process is not sufficient in terms of providing adequate safeguards for 
devices directly impacting upon morbidity, mortality and health related quality of life (Sorenson, 
Drummond 2014). 
In terms of the barriers to POCT uptake, economic issues are found to be most prevalent 
amongst US clinicians.  Whereas, within the UK health system the categories of economic issues 
and quality assurance & regulatory issues received equal ranking, those working in the US health 
system found that the economic issues were more significant in regard to impeding the adoption 
of POCT. 
Economic issues were found to be highly significant in terms of impact upon POCT uptake in 
both studies thereby providing evidence of its influence regardless of the payment processes 
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operating within the healthcare system concerned.  A noteworthy difference in the US and UK 
clinical opinion is seen with regard to the cost per test of POCT.  Those who participated in the 
US study were very unclear as to the real cost per test of POCT in comparison to CLT, with a 
higher percentage (43%) of clinicians disagreeing that POCT introduces increased costs than 
agreeing (33%).  By comparison, the majority opinion in the UK study (75%) was that POCT was 
indeed more expensive than CLT on a cost per test basis.  Based on comments made by study 
participants here, it is possible that their opinion is influenced by the levels of reimbursement 
found within the US healthcare system and the privatisation of central laboratories.  It would 
seem that in many cases, reimbursement is made for laboratory tests and that POCT is 
incorporated into this process, i.e. as a responsibility of the central laboratory, and so receives 
the same level of reimbursement as the equivalent CLT, which tends to be minimal.  As a result, 
from the clinician’s point of view, the cost of a specific test has no difference to them whether 
it is performed by CLT or POCT.  Privatisation of the central laboratory service can in some cases 
cause CLT to be more expensive to the patient than POCT, according to opinion attained in this 
study.  Outsourced central laboratory services can also be significantly inconvenient for the 
patient.  For example, a clinician in a fully equipped hospital may order a test for a patient, 
however the insurance company employed by the patient may insist on the test being carried 
out and a particular private facility, therefore resulting in the patient having to travel elsewhere 
for the test to be carried out.  This problem is especially relevant for outpatient situations 
(Chasin, Elliott et al. 2007). 
The insurance-based costing model operating in the US healthcare system can also affect the 
reimbursement of tests.  For example, according to participants of this study, certain insurance 
providers recommend the use of particular tests (or brands of test) and do not provide full 
payment if this advice is ignored.  This would appear to be in line with the situation of 
pharmaceuticals in the US, where levels of cover vary between different insurers based on FDA 
approvals and the patent status of drugs i.e. branded/generic (Stephane A. Regnier 2014).   As a 
result, the specific insurance policy that a patient has directly affects the types of tests that can 
be performed as part of their care (based on their availability within the hospital).  Hence, the 
cost to the hospital in terms of testing can vary considerably on a patient-by-patient basis.  It is 
interesting to note that the movement towards global payments made through DRGs 
(Diagnostic Related Groups) is very much taking place within the US healthcare system with 
many of the clinicians participating in the study alluding to this development.  This agenda 
results in a hospital receiving reimbursement based on the resolution of an episode, rather than 
the traditional cost-based system of reimbursement where the hospital gets paid based on the 
number of tests performed.  Therefore, although the cost to the clinician is equal in terms of 
comparing POCT and CLT, the method of reimbursement will be provided based on the outcome 
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and not the path used to get there.  It was noted by a proportion of participants in this study 
that the inappropriate use of POCT was a relevant issue within their place of work, i.e. over-use 
and reliance on test results which can undermine clinical expertise which is an issue that DRG-
based payments could rectify.  However, clinicians also alluded to the fact that this was not an 
issue specific to POCT, but rather was relevant to all types of testing.   As was observed in the 
responses for the UK study, the clinicians here were generally of the opinion that use of a POCT 
system was cost-effective.  It was stressed by a US cardiologist participating in the study that it’s 
important to note that POCT is not cost-saving, but is cost-effective, in the way that it makes 
good use of any extra expense that may be incurred as a result of its use.    
Whereas some of the potential solutions to understanding and overcoming economic issues 
associated with the use of POCT can be translated easily from the UK system to the US 
healthcare structure, there are some difficulties due to the insurance-focused nature of the 
latter system.  For example, it would be much more difficult to implement a centralised POCT 
budget within hospitals in the US due to the influence that insurers have on the types of tests 
carried out and the privatisation of the central laboratory in many institutions.  However, 
common themes were relayed here in this respect of a solutions-based approach that were of a 
similar nature to those found by the previous UK study.  In particular, the need to produce a 
stronger base of evidence regarding clinical outcome improvements that POCT can provide that 
would justify any costs incurred in their implementation or operation was common to both 
jurisdictions. 
Due to the obvious variations between the UK and US systems in terms of how healthcare is 
funded, differences of opinion on the economic considerations of POCT were somewhat 
expected.  However, an investigation of the other categories of barrier to POCT adoption can 
help ascertain whether or not the overarching model of healthcare has a direct impact on 
clinician opinion and to what extent this prevails.  For example, it is important to determine 
whether quality assurance & regulatory issues are regarded equally by those working within the 
2 different systems or if local/national considerations can have a significant influence on the 
clinical technologies utilised.  POCT is expected to grow steadily in the early part of this century 
(Scalise 2006) and, in doing so, become a more integral part of healthcare management.  As a 
result, expansive quality assurance protocols are required to optimise patient care and the 
efficiency of healthcare delivery (Larsson, Greig-Pylypczuk et al. 2015).  While traditional CLT has 
had quality assurance protocols in place for many years as part of regulatory frameworks 
imposed upon the diagnostics sector, POCT has been viewed differently by manufacturers in 
that it has been developed specifically to be used by clinicians rather than trained laboratory 
professionals.  Consequently, the POCT devices do not fit well with the traditional quality control 
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procedures (Martin 2008).  Regulatory requirements often mean that existing quality protocols 
must be still be applied to POCT or adapted as best possible.   
In line with what was discovered from the analysis of responses to the UK study, it was found 
that US clinicians from the clinical biosciences cohort were of a strong belief that the 
decentralised nature of POCT devices leads to increased opportunities for their use by untrained 
or non-competent staff, leading to an increased disregard for certain quality assurance steps 
and procedures, including quality control.  While opinion in general was significantly varied with 
respect to this particular issue, 4 study participants from this clinical group gave an average 
response of 8.25 in this study on the 10-point scale used to attain a measure of agreement.  The 
reasons for this are likely to be the same as suggested for the UK health system, with quality 
control inside the central laboratory being a direct responsibility of the highly skilled individuals 
who operate sophisticated instruments which are long embedded within health system 
processes.  By contrast, quality control for POCT devices is much more difficult to deliver with a 
significantly higher number of users, often analytically unskilled and utilising less sophisticated 
devices.  Although this particular issue was found to be of little relevance to the participants 
within the study, those clinicians who did cite it as an issue alluded to the fact that there is no 
monitoring system in place to ensure quality assurance in POCT and so errors are only ever 
caught if they are reported through official channels after the event, which often they are not.  
One such participant indicated that CLIA waived tests were of most concern due to the fact that 
individuals did not need a lot of training to be able to utilise them.  US congress passed the CLIA 
statute in 1988 in order to establish quality standards in laboratory testing.  This statute made 
provision for tests to be waived from regulatory oversight if certain requirements were met.  In 
order to be waived, tests must employ methodologies so simple that the likelihood of result 
error or harm to the patient through incorrect use is negligible (Bode, Irvin et al. 2007).  As such, 
operators with little or no training hence have access to waived POCT devices and the opinion 
of the clinician in this case was that their use can yield a higher risk of quality issues occurring in 
practice.   
Opinion was attained on how such complexities in the regulations for analytical testing 
accreditation can affect the use of POCT.  While opinion in general was varied, a clinician 
indicated that the manufacturer of a particular POCT glucose test does not recommend its use 
for critically ill patients.  Therefore, this device that is CLIA-waived in most areas within the 
hospital is promoted to non-waived status within the Intensive Care Unit (ICU).  As a result, a 
device which requires just very basic training to operate in the majority of clinical areas within 
the hospital system requires significantly increased operator qualifications for use within this 
particular department which many of the nursing staff do not possess, deeming it unusable in 
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many cases.  It is clear that a situation could therefore arise where a particular operator can 
utilise the device within one department, but then be prevented from utilising the same device 
in another department due to regulatory issues.  It is obvious that this could then act as an 
impediment to the uptake of such devices within a hospital or other healthcare environment. 
Hence, regulatory issues such as this should be addressed accordingly in order to standardise 
required operator qualifications across all potential departments of use.   
Another issue identified with respect to the accreditation regulations was difficulties in 
maintaining compliance as a result of the dispersed nature of this type of diagnostic testing.  A 
significant proportion of respondents here (36%) indicated that this issue was either relevant or 
very relevant to them in their area of practice. One clinician gave a specific example to explain 
this; glucometers are used within 2 locations in the clinician’s place of work by over 3000 nursing 
staff (who operate them) thereby making them very difficult to control.  It should also be noted 
that 6 clinicians did not answer questions regarding specific regulatory issues (13b, 13c, 13d) 
due to a lack of knowledge on the area.  This type of response was also observed in the UK study 
and hence it is apparent that individuals who operate such devices within both the UK the US 
healthcare systems would benefit from increased education on the particular regulatory 
requirements that pertain to their use.  It is imperative that, for a dispersed POCT analysis 
system, there is increased awareness of regulatory requirements hospital-wide, rather than the 
knowledge being held solely by those who are responsible for the application of such regulations 
i.e. the central laboratory services.  However, a fundamental difference between the US and UK 
healthcare systems that may be significant in this respect is that the privatisation of central 
laboratories within the US system may lead to education on regulatory requirements being held 
back from those responsible for operating such devices.  One US clinician involved in this study 
indicated that the central laboratory, being a private entity, saw POCT as direct competition.  
Private laboratories are operated with the purpose of making profit, and if POCT is perceived as 
a threat to this then it will not be actively supported.  There has been a growth in the outsourcing 
of healthcare operations in the US in this millennium, with around 75% of US hospitals now 
having at least 1 outsourced function (Guimares, de Carvalho 2011).  Due to the widespread 
privatisation of such facilities throughout the US, this has the potential to be very damaging to 
the more widespread uptake of POCT within hospitals.   
As was also the case in the findings from the UK study, in terms of overcoming quality and 
regulatory related issues, improved training processes was found to be a common suggestion 
offered by participants in order to negate the risk of untrained or non-competent individuals 
operating POCT devices.  Improved quality assurance processes, along with a dedicated team to 
oversee of this, was also found to be a common theme for improvement in the US system, again 
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mirroring the opinion attained from UK clinicians.  Moreover, the identified need for increased 
support from the central laboratory should be incorporated into this improvement of the 
appropriate processes.  However, it is recognised that an avenue to gain support from privatised 
labs must be investigated to ensure adequate support is given.  
The quality issues associated with the use of POCT have been linked in the past with the usability 
of such devices (Crook 2000, Linder 2007, Goodwin 2008), however the US clinicians involved in 
this study were overwhelmingly of the opinion that POCT devices were easy to use.  It can 
therefore be deducted that POCT devices have developed to the extent that usability is no longer 
an issue in terms of uptake, and has no or little influence upon the quality of the test results 
obtained.  Issues relating to the quality of test results can be due to human error and hence are 
not fundamental characteristics of POCT itself, but actually components of how the device is 
utilised in practice.   
Similarly, the analytical performance of POCT has historically been linked with quality assurance 
aspects of their utility (St-Louis 2000, Perry, Fitzmaurice et al. 2010, Murray, Fitzmaurice et al. 
2004, Melo, Clark et al. 2011).  However, like the UK clinicians studied in Chapter 4, the US 
clinicians have indicated that POCT is generally regarded as providing an acceptable level of 
diagnostic data in comparison to CLT.  Participants here alluded to the fact that, within the US 
health system, POCT is regarded more as a screening test rather than a standalone diagnostic 
solution and so analytical performance did not need to be to the same standard of instruments 
found within the central laboratory.   
One distinct difference between the UK and US studies was with regard to the connectivity of 
POCT devices in that clinicians within the US study indicated that levels of connectivity varied 
significantly across the hospital with some departments able to enter results directly into 
electronic records, while some departments rely on the manual method of physically writing 
results into records.  It was interesting to note that all of the 7 respondents here who indicated 
that connectivity was “poor” or “very poor” signified that this lack of connectivity made it 
difficult to attain a timely and reliable diagnosis in comparison to utilising CLT.  This is a 
significantly different finding to the expressed in the UK investigation where 25 of 33 
respondents indicating that connectivity was “poor” or “very poor” were of the opinion that the 
connectivity issues did not make it more difficult to attain a timely and reliable diagnosis (in 
comparison to CLT).  The main issue for the US clinicians seemed to be with respect to the loss 
of access to diagnostic data via the patient record systems when using of POCT.  The loss of 
access to this data has the potential to act as a significant barrier to uptake of POCT as it can 
make its use seem undesirable to a clinician who often requires as much data as possible to 
make appropriate clinical judgement on a situation which is often complex and time-critical.  The 
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reason that the issue of connectivity seems to be more significant in the US health system may 
be due to the privatisation of central laboratory services and the ensuing lack of updating of 
patient records that can result.  Canada also utilises for-profit corporations to provide medical 
laboratory services for a proportion of its healthcare system, and these have proved to cause 
difficulties in terms of integrating patient records, with the private laboratories operating their 
own standalone record systems (Sutherland 2012).   Opinion on the role of connectivity here 
was more varied than in the UK study and suggests that the US healthcare system has done 
more to improve connectivity of POCT devices within local healthcare networks.  However, it is 
the case that when connectivity is not of an adequate standard then this has an increased impact 
upon diagnostic services in the US compared to the UK healthcare system, where central 
laboratories are nearly always part of the same body.  Therefore, perhaps unsurprisingly, 
improving the connectivity of POCT devices within the patient record system was found to be a 
common suggestion by clinicians within this part of the study with respect to overcoming barrier 
to the more widespread adoption of the devices. 
Further to improved connectivity with central patient record systems, there have been 
indications from literature of issues with respect to how POCT interacts with the structure of 
healthcare organisations and the dynamic of staff and staffing groups within these processes, 
with 18 articles identified by the systematic review (Chapter 3) indicating these issues to act as 
barriers to uptake of POCT.  As was found to be the case for the UK study, POCT was not found 
to significantly increase the workload of front line US clinical staff.  However, the basis for this 
opinion appears to be different between the 2 jurisdictions.  Whereas, in the UK study much of 
the opinion was based on the fact that chasing the central laboratory for results took up as much 
staff time as carrying out the tests themselves using POCT, the US study was based on different 
reasoning.  Much of the rationale here was based on the fact that blood samples are taken 
regardless of which type of test was performed and so utilising POCT does not add any workload 
to what is already a standard CLT procedure.  It would appear that POCT is not utilised efficiently 
within the US structure, and is generally used when a parameter is needed quickly, i.e. for 
screening purposes.  A sample will then still be sent to the central laboratory for testing of 
further parameters even though these could often have been attained using the same POCT 
device.  The reason for this approach would seem to be down to clinical trust given that POCT is 
widely regarded in the US health system as primarily a screening tool and not as a fully-fledged 
diagnostic tool.  For this reason, POCT is only used in time-critical situations where a 
measurement parameter is needed quickly.  If the data is not needed quickly then the result 
from the central laboratory test will always be used.   
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With some of the US clinical opinion indicating that POCT is not utilised efficiently, it was not 
surprising to note that there was also some opinion indicating that the clinical care pathway and 
role of the central laboratory had not been altered sufficiently to incorporate the use of POCT.  
Much like in the case of the UK study, opinion here showed a significant variation on this topic.  
However, some of the opinion received alluded to the fact that the clinical care pathway didn’t 
actually need to be altered.  The attitude here was that POCT should not be forced into areas 
where it is not necessarily needed for a rapid diagnosis, and hence the traditional CLT model 
should be maintained in the majority of cases.  One participant from within the clinical 
biosciences cohort indicated that such alteration was required as the current model of shared 
responsibility between the clinicians and central laboratory staff does not work due to a lack of 
clear line of responsibility.  Better defined clinical governance is therefore a key requirement 
and the clinical laboratory service should therefore ultimately be responsible for the 
management of POCT devices and attendant data generation.  However, controlling such a 
dispersed range of devices remains the issue and must be addressed if they are to be utilised 
effectively.  The current issues associated with shared responsibility has led to accusations that 
the central laboratory service is reluctant to release the control of POCT beyond its confines and 
hence it is this that inhibits their more widespread adoption of such a range of testing (Huckle 
2008, Halpern 2000, Fermann, Suyama 2002).  Much like the findings from the UK study, opinion 
here was varied on this controversial issue.  Only those clinicians working in the clinical 
biosciences area of practice tended to consistently agree with this proposition (average 
response of 6.75 on the 10-point scale, where 10 was strongly agree).  It is assumed that this is 
again mostly due to the perceived risk of allowing clinicians to be responsible for test quality 
assurance when not sufficiently trained in laboratory analytical methods.  One individual from 
the clinical biosciences cohort noted that if a clinical decision is made based on incorrect POCT 
results attained by nursing staff, then it is considered a laboratory test that has gone wrong, but 
that nonetheless, those in the clinical biosciences field are held responsible and so they prefer 
to keep control of the devices within their own confines.  The solution to this issue appears to 
be improved training processes and increased aftercare support from the central laboratory 
service as suggested in both this and the UK study.  Interestingly, one participant in the US study 
cohort indicated that the CLIA regulations were set up to keep control within the central 
laboratory service in order to protect their existence, and it was this fact rather than any 
reluctance by staff that prevented control from being passed to other clinical groups.  It is 
however likely that regulations are more focused on attaining high quality test outputs and so 
control of testing will be regulated mostly by this consideration. 
In terms of an assessment of the general utility of POCT, US clinicians provided a strikingly similar 
evaluation to that reported within the UK study.  With respect to advantages attainable through 
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utilisation of this range of testing, a rapid TAT and hence quicker clinical decisions and/or 
interventions were found to be overwhelmingly the most common benefit provided by 
participants here.  Increased efficiency with respect to patient management and improved 
satisfaction and convenience for both the device operator and patients were again commonly 
cited as clear advantages to the use of POCT.  No single disadvantage was significantly more 
common than others, with cost and quality control issues resulting from their use by untrained 
or non-competent personnel were the more common issues in terms of drawbacks to increased 
utilisation.  Diseases and conditions that benefitted most from the use of POCT devices identified 
here included areas where they historically been most embedded i.e. blood glucose monitoring 
for diabetic patients, INR monitoring for patients receiving warfarin therapy and respiratory 
conditions, as was also the case for the UK study.  One participant alluded to the fact that there 
is a greater demand for POCT to be developed and enter the healthcare sector from influences 
outside of the national healthcare system in US than within.  This particular participant also 
indicated that the Department of Defence in the US has acted as a massive driver for POCT 
development, especially since the rise in threat of bioterrorism.  Emerging technologies in this 
regard must therefore be encouraged to enter the healthcare system and be adopted 
accordingly.   
The principal focus of the study described here was to achieve the fifth research objective as 
defined in Chapter 1; to compare and contrast clinical perspectives (opinions) on those issues 
that are seen as impediments to the uptake of POCT from clinicians working in the UK healthcare 
system, i.e. that is free at the point of delivery, with those in the US system where the cost of 
healthcare provision is insurance-based.  As a means to achieve this, primary data attained here 
has been mapped back onto the findings of the UK-based study described in Chapter 4 and areas 
where opinion has been influenced by the underlying health model have been identified 
accordingly.  Additionally, the study has collected data to further work toward achieving the 
final 4 research objectives noted in Chapter 1, namely; to identify the key advantages and 
potential benefits of POCT use within secondary healthcare; to identify the major disadvantages 
deemed to result from the use of POCT; to determine the clinical areas/situations in which POCT 
can provide the most benefit in secondary care; to suggest how the most significant barriers to 
adoption of POCT in the relevant secondary healthcare systems can be overcome based on the 
findings of the studies undertaken, i.e. what are the possible solutions that may encourage more 
effective adoption? 
Overall, it is apparent that many of the findings from the US study compare with what was found 
in the UK study and indeed that many of the pros and cons of POCT are universal across global 
healthcare systems.  Differences in opinion would seem to arise mostly in respect to some issues 
 138 
pertinent to the payment structures that operate within the respective healthcare systems.  In 
particular, how the central laboratory services are organised are reflected in the different 
opinions from the 2 studies.  Moreover, a disconnect between those responsible for POCT and 
those who utilise it is apparent in both systems.  As such, an international study (negating the 
influence of regional healthcare systems) was conducted focusing on the role of clinicians within 
the clinical biosciences cohort in order to compare to the findings of Chapters 4 and 5.  This 
study is described in the following chapter. 
5.5 Statistical Comment 
As conducted in the previous primary study (Chapter 4), an analysis was undertaken to 
determine if differences in opinion found between clinical groups were statistically significant.  
In this study, 2 areas were observed as presenting differences in response profile between the 
clinical bioscientists and clinicians.  Firstly, that the decentralised nature of POCT allowed for 
increased opportunity for untrained / non-competent users to operate the devices, hence 
leading to quality assurance issues.  Clinical Bioscientists were in stronger agreement that this 
was the case, in comparison to clinicians.  Applying the Chi-square test here, a p-value of 0.247 
was found, signifying the difference in opinion observed as not being statistically significant 
(>0.05). 
Similarly, the Chi-square test was applied to the second area where a difference in opinion was 
observed in this study; regarding the reluctance of the central laboratory to release the control 
of diagnostic testing.  Such as was found the UK-focused study, clinicians here were in stronger 
agreement with this, in comparison to the clinical bioscientists participating.  A p-value of 0.852 
was returned in this instance, again determining this as not being statistically significant. 
Due to the small sample number in this particular study it becomes more difficult to statistically 
prove observations as being significant.  As a result, it is not possible to rule out that these 
observed differences in opinion between clinical groups in this US-focused investigation are not 
simply down to chance. 
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Chapter 6 
Perspectives on Barriers to Adoption of Hospital-based POCT 
Specific to Clinical Biosciences Professionals 
6.1 Study Objective 
The research outputs reported thus far have addressed the initial 5 research objectives of this 
work, specifically; to determine from a systematic review of the academic literature the actual 
issues that affect the adoption of POCT devices within the hospital-based clinical environment; 
to categorise the issues identified from the literature as a means of understanding in detail their 
relative contribution to adoption of POCT devices in the hospital environment; to determine, in 
order of priority, which issues are currently impacting the adoption of POCT devices within the 
clinical environment; to determine the relationship between those issues identified from a 
consideration of the academic literature and the opinions of clinicians within the UK healthcare 
environment on the same issues, and; to compare and contrast clinical perspectives (opinions) 
on those issues that are seen as impediments to the uptake of POCT from clinicians working in 
the UK healthcare system, i.e. that is free at the point of delivery, with those in the US system 
where the cost of healthcare provision is insurance-based.   
Additionally, the previous 2 chapters have somewhat addressed the sixth research objective; to 
assess how the perception of issues effecting the uptake of POCT, including their impact and 
relevance, varies with respect to the specific clinical role.  As an extension of these findings, this 
chapter seeks to further address this sixth research objective and to specifically focus on 
achieving the seventh objective; to determine the global experiences of clinical bioscientists, as 
the professional group most closely aligned to hospital based diagnostic testing, in relation to 
the identified barriers to adoption of POCT.  The core objective here is therefore to determine 
the extent to which their opinion on the utilisation and uptake of these devices is influenced by 
their professional roles and responsibilities. 
6.2 Study Development & Design 
As the work carried out here is an extension of the research described in the previous 2 chapters, 
the operational basis remains the same.  As such, the configuration of a survey study is identical 
to that used in Chapter 5 but without any consideration of the location of the clinicians or the 
healthcare system in which they practice.  Hence, the final question added to the study in 
Chapter 5 regarding the impact of the participant’s healthcare system on POCT uptake has been 
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disregarded for this investigation.  In addition, this aspect of the research was carried out solely 
utilising electronic participation through an online survey tool.   
The information provided by the analyses undertaken in the previous 2 studies has indicated 
that there is a significant disconnect between the opinions provided from clinicians who simply 
wish to utilise POCT devices and those who are responsible for their safe and effective use in 
the hospital sector, specifically those in the Clinical Biosciences professional group.  Therefore, 
it was decided to seek opinion from a larger international sample of this clinical sub-group.  This 
part of the work was supported via endorsements and dispersion of the online survey tool link 
by members of a number of international POCT interest groups in North America, Europe and 
Australasia.  As such, the cohort of responders represents those working in the healthcare 
systems of Canada, USA, Belgium, Netherlands and Australia.  As before, the existing research 
governance and ethical approvals that comprehensively covered the study were applied. 
6.3 Study Results 
In total, a sample of 101 individuals from a clinical biosciences background participated in this 
study.  Hence, in terms of data collection this provided a much larger pool of opinion to analyse 
in comparison to either the UK or US specific general clinical studies that were carried out 
previously.  88 of the 101 participants noted that POCT is used to diagnose patients in their area 
of clinical specialism.  The sample of clinicians were found to be of high expertise with respect 
to the practical use of POCT, as illustrated in Figure 6.1, with 56% being “highly proficient” in 
their use, being recognised trainers in the operation of such devices.  A further 19% rated 
themselves as being “competent” in the use of POCT, with 14% holding a “basic level capability”.  
Just 11% of clinicians had completed no formal training in the use of POCT. 
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Figure 6.1 - Areas of clinical expertise as a function of POCT use by study participants (n=101). 
Figure 6.2 gives an overview of the types of POCT used in participant’s area of practice.  
Mimicking the findings of Chapters 4 and 5 in this regard, blood gas and blood glucose were 
again found to be most prevalent, being indicated by 77% and 76% of respondents respectively.  
A further 2 types of test were also found noted by more than half of the study sample; blood 
coagulation tests (63%) and urine pregnancy / urinalysis (52%). 
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Figure 6.2 - Most common POCT devices used in areas of clinical practice with respect to 
percentage of respondents for each (n=101). 
6.3.1 Economic Issues 
Despite the possible expectation that issues concerning quality assurance of testing and 
associated results when utilising POCT would be most important to those within the clinical 
biosciences group, it was the economics of testing that was the most prevalent issue with 90 of 
the 101 participants agreeing that POCT is more expensive than CLT on a cost per test basis, as 
illustrated in Figure 6.3. 
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Figure 6.3 - Response of clinical bioscientists to POCT cost per test in comparison to CLT (n=101). 
The study sample was more of the opinion that POCT provides longer term benefits than not, 
such as reduced hospital length of stay and a reduced number of outpatient appointments, with 
22% of the sample “strongly agreeing” and a further 30% “agreeing”, as shown in Figure 6.4.  
30% of the clinical bioscientists here gave a “neutral” response with an answer of 5-6 on the 10-
point scale used.  Only 9% “disagreed” with this, with a further 9% “strongly disagreeing”. 
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Respondents “disagreeing” or “strongly disagreeing” that POCT provides longer term economic 
benefits were questioned as to why they though such potential benefits were not being realised, 
with responses as follows: 
• “POCT is misused as an argument. Better logistics can often solve the problem.  
Although, there are sometimes better outcomes because POCT is [much quicker than] 
the whole procedure of taking blood and sending to [the] central lab.” 
• “Lab investigations are also very fast.” 
• “Usually need additional non-POCT test results to treat/diagnose patient.” 
• “Accuracy of the analysers and provider/physician mistrust.  Also cost.” 
• “Due to lack of skill/trust in results by ward operators most tests are duplicated in the 
main lab for confirmation. Also, there is high risk of unsuitable samples creating incorrect 
results, e.g. haemolysed blood gas samples giving falsely high potassiums, so unusual 
results are repeated in main lab. This means many of the time benefits associated with 
POCT are not realised in practice.” 
• “Length of stay not closely linked to TAT for laboratory tests performed by POCT.” 
• “Do not think that in a hospital setup there are long term economic benefits.” 
• “Poor quality systems.” 
• “The LOS [length of stay] at the emergency [department] does not really depend on the 
result of the POCT as often other procedures have to be done. Also, the admission may 
take some time depending on bed availability.” 
• “The rationality for using POCT is not linked to economic benefits.” 
• “Instrument complexity.” 
• “The benefits of early diagnosis and treatment are not quantified as a cost/benefit. 
Whereas, the costs of POCT are evident to all managers, in remote sites the reduced 
need for ambulance transfer is not stated back to POCT.” 
Notably however, as illustrated in Figure 6.5, 71% of the respondents in this study indicated that 
overall, they saw POCT as being a cost-effective system and one that made appropriate use of 
the increased expense incurred. 
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Figure 6.5 – Response of clinical bioscientists to the cost-effectiveness of POCT systems (n=98). 
As was found in the previous studies (Chapters 4 and 5), clinical opinion on procurement, 
reimbursement and budgeting with respect to the interdepartmental nature of devices was 
found to be significantly varied, as indicated by Figure 6.6.  Notably, of the 38 respondents who 
“disagreed” or “strongly disagreed” that these aspects sufficiently accommodated the 
interdepartmental nature of POCT in their institution, 27 indicated that this made it more 
difficult to utilise POCT to its full potential in their place of work. 
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 146 
 
 
The relevance of specific economic issues in regard to how this opinion is arrived at was also 
considered.  The respective issues include; difficulties in justifying the use of POCT due to the 
higher cost per test in comparison to traditional testing methods; difficulties in justifying the 
implementation of a POCT system due to unclear cost-effectiveness and complexities in 
comparing to traditional methods of testing; difficulties in justifying the implementation of a 
POCT system due to high initial outlay costs; issues with regard to budget contributions due to 
the “silo” nature of separate departmental budgeting, and; difficulties in obtaining 
reimbursement for POCT.  The distributions of responses received are shown in Figure 6.7 and 
it is interesting to note that the “not relevant” response category is the least frequently stated 
across all parts, with the “sometimes”, “fairly” or “very relevant” responses found to be most 
often used.  It is therefore apparent from these results that clinical biosciences cohort is very 
much of the opinion that these particular economic issues, as identified within the relevant 
literature base, are the most relevant to their profession. 
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Figure 6.6 – Clinical bioscientists opinion on procurement, reimbursement and budgeting for 
POCT with respect to the interdepartmental availability of such devices (n=99). 
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6.3.2 Quality Assurance & Regulatory Issues 
The initial focus for the consideration of quality assurance and regulatory issues was with 
respect to the dispersed nature of POCT devices leading to errors caused by untrained or non-
competent staff using the devices.  As illustrated in Figure 6.8, the opinion of these participants 
showed very strong agreement with this proposition, with 46% of the group “strongly agreeing” 
and with a further 28% “agreeing” with this sentiment.  Only a small proportion of the clinicians 
either “strongly disagreed” (8%) or “disagreed” (6%) that this was the case. 
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Figure 6.8 – Response of clinical bioscientists to how the dispersed nature of POCT devices leads to 
use by untrained or non-competent staff, resulting in quality assurance issues (n=93). 
Of the 69 respondents “agreeing” or “strongly agreeing” here, 37 indicated that this made it 
more difficult to attain a timely and reliable diagnosis in comparison to CLT, 22 indicated that it 
did not make it more difficult, and 10 did not offer a response. 
Regulatory compliance has been found to be an area of significant debate throughout the 
research outcomes reported thus far.  Much like the previous studies carried out, significant 
variation in opinion was found with respect to the complexity of regulations for analytical testing 
accreditation here, as noted in Figure 6.9.  15% of the sample group “strongly disagreed” that 
regulations were overly complex, while 13% “disagreed”.  25% of responses were “neutral” in 
terms of their position on the 10-point scale, while 29% of participants “agreed” an a further 
18% “strongly agreed” with the question statement. 
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Figure 6.9 – Clinical bioscientists opinion on the complexity of the regulatory requirements and 
accreditation for analytical testing using POCT devices (n=91). 
Of the 42 responders either “agreeing” or “strongly agreeing” that the regulations are overly 
complex, 25 indicated that this made it more difficult to attain a timely and reliable diagnosis in 
comparison to CLT, while 11 said that it did not make it more difficult.  6 participants failed to 
give a response to this question. 
With respect to the level of training and support provided by the central laboratory service in 
regard to attaining the necessary compliance, perhaps not surprisingly, the clinical sciences 
study group here was of a significantly strong opinion that levels of support are excellent, with 
42% of participants indicating a “very high” response and another 32% of individuals indicating 
a response of a “high”.  The overall response distribution can be seen in detail in Figure 6.10. 
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Figure 6.10 – Response of clinical bioscientists to the level of operator training and support on 
regulatory compliance for POCT provided by the central laboratory service (n=93). 
Of the 14 clinical bioscientists who indicated levels of training as being “low” or “very low”, 11 
believed this made it more difficult to make a timely and reliable diagnosis in comparison to CLT, 
while 3 believed it did not make it more difficult. 
As seen previously in the analyses of the data from the UK and USA studies, the perceived 
relevance of the same issues here was found to be pertinent with respect to this category of 
barrier to adoption of POCT, namely; errors caused by incorrect quality assurance procedures 
by untrained/non-competent staff operating the devices; issues caused by  non-laboratory 
operators of devices due to regulations written for traditional laboratory equipment being 
inappropriately applied to POCT; issues with maintaining regulatory compliance due to a 
number of changes in the relevant regulations; issues with maintaining regulatory compliance 
due to the dispersed nature of POCT, and a lack of improvement of POCT devices caused by 
product approval hurdles that discourage economic investment in their development.  As 
illustrated in Figure 6.11, all of these issues were found to be of some importance for the clinical 
biosciences cohort, with “sometimes relevant” and “fairly relevant” found in general to be the 
most popular response categories.  An exception here is with respect to the issue regarding a 
lack of development of POCT devices caused by product approval hurdles discouraging 
economic investment in their development.  Unlike previously, this specific issue was the one 
area in which “not relevant” was not the least frequent response category and, although 
“sometimes relevant” was the most frequent response, “rarely relevant” was the second most 
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frequent, indicating a general trend towards this being of lower relevance when considered by 
clinical biosciences only in comparison to the other specific issues identified within this category 
of barrier to adoption. 
 
Figure 6.11 – Response from clinical bioscientists on the relevance of specific quality assurance 
and regulatory issues within their own area of professional practice (n=93). 
6.3.3 Device Performance & Data Management Issues 
As clinical bioscientists are most aligned with the central laboratory service in professional 
practice, opinion was gauged with respect to their views on the analytical performance of POCT 
devices in comparison to CLT instruments.  This study found that 44% of participants indicated 
that the level of analytical performance of POCT devices was “high” in comparison to CLT, 22% 
indicated a “neutral” level of performance and a further 21% considered the analytical 
performance of POCT to be at a “lower” level in comparison to POCT.  The full results are 
indicated in Figure 6.12.  Only a small proportion of the study group were aligned with either 
end of the response scale with, with 9% and 4% indicating “very high” or “very low” levels of 
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performance, respectively.  OF the 23 participants who indicated analytical performance as 
being “low” or “very low”, 16 believed this makes it more difficult to attain a timely and reliable 
diagnosis in comparison to CLT, while 7 did not believe it makes it more difficult. 
 
Figure 6.12 – Response of clinical bioscientists on the level of analytic performance of POCT 
devices (n=92). 
As in the previous studies, the sample group were questioned with regards to the connectivity 
of POCT devices in comparison to CLT, with results in Figure 6.13.  Opinion was significantly 
varied here; 21% indicating connectivity to be “very good”, 26% as “good”, 23% as “neutral”, 
14% as “poor” and 16% as “very poor”.  Of the 27 respondents indicating connectivity as “poor” 
or “very poor”, a large majority of 24 believed that this made it more difficult to attain a timely 
and reliable diagnosis in comparison to POCT. 
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Figure 6.13 – Clinical bioscientists opinion on the connectivity and data management capabilities 
of a POCT system (n=91). 
Clinicians in this study, in general, indicated that POCT devices are not difficult to use, as 
illustrated in Figure 6.14.  The largest frequency of response here was to indicate that POCT 
devices are “very easy” to use, with 44% of the clinical bioscientists here indicating this to be 
the case.  A further 31% indicated their use to be “easy”, while 14% were of “neutral” opinion 
and 9% found POCT devices “difficult” to operate.  Just 2% of the response indicated that POCT 
devices were “very difficult” to utilise in comparison to CLT.  Of the 10 participants believing the 
use of POCT to either be “difficult” or “very difficult”, 3 indicated this made it more difficult to 
make a timely and reliable diagnosis in comparison to CLT, while 4 thought this did not make it 
more difficult.  3 responders here failed to give a response.  These 10 respondents were also 
invited to make suggestions as to how the usability of POCT devices could be improved, with 
responses as follows: 
• “It’s idealistic to compare each and every POCT device with the quality testing of 
laboratory instrumentation, however, POCT devices, having internal calibration 
mechanisms, quality control shut off points and reporting (all results directly) to 
clinicians would be ideal.” 
• “Suffice to say that if more than 1 POCT device has to be used for testing on a patient, 
the efficiency goes way down; i.e. TAT may be no better than CLT and the labour 
involvement of the caregivers becomes prohibitively large.” 
• “Greater connectivity, greater sensitivity and specificity of the devices/kits.” 
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• “1) Better analytical performance (e.g. troponin, the poor performance at low 
concentrations is why we won't allow it, despite multiple requests by our emergency 
department).  2) Automatic checks for pre-analytical interferences such as haemolysis.  
3) Less false advertising from manufacturers as to POCT's capabilities.  4) Smarter 
systems, e.g. alarming when the wrong barcode is scanned.” 
 
Figure 6.14 – Clinical bioscientists opinion on the degree of difficulty associated with performing 
tests using POCT devices (n=91). 
Whereas, the majority of the findings on data management issues from this part of the study 
compare to those from the previous UK and USA elements, there are some interesting findings 
with respect to the relevance of specific issues namely; POCT devices producing reduced 
analytical performance in comparison to Central Laboratory Testing (CLT); data management 
issues resulting from poor connectivity between the POCT system and patient record systems, 
and; operators encountering difficulties with the use of POCT devices.  As indicated in Figure 
6.15, the most frequent response from the clinical biosciences group for the issues relating to 
reduced analytical performance and usability difficulties, were “sometimes relevant”, while the 
remaining issue, that regarding problems with data management due to poor connectivity was 
found to be “very relevant” to a significant number of participants (32 of 101).  Across all 3 of 
the specific issues concerned, “not relevant” area of response was found to be the least 
frequently indicated, with only 2, 3 and 1 participant indicating this response, respectively.   
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Figure 6.15 – Response of clinician bioscientists on relevance of specific device performance and 
data management issues within their professional practice (n=91). 
6.3.4 Staff & Operational Issues 
In terms of how staff and operational issues may act as barriers to the adoption of POCT, as 
highlighted by a systematic review of the relevant academic literature, this part of study showed 
several interesting findings.  Firstly, the opinion of the clinical bioscientists with regard to the 
impact of POCT utilisation on the workload of front line clinical staff indicated that 50% of 
participants were either “agree” or “strongly agree” that there was a significant increase in 
workload as a result of POCT use.  A further 20% of response was “neutral”, while 19% 
“disagreed” and the remaining 11% “strongly disagreed” that this was the case.  The results are 
shown in detail in Figure 6.16.  Of the 46 respondents indicating that they “agreed” or “strongly 
agreed”, 28 suggested that this reduced staff satisfaction levels in comparison to when utilising 
CLT, while 16 of the group did not think this was the case.  2 respondents here failed to give a 
response. 
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Figure 6.16 – Response of clinical bioscientists of the impact of POCT upon the workload of device 
operators (n=91). 
The sample group were questioned on whether they believed that the central laboratory is 
reluctant to allow the control of diagnostic testing to be passed on, with results shown in Figure 
6.17.  Response demonstrated significant variation across the framed categories; 17% as 
“strongly agree”, 24% as “agree”, 26% as “neutral”, 15% as “disagree” and 18% as “strongly 
disagree”.  The 37 respondents “agreeing” or “strongly agreeing” that the central laboratory was 
reluctant to allow the control of testing to be passed on were questioned as to whether they 
believed this acted as an impediment to the more widespread uptake of POCT.  20 believed this 
to be the case and 13 did not think this acted as an impediment, with 4 failing to give a response. 
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Figure 6.17 – Clinical bioscientists opinion on the reluctance of the central laboratory to release 
the control of POCT testing to the clinic (n=91). 
Figure 6.18 illustrates the response profile of opinion when the respondents were questioned 
as to whether they believed the clinical care pathway and role of the central laboratory had 
been altered sufficiently to incorporate the use of POCT, with few responses “disagreeing” (10%) 
or “strongly disagreeing” (7%) that this was the case.  A significant proportion (34%) of the study 
sample were of a neutral opinion, while 31% “agreed” and 18% “strongly agreed” that sufficient 
alteration had been carried out.  Of the 15 clinical bioscientists that “disagreed” or “strongly 
disagreed”, 10 believed that this makes it more difficult to attain a timely and reliable diagnosis 
in comparison to CLT, 2 believed it does not make it more difficult, and 3 failed to give a 
response. 
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Figure 6.18 – Clinical bioscientists opinion of how the clinical care pathway and role of the central 
laboratory have been altered to incorporate the use of POCT (n=90). 
Consideration of the relevance of the specific issues also yielded findings of interest.  These 
issues relate to the following issues; reduced staff satisfaction levels and increased friction 
between clinical staff groups due to the use of POCT; impeded uptake of POCT caused by the 
reluctance of the central laboratory service to release the control of diagnostic testing; 
inappropriate use of POCT, including over-use and reliance on test results; benefits of POCT 
being negated due to a requirement for clinical care pathways and role of the central lab to be 
altered sufficiently; POCT system running inefficiently due to the requirement for an 
interdepartmental management structure with clear clinical governance for POCT, and; 
difficulties implementing POCT due to a reluctance to change within healthcare bodies along 
with a lack of evidence justifying POCT.   As shown in Figure 6.19, the “not relevant” response 
area was found to be very low for the perceived relevance of other categories of impediment, 
being the least frequent response across all 6 issues investigated here.  The inappropriate use 
of POCT was found to be the most frequent response here, with “fairly relevant” and “very 
relevant” found to the most popular responses.  The most frequent response in all 5 categories 
of specific interest was found to be “sometimes relevant”. 
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Figure 6.19 – Response from clinical bioscientists of relevance of specific staff and operational 
issues within their own clinical institution (n=91). 
6.3.5 Other General Issues 
As this investigation was carried out entirely through an online survey tool, no face-to-face 
interviews were carried out.  The additional information obtained directly from the face-to-face 
interviews presented in Chapters 4 and 5 were found to be extremely important for attaining 
insight into participant response and, in many cases, offered clarification of reasons for such 
responses.  The final section of the remote survey tool employed here, as before, incorporates 
a free-response section related to the core questions, providing an avenue for clinical 
bioscientists to provide added value to their responses.  Participants were firstly asked to give 
their opinion on the main advantages of POCT in comparison to CLT, with the most frequent 
responses attained as follows: 
• Rapid TAT results in a quicker decision/diagnosis and earlier clinical intervention (73% 
of respondents). 
0
5
10
15
20
25
30
35
40
45
Reduced staff
satisfaction levels
and increased
friction between
staff groups.
The widespread
uptake of POCT is
impeded by the
resistance of the
central lab to
release the control
of testing.
There is
inappropriate use
of POCT (i.e. over-
use and reliance
on test results,
undermining
clinical expertise).
The full benefits of
POCT are not
being realised as
significant
alterations to
clinical care
pathways and the
role of the central
laboratory are
required.
The POCT system
does not run
efficiently as an
interdepartmental
management
structure is
required with clear
clinical governance
for POCT.
Difficulties
implementing
POCT due to a
reluctance to
change and a lack
of evidence
justifying POCT.
N
u
m
b
er
 o
f 
P
ar
ti
ci
p
an
ts
Identified staff / operational issue
Question 21 - Relevance of specific staff & operational 
issues
Not Relevant Rarely Relevant Sometimes Relevant Fairly Relevant Very Relevant
 160 
• Improved patient/operator satisfaction and convenience (including lower blood sample 
volumes, patient education and buy-in/responsibility) (21% of respondents). 
• More efficient patient management (10% of respondents). 
• Avoids sample transfer where no laboratory on site or within close proximity (4% of 
respondents). 
• Overcome problems of bad access to hospital/medical care (4% of respondents). 
• Offers improved quality of care and better patient outcomes (3% of respondents). 
• Reduces risk of sample mix up and simpler sampling process (3% of respondents). 
• Improved sensitivity/accuracy (3% of respondents). 
• Avoids sample instability issues during transport (2% of respondents). 
• Cost savings (including patient education and staff taking pathology call-backs) (2% of 
respondents). 
• Ease of use (2% of respondents). 
• Less reliance on a chain of services where delays are more likely with POCT devices 
(individual response). 
• POCT devices take up a low amount of space (individual response). 
• Improves direct communication between patient and doctor (individual response). 
• Offers increased user control of testing/treatment (individual response). 
Similarly, study participants were asked about the main disadvantages of POCT in comparison 
to CLT.  The most frequent responses here include: 
• Poor quality/inaccuracy of result obtained by untrained or non-competent staff 
(including user awareness limitations, inexperience of clinical staff etc.) (38% of 
respondents). 
• Increased cost (30% of respondents). 
• Reduced accuracy compared to CLT and subsequent lack of confidence in results (17% 
of respondents). 
• Poor connectivity to central healthcare and patient record systems/other ICT issues 
(13% of respondents) 
• Significant amount of staff training required (time, cost & management) (13% of 
respondents). 
• Takes up a lot of staff time to operate (increased workload) (9% of respondents). 
• Quality management requires significant resources and is difficult to control due to 
dispersed nature (9% of respondents). 
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• Difficulty in ensuring continued staff competency and unfamiliarity caused by a lack of 
regular use (7% of respondents). 
• Physical distance from CLT / experts and troubleshooting help thereby making it difficult 
to remotely manage (5% of respondents). 
• Lack of CLT oversight, dedicated staff or quality programme (3% of respondents). 
• Risk of inappropriate use (2% of respondents). 
• Reduced test menu in comparison to CLT (2% of respondents). 
• Clinical governance unclear (individual response). 
• Maintenance of dispersed devices is difficult (individual response). 
• POCT is inefficient for handling large test volumes (individual response). 
• Lack of outcome study evidence available for POCT (individual response). 
• Manufacturers interfering with hospital policies (individual response). 
• Poor general usability of devices (individual response). 
In order to ascertain where POCT is deemed to be most valuable to clinical bioscientists, 
participants were also asked which diseases and/or conditions benefited the most through its 
use.  The most frequent responses received are summarised here: 
• Diabetes i.e. glucose monitoring (44% of respondents). 
• Cardiac conditions (29% of respondents). 
• Blood coagulation, i.e. International Normalised Ratio (INR) monitoring (25% of 
respondents). 
• Critical care conditions, i.e. Intensive Care Unit & Emergency Department (25% of 
respondents). 
• Respiratory conditions, i.e. blood gas testing (15% of respondents). 
• Pregnancy / Obstetrics / Neonatology (14% of respondents). 
• Infectious diseases (7% of respondents). 
• Sepsis testing (7% of respondents). 
• Other blood tests, e.g. pH, bilirubin, lactate etc. (7% of respondents). 
• Surgical procedures (6% of respondents). 
• General blood issues, i.e. Blood counts and haemoglobin tests (5% of respondents). 
• Deep vein thrombosis (5% of respondents). 
• General triage (4% of respondents). 
• Electrolytes issues (4% of respondents). 
• Urinalysis tests (4% of respondents). 
• Renal conditions (4% of respondents). 
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• Drug abuse patients (3% of respondents). 
• Skin conditions (2% of respondents). 
• Dehydration (individual response). 
• Influenza (individual response). 
The most valuable insight here, in terms of achieving a solutions-based approach to the research 
question, was gained through the study of this groups opinion on how to overcome the 
impediments that exist in relation to the more widespread uptake and use of POCT within 
hospital environments.  The core opinions and frequency of response attained from clinical 
bioscientists in this regard are summarised below: 
• Audit the use of POCT to provide evidence of clinical and/or economic benefits to 
stakeholders as a way to overcome issues such as mistrust in its utility and a lack of full 
backing for its implementation by the healthcare system, including dissuading negative 
opinions on POCT e.g. competition to the laboratory, etc. (11% of respondents). 
• Improve the training processes and periodic competency assessments for all users (10% 
of respondents). 
• Improve the connectivity of POCT devices to central healthcare systems and develop 
appropriate connectivity regulations (9% of respondents). 
• Central laboratory to provide oversight of QA, maintenance and training (8% of 
respondents). 
• Increase the support for POCT via dedicated central laboratory staff to operate the 
devices (7% of respondents). 
• Reduce costs (6% of respondents). 
• Improve the analytical performance of devices (6% of respondents). 
• Improve/simplify the QA processes (4% of respondents). 
• Support close collaboration/communication between the areas of clinical specialism 
involved in the use of POCT (3% of respondents). 
• Offer more tests on fewer devices (3% of respondents). 
• Increase buy-in from top management (3% of respondents). 
• Improve usability of the devices (2% of respondents). 
• Attain better correlation between POCT and central laboratory tests, i.e. regulate the 
exact parameters/analytes for each test (2% of respondents). 
• Increase the test menu available through POCT (2% of respondents). 
• Implement a clear POCT policy/strategy (2% of respondents). 
• Increase reimbursement based on total costs of healthcare chain involved and not just 
the test itself (individual response). 
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• Re-evaluate the "traditional lab" standards of regulation/accreditation and introduce 
specific POCT regulations (individual response). 
• Increase POCT development for infectious diseases (individual response). 
• Focus POCT on qualitative tests only (individual response). 
• POCT devices should be leased from the manufacturer such that the hospital pays for 
the test strips it uses (individual response). 
• Limit use to where POCT is strictly necessary (individual response). 
• Implement "user pays” for POCT, i.e. pays for the convenience (individual response). 
• Increase the resources made available to manage POCT (individual response). 
In the final part of this survey, clinical opinion was investigated with respect to the relation 
between the cited categories of impediment and their impact upon the current mode of POCT 
adoption.  The clinical study group here were asked to rank the 4 categories of issue that had 
been identified from the previous systematic literature review (economic, quality assurance & 
regulatory, device performance & data management and staff & operational issues) on a scale 
of 1 to 4, with 1 being most important in regard to POCT uptake and 4 being least.  As in previous 
chapters, the data was managed using a tiered scoring system to accumulate the categories into 
a final ranking order (4 points for first-place ranking, 3 for second, 2 for third and 1 point for 
fourth-place).  The scoring frequency of the resulting responses are provided in Figure 6.20.  As 
indicated, economic issues received the highest pooled score of 220.  This was followed by 
device performance & data management and quality assurance & regulatory issues with scores 
of 200 and 196, respectively.  Finally, perhaps surprisingly, staff & operational issues received 
had score of 144 which fell considerably behind the other studied categories. 
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Figure 6.20 - Clinician opinion of clinical bioscientists on the ranking of those categories of barrier 
to adoption of POCT indicated by the systematic literature review (n=76). 
6.4 Discussion 
As was the case for the studies conducted amongst a range of UK and US hospital-based 
clinicians, presented in Chapters 4 and 5, economic issues were deemed to be a significantly 
important barrier to adoption for POCT by the clinical bioscientists in terms of current impact 
upon uptake, ranked in first-place here.  However, whereas quality assurance and regulatory 
issues were ranked as being as important as economic issues (in terms of impact on uptake) by 
UK clinicians, the clinical bioscientists ranked device performance and data management issues 
as being in second-place, with quality assurance and regulatory issues third.  Although, it is 
recognised that the difference of 4 points in this scoring system employed here is not significant, 
it can be stated that the clinical biosciences cohort is of the opinion that the category of device 
performance and data management issues, has at the very least as much an impact on POCT 
uptake as quality assurance and regulatory issues.  It is suggested that the reason for the 
prevalence of this opinion may centre around the responsibility that clinical bioscientists hold 
with respect to ensuring that accurate information and guidance is provided to other healthcare 
professionals regarding the operation of POCT devices.  The role of clinical bioscientists is 
becoming increasingly important with respect to ensuring that the quality of diagnostic testing 
is not diminished as testing moves increasingly away from the central laboratory (Shaw 2016).  
The general opinion indicated by this study (Question 14) represents the belief that, although 
POCT performance is adequate, it is not at a level that is on par with the instruments employed 
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in the central laboratory, which are considered to represent the gold standard in the diagnostic 
sector.  When such performance is considered as being adequate, it should be noted that this 
translates as being adequate if the inherent limitations in the use of POCT in comparison to CLT 
are recognised.  The clinical biosciences cohort, being closely aligned to the equipment utilised 
in the central laboratory, have a specific form of awareness of these limitations and hence a 
responsibility to make other healthcare professionals aware of these limitations.  For example, 
previous research has pointed to the poor analytical performance of certain HbA1c devices 
(Lenters-Westra, Slingerland 2009) and places emphasis on the importance of being aware of 
the limitations of POCT devices in their effective utilisation.  As such, those in the clinical 
biosciences profession, who are working regularly with central laboratory instruments, are most 
aware of the differences in levels of analytical performance between these instruments and 
POCT devices and so are perhaps best placed to direct their utilisation and hence uptake within 
the hospital environment.   
As part of the consideration of device performance and data management issues, improved 
connectivity and the introduction of connectivity regulations in order to standardise the 
connectivity of devices was highlighted as being the third most common suggestion by the 
sample of clinical bioscientists with regards to potential solutions to overcoming issues of 
uptake/adoption (Question 25).  It should be highlighted however, that in some healthcare 
systems connectivity standards do already exist, however it is the lack of standardisation of the 
interface between the devices and the clinical records that is the problem.  Wiencek and Nichols 
(Wiencek, Nichols 2016) found that POCT devices from various manufacturers utilised 
proprietary communication protocols that require either separate computers and software to 
communicate results electronically or some form of middleware software solution.  This can 
ultimately result in the need for separate computers and software for each type of POCT device 
used within a single hospital with obvious inefficiencies and comparability problems.  Although 
there are now offerings by some manufacturers by way of POCT middleware to interface 
multiple devices, it would be substantially beneficial if a particular health system within a single 
location had one agreed and standardised interface that could be used by all POCT devices. 
As indicated above, economic issues were regarded by clinical bioscientists as having the 
greatest impact upon POCT uptake within the hospital environment.  A strong majority (89%) of 
participants in this study group believe that the cost per test of POCT is higher than CLT.  This is 
a stark contrast to the clinicians within the US study group (Chapter 5), where 43% of individuals 
were of the belief that the cost per test of POCT was not higher than CLT.  This reflects the fact 
that clinical biosciences staff are, in general, more aware of the economies of scale that are 
available from effective utilisation of the central laboratory services due to their close alignment 
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with it.  As POCT is carried out on a one-off basis by an individual, rather than by using 
automation (as is the case for CLT), it is impossible for POCT to match that afforded by high-
volume CLT (Lee-Lewandrowski, Lewandrowski 2009).  In this regard, at an economic level, CLT 
is driven by providing significantly higher testing numbers than those carried out using POCT.  
The increased cost of POCT is cited here as being the second most relevant disadvantage of this 
particular type of testing, being indicated as such by 30% of study respondents.  Interestingly 
however, the majority (71%) of participants were of the opinion that the use of a POCT system 
is cost-effective overall.  This is a common finding throughout the 3 survey studies carried out 
as part of this research (UK, US and Clinical Biosciences).  Hence, it is clear that, despite varying 
opinion on the cost per test of POCT, the consensus is that any increased cost incurred is 
justifiable and that POCT plays an important role within diagnostic pathways for patients within 
hospital healthcare systems.  Debate however does exist as to exactly what is the role of POCT.  
The research carried out here, and in the studies presented in the previous chapters, addresses 
the proposition; is POCT an effective diagnostic asset in its own right?  Or, is it simply a rapid 
screening test with limited diagnostic capabilities?  What is important from the findings 
presented here is that the role of POCT must be clearly defined within a particular healthcare 
system in order for it to run effectively.  For example, the British Committee for Standards in 
Haematology provide guidelines on use of haematological POCT, while the Medicines and 
Healthcare Products Regulatory Agency also provide recommendations for POCT in general.  
One of the key recommendations from both of these agencies is that those responsible for the 
provision of POCT within a healthcare organisation should clearly define the purpose of a 
particular test, including whether its role is as a defined diagnostic test or simply as a screening 
process, and whether it should be used for monitoring disease or as a method for determining 
a course of treatment (Boyd, Woolley 2016).  The clinical opinion attained here clearly concurs 
that robust frameworks such as these are required in every healthcare system that wants to 
maximise the effectiveness of POCT in an evidenced-based manner. 
Given that the responsibility for quality assurance of testing is associated with the professional 
practice of the clinical biosciences cohort, there was a much stronger opinion here on the issues 
caused by non-competent or untrained staff operating the POCT devices.  This part of the study 
found that it is the dispersion of devices throughout the clinical system that is a main cause of 
such issues, with a very large majority “agreeing” (28%) or “strongly agreeing” (46%) with this 
proposition (Question 10a).  These data reflected a stronger force of opinion than that found in 
the previous UK (Chapter 4) and US (Chapter 5) studies that include a majority of clinical 
specialists in each.  The effects of inaccurate and/or poor quality tests that result from the use 
of POCT by untrained or non-competent staff was cited as being the most common disadvantage 
in this study (Question 23).  Both the inexperience of clinical staff in terms of diagnostic testing 
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and a lack of awareness of the limitations of POCT were cited by participants here as contributing 
to this.  As already discussed, awareness of the limitations of POCT in comparison to CLT is a 
vital component in deriving effective utilisation of a POCT system.  While the use of satellite 
POCT laboratories has been suggested to overcome this problem, by allowing trained clinical 
biosciences professionals to operate the POCT devices throughout the clinical system, there are 
also issues with this approach, namely; there is increased cost associated with having trained 
laboratory professionals placed throughout the clinical system to perform the tests instead of 
nursing staff, and; the practicalities in situations where results are required immediately at the 
patient bedside to assist clinical decision making (Shaw 2016).  Alternative potential solutions 
to overcoming this barrier to adoption, provided by participants in this study, included; 
increased and improved training processes (including periodic competency assessments), and; 
more involvement of the central laboratory in both the oversight of quality assurance 
procedures, maintenance and training.  Whereas, some POCT devices have been developed to 
the extent that they contain many controls to negate quality issues that may result from 
operator error, many devices still are largely dependent on the competency of the individual 
carrying out the test, both in the execution of the test and reading/assessment of the result 
(Lewandrowski, Gregory et al. 2011).  In order to further improve this situation, it would be 
beneficial to have a set of agreed standards that manufacturers adhere to for the development 
of their POCT devices, including regulations of the controls that can prevent (inexperienced) user 
error.   
This study found that clinical biosciences professionals were of very strong opinion that “high” 
or “very high” levels of operator training and support on regulatory compliance were provided 
to device operators, which is seen as necessary for the effective use of POCT.  By comparison, 
the data from the UK and US studies was much more varied across the scale. This variation in 
opinion between the clinical groups suggests that this support is not being provided on a wide 
enough level or, perhaps, not always to the correct individuals.  The continued growth of POCT, 
along with its dispersion across numerous clinical settings, means that it will continue to exist as 
a regulatory focus and as a focal point of the struggle to comply with strict regulations (Dyhdalo, 
Howanitz et al. 2014). 
Clinical bioscientists are stronger in their opinion that POCT increases the workload of front line 
clinical staff while individuals from other specialist areas tended to disagree that this was the 
case.  The general consensus for this opinion from the other clinical specialists was that the time 
taken to carry out a test using POCT was less than that required to attain results from the central 
laboratory.  It is possible that the clinical biosciences cohort is less aware of the time needed to 
transport samples to the central laboratory for testing and to wait on the findings.  Furthermore, 
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clinicians place more of an importance on the timeliness of test result in comparison to test 
accuracy and/or reliability, while, to those in the clinical biosciences profession, accuracy and 
reliability are paramount (Pati, Singh 2014).  Whereas, POCT can be seen as a method for shifting 
some of the central laboratory workload to other areas of the healthcare system (by moving the 
operation to other clinical professionals), it in fact can increase workload if not managed 
appropriately.  For example, if tests are duplicated, i.e. both POCT and CLT are utilised and the 
POCT data is simply used for initial screening purposes, then the laboratory are carrying out the 
work to acquire data that may already exist.  Therefore, paradoxically it may be the workload of 
the laboratory staff responsible for QA processes that may be increased as a result of the 
utilisation of POCT.   
While, in the previous studies, the position within the health system of the various clinical 
participants were generally found to have little effect on responses to the key issues of interest, 
in the case of the clinical bioscientists cohort there was clear evidence of a common experience.  
Their increased responsibility with respect to the assuring quality of testing aligned to that 
provided by the central laboratory leads to them being more aware of issues within their specific 
area of work.  Comparison of responses to specific quality assurance and regulatory issues 
(Question 13) indicated that in the UK study the “not relevant” category was the most cited for 
4 of the 5 issues and in the US study it was the response category most cited across all 5 issues, 
while clinical bioscientists cited “not relevant” the least for 4 of the 5 issues stated.  This was 
found to be a common theme across other related categories, as indicated in Questions 9, 17 
and 21.  
Overall, these data suggest that opinion on POCT utilisation is significantly influenced by the 
clinical background of the respondents, regardless of the health system in which they practice. 
The body of work described in this chapter has completed the remaining research objectives as 
defined in Chapter 1, namely; to assess how the perception of issues effecting the uptake of 
POCT, including their impact and relevance, varies with respect to the specific clinical role, and; 
to determine the global experiences of clinical bioscientists, as the professional group most 
closely aligned to hospital based diagnostic testing, in relation to the identified barriers to 
adoption of POCT.  By conducting this study on an international scale, any influences of 
underlying health model have been negated.  Furthermore, the clinical opinion gathered here 
from clinical bioscientists has been mapped back onto the data collected from the previous 2 
primary studies as described in Chapters 4 and 5.  Additionally, this study was used to complete 
the data collection necessary to successfully accomplish the final 4 research objectives defined 
in Chapter 1; to identify the key advantages and potential benefits of POCT use within secondary 
healthcare; to identify the major disadvantages deemed to result from the use of POCT; to 
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determine the clinical areas/situations in which POCT can provide the most benefit in secondary 
care, and; to suggest how the most significant barriers to adoption of POCT in the relevant 
secondary healthcare systems can be overcome based on the findings of the studies undertaken, 
i.e. what are the possible solutions that may encourage more effective adoption?  The study 
sample here has been used, along with the previous 2 study samples, to collate data to satisfy 
these objectives accordingly. 
6.5 Statistical Comment 
In the previous primary studies found in Chapters 4 and 5, a statistical analysis could be applied 
to determine if differences in opinion between clinical groups were statistically significant.  The 
participants in this study were deliberately recruited from the one respondent group (clinical 
bioscientists) and, as such, the same process cannot be followed.  However, a number of areas 
have been highlighted as observing differences in opinion in comparison to the previous studies, 
in which participants from the “clinicians” respondent group were in the majority.  For 
completeness, the next chapter aims to investigate the study group as a whole, combining 
respondents from the studies in Chapters 4, 5 and 6, as a means of assessing, firstly; UK vs US 
clinicians and, secondly; clinicians vs clinical bioscientists.  This will be achieved using statistical 
analysis tools as a means of validating the research findings. 
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Chapter 7 
Statistical Analysis 
7.1 Study Objective 
As a means of extruding additional value from the primary studies conducted herein, inferential 
statistics are applied here to the accumulated response data in order to determine if the findings 
deducted are statistically significant.  The purpose of this study is to ensure that the research 
findings are as robust as possible and, as such, clarify the conclusions and recommendations 
made as a result of this piece of work. 
7.2 Study Development & Design 
The association of categorical variables and the comparison of opinions between response 
groups is to be statistically analysed using the Chi-square test and the calculation of odds ratios 
with 95% confidence intervals.  Calculation of p-values using the Chi-square test allows for the 
testing of a specific null hypothesis; a significant p-value (i.e. < 0.05) rejects the null hypothesis 
and, in doing so, gives insight into both the response groups analysed and the strength of the 
results.  Odds ratios are used to further compare the responses of the various response groups, 
by dividing the odds of an event happening in one group by the odds of an event happening in 
the other.  95% confidence intervals are applied to provide a guidance on the true odds ratio; 
that the figure lies within this interval 95% of the time.  This study is designed to analyse the 
entire participant group as a whole, first of all as a comparison of UK respondents vs US 
respondents and, secondly, as a comparison of clinicians vs clinical bioscientists.  Inferential 
statistics are applied where relevant and, as such, questions where participants can give more 
than one answer or can offer a free response have been omitted from this process of analysis. 
7.3 Study Results 
Firstly, an analysis of UK vs US study respondents has been carried out here with the results 
summarised in Table 7.1.  Use of the Chi-square test has been used to identify statistically 
significant differences in opinion between the study groups, with a p-value of <0.05 signifying 
such.  Within this data set, 7 questions have been found to be indicating statistically significant 
responses between participants in the UK and in the US by way of this method of statistical 
analysis.  Of these, 2 (Questions 2 and 3) relate to the demographics of the participants.  When 
considering perceived levels of proficiency in the use of POCT (Question 2), the participants from 
the US were more likely to be at polar ends of the scale; either rating themselves as “highly 
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proficient” (i.e. recognised trainers) or having completed no training themselves at all.  A p-value 
of 0.006 was returned here with odds ratios (UK to US) of 0.182 (95% confidence intervals of 
0.046-0.714) for “not completed any training” and 0.227 (0.056-0.916) for “highly proficient” 
(i.e. recognised trainer).  Considering Question 3, which concerns the use of POCT in the 
participants place of work, a p-value of 0.03 was returned as all UK participants answered 
positively to this question, while 2 individuals in the US took part in the study when POCT was 
not actually utilised within their own department. 
4 areas of particular interest were identified here.  Question 7a regards the increased cost per 
test of POCT in comparison to CLT.  A p-value of 0.002 was found here, with the UK participants 
found to be of a stronger opinion that POCT is of a higher cost per test.  Secondly; Question 15b 
returned a p-value of less than 0.0001.  This was with regards to whether perceived poor levels 
of connectivity could affect the clinician’s ability to deduct a timely and accurate diagnosis 
through the use of POCT.  The US participants were found to be of a stronger opinion that the 
poor connectivity made it more difficult to make such a diagnosis.  Thirdly; Question 21c, which 
asked participants if the inappropriate use of POCT was a relevant issue in their place of work, 
returned a p-value of 0.001.  Here, the US clinicians were of a stronger opinion that this was not 
a relevant issue.  Finally, 21e concerned the relevance of another specific issue; whether POCT 
was not utilised effectively due to a lack of an interdepartmental management structure and 
clear clinical governance, with a p-value of 0.034.  Again, the US clinicians were found to be more 
of the opinion that this issue was not relevant in their place of work. 
When considering the odds ratios where these significant differences have been identified, it 
can be seen that the odds ratio of a UK participant vs US participant agreeing that the cost per 
test of POCT is higher than CLT (Question 7a) is 6.612 (with 95% confidence intervals of 1.844 to 
23.715).  As the interval does not cross the line of no difference (i.e. 1) then we can deem this 
to be statistically significant.  Similarly, for Question 21c, the odds ratio for UK vs US participants 
indicating the inappropriate use of POCT as being “not relevant” within their place of work is 
0.142 (with 95% confidence intervals of 0.045 to 0.444).  As such, again this can be determined 
as being statistically significant.  As for Question 21e, the odds ratio for the “not relevant” 
response category was calculated as 0.168 (0.049-0.576), again being deemed statistically 
significant. 
A p-value of 0.025 was found for Question 18b, however as only 3 participants from the US study 
answered this question, little value can be extruded here. 
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Table 7.1 – Statistical analysis of UK vs US study participants. 
Question / Response UK (x) 
(n=48) 
US (y) 
(n=21) 
P-Value Odds 
Ratio 
(x/y) 
95% Confidence 
Intervals 
2) How would you rate your own expertise in the 
practical use of a POCT device? 
  
0.006 
   
Not yet completed training. 4 (8%) 7 (33%) 
 
0.182 0.046 0.714 
Use under supervision. 2 (4%) 0 (0%) 
 
- - - 
Basic level capability – Unsupervised use. 21 (44%) 5 (24%) 
 
2.489 0.784 7.898 
Competent – Unsupervised use and maintenance. 17 (35%) 3 (14%) 
 
3.290 0.846 12.793 
Highly proficient – Recognised trainer. 4 (8%) 6 (19%) 
 
0.227 0.056 0.916 
       
3) Are any point-of-care testing devices used to 
diagnose patients in your area of clinical 
practice/specialism? 
  
0.030 
   
Yes 48 (100%) 19 (90%) 
 
- - - 
No 0 (0%) 2 (10%) 
 
- - - 
       
7a) Do you agree that the cost per test of POCT is 
higher than CLT? 
  
0.002 
   
Yes 36 (75%) 7 (33%) 
 
6.612 1.844 23.715 
No 7 (15%) 9 (43%) 
 
0.151 0.042 0.542 
       
7bi) On a scale of 1 to 10, to what extent do you 
agree or disagree that, POCT provides longer term 
economic benefits e.g. reduced hospital stay, 
reduced outpatient appointments etc. 
  
0.633 
   
Strongly Disagree 2 (4%) 2 (10%) 
 
0.413 0.054 3.150 
Disagree 3 (6%) 2 (10%) 
 
0.633 0.098 4.100 
Neutral 18 (38%) 5 (24%) 
 
1.920 0.601 6.136 
Agree 13 (27%) 8 (38%) 
 
0.604 0.204 1.789 
Strongly Agree 12 (25%) 4 (19%) 
 
1.417 0.398 5.045 
       
7c) Would you agree that the use of a POCT system 
is cost-effective? 
  
0.053 
   
Yes 36 (75%) 18 (86%) 
 
- - - 
No 8 (17%) 0 (0%) 
 
- - - 
       
8a) On a scale of 1 to 10, to what extent do you 
agree or disagree that procurement, 
reimbursement and budgeting in your institution 
sufficiently accommodate the interdepartmental 
nature of POCT, especially where it is a shared 
resource? 
  
0.304 
   
Strongly Disagree 5 (10%) 4 (19%) 
 
0.344 0.079 1.502 
Disagree 14 (29%) 1 (5%) 
 
6.323 0.755 52.922 
Neutral 12 (25%) 5 (24%) 
 
0.727 0.206 2.565 
Agree 10 (21%) 4 (19%) 
 
0.786 0.205 3.010 
Strongly Agree 4 (8%) 1 (5%) 
 
1.366 0.141 13.271 
       
8b) Does this lack of specific accommodation make 
it difficult to utilise POCT to its full potential in your 
institution? 
  
0.461 
   
Yes 18 (38%) 5 (24%) 
 
- - - 
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No 2 (4%) 0 (0%) 
 
- - - 
       
9a) Difficult to justify the use of POCT devices as the 
simple cost per test of POCT is higher than 
traditional CLT. 
  
0.324 
   
Not relevant 13 (27%) 9 (43%) 
 
0.454 0.153 1.346 
Rarely relevant 5 (10%) 4 (19%) 
 
0.465 0.111 1.953 
Sometimes relevant 9 (19%) 3 (14%) 
 
1.308 0.314 5.440 
Fairly relevant 11 (23%) 2 (10%) 
 
2.676 0.536 13.366 
Very relevant 10 (21%) 2 (10%) 
 
2.368 0.469 11.950 
       
9b) Difficult to justify the implementation of a POCT 
system as the true cost-effectiveness of such a 
system is difficult to gauge and cost comparison 
studies against traditional central laboratory testing 
methods are complex. 
  
0.564 
   
Not relevant 13 (27%) 6 (29%) 
 
0.867 0.275 2.734 
Rarely relevant 5 (10%) 3 (14%) 
 
0.659 0.142 3.066 
Sometimes relevant 6 (13%) 5 (24%) 
 
0.429 0.114 1.613 
Fairly relevant 13 (27%) 3 (14%) 
 
2.105 0.528 8.389 
Very relevant 11 (23%) 3 (14%) 
 
1.685 0.416 6.831 
       
9c) Difficult to justify the implementation of a POCT 
system as the initial costs of implementing such a 
system are high. 
  
0.058 
   
Not relevant 14 (29%) 7 (33%) 
 
0.824 0.274 2.475 
Rarely relevant 4 (8%) 5 (24%) 
 
0.291 0.069 1.220 
Sometimes relevant 8 (17%) 6 (29%) 
 
0.500 0.149 1.683 
Fairly relevant 11 (23%) 0 (0%) 
 
- - - 
Very relevant 11 (23%) 3 (14%) 
 
1.784 0.442 7.200 
       
9d) Issues with regards to budget contributions 
towards POCT due to the allocation of separate 
budgets for separate departments which is not 
appropriate for interdepartmental nature of POCT. 
  
0.316 
   
Not relevant 12 (25%) 9 (43%) 
 
0.419 0.140 1.257 
Rarely relevant 8 (17%) 1 (5%) 
 
3.897 0.454 33.459 
Sometimes relevant 11 (23%) 2 (10%) 
 
2.750 0.550 13.749 
Fairly relevant 9 (19%) 5 (24%) 
 
0.711 0.204 2.470 
Very relevant 7 (15%) 3 (14%) 
 
0.992 0.229 4.299 
       
9e) Difficulty in obtaining reimbursement for POCT. 
(i.e. who pays for the test?) 
  
0.457 
   
Not relevant 20 (42%) 12 (57%) 
 
0.533 0.183 1.556 
Rarely relevant 2 (4%) 0 (0%) 
 
- - - 
Sometimes relevant 6 (13%) 1 (5%) 
 
2.923 0.328 26.038 
Fairly relevant 9 (19%) 2 (10%) 
 
2.250 0.439 11.522 
Very relevant 8 (17%) 5 (24%) 
 
0.649 0.182 2.306 
       
10a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the dispersion of POCT 
devices through the healthcare system gives rise to 
opportunities for untrained or non-competent staff 
to use the devices, leading to an increased 
  
0.262 
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disregard of certain quality assurance steps and 
procedures, including quality control? 
Strongly Disagree 5 (10%) 6 (29%) 
 
0.271 0.072 1.027 
Disagree 7 (15%) 3 (14%) 
 
0.967 0.223 4.191 
Neutral 8 (17%) 1 (5%) 
 
3.800 0.443 32.604 
Agree 14 (29%) 6 (29%) 
 
0.961 0.307 3.007 
Strongly Agree 14 (29%) 4 (19%) 
 
1.647 0.467 5.807 
       
10b) Does the increased disregard of certain quality 
assurance steps and procedures that you have 
indicated in part (a) make it more difficult to attain 
a timely and reliable diagnosis in comparison to 
utilising CLT? 
  
0.744 
   
Yes 18 (38%) 7 (33%) 
 
0.771 0.162 3.663 
No 10 (21%) 3 (14%) 
 
1.296 0.273 6.156 
       
11a) On a scale of 1 to 10, to what extent do you 
agree or disagree that regulations for analytical 
testing accreditation for POCT are overly complex?  
  
0.904 
   
Strongly Disagree 7 (15%) 4 (19%) 
 
0.650 0.163 2.593 
Disagree 9 (19%) 4 (19%) 
 
0.886 0.232 3.390 
Neutral 15 (31%) 4 (19%) 
 
1.806 0.499 6.534 
Agree 8 (17%) 4 (19%) 
 
0.765 0.196 2.979 
Strongly Agree 3 (6%) 1 (5%) 
 
1.231 0.119 12.736 
       
11b) Does the burden imposed by such 
requirements that you have indicated in part (a) 
make it more difficult to attain a timely and reliable 
diagnosis in comparison to utilising CLT? 
  
0.210 
   
Yes 8 (17%) 2 (10%) 
 
4.000 0.431 37.109 
No 3 (6%) 3 (14%) 
 
0.250 0.027 2.319 
       
12a) On a scale of 1 to 10, how much operator 
training and support on regulatory compliance for 
POCT are provided by your central laboratory? 
  
0.140 
   
Very Low 9 (19%) 7 (33%) 
 
0.297 0.087 1.010 
Low 3 (6%) 0 (0%) 
 
- - - 
Neutral 13 (27%) 1 (5%) 
 
5.571 0.667 46.510 
High 11 (23%) 5 (24%) 
 
0.654 0.187 2.290 
Very High 12 (25%) 3 (14%) 
 
1.444 0.351 5.947 
       
12b) Does this lack of training and support that you 
have indicated in part (a) make it more difficult to 
attain a timely & reliable diagnosis in comparison to 
utilising CLT? 
  
0.061 
   
Yes 4 (8%) 5 (24%) 
 
0.160 0.021 1.192 
No 10 (21%) 2 (10%) 
 
6.250 0.839 46.571 
       
13a) Errors due to incorrect quality assurance steps 
or procedures by untrained or non-competent staff 
operating the POCT devices. 
  
0.118 
   
Not relevant 12 (25%) 11 (52%) 
 
0.272 0.091 0.817 
Rarely relevant 20 (42%) 4 (19%) 
 
2.857 0.829 9.842 
Sometimes relevant 8 (17%) 3 (14%) 
 
1.133 0.268 4.799 
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Fairly relevant 4 (8%) 0 (0%) 
 
- - - 
Very relevant 4 (8%) 2 (10%) 
 
0.818 0.137 4.870 
       
13b) Complex accreditation regulations written for 
traditional laboratory instrumentation are blindly 
applied to modern POCT devices, causing issues for 
non-laboratory operators. 
  
0.824 
   
Not relevant 19 (40%) 6 (29%) 
 
1.101 0.325 3.733 
Rarely relevant 7 (15%) 2 (10%) 
 
1.200 0.219 6.587 
Sometimes relevant 6 (13%) 3 (14%) 
 
0.611 0.131 2.855 
Fairly relevant 7 (15%) 3 (14%) 
 
0.733 0.162 3.329 
Very relevant 3 (6%) 0 (0%) 
 
- - - 
       
13c) Issues with maintaining compliance with 
regulatory requirements due to a number of 
changes in the accreditation regulations. 
  
0.100 
   
Not relevant 18 (38%) 10 (48%) 
 
0.277 0.075 1.022 
Rarely relevant 6 (13%) 0 (0%) 
 
- - - 
Sometimes relevant 9 (19%) 0 (0%) 
 
- - - 
Fairly relevant 9 (19%) 4 (19%) 
 
0.643 0.163 2.534 
Very relevant 2 (4%) 0 (0%) 
 
- - - 
       
13d) Issues with maintaining compliance with 
regulatory requirements due to the dispersed 
nature of POCT devices making them difficult to 
control. 
  
0.931 
   
Not relevant 18 (38%) 7 (33%) 
 
0.692 0.207 2.317 
Rarely relevant 4 (8%) 1 (5%) 
 
1.300 0.133 12.696 
Sometimes relevant 5 (10%) 1 (5%) 
 
1.667 0.178 15.608 
Fairly relevant 11 (23%) 4 (19%) 
 
0.833 0.217 3.200 
Very relevant 6 (13%) 1 (5%) 
 
2.053 0.225 18.687 
       
13e) A lack of development of POCT devices, caused 
by product approval hurdles discouraging economic 
investment in their development. 
  
0.100 
   
Not relevant 16 (33%) 14 (67%) 
 
0.245 0.079 0.763 
Rarely relevant 5 (10%) 2 (10%) 
 
1.154 0.204 6.524 
Sometimes relevant 7 (15%) 1 (5%) 
 
3.595 0.412 31.392 
Fairly relevant 10 (21%) 3 (14%) 
 
1.667 0.405 6.864 
Very relevant 6 (13%) 0 (0%) 
 
- - - 
       
14a) On a scale of 1 to 10, how do you rate the level 
of analytical performance (i.e. specificity, sensitivity 
& precision) of a POCT device in comparison to a 
traditional CLT instrument? 
  
- 
   
Very Low 0 (0%) 0 (0%) 
 
- - - 
Low 1 (2%) 0 (0%) 
 
- - - 
Neutral 7 (15%) 4 (19%) 
 
0.640 0.164 2.503 
High 22 (46%) 11 (52%) 
 
0.615 0.210 1.800 
Very High 18 (38%) 4 (19%) 
 
2.250 0.646 7.839 
       
14b) Does the reduced analytical performance that 
you have indicated in part (a) make it more difficult 
  
- 
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to make a timely and reliable diagnosis in 
comparison to utilising CLT? 
Yes 0 (0%) 0 (0%) 
 
- - - 
No 0 (0%) 0 (0%) 
 
- - - 
       
15a) On a scale of 1 to 10, how do you rate the 
connectivity (i.e. to the central healthcare and 
patient record systems) and data management of a 
POCT system in comparison to a traditional CLT 
instrument? 
  
0.127 
   
Very Poor 17 (35%) 4 (19%) 
 
2.056 0.588 7.189 
Poor 16 (33%) 3 (14%) 
 
2.667 0.677 10.509 
Neutral 4 (8%) 5 (24%) 
 
0.255 0.060 1.081 
Good 3 (6%) 3 (14%) 
 
0.356 0.065 1.944 
Excellent 8 (17%) 4 (19%) 
 
0.750 0.197 2.861 
       
15b) Does the poor connectivity and data 
management that you have indicated in part (a) 
make it more difficult to make a timely & reliable 
diagnosis in comparison to utilising CLT? 
  
<0.0001 
   
Yes 8 (17%) 7 (33%) 
 
- - - 
No 26 (54%) 0 (0%) 
 
- - - 
       
16a) On a scale of 1 to 10, how do you rate the 
difficulty of performing tests using POCT devices 
compared to that of a CLT system? 
  
- 
   
Very Easy 33 (69%) 16 (76%) 
 
0.737 0.226 2.404 
Easy 6 (13%) 2 (10%) 
 
1.390 0.256 7.536 
Neutral 3 (6%) 3 (14%) 
 
0.409 0.075 2.221 
Difficult 5 (10%) 0 (0%) 
 
- - - 
Very Difficult 0 (0%) 0 (0%) 
 
- - - 
       
16bi) Does the increased difficulty that you have 
indicated in part (a) make it more difficult to attain 
a timely & reliable diagnosis in comparison to 
utilising CLT? 
  
- 
   
Yes 2 (4%) 0 (0%) 
 
- - - 
No 3 (6%) 0 (0%) 
 
- - - 
       
17a) POCT devices producing reduced analytical 
performance in comparison to traditional 
centralised testing. 
  
0.929 
   
Not relevant 21 (44%) 8 (38%) 
 
1.167 0.404 3.371 
Rarely relevant 13 (27%) 5 (24%) 
 
1.114 0.337 3.684 
Sometimes relevant 10 (21%) 5 (24%) 
 
0.789 0.231 2.697 
Fairly relevant 3 (6%) 2 (10%) 
 
0.600 0.092 3.896 
Very relevant 1 (2%) 0 (0%) 
 
- - - 
       
17b) POCT system poorly connected to main 
healthcare and patient record systems, causing 
data management issues. 
  
0.058 
   
Not relevant 8 (17%) 8 (38%) 
 
0.300 0.093 0.970 
Rarely relevant 10 (21%) 2 (10%) 
 
2.368 0.469 11.950 
Sometimes relevant 13 (27%) 3 (14%) 
 
2.105 0.528 8.389 
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Fairly relevant 7 (15%) 0 (0%) 
 
- - - 
Very relevant 10 (21%) 7 (33%) 
 
0.489 0.154 1.548 
       
17c) POCT device operators encountering 
difficulties with their use. 
  
- 
   
Not relevant 18 (38%) 16 (76%) 
 
0.150 0.043 0.519 
Rarely relevant 11 (23%) 3 (14%) 
 
1.685 0.416 6.831 
Sometimes relevant 11 (23%) 0 (0%) 
 
- - - 
Fairly relevant 8 (17%) 1 (5%) 
 
3.800 0.443 32.604 
Very relevant 0 (0%) 0 (0%) 
 
- - - 
       
18a) On a scale of 1 to 10, to what extent do you 
agree or disagree that POCT significantly increases 
the workload of front line clinical staff (i.e. device 
operators)?  
  
0.857 
   
Strongly Disagree 18 (38%) 8 (38%) 
 
0.975 0.339 2.806 
Disagree 13 (27%) 5 (24%) 
 
1.189 0.362 3.903 
Neutral 7 (15%) 5 (24%) 
 
0.546 0.151 1.975 
Agree 5 (10%) 1 (5%) 
 
2.326 0.255 21.234 
Strongly Agree 5 (10%) 2 (10%) 
 
1.105 0.197 6.209 
       
18b) Does the increased workload that you have 
indicated in part (a) reduce staff satisfaction levels 
in comparison to when utilising CLT? 
  
0.025 
   
Yes 6 (13%) 3 (14%) 
 
- - - 
No 13 (27%) 0 (0%) 
 
- - - 
       
19a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the central laboratory are 
reluctant to allow the control of testing to be 
passed on? 
  
0.272 
   
Strongly Disagree 10 (21%) 5 (24%) 
 
0.757 0.220 2.608 
Disagree 7 (15%) 1 (5%) 
 
3.150 0.360 27.531 
Neutral 14 (29%) 2 (10%) 
 
3.606 0.733 17.736 
Agree 9 (19%) 6 (29%) 
 
0.513 0.153 1.721 
Strongly Agree 7 (15%) 5 (24%) 
 
0.490 0.134 1.796 
       
19b) Does the resistance that you have indicated in 
part (a) act as an impediment to the more 
widespread adoption of POCT within the clinical 
environment? 
  
0.794 
   
Yes 14 (29%) 9 (43%) 
 
0.778 0.117 5.162 
No 4 (8%) 2 (10%) 
 
1.286 0.194 8.534 
       
20a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the clinical care pathway and 
role of the central laboratory have been altered 
sufficiently to incorporate the use of POCT? 
  
0.585 
   
Strongly Disagree 3 (6%) 4 (19%) 
 
0.273 0.055 1.354 
Disagree 6 (13%) 2 (10%) 
 
1.317 0.242 7.163 
Neutral 12 (25%) 4 (19%) 
 
1.371 0.383 4.917 
Agree 16 (33%) 6 (29%) 
 
1.204 0.389 3.731 
Strongly Agree 10 (21%) 4 (19%) 
 
1.081 0.295 3.965 
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20b) Does this poor integration of POCT that you 
have indicated in part (a) make it more difficult to 
attain a timely and reliable diagnosis in comparison 
to utilising CLT? 
  
0.205 
   
Yes 3 (6%) 4 (19%) 
 
0.250 0.028 2.237 
No 6 (13%) 2 (10%) 
 
4 0.447 35.789 
       
21a) Reduced staff satisfaction levels and increased 
friction between staff groups. 
  
- 
   
Not relevant 25 (52%) 15 (71%) 
 
0.455 0.150 1.375 
Rarely relevant 11 (23%) 1 (5%) 
 
6.111 0.734 50.855 
Sometimes relevant 8 (17%) 2 (10%) 
 
1.949 0.377 10.083 
Fairly relevant 3 (6%) 3 (14%) 
 
0.409 0.075 2.221 
Very relevant 0 (0%) 0 (0%) 
 
- - - 
       
21b) The resistance of central laboratory to allow 
the control of testing to be passed on acts as an 
impediment to the more widespread uptake of 
POCT. 
  
0.112 
   
Not relevant 17 (35%) 7 (33%) 
 
0.940 0.312 2.836 
Rarely relevant 7 (15%) 2 (10%) 
 
1.451 0.273 7.710 
Sometimes relevant 11 (23%) 0 (0%) 
 
- - - 
Fairly relevant 5 (10%) 5 (24%) 
 
0.326 0.082 1.292 
Very relevant 8 (17%) 5 (24%) 
 
0.560 0.157 1.999 
       
21c) Inappropriate use of POCT (i.e. over-use and 
reliance on test results, undermining clinical 
expertise). 
  
0.001 
   
Not relevant 9 (19%) 13 (62%) 
 
0.142 0.045 0.444 
Rarely relevant 8 (17%) 0 (0%) 
 
- - - 
Sometimes relevant 13 (27%) 2 (10%) 
 
3.529 0.720 17.304 
Fairly relevant 11 (23%) 1 (5%) 
 
5.946 0.715 49.447 
Very relevant 7 (15%) 5 (24%) 
 
0.546 0.151 1.975 
       
21d) The full benefits of POCT are not being realised 
as significant alterations to clinical care pathways 
and the central laboratory are required. 
  
0.674 
   
Not relevant 22 (46%) 12 (57%) 
 
0.634 0.225 1.785 
Rarely relevant 10 (21%) 3 (14%) 
 
1.579 0.387 6.447 
Sometimes relevant 5 (10%) 3 (14%) 
 
0.698 0.151 3.233 
Fairly relevant 10 (21%) 2 (10%) 
 
2.500 0.497 12.570 
Very relevant 1 (2%) 1 (5%) 
 
0.426 0.025 7.145 
       
21e) POCT system does not run efficiently as an 
interdepartmental management structure is 
required with clear clinical governance for POCT. 
  
0.034 
   
Not relevant 20 (42%) 17 (81%) 
 
0.168 0.049 0.576 
Rarely relevant 7 (15%) 0 (0%) 
 
- - - 
Sometimes relevant 6 (13%) 2 (10%) 
 
1.357 0.251 7.352 
Fairly relevant 11 (23%) 1 (5%) 
 
5.946 0.715 49.447 
Very relevant 4 (8%) 1 (5%) 
 
1.818 0.191 17.323 
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21f) Reluctance to change within health services 
and a lack of evidence justifying POCT makes it hard 
to justify the implementation of such a system. 
  
0.383 
   
Not relevant 10 (21%) 5 (24%) 
 
0.842 0.248 2.859 
Rarely relevant 8 (17%) 1 (5%) 
 
4.000 0.467 34.239 
Sometimes relevant 15 (31%) 4 (19%) 
 
1.932 0.554 6.733 
Fairly relevant 8 (17%) 6 (29%) 
 
0.500 0.149 1.683 
Very relevant 7 (15%) 5 (24%) 
 
0.546 0.151 1.975 
       
26) Please rank the following categories of issues in 
order of current impact on POCT adoption, using 
the table below (from 1 to 4 where 1 is most current 
impact and 4 is least current impact).* 
  
0.389 
   
Economic Issues 123 65 
 
0.781 0.544 1.121 
Quality Assurance & Regulatory Issues 123 46 
 
1.259 0.853 1.858 
Device Performance & Data Management Issues 105 41 
 
1.180 0.786 1.773 
Staff & Operational Issues 99 48 
 
0.893 0.602 1.324 
*Scoring system used: 1st place rank = 4 points, 2nd = 3 points, 3rd = 2 points, 4th = 1 point. 
 
A process of analysis has also been carried out comparing study participants from the clinicians 
group against those from the clinical bioscientists group.  All 3 primary studies have been 
included in this investigation; the UK study (Chapter 4), the US study (Chapter 5) and the Clinical 
Bioscientists study (Chapter 6).  As before, the Chi-square test has been applied in order to 
calculate p-values to identify where differences in response between the 2 study groups can be 
determined as having a statistically significant differentiation.  Results are summarised in Table 
7.2.  There are 30 identified areas where a significant difference in response is indicated.   
The first area concerns the perceived expertise of study respondents, with a p-value of less than 
0.0001 calculated.  By assessment of the odds ratios, it is seen that the odds ratio of a clinician 
determining themselves as being highly proficient in the use of POCT (i.e. a recognised trainer) 
in comparison to a participant from the other study group is 0.058 (95% confidence intervals 
0.020-0.170). 
2 parts of Question 7 (a and c), which focus on the economics of POCT, are indicated as having 
statistically significant differences in their responses.  Question 7a, which asks participants if 
they agreed that POCT was of a higher cost per test in comparison to POCT, returned a p-value 
of 0.007.  The clinicians were found to be less likely to agree with this notion, with an odds ratio 
(clinicians to clinical bioscientists) calculated for agreement as 0.319 (0.136-0.746).  Question 7c 
asked participants if they thought the use of a POCT system was cost-effective; a p-value of 
0.037 was calculated here, indicating a statistically significant difference in response.  The 
clinicians were found more likely to be in agreement that this was true, with an odds ratio of 
2.683 (1.034-6.962) returned. 
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A statistically significant p-value of 0.037 was observed for Question 8b, however the resulting 
odds ratios were not found to be statistically significant.  As such, and due to the decreased 
participation in this question, little value can be extruded here.  This question asked those 
participants who did not believe that procurement, reimbursement and budgeting in their 
institution sufficiently accommodated the interdepartmental nature of POCT if this perceived 
lack of accommodation made it more difficult for POCT to realise its full potential. 
4 parts of Question 9 (a, b, c and e) have been determined as being statistically significant in 
terms of response differentiation.  This question considers opinion on the relevance of certain 
economic issues within the participant’s place of work.  The p-values returned here are <0.0001, 
0.001, 0.001 and <0.0001 respectively.  For all 4 parts noted here, the clinicians group provide a 
much stronger response in the “not relevant” category, with calculated odds ratios (in 
comparison to clinical bioscientists) and confidence limits of; 6.438 (2.602-15.929), 5.827 (2.343-
14.492), 5.794 (2.334-14.385) and 6.892 (3.216-14.771). 
A significant difference in response was found with respect to agreement with how the 
dispersed nature of POCT contributes to misuse of the devices, leading to quality issues 
(Question 10a), with a p-value of 0.0003 indicating such.  The clinical bioscientists study group 
were found to be much more likely to strongly agree with this statement.  The odds ratio of 
clinicians to clinical bioscientists responding in this category was calculated as being 0.221 
(0.101-0.484). 
Levels of operator training and support on regulatory compliance provided by the central 
laboratory was another area where a significant disparity in response was observed (Question 
12a).  Here, a p-value of 0.0004 was returned by way of the Chi-square test.  The clinicians were 
found to be much less likely to respond in the “very high” category here, with an odds ratio in 
comparison to the clinical bioscientists of 0.216 (0.093-0.502).  The second part of this question 
(12b) was also an area where a significant difference in response was observed, with a p-value 
of 0.018 calculated.  This question asked those participants who ranked levels of training and 
support as “low” or “very low” if this made it more difficult to attain a timely and reliable 
diagnosis as a result.  The clinicians were found more likely to indicate that this was, in fact, not 
the case, with an odds ratio here of 6.000 (1.274-28.255). 
All 5 parts of Question 13 (a, b, c, d and e) were found to indicate significant differences in 
responses between the 2 study groups; these were in relation to the relevance of quality 
assurance and regulatory issues in the participant’s place of work.  P-values calculated were 
<0.0001, <0.0001, <0.0001, <0.0001 and 0.004.  Clinicians were found to be of much stronger 
opinion that the specific issues were “not relevant”, with calculated odds ratios and confidence 
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limits in this response category of 8.167 (3.030-22.008), 7.583 (3.292-17.470), 14.034 (5.603-
35.151), 14.873 (5.470-40.441) and 2.416 (1.171-4.987). 
Significantly different response profiles were also found with respect to opinion on the level of 
analytical performance of POCT in comparison to CLT instruments (Question 14a), with a p-value 
of less than 0.0001 calculated.  The clinicians were found to be much more likely to rate the 
levels of performance as very high.  The odds ratio for this category of response was calculated 
as being 5.167 (2.206-12.101). 
Both parts of Question 15 were also found to be statistically significant in terms of the 
differential in response profile between the 2 study groups (p-values of 0.004 and <0.0001 
correspondingly).  This question was with respect to the levels of connectivity and data 
management of a POCT system in comparison to CLT.  The clinicians were found to be more 
likely to rank connectivity and data management as being “very low” with an odds ratio in 
comparison to the clinical bioscientists of 3.222 (1.486-6.987).  Furthermore, of the participants 
who ranked the connectivity and data management capabilities of POCT as being low or very 
low, clinicians here were found to be much more likely to indicate that the reduced levels of 
connectivity and data management made it more difficult to attain a timely and accurate 
diagnosis.  The odds ratio here (clinicians to clinical bioscientists) was calculated as being 0.093 
(0.028-0.301). 
All 3 parts of Question 17 (a, b and c) were further identified as areas of significant 
differentiation between response profiles of the participant groups.  This question was in 
relation to the relevance of specific device performance and data management issues in the 
participant’s place of work.  The p-values calculated here were <0.0001, 0.009 and <0.0001 
respectively.  As previously, when considering questions regarding the relevance of specific 
issues, the clinicians were found to be much more likely to respond in the “not relevant” 
category, in comparison to the clinical bioscientists.  The odds ratios here were found to be 
12.500 (4.707-33.197), 4.727 (1.686-13.256) and 16.399 (6.186-43.470). 
The workload of front line clinical staff (Question 18a) was found to be an area of disparity also 
(p-value <0.0001) with clinicians much less likely to “agree” or “strongly agree” that the 
utilisation of POCT increased the workload of front line clinical staff, in comparison to CLT.  The 
calculated odds ratios (clinicians to clinical bioscientists) for these categories were 0.291 (0.105-
0.807) and 0.159 (0.046-0.553) respectively.  The second part of this particular question (18b) 
was also identified as being an area of particular interest, with a p-value of 0.022.  Of all the 
participants who believed that POCT did increase the workload of front-line clinical staff, the 
clinicians here were found to be less likely to agree that this increased workload resulted in 
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reduced staff satisfaction levels.  The calculated odds ratio for this response was 0.256 (0.077-
0.853). 
Furthermore, of the study participants who “disagreed” or “strongly disagreed” that the clinical 
care pathway and role of the central laboratory had been altered sufficiently to incorporate the 
use of POCT (Question 20b), the clinicians were less likely to agree that this lack of 
accommodation made it more difficult to attain a timely and reliable diagnosis.  The p-value 
calculated here was 0.025 and odds ratio 0.156 (0.029-0.845). 
The final area where a statistically significant difference in response profile between clinicians 
and clinical bioscientists was observed within 5 parts of Question 21 (a, b, c, d and e).  Question 
21 was focused on attaining clinical opinion on the relevance of specific staff and operational 
issues within the participant’s place of work.  Application of the Chi-square test, as previously, 
returned p-values of <0.0001, 0.037, 0.0003, <0.0001 and 0.0003 respectively.  Once more the 
clinicians were observed to be of a stronger opinion of finding these specific issues as “not 
relevant” within their place of work.  Calculation of odds ratios ratifies this notion, with the 
comparison of clinicians against clinical bioscientists here found to be 7.489 (3.596-15.595), 
1.722 (0.828-3.585), 7.125 (2.634-19.273), 8.273 (3.680-18.600) and 4.680 (2.286-9.584) 
respectively.  The exception here is Question 21b where the odds ratio is not statistically 
significant as it crosses the threshold of no difference (i.e. 1). 
Table 7.2 – Statistical analysis of Clinicians vs Clinical Bioscientists across 3 primary studies. 
Question / Response 
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P-Value Odds 
Ratio 
(x/y) 
95% Confidence 
Intervals 
2) How would you rate your own expertise in the 
practical use of a POCT device? 
  
<0.0001 
   
Not yet completed training. 9 (16%) 13 (12%) 
 
1.399 0.560 3.497 
Use under supervision. 1 (2%) 1 (1%) 
 
1.947 0.120 31.711 
Basic level capability – Unsupervised use. 26 (45%) 14 (13%) 
 
5.688 2.653 12.192 
Competent – Unsupervised use and maintenance. 18 (31%) 21 (19%) 
 
1.950 0.939 4.051 
Highly proficient – Recognised trainer. 4 (7%) 63 (56%) 
 
0.058 0.020 0.170 
       
3) Are any point-of-care testing devices used to 
diagnose patients in your area of clinical 
practice/specialism? 
  
0.073 
   
Yes 56 (97%) 98 (88%) 
 
3.714 0.809 17.059 
No 2 (3%) 13 (12%) 
 
0.269 0.059 1.237 
       
7a) Do you agree that the cost per test of POCT is 
higher than CLT? 
  
0.007 
   
Yes 34 (59%) 99 (88%) 
 
0.319 0.136 0.746 
No 14 (24%) 13 (12%) 
 
3.136 1.341 7.333 
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7bi) On a scale of 1 to 10, to what extent do you 
agree or disagree that, POCT provides longer term 
economic benefits e.g. reduced hospital stay, 
reduced outpatient appointments etc. 
  
0.700 
   
Strongly Disagree 4 (7%) 9 (8%) 
 
0.848 0.250 2.880 
Disagree 5 (9%) 9 (8%) 
 
1.080 0.344 3.384 
Neutral 19 (33%) 35 (31%) 
 
1.072 0.544 2.112 
Agree 14 (24%) 37 (33%) 
 
0.645 0.314 1.324 
Strongly Agree 16 (28%) 22 (20%) 
 
1.558 0.743 3.269 
       
7c) Would you agree that the use of a POCT system 
is cost-effective? 
  
0.037 
   
Yes 46 (79%) 80 (71%) 
 
2.683 1.034 6.962 
No 6 (10%) 28 (25%) 
 
0.373 0.144 0.967 
       
8a) On a scale of 1 to 10, to what extent do you 
agree or disagree that procurement, 
reimbursement and budgeting in your institution 
sufficiently accommodate the interdepartmental 
nature of POCT, especially where it is a shared 
resource? 
  
0.399 
   
Strongly Disagree 7 (12%) 18 (16%) 
 
0.823 0.320 2.118 
Disagree 13 (22%) 24 (21%) 
 
1.244 0.572 2.708 
Neutral 16 (28%) 22 (20%) 
 
1.861 0.874 3.964 
Agree 11 (19%) 34 (30%) 
 
0.622 0.285 1.360 
Strongly Agree 3 (5%) 11 (10%) 
 
0.569 0.151 2.135 
       
8b) Does this lack of specific accommodation make 
it difficult to utilise POCT to its full potential in your 
institution? 
  
0.037 
   
Yes 20 (34%) 30 (27%) 
 
7.333 0.877 61.334 
No 1 (2%) 11 (10%) 
 
0.136 0.016 1.141 
       
9a) Difficult to justify the use of POCT devices as the 
simple cost per test of POCT is higher than 
traditional CLT. 
  
<0.0001 
   
Not relevant 19 (33%) 8 (7%) 
 
6.438 2.602 15.929 
Rarely relevant 5 (9%) 12 (11%) 
 
0.793 0.265 2.374 
Sometimes relevant 12 (21%) 40 (36%) 
 
0.473 0.225 0.997 
Fairly relevant 9 (16%) 37 (33%) 
 
0.375 0.166 0.846 
Very relevant 12 (21%) 14 (13%) 
 
1.848 0.791 4.315 
       
9b) Difficult to justify the implementation of a POCT 
system as the true cost-effectiveness of such a 
system is difficult to gauge and cost comparison 
studies against traditional central laboratory testing 
methods are complex. 
  
0.001 
   
Not relevant 18 (31%) 8 (7%) 
 
5.827 2.343 14.492 
Rarely relevant 7 (12%) 8 (7%) 
 
1.768 0.607 5.150 
Sometimes relevant 9 (16%) 30 (27%) 
 
0.494 0.216 1.129 
Fairly relevant 14 (24%) 34 (30%) 
 
0.718 0.347 1.485 
Very relevant 9 (16%) 29 (26%) 
 
0.517 0.226 1.185 
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9c) Difficult to justify the implementation of a POCT 
system as the initial costs of implementing such a 
system are high. 
  
0.001 
   
Not relevant 18 (31%) 8 (7%) 
 
5.794 2.334 14.385 
Rarely relevant 8 (14%) 20 (18%) 
 
0.728 0.299 1.772 
Sometimes relevant 11 (19%) 39 (35%) 
 
0.432 0.201 0.927 
Fairly relevant 10 (17%) 28 (25%) 
 
0.618 0.276 1.381 
Very relevant 11 (19%) 16 (14%) 
 
1.390 0.598 3.230 
       
9d) Issues with regards to budget contributions 
towards POCT due to the allocation of separate 
budgets for separate departments which is not 
appropriate for interdepartmental nature of POCT. 
  
0.118 
   
Not relevant 17 (29%) 17 (15%) 
 
2.410 1.117 5.200 
Rarely relevant 8 (14%) 15 (13%) 
 
1.067 0.423 2.691 
Sometimes relevant 12 (21%) 33 (29%) 
 
0.645 0.302 1.374 
Fairly relevant 13 (22%) 23 (21%) 
 
1.157 0.535 2.502 
Very relevant 6 (10%) 23 (21%) 
 
0.459 0.175 1.203 
       
9e) Difficulty in obtaining reimbursement for POCT. 
(i.e. who pays for the test?) 
  
<0.0001 
   
Not relevant 28 (48%) 15 (13%) 
 
6.892 3.216 14.771 
Rarely relevant 2 (3%) 20 (18%) 
 
0.175 0.039 0.779 
Sometimes relevant 7 (12%) 28 (25%) 
 
0.441 0.179 1.089 
Fairly relevant 9 (16%) 20 (18%) 
 
0.910 0.384 2.159 
Very relevant 8 (14%) 28 (25%) 
 
0.515 0.217 1.224 
       
10a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the dispersion of POCT 
devices through the healthcare system gives rise to 
opportunities for untrained or non-competent staff 
to use the devices, leading to an increased disregard 
of certain quality assurance steps and procedures, 
including quality control? 
  
0.0003 
   
Strongly Disagree 11 (19%) 7 (6%) 
 
3.314 1.206 9.103 
Disagree 10 (17%) 6 (5%) 
 
3.475 1.192 10.134 
Neutral 9 (16%) 11 (10%) 
 
1.585 0.615 4.088 
Agree 17 (29%) 29 (26%) 
 
1.099 0.540 2.238 
Strongly Agree 10 (17%) 51 (46%) 
 
0.221 0.101 0.484 
       
10b) Does the increased disregard of certain quality 
assurance steps and procedures that you have 
indicated in part (a) make it more difficult to attain 
a timely and reliable diagnosis in comparison to 
utilising CLT? 
  
0.903 
   
Yes 17 (29%) 45 (40%) 
 
0.944 0.376 2.373 
No 10 (17%) 25 (22%) 
 
1.059 0.421 2.661 
       
11a) On a scale of 1 to 10, to what extent do you 
agree or disagree that regulations for analytical 
testing accreditation for POCT are overly complex?  
  
0.132 
   
Strongly Disagree 8 (14%) 17 (15%) 
 
1.000 0.398 2.511 
Disagree 12 (21%) 13 (12%) 
 
2.282 0.951 5.474 
Neutral 16 (28%) 26 (23%) 
 
1.462 0.692 3.086 
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Agree 8 (14%) 30 (27%) 
 
0.480 0.201 1.146 
Strongly Agree 4 (7%) 16 (14%) 
 
0.489 0.154 1.550 
       
11b) Does the burden imposed by such 
requirements that you have indicated in part (a) 
make it more difficult to attain a timely and reliable 
diagnosis in comparison to utilising CLT? 
  
0.517 
   
Yes 9 (16%) 26 (23%) 
 
1.615 0.375 6.951 
No 3 (5%) 14 (13%) 
 
0.619 0.144 2.664 
       
12a) On a scale of 1 to 10, how much operator 
training and support on regulatory compliance for 
POCT are provided by your central laboratory? 
  
0.0004 
   
Very Low 15 (26%) 10 (9%) 
 
3.577 1.479 8.651 
Low 3 (5%) 5 (4%) 
 
1.153 0.265 5.019 
Neutral 13 (22%) 11 (10%) 
 
2.652 1.096 6.414 
High 15 (26%) 31 (28%) 
 
0.893 0.431 1.852 
Very High 8 (14%) 46 (41%) 
 
0.216 0.093 0.502 
       
12b) Does this lack of training and support that you 
have indicated in part (a) make it more difficult to 
attain a timely & reliable diagnosis in comparison to 
utilising CLT? 
  
0.018 
   
Yes 8 (14%) 12 (11%) 
 
0.167 0.035 0.785 
No 12 (21%) 3 (3%) 
 
6.000 1.274 28.255 
       
13a) Errors due to incorrect quality assurance steps 
or procedures by untrained or non-competent staff 
operating the POCT devices. 
  
<0.0001 
   
Not relevant 19 (33%) 6 (5%) 
 
8.167 3.030 22.008 
Rarely relevant 22 (38%) 22 (20%) 
 
2.343 1.150 4.771 
Sometimes relevant 11 (19%) 34 (30%) 
 
0.492 0.227 1.069 
Fairly relevant 3 (5%) 23 (21%) 
 
0.196 0.056 0.684 
Very relevant 2 (3%) 19 (17%) 
 
0.163 0.0364 0.726 
       
13b) Complex accreditation regulations written for 
traditional laboratory instrumentation are blindly 
applied to modern POCT devices, causing issues for 
non-laboratory operators. 
  
<0.0001 
   
Not relevant 23 (40%) 12 (11%) 
 
7.583 3.292 17.470 
Rarely relevant 7 (12%) 24 (21%) 
 
0.591 0.234 1.490 
Sometimes relevant 7 (12%) 28 (25%) 
 
0.481 0.193 1.199 
Fairly relevant 8 (14%) 25 (22%) 
 
0.657 0.271 1.592 
Very relevant 1 (2%) 14 (13%) 
 
0.141 0.018 1.109 
       
13c) Issues with maintaining compliance with 
regulatory requirements due to a number of 
changes in the accreditation regulations. 
  
<0.0001 
   
Not relevant 26 (45%) 8 (7%) 
 
14.034 5.603 35.151 
Rarely relevant 6 (10%) 15 (13%) 
 
0.838 0.304 2.314 
Sometimes relevant 5 (9%) 33 (29%) 
 
0.247 0.089 0.680 
Fairly relevant 10 (17%) 32 (29%) 
 
0.584 0.259 1.315 
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Very relevant 1 (2%) 15 (13%) 
 
0.125 0.016 0.974 
       
13d) Issues with maintaining compliance with 
regulatory requirements due to the dispersed 
nature of POCT devices making them difficult to 
control. 
  
<0.0001 
   
Not relevant 23 (40%) 6 (5%) 
 
14.873 5.470 40.441 
Rarely relevant 5 (9%) 15 (13%) 
 
0.682 0.233 2.000 
Sometimes relevant 6 (10%) 22 (20%) 
 
0.526 0.198 1.397 
Fairly relevant 13 (22%) 34 (30%) 
 
0.754 0.353 1.608 
Very relevant 1 (2%) 26 (23%) 
 
0.063 0.008 0.480 
       
13e) A lack of development of POCT devices, caused 
by product approval hurdles discouraging economic 
investment in their development. 
  
0.004 
   
Not relevant 21 (36%) 22 (20%) 
 
2.416 1.171 4.987 
Rarely relevant 6 (10%) 26 (23%) 
 
0.378 0.145 0.986 
Sometimes relevant 7 (12%) 29 (26%) 
 
0.388 0.157 0.959 
Fairly relevant 13 (22%) 11 (10%) 
 
2.718 1.122 6.584 
Very relevant 6 (10%) 15 (13%) 
 
0.749 0.273 2.058 
       
14a) On a scale of 1 to 10, how do you rate the level 
of analytical performance (i.e. specificity, sensitivity 
& precision) of a POCT device in comparison to a 
traditional CLT instrument? 
  
<0.0001 
   
Very Low 0 (0%) 4 (4%) 
 
- - - 
Low 1 (2%) 19 (17%) 
 
0.080 0.010 0.618 
Neutral 7 (12%) 24 (21%) 
 
0.470 0.188 1.173 
High 28 (48%)  46 (41%) 
 
1.239 0.645 2.379 
Very High 20 (34%) 10 (9%) 
 
5.167 2.206 12.101 
       
14b) Does the reduced analytical performance that 
you have indicated in part (a) make it more difficult 
to make a timely and reliable diagnosis in 
comparison to utilising CLT? 
  
- 
   
Yes 0 (0%) 16 (14%) 
 
- - - 
No 0 (0%) 7 (6%) 
 
- - - 
       
15a) On a scale of 1 to 10, how do you rate the 
connectivity (i.e. to the central healthcare and 
patient record systems) and data management of a 
POCT system in comparison to a traditional CLT 
instrument? 
  
0.004 
   
Very Poor 20 (34%) 15 (13%) 
 
3.222 1.486 6.987 
Poor 15 (26%) 17 (15%) 
 
1.829 0.832 4.023 
Neutral 7 (12%) 23 (21%) 
 
0.491 0.196 1.229 
Good 6 (10%) 24 (21%) 
 
0.390 0.149 1.021 
Excellent 8 (14%) 23 (21%) 
 
0.572 0.237 1.381 
       
15b) Does the poor connectivity and data 
management that you have indicated in part (a) 
make it more difficult to make a timely & reliable 
diagnosis in comparison to utilising CLT? 
  
<0.0001 
   
Yes 12 (21%) 27 (24%) 
 
0.093 0.028 0.301 
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No 24 (41%) 5 (4%) 
 
10.800 3.321 35.123 
       
16a) On a scale of 1 to 10, how do you rate the 
difficulty of performing tests using POCT devices 
compared to that of a CLT system? 
  
0.066 
   
Very Easy 40 (69%) 49 (44%) 
 
2.545 1.279 5.062 
Easy 7 (12%) 29 (26%) 
 
0.352 0.143 0.867 
Neutral 6 (10%) 13 (12%) 
 
0.805 0.288 2.249 
Difficult 4 (7%) 9 (8%) 
 
0.780 0.229 2.655 
Very Difficult 0 (0%) 2 (2%) 
 
- - - 
       
16bi) Does the increased difficulty that you have 
indicated in part (a) make it more difficult to attain 
a timely & reliable diagnosis in comparison to 
utilising CLT? 
  
0.679 
   
Yes 2 (3%) 3 (3%) 
 
1.667 0.147 18.875 
No 2 (3%) 5 (4%) 
 
0.600 0.053 6.795 
       
17a) POCT devices producing reduced analytical 
performance in comparison to traditional 
centralised testing. 
  
<0.0001 
   
Not relevant 25 (43%) 6 (5%) 
 
12.500 4.707 33.197 
Rarely relevant 15 (26%) 16 (14%) 
 
1.920 0.867 4.252 
Sometimes relevant 12 (21%) 39 (35%) 
 
0.431 0.203 0.913 
Fairly relevant 4 (7%) 21 (19%) 
 
0.291 0.095 0.896 
Very relevant 1 (2%) 20 (18%) 
 
0.073 0.010 0.561 
       
17b) POCT system poorly connected to main 
healthcare and patient record systems, causing 
data management issues. 
  
0.009 
   
Not relevant 13 (22%) 6 (5%) 
 
4.727 1.686 13.256 
Rarely relevant 10 (17%) 16 (14%) 
 
1.144 0.481 2.720 
Sometimes relevant 14 (24%) 20 (18%) 
 
1.335 0.614 2.901 
Fairly relevant 7 (12%) 24 (21%) 
 
0.455 0.182 1.135 
Very relevant 13 (22%) 36 (32%) 
 
0.542 0.258 1.135 
       
17c) POCT device operators encountering 
difficulties with their use. 
  
<0.0001 
   
Not relevant 29 (50%) 6 (5%) 
 
16.399 6.186 43.470 
Rarely relevant 11 (19%) 21 (19%) 
 
0.911 0.403 2.057 
Sometimes relevant 9 (16%) 33 (29%) 
 
0.386 0.169 0.881 
Fairly relevant 8 (14%) 24 (21%) 
 
0.524 0.218 1.259 
Very relevant 0 (0%) 17 (15%) 
 
- - - 
       
18a) On a scale of 1 to 10, to what extent do you 
agree or disagree that POCT significantly increases 
the workload of front line clinical staff (i.e. device 
operators)?  
  
<0.0001 
   
Strongly Disagree 22 (38%) 14 (13%) 
 
3.841 1.771 8.331 
Disagree 17 (29%) 18 (16%) 
 
1.935 0.904 4.141 
Neutral 11 (19%) 19 (17%) 
 
1.022 0.448 2.331 
Agree 5 (9%) 25 (22%) 
 
0.291 0.105 0.807 
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Strongly Agree 3 (5%) 26 (23%) 
 
0.159 0.046 0.553 
       
18b) Does the increased workload that you have 
indicated in part (a) reduce staff satisfaction levels 
in comparison to when utilising CLT? 
  
0.022 
   
Yes 5 (9%) 32 (29%) 
 
0.256 0.077 0.853 
No 11 (19%) 18 (16%) 
 
3.911 1.173 13.045 
       
19a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the central laboratory are 
reluctant to allow the control of testing to be 
passed on? 
  
0.960 
   
Strongly Disagree 11 (19%) 20 (18%) 
 
1.025 0.451 2.332 
Disagree 8 (14%) 14 (13%) 
 
1.070 0.419 2.734 
Neutral 13 (22%) 27 (24%) 
 
0.860 0.401 1.842 
Agree 12 (21%) 25 (22%) 
 
0.860 0.393 1.881 
Strongly Agree 11 (19%) 16 (14%) 
 
1.344 0.575 3.142 
       
19b) Does the resistance that you have indicated in 
part (a) act as an impediment to the more 
widespread adoption of POCT within the clinical 
environment? 
  
0.183 
   
Yes 19 (33%) 24 (21%) 
 
2.217 0.678 7.252 
No 5 (9%) 14 (13%) 
 
0.451 0.138 1.476 
       
20a) On a scale of 1 to 10, to what extent do you 
agree or disagree that the clinical care pathway and 
role of the central laboratory have been altered 
sufficiently to incorporate the use of POCT? 
  
0.844 
   
Strongly Disagree 6 (10%) 7 (6%) 
 
1.563 0.499 4.900 
Disagree 7 (12%) 10 (9%) 
 
1.260 0.452 3.515 
Neutral 15 (26%) 32 (29%) 
 
0.759 0.368 1.565 
Agree 17 (29%) 33 (29%) 
 
0.863 0.427 1.745 
Strongly Agree 12 (21%) 18 (16%) 
 
1.215 0.537 2.747 
       
20b) Does this poor integration of POCT that you 
have indicated in part (a) make it more difficult to 
attain a timely and reliable diagnosis in comparison 
to utilising CLT? 
  
0.025 
   
Yes 5 (9%) 12 (11%) 
 
0.156 0.029 0.845 
No 8 (14%) 3 (3%) 
 
6.400 1.183 34.614 
       
21a) Reduced staff satisfaction levels and increased 
friction between staff groups. 
  
<0.0001 
   
Not relevant 36 (62%) 19 (17%) 
 
7.489 3.596 15.595 
Rarely relevant 10 (17%) 22 (20%) 
 
0.774 0.337 1.774 
Sometimes relevant 8 (14%) 43 (38%) 
 
0.224 0.096 0.521 
Fairly relevant 3 (5%) 13 (12%) 
 
0.380 0.104 1.396 
Very relevant 0 (0%) 5 (4%) 
 
- - - 
       
21b) The resistance of central laboratory to allow 
the control of testing to be passed on acts as an 
impediment to the more widespread uptake of 
POCT. 
  
0.037 
   
Not relevant 18 (31%) 22 (20%) 
 
1.722 0.828 3.585 
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Rarely relevant 9 (16%) 27 (24%) 
 
0.532 0.230 1.230 
Sometimes relevant 9 (16%) 26 (23%) 
 
0.560 0.241 1.298 
Fairly relevant 9 (16%) 20 (18%) 
 
0.785 0.331 1.864 
Very relevant 11 (19%) 7 (6%) 
 
3.317 1.206 9.125 
       
21c) Inappropriate use of POCT (i.e. over-use and 
reliance on test results, undermining clinical 
expertise). 
  
0.0003 
   
Not relevant 18 (31%) 6 (5%) 
 
7.125 2.634 19.273 
Rarely relevant 8 (14%) 13 (12%) 
 
1.083 0.420 2.791 
Sometimes relevant 14 (24%) 23 (21%) 
 
1.079 0.505 2.308 
Fairly relevant 10 (17%) 31 (28%) 
 
0.470 0.211 1.049 
Very relevant 8 (14%) 28 (25%) 
 
0.417 0.176 0.990 
       
21d) The full benefits of POCT are not being realised 
as significant alterations to clinical care pathways 
and the central laboratory are required. 
  
<0.0001 
   
Not relevant 29 (50%) 11 (10%) 
 
8.273 3.680 18.600 
Rarely relevant 11 (19%) 22 (20%) 
 
0.851 0.379 1.910 
Sometimes relevant 6 (10%) 33 (29%) 
 
0.241 0.094 0.618 
Fairly relevant 11 (19%) 24 (21%) 
 
0.761 0.342 1.693 
Very relevant 1 (2%) 12 (11%) 
 
0.132 0.017 1.039 
       
21e) POCT system does not run efficiently as an 
interdepartmental management structure is 
required with clear clinical governance for POCT. 
  
0.0003 
   
Not relevant 30 (52%) 19 (17%) 
 
4.680 2.286 9.584 
Rarely relevant 7 (12%) 19 (17%) 
 
0.600 0.236 1.526 
Sometimes relevant 7 (12%) 24 (21%) 
 
0.446 0.179 1.111 
Fairly relevant 11 (19%) 22 (20%) 
 
0.851 0.379 1.910 
Very relevant 3 (5%) 18 (16%) 
 
0.255 0.072 0.905 
       
21f) Reluctance to change within health services 
and a lack of evidence justifying POCT makes it hard 
to justify the implementation of such a system. 
  
0.597 
   
Not relevant 10 (17%) 12 (11%) 
 
1.545 0.622 3.837 
Rarely relevant 8 (14%) 21 (19%) 
 
0.610 0.251 1.481 
Sometimes relevant 18 (31%) 26 (23%) 
 
1.298 0.636 2.648 
Fairly relevant 11 (19%) 25 (22%) 
 
0.711 0.321 1.579 
Very relevant 11 (19%) 17 (15%) 
 
1.156 0.500 2.674 
       
26) Please rank the following categories of issues in 
order of current impact on POCT adoption, using 
the table below (from 1 to 4 where 1 is most current 
impact and 4 is least current impact).* 
  
0.469 
   
Economic Issues 164 244 
 
1.073 0.848 1.357 
Quality Assurance & Regulatory Issues 141 224 
 
0.979 0.766 1.250 
Device Performance & Data Management Issues 124 222 
 
0.837 0.650 1.076 
Staff & Operational Issues 121 170 
 
1.145 0.881 1.488 
*Scoring system used: 1st place rank = 4 points, 2nd = 3 points, 3rd = 2 points, 4th = 1 point. 
 
 190 
7.4 Discussion 
It was noted in Chapter 5 that responses from US participants in the study differed from those 
in the UK in 2 particular areas; namely the cost per test of POCT and with regards to the 
connectivity and data management capabilities of POCT.  A statistical analysis by way of the Chi-
square test and calculation of odds ratios has been conducted in order to assess if these 
differences are indeed statistically significant and if any other significant differences in response 
have been observed.  Differences in response regarding the cost per test of POCT (Question 7a) 
have been found to be statistically significant here.  UK study participants were found to be more 
likely to agree that the cost per test of POCT is higher than CLT.  As was discussed in Chapter 5, 
it is possible that the opinion of the US study participants is influenced by the levels of 
reimbursement found within the US healthcare system and the privatisation of central 
laboratories.  It is apparent that reimbursement is made for laboratory tests and that POCT is 
incorporated into this process, i.e. as a responsibility of the central laboratory, and so receives 
the same level of reimbursement as the equivalent CLT (which often is a minimal amount).  As 
a result, from the clinician’s point of view, the cost of a specific test has no difference to them 
whether it is performed by CLT or POCT.  It was also found by the primary study conducted in 
Chapter 5 that the privatisation of the central laboratory service can in some cases cause CLT to 
be more expensive to the patient than POCT. 
The study conducted in Chapter 5 found that US participants suggested levels of connectivity 
were much more varied within their health system in comparison to the UK.  The difference in 
response profile was with regard to whether those participants who believed levels of 
connectivity and data management of POCT were poor subsequently believed that this made it 
more difficult to attain a timely and reliable diagnosis (Question 15b).  The analysis here has 
proven this difference in response to be statistically significant.  The US participants were found 
to believe that the perceived poor levels of connectivity and data management did not affect 
their ability to attain a sufficient quality of diagnosis (while UK participants were in stronger 
agreement that they did).  The main issue for the US participants was found to be with respect 
to the loss of access to diagnostic data via the patient record systems when using of POCT. 
The statistical analysis conducted has identified one further area where a statistically significant 
disparity in response profile between UK and US participants has been observed; namely, the 
relevance of 2 specific staff and operational issues within the participant’s place of work; the 
inappropriate use of POCT (i.e. over-use and reliance on test results, undermining clinical 
expertise) and the inefficient use of POCT due to a lack of an interdepartmental management 
structure and clear clinical governance.  The US participants were found to be much more likely 
to indicate these specific issues as being “not relevant” in comparison to the UK response profile.  
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The reasoning for this is perhaps the utility of POCT within the US health system.  The primary 
study conducted in Chapter 5 has found indications that POCT is used as a screening tool rather 
than as a standalone diagnostic solution that ultimately could replace CLT.  As such, the nature 
of its use within the US health system would make it less likely to be seen as being over-used or 
relied upon, or further to undermine clinical expertise.  Additionally, use as a screening tool 
could potentially simplify the requirement for clearer clinical governance. 
With 48 UK participants and 21 US participants amalgamated from the first 2 primary studies 
(Chapters 4 and 5) it is perhaps difficult to ascertain statistically significant differentiation with 
such a size of sample.  The increased participation attained through the study carried out in 
Chapter 6 allowed for a substantially increased sample size to be assessed when considering 
Clinicians (n=58) as a comparison against Clinical Bioscientists (n=112) across all 3 primary 
studies.  Much of the disparity in response profiles found here was with regards to the relevance 
of specific issues within the participant’s place of work.  This was indicated as a constant 
disconnect in Chapter 6 in comparison to the previous studies.  Consistently, it was observed 
that the clinicians were much more likely to suggest that specific issues were “not relevant” in 
comparison to the response data from the clinical bioscientists.  In fact, of the 30 areas where a 
statistically significant difference in response was found here, this accounted for 17 of such 
instances.  The clear disconnect in the perception of relevance of specific issues is a major barrier 
to the uptake of POCT within secondary care.  In order to overcome barriers there must be a 
clear agreement on what actually exists in reality between those who are responsible for the 
utility of POCT and those who are responsible for test quality assurance.  The clinical 
bioscientists are perhaps more acutely aware of the relevance of specific issues due to the 
responsibility that they hold with respect to the assurance of test quality and accuracy within 
healthcare systems. 
Further areas of response identified within Chapter 6 as being dissimilar to the previous studies 
(which held a majority of clinician participation) included the dispersion of devices leading to 
untrained / non-competent users operating the devices, ultimately resulting in quality assurance 
issues, levels of operator training and support on regulatory compliance provided by the central 
laboratory and the increased workload of front-line clinical staff as a result of the utilisation of 
POCT.  By way of statistical analysis, the work carried out here has confirmed these differences 
in response between the 2 study groups as being statistically significant (Questions 10a, 12a, 
12b, 18a and 18b).   
Clinical bioscientists were found to be much more likely to “strongly agree” with the notion that 
the dispersed nature of devices ultimately leads to issues with test quality due to incorrect 
operation of the POCT machines and instruments.  Being substantially more familiar with the 
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traditional CLT method, this study group are hence further aware of the benefits of confining 
testing to a highly specialised team of operators.  As such, they are perhaps more acutely 
mindful of the risks to test quality borne as a result of providing access across a much wider (and 
less specialised) workforce.   
Furthermore, the clinical bioscientists were found to rate the levels of operator training and 
support on regulatory compliance provided by the central laboratory significantly higher than 
the clinician group of participants.  It is to be expected that those providing a service will be 
more inclined to be of the opinion that the service being provided is of a sufficient level.  This 
variation in opinion between the clinical groups suggests that this support is not being provided 
on a wide enough level or, perhaps, not always to the correct individuals.  However, clinicians 
of the opinion that levels of support and training were “low” or “very low” were less likely to 
agree (in comparison to clinical bioscientists of the same opinion) that this made it more difficult 
for them to attain a timely and reliable diagnosis.  As was indicated in Chapter 4, a detailed 
analysis and consideration of comments made by face-to-face responders in the first primary 
(UK) study suggested that poor levels of support by the central laboratory are not necessarily 
considered to be a barrier to the uptake of POCT.  In fact, the majority of responders in this study 
suggested that much of the training (and support) is actually provided by the device 
manufacturers themselves, rather than the central laboratory. 
Clinical bioscientists were found to be of stronger opinion also that POCT increased the workload 
of front-line clinical staff.  As discussed in the previous chapters, the consensus (for clinicians) 
to disagree with this opinion was, in general, that the time taken to carry out a test using POCT 
was less than that required to attain results via the CLT method.  The possibility remains that 
the clinical biosciences cohort is less aware of the time burden endured to transport samples to 
the central laboratory for testing and the subsequent wait for test results.  Furthermore, it has 
been suggested that clinicians place more of an importance on the timeliness of test result in 
comparison to test accuracy and/or reliability, while, to those in the clinical biosciences 
profession, accuracy and reliability are paramount (Pati, Singh 2014).  Whereas, POCT can be 
seen as a method for shifting some of the central laboratory workload to other areas of the 
healthcare system (by moving the operation to other clinical professionals), it in fact can 
increase workload if not managed appropriately.  Paradoxically, it may be the workload of the 
laboratory staff responsible for QA processes that may be increased as a result of the utilisation 
of POCT.   
The analysis conducted here has identified further areas where a statistically significant 
difference in opinion has been observed between clinicians and clinical bioscientists.  Firstly, the 
levels of analytical performance provided by POCT devices in comparison to CLT instruments; 
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clinicians were found much more likely to rate the level of analytical performance as being “very 
high”.  Those in the clinical biosciences profession, who are working regularly with CLT 
instruments, are perhaps most aware of the differences in levels of analytical performance 
between these instruments and POCT devices.  Whereas POCT can produce clinically acceptable 
results, which to clinicians can translate as being “high” or “very high” in terms of performance, 
the “gold standard” in terms of diagnostic testing (i.e. the CLT instrumentation) can perform at 
a much higher level, often above and beyond what is required in terms of clinical acceptability.   
Secondly, differences in response were observed with respect to the connectivity and data 
management capabilities of POCT.  Clinicians were found to be more likely to rate such 
capabilities of POCT as being “very poor”.  However, of those participants who perceived such 
capabilities to be “poor” or “very poor”, it was the clinical bioscientists who were of stronger 
opinion that this subsequently made it more difficult to attain a timely and reliable diagnosis.  
As those responsible for the utility of POCT, the clinicians are more likely to experience issues 
with connectivity and data management.  However, their use as a tool in “real-time” for quick 
decisions in time-critical situations hence lends itself to the opinion amongst this clinical group 
that these issues don’t necessarily translate into an issue with respect to the deduction of an 
accurate and timely diagnosis. 
Thirdly, statistically significant differences in opinion were found with respect to the economics 
of POCT.  Clinical bioscientists were, perhaps unsurprisingly, found to be of a stronger opinion 
that POCT is of a higher cost per test than CLT.  As indicated previously, within Chapter 6, 
economic issues were regarded by clinical bioscientists as having the greatest impact upon POCT 
uptake within the hospital environment.  This reflects the fact that clinical biosciences staff are, 
in general, more aware of the economies of scale that are available from effective utilisation of 
the central laboratory services due to their close alignment with it.  The increased cost of POCT 
was cited in the clinical biosciences primary study as being the second most relevant 
disadvantage of POCT.  Similarly, the clinicians were of a stronger opinion that the use of POCT 
was cost-effective (despite any perceived increases in costs).  Again, this perhaps is a 
consequence of the fact that clinicians, by virtue of their role, place more of an importance on 
the timeliness of test result in comparison to test accuracy and/or reliability.  As such, the value 
of POCT is higher and hence it is seen as being more cost-effective in comparison to someone 
from the clinical biosciences cohort, who is more likely to place more importance on test 
accuracy and/or reliability. 
The process of a systematic statistical analysis reveals the significance of the demographics 
between the clinicians and clinical bioscientists.  It has been demonstrated (Question 2) that the 
clinical bioscientists are further inclined to rate themselves as being “highly proficient” in the 
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use of POCT (i.e. recognised trainers), while the most common category for the clinicians was 
“basic level capability” (i.e. unsupervised use).  It is hence apparent that levels of proficiency in 
use and/or training capability may influence perception of barriers to adoption of POCT.  
Ultimately, the analysis conducted here endorses the deduction propositioned in Chapter 6 that 
opinion on POCT utilisation is significantly influenced by the clinical background of the 
respondents, regardless of the health system in which they practice. 
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Chapter 8 
Conclusions & Recommendations for Further Work 
8.1 Conclusions 
The work presented in this thesis provides the findings from a major body of research which 
seeks to define, categorise and prioritise the barriers to adoption of POCT within hospital-based 
healthcare.  The core issues are considered in a manner that also considers solutions by which 
these barriers may be overcome.  In doing so, the work addresses for the first time how both 
the healthcare funding system and respective clinical roles can affect opinions (and in some 
cases perceptions) of the core issues which impact upon POCT adoption and its subsequent 
utilisation. 
With respect to the key objectives of the research, a substantial systematic review of the 
relevant academic literature has identified the specific issues most pertinent to POCT adoption 
within hospital-based healthcare, allowing them to be categorised accordingly and hence 
satisfying the first two objectives of the research as defined in Chapter 1; to determine from a 
systematic review of the academic literature the actual issues that affect the adoption of POCT 
devices within the hospital-based clinical environment, and; to categorise the issues identified 
from the literature as a means of understanding in detail their relative contribution to adoption 
of POCT devices in the hospital environment.  Based on the information garnered from the 
literature reviewed herein (2000 to 2016), economic issues and quality assurance and regulatory 
considerations were the joint most highly cited barriers to hospital-based POCT adoption.  The 
next most important aspects relate to device performance and data management issues with 
operational issues then somewhat further behind in terms of the number of citations in the 
literature during the review period.  The number of publications in the reviewed literature that 
relate to each of the barriers was assessed as an indication of their respective relevance in terms 
of impact upon POCT adoption in hospital-delivered care.  This exercise was carried out by way 
of satisfying the third research objective described in Chapter 1; to determine, in order of 
priority, which issues are currently impacting the adoption of POCT devices within the clinical 
environment. 
The outcomes from this 16-year longitudinal systematic review was then used as the basis of a 
primary study wherein the opinion of clinicians was obtained on the nature and scale of the 
barriers to adoption of POCT identified from the literature.  The findings from the core part of 
this primary study has engaged a range of clinicians and clinical bioscientists from UK hospitals, 
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as presented in Chapter 4.  The focus of this study was to accomplish the fourth research 
objective; to determine the relationship between those issues identified from a consideration 
of the academic literature and the opinions of clinicians within the UK healthcare environment 
on the same issues.  By way of satisfying the fifth research objective (to compare and contrast 
clinical perspectives (opinions) on those issues that are seen as impediments to the uptake of 
POCT from clinicians working in the UK healthcare system, i.e. that is free at the point of delivery, 
with those in the US system where the cost of healthcare provision is insurance-based), the UK 
outcomes from the survey tool concerned have then been compared with the experiences of a 
small cohort of US practitioners (Chapter 5).  Finally, a more detailed consideration of the 
specific opinions of clinical bioscientists was undertaken with the respondents representing 
international perspectives (Chapter 6).  The study executed here focused on attaining the sixth 
and seventh research objectives; to assess how the perception of issues effecting the uptake of 
POCT, including their impact and relevance, varies with respect to the specific clinical role, and; 
to determine the global experiences of clinical bioscientists, as the professional group most 
closely aligned to hospital based diagnostic testing, in relation to the identified barriers to 
adoption of POCT.  Overall, the body of clinical professionals who participated across the 3 
interrelated components of the study have provided validation for the ranking of both economic 
and quality assurance/regulatory issues as having the highest impact upon POCT uptake (as 
considered from the systematic literature review).  Device performance and data management 
issues were ranked as being of less importance by clinicians when compared to the opinions of 
the clinical biosciences cohort.  Clearly, the data gathered directly from the clinical professionals 
indicates that the debate with respect to the utility of POCT has still not been resolved.  
Notwithstanding these on-going issues with adoption in hospital-based care settings, POCT 
usage is still expected to grow in the coming years due to the increased decentralisation of 
healthcare and technological improvements that will continue the trend towards increased 
home-monitoring (Abel 2015). 
The primary research undertaken here was purposefully shaped to determine the relationship 
between the issues identified in the academic literature and the opinions of clinical professionals 
acting within the UK National Health Service (NHS), which exists as a unique system providing 
healthcare to patients free at the point of delivery (i.e. Research Objective 4).  The UK clinical 
professionals sampled indicated that economic issues have the most impact upon POCT 
adoption.  The UK commits a significantly lower proportion of Gross Domestic Product (GDP) to 
healthcare compared to other developed nations, with reasons for this being twofold; firstly, 
the NHS is undoubtedly a lean and efficient model of healthcare provision in comparison to that 
operating in many other developed nations and, secondly; low levels of financial commitment 
to healthcare is an entrenched and established trend in the UK, which many experts believe has 
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resulted in many NHS providers currently being in deficit and described as being in “crisis” 
(Harding, Pritchard 2016).  With this in mind, the perception of economic issues having the 
greatest impact upon POCT adoption within NHS hospitals is both insightful and logical.  In 
general, UK clinicians agreed that POCT is associated with increased testing costs as compared 
to those undertaken via the central laboratory testing (CLT) services in the NHS.  As such, 
significant debate exists with regard to the true value of POCT in terms of the assessment of 
these increased costs compared to the possible clinical benefits that this type of near patient of 
testing can provide, for example in terms of enhanced turnaround time (TAT) for the 
management of critically ill patients. 
While regulations to ensure test accreditation were raised as issues with respect to both their 
complexity and appropriateness for POCT, the opinion of both UK clinicians, and subsequently 
also those in the US study, has highlighted a lack of knowledge by many clinicians in respect to 
the specifics involved.  This was seen as ambiguity in participant responses across both studies, 
leading to significant variation in opinion and high numbers of non-responses.  Many of the 
problems with regulation have been attributed to errors in readings from POCT devices.  This is 
particularly an issue for “waived” tests in the US where regulatory steps (i.e. trained operators, 
internal quality control assessment, quality assurance programmes and external quality 
assessment) are not a requirement with clinicians finding themselves unfamiliar with the 
specifics of the regulatory requirements as a result.  By definition, a waived test is one deemed 
to be “so simple and accurate to perform that the likelihood of erroneous results could be 
negligible”.  However, studies have shown that significant numbers of misclassifications of 
warfarin patients and misleading blood glucose level results have resulted from the use of 
waived POCT to deliver these type of test data (Plebani 2009).  In Europe, the regulatory 
framework of simply using the CE Marking process to ensure that medical devices conform with 
basic health, safety and environmental standards is also seen as being weak in the context of 
ensuring that POCT test data is correct. 
It is important to consider whether the barriers identified by literature, and subsequently 
validated by clinical opinion, are unique to POCT or pertain to the uptake of new technologies 
within secondary care more generally.  With reduced healthcare budgets globally, it is obvious 
that the adoption of any technology is increasingly prioritised based on an economic evaluation 
of its utilisation.  Furthermore, there are known to be certain difficulties in the assessment of 
healthcare technologies with respect to the provision of efficacy evidence (Chapman, Taylor et 
al. 2014).  However, both these economic considerations and those of quality assurance & 
regulatory issues (and other barriers to adoption for that matter) are exaggerated when 
considering POCT due to the existence of an acceptable service in the central laboratory that 
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often POCT will run alongside and, in some cases, duplicate.  As such, these barriers are 
considered to be unique in their existence with respect to POCT.  Another characteristic of POCT 
leads itself to complications in regard to the utilisation of new technologies; multiplexing i.e. the 
ability to simultaneously measure multiple analytes on the same cartridge or test.  Multi-analyte 
devices are more desirable with the increasing decentralisation of healthcare.  However, the 
number of these types of POCT device is known to be low (bar critical care devices such as blood 
gas analysers) (St John, Price 2014).  Therefore, while the introduction and uptake of new 
technologies into healthcare have their own difficulties, the combination of these technologies 
to produce multi-analyte devices adds an additional complication with respect to uptake, unique 
to POCT. 
While the ranking (and associated importance) of many of the barriers to adoption of POCT 
found in the literature review were validated by UK clinicians as being relevant within the NHS, 
in several cases there were pronounced differences.  It was apparent from the literature that, 
although the use of POCT can displace some of the workload of the central laboratory to other 
areas of the hospital, this could result in increased workloads of front-line clinical staff who are 
already stretched within a busy and hectic role.  Moreover, previous work indicated that this led 
to high levels of stress and reduced staff satisfaction in the case of a significant proportion of 
operators/clinicians.  However, the findings from the primary part of the research, as indicated 
in the opinions of both the UK and US clinicians, pointedly contradicts this notion.  In particular, 
the UK respondents noted that the elimination of the reliance on a chain of services, i.e. sample 
transport and testing at the central laboratory site, allowing the clinicians to take control of 
diagnostic testing, has in fact been shown to reduce their workload and improve staff 
satisfaction.  This is clearly an important finding for the future adoption of these technologies 
and could provide a means to justify their clinical utility as long as appropriate training and 
quality assurance processes are in place.  
While usability and analytical performance of POCT devices have been found to be historical 
issues through the longitudinal systematic literature review study, clinicians based within both 
the UK and US healthcare systems have categorically stated that in the present day neither of 
these aspects remain an issue.  Although it is not clear what has caused this change in opinion, 
the research carried out here has provided the first direct evidence based on primary data that 
demonstrates the evolution and advancements of the relevant test devices and technologies.  
The research carried out within the UK clinical cohort also provides noteworthy insight into 
another of the significant issues of POCT adoption that has a historical context; connectivity and 
data management.  While previous research has indicated that these aspects of POCT 
performance are poor in comparison to solutions from CLT, the research outcomes attained 
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here have suggested that, in the NHS, poor connectivity and data management does not 
necessarily transfer itself into an impediment to its adoption within hospital-based care.  Given 
that POCT has the most benefit in time-critical situations when it can be used to manage patient 
care at an earlier intervention, it does not have to rely on historical data or previous test results 
to be clinically effective.  As such, a consideration of where POCT should be positioned within 
the care pathway would suggest that connectivity and data management are strictly not 
significant barriers to the adoption of POCT in such circumstances. 
While previous academic work has addressed barriers to adoption of POCT, none to date has 
investigated the impact of the model of healthcare funding on clinical uptake.  In this work, the 
opinions of the UK clinicians working within the NHS (free to users at the point of delivery) have 
been compared with those working within the US system of healthcare (insurance-based) to 
determine relationships and identify any disconnects (i.e. Research Objective 5).  It has been 
found here that in the US the role of insurance acts as an additional hurdle with regards to POCT 
uptake.  The role of the insurers within the US system of healthcare makes reimbursement 
processes more complex with both insurers and patients playing an increased role with respect 
to the pathway of care.  Furthermore, the fragmented nature of the US system makes it more 
difficult to implement centralised budgets or procurement policies with respect to POCT of the 
type that are typical of the UK system.  The role of insurers also acts to mask the true costs of 
the POCT diagnostics, with many clinicians unsure of the true cost per test.  This is reflected in 
the fact that more respondents disagreed (43%) than agreeing (33%) that a POCT test was more 
expensive than that from CLT.  It is therefore suggested that the economic issues that have been 
shown to be of significance with respect to impact upon POCT adoption need to be considered 
in the context of the underlying healthcare funding model.   
The research outcomes presented here have also identified that privatised laboratories 
operating in the US can affect the usage of POCT in comparison to the processes that operate in 
the UK, particularly with respect to providing guidance on regulatory requirements and 
training/support for the use of the devices.  While the UK has moved towards engaging with the 
private sector in recent decades, it does not have the same reliance on outsourced provision as 
is the case for the US system (Guimares, de Carvalho 2011).  This research suggests that private 
laboratories see POCT as competition and hence will not actively support it.  Private laboratories 
are very common in the US, perhaps in part due to the relatively low qualification requirements 
for medical laboratory technicians and assistants in the US.  In fact, only 12 states in the US 
licence such professions, while Clinical Laboratory Improvements Amendments (CLIA) only 
requires an Associate degree and little experience in order to perform highly complex tests 
(Rohde, Falleur et al. 2015).  In addition, the more decentralised nature of US healthcare was 
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found to cause connectivity issues and hence a heightened impact upon POCT utilisation, in 
comparison to the UK environment. 
An interesting finding from the research in this thesis is the fundamental classification of POCT 
in the US, in that it is seen generally as a screening test, rather than a standalone diagnostic 
solution (equivalent to CLT testing).  The study findings here indicate that, although US 
participants to the survey agreed with the UK clinicians that POCT did not result in increased 
workload for clinical staff, their reasoning for this was different.  The US clinicians suggested that 
a sample would always be taken and sent to the central laboratory regardless of whether POCT 
was used or not.  Moreover, when POCT was used to ascertain a certain parameter, the 
laboratory sample would be used for other test parameters, even if they were available through 
use of the POCT test/device.  This major finding is reflective of the operational aspects of the 
“free at point of delivery” NHS compared to the insurance-based model that is prevalent in the 
US.  The US study participants indicated that POCT testing would only generally be used for a 
diagnostic parameter if the clinical situation absolutely required an instantaneous result.   
This research also investigated the influence of clinical speciality on perspectives on barriers to 
adoption of POCT (i.e. Research Objective 6).  By assessment of the responses by both UK and 
US samples, it was apparent that there was a disconnect in opinion of those responsible for the 
quality assurance of POCT, i.e. the Clinical Biosciences cohort, and those solely responsible for 
its operation and utilisation in the clinical areas of hospitals.  Differences in opinion between 
these clinical groups was found to be present with respect to quality-related issues, such as; the 
decentralised nature of POCT resulting in its use by untrained/non-competent staff; overly 
complex analytical testing accreditation regulations; levels of training and support provided by 
the central laboratory, and the reluctance of the central laboratory service to release control of 
testing outside of CLT locations, i.e. on wards and in the Emergency Room/Department (ER/D) 
etc.  The nature of this part of the research, which concerns 2 very different healthcare systems 
(i.e. UK and US) has provided a validation that key disconnects in clinical opinion exist 
irrespective of the underlying healthcare funding model, and hence ratifies the hypothesis that 
clinical role influences perspective on POCT uptake. 
The research was further developed to investigate, in detail, the role of the clinical bioscientist, 
i.e. the clinical role most aligned with diagnostic testing with respect to barriers to POCT 
adoption (i.e. Research Objective 7).  The survey tool for this element of the work was 
implemented internationally without any consideration of the influence of respective 
healthcare funding systems upon participant perspectives.  To the best of the authors 
knowledge, no previous work has been identified that incorporates a study investigating a 
specific clinical role with respect to the barriers to adoption of POCT at this scale.  One of the 
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most noteworthy findings here was that, for this specialist cohort, device performance and data 
management issues had, at least as much impact upon POCT uptake as quality assurance and 
regulatory issues.  The inherent responsibility of the clinical laboratory service to make device 
operators aware of the limitations of POCT is paramount in this regard.  While the analytical 
capabilities of POCT cannot match those of the more sophisticated instruments found in the 
central laboratory, the outputs from such devices are enough for them to be considered 
clinically acceptable in terms of providing a useful test result and the consequent clinical 
diagnosis upon which subsequent treatment is based.  However, a sound understanding of the 
limitations of POCT is vital to ensure the overall quality and effectiveness of the attendant 
clinical outcome.  The perspective of the clinical biosciences cohort was that quality-related 
issues were deemed to be of more importance than was the case for the other clinicians. 
Being most associated with diagnostic testing, clinical bioscientists are aware of the associated 
economies of scale associated with CLT.  As such, issues, such as the cost per test, were signified 
as being of increased importance in comparison to the perspectives of some other clinicians.  In 
a broad sense, reimbursement for diagnostic testing is based on test complexity; a product of 
reagent cost and resource investment in performing the test.  Hence, cost per test and 
automation have always been a major focus of laboratory medicine in respect of their role in 
sustaining an effective business model (St John, Price 2013).  Consequently, the economics of 
testing are a higher priority to the clinical bioscientists than the immediacy of result. 
The attributes of testing upon which the clinical cohorts place priority differs with respect to 
timeliness of the data (which the front-line clinician prioritises) and quality/accuracy of result 
(the priority of the clinical bioscientists).  While the clinical bioscientists viewed POCT as 
increasing workload of clinical staff, due to the displacement of the testing from the central 
laboratory to the ward or ER/D, the clinicians did not agree with this due to the time required 
to retrieve CLT results.  Hence, this research has demonstrated that POCT can actually increase 
the workload of the central laboratory service rather than that of the clinical staff, due to the 
responsibility of the laboratory to perform quality assurance activities.  Furthermore, as 
indicated earlier, this research has found that POCT is used (broadly speaking) as a screening 
tool rather than a diagnostic solution in the US system of healthcare and as such duplicates 
testing, resulting in a further increased workload for the central laboratory.  Hence, a 
fundamental conclusion of this research relates to the importance of defining both the role of 
POCT within a specific healthcare system, i.e. standalone diagnostic asset or rapid screening tool 
and the purpose of specific tests within the clinical care pathway. 
The 3 clinical-based primary studies conducted have, together, acted to achieve the eighth, 
ninth, tenth and eleventh research objectives, as defined in Chapter 1, specifically; to identify 
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the key advantages and potential benefits of POCT use within secondary healthcare; to identify 
the major disadvantages deemed to result from the use of POCT; to determine the clinical 
areas/situations in which POCT can provide the most benefit in secondary care, and; to suggest 
how the most significant barriers to adoption of POCT in the relevant secondary healthcare 
systems can be overcome based on the findings of the studies undertaken, i.e. what are the 
possible solutions that may encourage more effective adoption?  All 3 studies were designed to 
collect this data and through assessment and amalgamation findings have been identified as 
described herein. 
The eighth objective of this research was to identify, in the opinion of study participants, the key 
advantages that POCT offers, specifically within the hospital-based environment.  The most 
commonly cited advantages from participants were; rapid test TAT and associated earlier clinical 
intervention; more efficient patient management, including reduced hospital lengths of stay and 
a decreased number of outpatient appointments; improved patient/operator satisfaction and 
convenience, including lower volumes of blood required as samples and increased buy-
in/responsibility, and; improved quality of care resulting overall in better patient outcomes.  As 
such, this study has been able to define those situations in which POCT provides most benefit 
and hence satisfy the tenth research objective, including; the diagnosis of respiratory conditions 
(e.g. blood gas testing); monitoring of diabetic patients (e.g. blood glucose testing); monitoring 
of blood coagulation patients (e.g. INR testing); cardiac conditions (e.g. troponin testing), and; 
sepsis testing. 
Similarly, the ninth objective of the research was to identify the major disadvantages of using 
POCT in hospital-based care.  The most commonly cited issues in this regard were; increased 
cost compared to CLT; poor quality and/or inaccuracy of test result due to operator error; issues 
of connectivity to central patient record systems; significant resource required to sustain an 
appropriate quality management system, which is difficult to control due to the dispersed 
nature of POCT; staff training requires a substantial amount of time dedication, and; POCT will 
not give you the same accuracy as CLT, and can therefore cause duplication of tests already 
being carried out by the central laboratory. 
As indicated at the outset, this research was designed with the intent of not only identifying 
problems with the adoption of POCT in hospital-based healthcare but also providing potential 
solutions to the issues impeding its further uptake.  Importantly, the nature of the solutions 
need to be defined following a sound and complete understanding of the underlying problems.  
In this regard, by way of achieving the eleventh and final research objective, the following 
solutions are suggested as a means to overcome the issues identified and categorised within 
this thesis: 
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• POCT use should be audited in a long-term evidence gathering exercise in order to 
provide verification of both the clinical and economic benefits that may be available 
through its utilisation.  As such, the increased cost associated with POCT can be justified 
by the improvements in patient care and cost-effectiveness could be better judged.  This 
would overcome much scepticism with regard to POCT that has been identified as 
existing; 
• POCT results should be better connected to the patient record systems, without the use 
of multiple middleware interface systems.  Appropriate regional/national standards 
should be implemented for POCT data in a way that makes it as compatible with CLT 
data as possible; 
• Training processes should be improved, to include re-training and periodic competency 
tests of all users to ensure familiarity with operational aspects of devices.  The 
effectiveness of POCT devices to provide high quality results is largely dependent on the 
competence of the operator and, as such, training is a vital component for minimising 
the risk of poor quality and/or inaccurate results, which can result in patient morbidity 
or mortality; 
• Costs of both POCT devices and implementation should be reduced and their uptake in 
healthcare facilities targeted to deliver specified outcomes.  This can be achieved 
through a central POCT funding source.  In a time of shrinking healthcare budgets across 
the globe, any increase in cost is difficult to justify when evidence of clinical benefit is 
currently limited; 
• A regional consensus and/or strategy on POCT procurement should be agreed.  A 
defined (capability led) procurement strategy for POCT would lead to increased 
efficiency in their use.  POCT devices are generally a form of mobile technology and 
hence can be utilised within different locations if proper planning is in place to allow for 
this without any loss of quality; 
• Central Laboratory Service support for POCT and a plan for sufficient aftercare provision 
should be implemented, with a dedicated team provided to manage quality assurance 
processes.  A team of analytically trained professionals, who are familiar with the 
regulatory requirements of diagnostic testing, would ensure that errors are kept to a 
minimum and, as such, this arrangement would increase operator confidence in the 
system overall; 
• Fit for purpose quality assurance programmes should be improved and audited.  
Auditing the quality systems in place will overcome both clinician and laboratory anxiety 
about testing quality; and  
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• All areas involved in POCT operation must collaborate more closely to ensure the 
effective utilisation of POCT.  Clear lines of clinical governance along with roles and 
responsibilities must be defined. 
8.2 Recommendations for Further Work 
While the merits and contribution to knowledge of this body of research have been described, 
above, its limitations are also recognised.  Resource constraints have allowed for only 
representation clinical groups from the UK and US healthcare systems to participate.  As such, 
the findings of this research could be validated on a larger scale, incorporating larger samples of 
each of the respective healthcare professionals.  Furthermore, while the UK and US health 
systems were compared herein, other examples of the specifics of national healthcare provision 
in Europe, the Americas and Asia could be added to provide a more global dimension.  Finally, 
while this body of research has focused on POCT use within the secondary care (hospital) 
system, additional research could be conducted to investigate the barriers to adoption of POCT 
within primary care and how these relate to the situation found here within the hospital-based 
care environment. 
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Appendix A 
UK Study Questionnaire 
Study:  A survey of clinical opinion on the utility of point-of-care testing (POCT) 
devices. 
Note:  Participants are encouraged to answer only those questions which they feel are relevant. 
Responses to interview questions should be made today.  
 
Questions 1-4 will be used to qualify the responses in respect to clinical speciality, user 
experience and category of device.    
 
1. Please state your area of clinical practice/specialty. 
 
2. How would you rate your own expertise in the practical use of a POCT device? (Please tick 
the appropriate box below) 
Not yet 
completed 
training. 
Use under 
supervision. 
Basic level 
capability – 
Unsupervised 
use. 
Competent – 
Unsupervised 
use and 
maintenance. 
Highly 
proficient-
Recognised 
trainer. 
     
 
3. Are any point-of-care testing devices used to diagnose patients in your area of clinical 
practice/specialism? (Please tick the appropriate box below) If yes continue to Question 4, if 
no please go to Question 7. 
Yes No 
  
 
4. Please tick the type(s) of POCT device used in your area of clinical practice/specialism. 
Blood Lactate Analyser  
Cardiac Marker Analyser  
Urine Pregnancy Test Kit  
Coagulation Analyser  
Urea, Electrolytes & Creatinine Test  
CRP Analyser  
Blood Glucose Analyser  
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Blood Gas Analyser  
Drugs of Abuse Screening  
Other (please specify)  
 
Questions 5 and 6 address experience of POCT usage within a clinical environment. 
5. Approximately, what percentage of diagnostic tests in your area of clinical 
practice/specialism is performed using POCT? 
 % 
 
6.   (a)  Have you experienced any levels of patient mistrust of POCT devices? (Please tick all 
of the appropriate boxes below)  
 
I have never 
experienced any 
level of patient 
mistrust towards a 
POCT device. 
Patient queries the 
capability of a POCT 
device. 
Patient requests 
evidence of the 
capability of a POCT 
device. 
Patient refuses test 
to be carried out 
with a POCT device. 
    
If you have experienced a situation where a patient has refused a test to be carried out 
using a POCT device then please continue to part (b).  Otherwise, please go to Question 
7. 
(b)  In your experience, approximately how often does a patient refuse a test to be 
carried out using a POCT device? (Please tick the appropriate box below) 
Almost never (<1%) Rarely (1%-5%) 
Not very often (6%-
10%) 
Significantly often 
(>10%) 
    
Questions 7 to 21 seek to attain a semi-quantitative assessment of the practical utility 
of POCT devices.   
• Questions preferably should be answered in relation to the type(s) of device used in 
your area of clinical practice/specialism, as selected in Question 4. 
• POCT refers to Point-of-Care Testing. 
• CLT refers to traditional Central Laboratory Testing. 
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Economic Issues 
7.   (a)  Do you agree that the cost per test of POCT is higher than CLT? (Please tick the  
appropriate box below) 
Yes No 
  
(b) (i)  On a scale of 1 to 10, to what extent do you agree or disagree that, POCT 
provides longer term economic benefits e.g. reduced hospital stay, reduced 
outpatient appointments etc. 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 5 or below then please continue to part (b)(ii).  
Otherwise, please go to part (c). 
(ii)  In your opinion, why are the longer term economic benefits potentially 
available through the use of POCT not being realised fully? 
 
 
 
 
 
(c)  Would you agree that the use of a POCT system is cost-effective? (Please tick the 
appropriate box below). 
Yes No 
  
 
 
      Strongly Disagree Strongly Agree 
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8.   (a)  On a scale of 1 to 10, to what extent do you agree or disagree that procurement,  
reimbursement and budgeting in your institution sufficiently accommodate the 
interdepartmental nature of POCT, especially where it is a shared resource? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 5 or below then please continue to part (b).  
Otherwise, please go to Question 9. 
(b)  Does this lack of specific accommodation make it difficult to utilise POCT to its full 
potential in your institution? (Please tick the appropriate box below) 
Yes No 
  
 
9. Please rate the following issues in terms of relevance within your clinical environment, using 
the table below. (Please tick the appropriate box below for each issue) 
Issue Not 
relevant 
Rarely 
relevant 
Sometimes 
relevant 
Fairly 
relevant 
Very 
relevant 
Difficult to justify the use of POCT 
devices as the simple cost per test of 
POCT is higher than traditional CLT. 
 
    
Difficult to justify the implementation 
of a POCT system as the true cost-
effectiveness of such a system is 
difficult to gauge and cost comparison 
studies against traditional central 
laboratory testing methods are 
complex. 
 
    
Difficult to justify the implementation 
of a POCT system as the initial costs of 
implementing such a system are high. 
     
Issues with regards to budget 
contributions towards POCT due to the 
allocation of separate budgets for 
separate departments which is not 
appropriate for interdepartmental 
nature of POCT. 
     
Strongly Disagree Strongly Agree 
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Difficulty in obtaining reimbursement 
for POCT. (i.e. who pays for the test?) 
     
 
Quality Assurance & Regulatory Issues 
10.  (a)  On a scale of 1 to 10, to what extent do you agree or disagree that the dispersion of  
POCT devices through the healthcare system gives rise to opportunities for 
untrained or non-competent staff to use the devices, leading to an increased disregard 
of certain quality assurance steps and procedures, including quality control? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 6 or above then please continue to part (b).  
Otherwise, please go to Question 11. 
(b)  Does the increased disregard of certain quality assurance steps and procedures that 
you have indicated in part (a) make it more difficult to attain a timely and reliable 
diagnosis in comparison to utilising CLT? (Please tick the appropriate box below) 
Yes No 
  
 
11.   (a)  On a scale of 1 to 10, to what extent do you agree or disagree that regulations for  
analytical testing accreditation for POCT are overly complex?  
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 6 or above then please continue to part (b).  
Otherwise, please go to Question 12. 
Strongly Disagree Strongly Agree 
Strongly Disagree Strongly Agree 
 210 
(b)  Does the burden imposed by such requirements that you have indicated in part (a) 
make it more difficult to attain a timely and reliable diagnosis in comparison to utilising 
CLT? (Please tick the appropriate box below) 
Yes No 
  
 
 
12.   (a)  On a scale of 1 to 10, how much operator training and support on regulatory 
compliance  
for POCT are provided by your central laboratory? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated this level of training and support as 5 or below then please continue to part 
(b).  Otherwise, please go to Question 13. 
(b)  Does this lack of training and support that you have indicated in part (a) make it 
more difficult to attain a timely & reliable diagnosis in comparison to utilising CLT? 
(Please tick the appropriate box below) 
Yes No 
  
 
13. Please rate the following issues in terms of relevance within your clinical environment, using 
the table below. (Please tick the appropriate box below for each issue) 
Issue Not 
relevant 
Rarely 
relevant 
Sometimes 
relevant 
Fairly 
relevant 
Very 
relevant 
Errors due to incorrect quality assurance 
steps or procedures by untrained or non-
competent staff operating the POCT 
devices. 
 
    
Complex accreditation regulations 
written for traditional laboratory 
instrumentation are blindly applied to 
modern POCT devices, causing issues for 
non-laboratory operators. 
 
    
Very Little Very Much 
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Issues with maintaining compliance with 
regulatory requirements due to a 
number of changes in the accreditation 
regulations. 
 
    
Issues with maintaining compliance with 
regulatory requirements due to the 
dispersed nature of POCT devices making 
them difficult to control.  
     
A lack of development of POCT devices, 
caused by product approval hurdles 
discouraging economic investment in 
their development. 
     
 
Device Performance & Data Management Issues 
14.    (a)  On a scale of 1 to 10, how do you rate the level of analytical performance (i.e. 
specificity,  
sensitivity & precision) of a POCT device in comparison to a traditional CLT instrument? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated the level of analytical performance as 5 or below then please continue to 
part (b).  Otherwise, please go to Question 15. 
(b)  Does the reduced analytical performance that you have indicated in part (a) make 
it more difficult to make a timely and reliable diagnosis in comparison to utilising CLT? 
(Please tick the appropriate box below) 
Yes No 
  
 
 
 
Very Low  Very High 
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15.  (a)  On a scale of 1 to 10, how do you rate the connectivity (i.e. to the central healthcare 
and  
patient record systems) and data management of a POCT system in comparison to a 
traditional CLT instrument? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated the connectivity and data management as 5 or below then please continue 
to part (b). Otherwise, please go to Question 16. 
 
(b)  Does the poor connectivity and data management that you have indicated in part 
(a) make it more difficult to make a timely & reliable diagnosis in comparison to utilising 
CLT? (Please tick the appropriate box below) 
Yes No 
  
 
16.  (a)  On a scale of 1 to 10, how do you rate the difficulty of performing tests using POCT  
devices compared to that of a CLT system? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated the difficulty of performing tests using POCT devices as 6 or above then 
please continue to part (b).  Otherwise, please go to Question 17. 
(b)  (i)  Does the increased difficulty that you have indicated in part (a) make it more 
difficult to attain a timely & reliable diagnosis in comparison to utilising CLT? 
(Please tick the appropriate box below) 
Yes No 
  
Very Poor Very Good 
Very Easy Very Difficult 
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  (ii)  In your opinion, how could the usability of POCT devices be improved? 
 
 
 
 
 
 
17. Please rate the following issues in terms of relevance within the clinical environment, using 
the table below. (Please tick the appropriate box below for each issue) 
 
Issue Not 
relevant 
Rarely 
relevant 
Sometime
s relevant 
Fairly 
relevant 
Very 
relevant 
POCT devices producing reduced 
analytical performance in comparison to 
traditional centralised testing. 
 
    
POCT system poorly connected to main 
healthcare and patient record systems, 
causing data management issues. 
 
    
POCT device operators encountering 
difficulties with their use.  
    
 
Staff & Operational Issues 
18.  (a)  On a scale of 1 to 10, to what extent do you agree or disagree that POCT significantly 
increases the workload of front line clinical staff (i.e. device operators)?  
 
1 2 3 4 5 6 7 8 9 10 
          
Strongly Disagree Strongly Agree 
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If you rated your level of agreement as 6 or above then please continue to part (b).  
Otherwise, please go to Question 19. 
(b)  Does the increased workload that you have indicated in part (a) reduce staff 
satisfaction levels in comparison to when utilising CLT? (Please tick the appropriate box 
below) 
Yes No 
  
  
19. (a)  On a scale of 1 to 10, to what extent do you agree or disagree that the central 
laboratory are reluctant to allow the control of testing to be passed on?  
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 6 or above then please continue to part (b).  
Otherwise, please go to Question 20. 
(b)  Does the resistance that you have indicated in part (a) act as an impediment to the 
more widespread adoption of POCT within the clinical environment? (Please tick the 
appropriate box below) 
Yes No 
  
 
20.   (a)  On a scale of 1 to 10, to what extent do you agree or disagree that the clinical care  
pathway and role of the central laboratory have been altered sufficiently to incorporate 
the use of POCT? 
 
1 2 3 4 5 6 7 8 9 10 
          
If you rated your level of agreement as 5 or below then please continue to part (b).  
Otherwise, please go to Question 21. 
Strongly Disagree Strongly Agree 
Strongly Disagree Strongly Agree 
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(b)  Does this poor integration of POCT that you have indicated in part (a) make it more 
difficult to attain a timely and reliable diagnosis in comparison to utilising CLT? (Please 
tick the appropriate box below) 
Yes No 
  
 
21. Please rate the following issues in terms of relevance within your clinical environment, using 
the table below. (Please tick the appropriate box below for each issue) 
Issue Not 
relevant 
Rarely 
relevant 
Sometimes 
relevant 
Fairly 
relevant 
Very 
relevant 
Reduced staff satisfaction levels and 
increased friction between staff groups.  
    
The resistance of central laboratory to 
allow the control of testing to be 
passed on acts as an impediment to the 
more widespread uptake of POCT. 
 
    
Inappropriate use of POCT (i.e. over-use 
and reliance on test results, 
undermining clinical expertise). 
 
    
The full benefits of POCT are not being 
realised as significant alterations to 
clinical care pathways and the central 
laboratory are required. 
     
POCT system does not run efficiently as 
an interdepartmental management 
structure is required with clear clinical 
governance for POCT.  
     
Reluctance to change within health 
services and a lack of evidence 
justifying POCT makes it hard to justify 
the implementation of such a system. 
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Questions 22-26 seek to gain opinion on the general use and adoption of POCT. 
22.  What do you think are the main advantages of using POCT in comparison to CLT? 
 
 
 
 
 
 
 
23.  What do you think are the main disadvantages of using POCT in comparison to CLT? 
 
 
 
 
 
 
 
24. Which diseases and/or conditions do you feel benefit the most from the use of POCT for 
more effective diagnosis and/or monitoring? 
 
 
 
 
 
 
 
25.  What do you suggest could be possible solutions to overcoming any of the real or perceived 
barriers to the adoption of POCT technologies? 
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26.  Please rank the following categories of issues in order of current impact on POCT adoption, 
using the table below (from 1 to 4 where 1 is most current impact and 4 is least current 
impact). 
a. Economic Issues 
(i.e. higher cost/test ratio, difficult to gauge cost-effectiveness, high initial implementation 
costs, inappropriate budget allocations, reimbursement hurdles) 
b. Quality Assurance & Regulatory Issues 
(i.e. device operation by untrained/non-competent staff, complex regulatory requirements, 
product qualification hurdles) 
c. Device Performance & Data Management Issues 
(i.e. reduced analytical performance in comparison to centralised testing, connectivity & data 
management issues, poor usability of devices) 
d. Staff & Operational Issues  
(i.e. reduced staff satisfaction levels and friction between staff groups, reluctance of central lab 
to allow testing to be passed on, significant alterations to clinical care pathways and the central 
lab are required, an interdepartmental management structure with clear clinical governance 
for POCT is required, a lack of evidence justifying POCT and a reluctance to change within the 
healthcare sector)  
 
 
Rank 1 2 3 4 
Category (letter)     
 
 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE AND 
CONTRIBUTING TO THE ASSOCIATED RESEARCH PROJECT.  
– YOUR CONTRIBUTION IS GREATLY APPRECIATED. 
 
  
Most 
Current 
Impact 
Least 
Current 
Impact 
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